Molecular and cellular expression of novel genes associated with breast cancer by Laversin, S
MOLECULAR AND CELLULAR EXPRESSION
OF NOVEL GENES ASSOCIATED
WITH BREAST CANCER
STEPHANIE ANNE-SOPHIE LAVERSIN
A thesis submitted in partial fulfilment of the
requirements of Nottingham Trent University
for the degree of Doctor of Philosophy
September 2009
Copyright Statement
This work is the intellectual property of the author, and may also be owned by the re-
search sponsor(s) and/or Nottingham Trent University. You may copy up to 5% of this
work for private study, or personal, non-commercial research. Any re-use of the informa-
tion contained within this document should be fully referenced, quoting the author, title,
university, degree level and pagination. Queries or requests for any other use, or if a more
substantial copy is required, should be directed in the first instance to the author.
i
J’aimerais de´dier cette the`se tout particulie`rement a` ma maman, la meilleure maman
du monde, mais aussi a` toutes les personnes qui comptent ou ont compte´ pour moi. Merci
d’eˆtre ou d’avoir e´te´ la` pour moi, tout simplement.
“Soyons reconnaissants aux personnes qui nous donnent du bonheur, elles sont les
charmants jardiniers par qui nos aˆmes sont fleuries.” Marcel Proust
ii
Acknowledgements
To start, I would like to thank Professor Robert Rees for allowing me to undertake this
PhD within his research group and for his continuous guidance and support during the
course of this work. I would also like to thank Dr Geng Li for his supervision at the
beginning of the study. I am extremely grateful to my supervisors Dr Amanda Miles and
Dr Graham Ball who have provided helpful suggestions, important advice and constant
encouragement throughout the time of the research. I also wish to express my Apprecia-
tion to Dr Morgan Mathieu and Dr Ste´phanie Mcardle who gave me constructive advice
and valuable help in the lab.
Special thanks are due to Steve for providing great technical assistance during my re-
search. Thank you to Dr Balwir Matharoo-Ball, Clare and Christophe for giving me great
support for the mass spectrometry and bioinformatics side of the project.
An extended thank you to Professor Ian Ellis, Dr Des Powe and colleagues at the QMC
in Nottingham as well as Dr Sonia Perez and Dr Angelos Gritzapis at Saint Savas Cancer
Hospital (Greece) and Dr Aija Line at the Latvian University Biomedical Centre for the
collaborative work and for providing samples which are crucial for this kind of expression
analysis based project. Special Gratitude goes to the other group members of the John van
Geest Cancer Research Centre, past and present, for offering me countless advice, valued
conversations and laughter.
I would like to express my warmest thanks to my fellow PhD students, my dearest friend
Florence and also Krish, Baharak, Gary, who shared with me the good times and the bad
times that go with doing a PhD thesis and who gave me great moral support when needed
and sincere friendship. My heartiest thanks also go to Richard for our comforting conver-
sations and to my closest friends, in France and in England, Christelle, Natali, Marie and
Olivier for their invaluable friendship and the great times we shared during all these years.
Finally, I would like to express my wholehearted special thanks to my family for their in-
finite encouragement and support: thank you to Alison, David and Graham; thank you to
my mum Liliane, my dad Michel and my brother Christophe; thank you to my grandpa
Robert, my brother Se´bastien and my grandma Odette, all who sadly passed away and
who I greatly miss; and last but not least, thank you to Alex, the love of my life, for his
patience, understanding, care and love which are basically everything a girlfriend doing a
PhD thesis could dream of.
iii
Contents
Abstract 1
1 Introduction 2
1.1 Cancer: an overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.1.1 Cancer is a class of diseases which has a multifactorial, multistep
causation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.1.2 Oncogenes and tumour suppressor genes . . . . . . . . . . . . . 5
1.1.2.1 Oncogenes . . . . . . . . . . . . . . . . . . . . . . . . 5
1.1.2.2 Tumour suppressor genes . . . . . . . . . . . . . . . . 6
1.1.3 Tumour-associated antigens . . . . . . . . . . . . . . . . . . . . 9
1.1.4 The immune system: first line of defense against cancer . . . . . 10
1.1.4.1 Innate immune system . . . . . . . . . . . . . . . . . . 10
1.1.4.2 Adaptive immune system . . . . . . . . . . . . . . . . 12
1.1.5 Tumour evasion: immunological tolerance to cancer cells . . . . . 14
1.1.6 Cancer vaccines: boosting the immune system to break immune
tolerance to cancer . . . . . . . . . . . . . . . . . . . . . . . . . 16
1.1.6.1 Active immunotherapy . . . . . . . . . . . . . . . . . 17
1.1.6.2 Adoptive immunotherapy . . . . . . . . . . . . . . . . 20
1.1.6.3 Passive immunotherapy . . . . . . . . . . . . . . . . . 20
1.1.7 Cancer stem cells . . . . . . . . . . . . . . . . . . . . . . . . . . 21
1.2 Breast cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
1.2.1 Breast cancer statistics . . . . . . . . . . . . . . . . . . . . . . . 22
1.2.2 Epidemiology of breast cancer . . . . . . . . . . . . . . . . . . . 24
1.2.3 Etiology of breast cancer . . . . . . . . . . . . . . . . . . . . . . 25
1.2.4 Pathological types and molecular classification of breast cancer . 26
1.2.4.1 Pathological types . . . . . . . . . . . . . . . . . . . . 26
1.2.4.2 Molecular profiling of breast cancer . . . . . . . . . . . 28
1.2.5 Detection of breast cancer . . . . . . . . . . . . . . . . . . . . . 29
1.2.5.1 Breast self-examination . . . . . . . . . . . . . . . . . 29
1.2.5.2 Imaging . . . . . . . . . . . . . . . . . . . . . . . . . 29
1.2.5.3 Genetic testing . . . . . . . . . . . . . . . . . . . . . . 30
1.2.6 Diagnosis and prognosis of breast cancer . . . . . . . . . . . . . 31
iv
Contents
1.2.6.1 Diagnosis and staging . . . . . . . . . . . . . . . . . . 31
1.2.6.2 Prognosis . . . . . . . . . . . . . . . . . . . . . . . . 31
1.2.7 Therapies for breast cancer . . . . . . . . . . . . . . . . . . . . . 32
1.3 Towards personalised management of breast cancer . . . . . . . . . . . . 34
1.3.1 Breast cancer biomarkers for screening and diagnosis . . . . . . . 36
1.3.2 Breast cancer biomarkers for prognosis and prediction of treat-
ment outcome . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
1.3.3 Breast cancer biomarkers for treatment . . . . . . . . . . . . . . 39
1.3.4 Breast cancer biomarkers for monitoring the disease . . . . . . . 39
1.4 Rationale and outline of the study . . . . . . . . . . . . . . . . . . . . . 40
2 Materials and Methods 41
2.1 General laboratory consumables and equipments . . . . . . . . . . . . . 41
2.1.1 Reagents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
2.1.2 Equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
2.1.3 Buffers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
2.1.4 Gels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
2.1.5 Primary culture media . . . . . . . . . . . . . . . . . . . . . . . 55
2.1.6 Cell lines and their media . . . . . . . . . . . . . . . . . . . . . 56
2.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
2.2.1 Expression analysis . . . . . . . . . . . . . . . . . . . . . . . . . 56
2.2.1.1 RNA extraction and cDNA synthesis . . . . . . . . . . 56
2.2.1.2 Primers for Polymerase Chain Reaction (PCR) . . . . . 58
2.2.1.3 Semi-quantitative Polymerase Chain Reaction . . . . . 59
2.2.1.4 Agarose gel electrophoresis . . . . . . . . . . . . . . . 60
2.2.1.5 Quantitative Polymerase Chain Reaction . . . . . . . . 60
2.2.1.6 Cell lysate preparation . . . . . . . . . . . . . . . . . . 61
2.2.1.7 Protein assay . . . . . . . . . . . . . . . . . . . . . . . 61
2.2.1.8 Sodium Dodecyl Sulphate PolyAcrylamide Gel Elec-
trophoresis (SDS-PAGE) . . . . . . . . . . . . . . . . 61
2.2.1.9 Semi-Dry Western Blotting . . . . . . . . . . . . . . . 62
2.2.1.10 Fluorescent activated cell sorting (FACS) . . . . . . . . 62
2.2.1.11 Enzyme-Linked ImmunoSorbent Assay (ELISA) . . . . 62
2.2.1.12 Immunofluorescence . . . . . . . . . . . . . . . . . . . 63
2.2.1.13 Immunohistochemistry . . . . . . . . . . . . . . . . . 64
2.2.2 Cloning of BUC11 . . . . . . . . . . . . . . . . . . . . . . . . . 65
2.2.2.1 DNA band extraction . . . . . . . . . . . . . . . . . . 65
2.2.2.2 DNA ligation . . . . . . . . . . . . . . . . . . . . . . 66
2.2.2.3 Transformation into competent XL1-Blue E.coli cells
and bulking up of the plasmid . . . . . . . . . . . . . . 66
2.2.2.4 Enzyme digestion . . . . . . . . . . . . . . . . . . . . 66
v
Contents
2.2.2.5 DNA isolation and sequencing . . . . . . . . . . . . . 67
2.2.3 Gene induction or silencing . . . . . . . . . . . . . . . . . . . . 68
2.2.3.1 DNA transfection . . . . . . . . . . . . . . . . . . . . 68
2.2.3.2 Small interfering RNA (siRNA) transfection . . . . . . 68
2.2.3.3 Proliferation assay . . . . . . . . . . . . . . . . . . . . 69
2.2.3.4 Affymetrix GeneChip R©Microarray . . . . . . . . . . . 70
2.2.4 Animals and immunisation . . . . . . . . . . . . . . . . . . . . . 70
2.2.4.1 Animals . . . . . . . . . . . . . . . . . . . . . . . . . 70
2.2.4.2 DNA bullets and DNA immunisation . . . . . . . . . . 70
2.2.5 Cytotoxicity assay, proliferation assay and Enzyme-Linked Im-
munoSorbent SPOT (ELISPOT) in mice . . . . . . . . . . . . . . 71
2.2.5.1 Generation of murine BM-DC . . . . . . . . . . . . . . 71
2.2.5.2 Isolation of murine leukocytes . . . . . . . . . . . . . 71
2.2.5.3 Proliferation assay for murine T cells . . . . . . . . . . 72
2.2.5.4 ELISPOT . . . . . . . . . . . . . . . . . . . . . . . . 72
2.2.5.5 Chromium release cytotoxicity assay . . . . . . . . . . 73
3 BUC Family Identification and mRNA Expression Analysis 74
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
3.1.1 The importance of breast cancer-associated markers . . . . . . . 74
3.1.2 The discovery of the breast-associated UniGene clusters family . 75
3.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
3.2.1 Characterisation of the full length mRNA sequences of the BUC
family . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
3.2.2 mRNA expression analysis of the BUC family . . . . . . . . . . 94
3.2.3 Focus on BUC11 mRNA expression analysis . . . . . . . . . . . 108
3.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
4 BUC11 Protein Expression Analysis 127
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
4.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
4.2.1 Data mining with BUC11 predicted protein sequence . . . . . . . 128
4.2.2 ELISA using anti-BUC11 antibody . . . . . . . . . . . . . . . . 137
4.2.3 Western Blotting using anti-BUC11 antibody . . . . . . . . . . . 140
4.2.4 Immunofluorescence using anti-BUC11 antibody . . . . . . . . . 143
4.2.5 Immunohistochemistry using anti-BUC11 antibody . . . . . . . . 147
4.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
5 BUC11 Functional Analysis 166
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166
5.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167
vi
Contents
5.2.1 Cloning of BUC11 DNA into pBudCE4.1 . . . . . . . . . . . . . 167
5.2.2 Transfection of pBudCE4.1/BUC11 in mouse lymphoma cells . . 171
5.2.3 siRNA-mediated BUC11 gene silencing . . . . . . . . . . . . . . 172
5.2.4 Proliferation assays . . . . . . . . . . . . . . . . . . . . . . . . . 173
5.2.5 Cell cycle analysis . . . . . . . . . . . . . . . . . . . . . . . . . 175
5.2.6 Affymetrix GeneChip R©Microarray . . . . . . . . . . . . . . . . 176
5.2.7 Preliminary studies on the immunogenicity of BUC11 protein . . 189
5.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191
6 Discussion 195
6.1 The BUC genes - novel breast-associated genes . . . . . . . . . . . . . . 195
6.2 BUC11 - a novel marker of epithelial luminal-type breast cancers? . . . . 199
6.3 BUC11 - a gene involved in cell proliferation pathways? . . . . . . . . . 200
6.4 BUC11 - a potential candidate for immunotherapy? . . . . . . . . . . . . 201
6.5 Conclusions and future work . . . . . . . . . . . . . . . . . . . . . . . . 202
Appendices 205
References 212
Communications 248
vii
List of Figures
1.1 The six hallmarks of cancer . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.2 The mammalian cell cycle . . . . . . . . . . . . . . . . . . . . . . . . . 8
1.3 Overview of the humoral and cellular arms of the immune system . . . . 13
1.4 Anti-tumour responses mediated by CD4+ and CD8+ T cells . . . . . . . 14
1.5 Age standardised (European) incidence and mortality rates, female breast
cancer, Great Britain, 1975-2004 . . . . . . . . . . . . . . . . . . . . . . 24
1.6 Hypothetical model of breast tumour progression . . . . . . . . . . . . . 28
3.1 UniGene Homepage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
3.2 Spidey Homepage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
3.3 Spidey alignment of the BUC original mRNA sequences against genomic
Human DNA sequence from clone RP11-20F24 on chromosome 10p11.21-
12.1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
3.4 Spidey alignment of the BUC sequencing results against genomic Human
DNA sequence from clone RP11-20F24 on chromosome 10p11.21-12.1 . 80
3.5 BUC6 nucleotide sequence . . . . . . . . . . . . . . . . . . . . . . . . . 81
3.6 BUC6 predicted protein sequence . . . . . . . . . . . . . . . . . . . . . 82
3.7 BUC9 nucleotide sequence . . . . . . . . . . . . . . . . . . . . . . . . . 83
3.8 BUC9 predicted protein sequence . . . . . . . . . . . . . . . . . . . . . 83
3.9 BUC10 nucleotide sequence . . . . . . . . . . . . . . . . . . . . . . . . 84
3.10 BUC10 predicted protein sequence . . . . . . . . . . . . . . . . . . . . . 85
3.11 BUC11 nucleotide sequence . . . . . . . . . . . . . . . . . . . . . . . . 86
3.12 BUC11 predicted protein sequence . . . . . . . . . . . . . . . . . . . . . 86
3.13 hCG25653 mRNA and predicted protein sequences . . . . . . . . . . . . 93
3.14 Spidey alignment of the BUC, NY-BR-1 and hCG25653 mRNA sequences 93
3.15 BUC6 mRNA expression analysis by semi-quantitative RT-PCR . . . . . 95
3.16 BUC9, BUC10 and BUC11 mRNA expression analysis by semi-quantitative
RT-PCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
3.17 BUC9 mRNA expression analysis in breast cancer tissues and cell lines . 99
3.18 BUC9 mRNA expression analysis in normal tissues . . . . . . . . . . . . 99
3.19 BUC11 mRNA expression analysis in normal tissues . . . . . . . . . . . 100
3.20 BUC11 mRNA expression analysis in breast cancer tissues and cell lines . 101
viii
List of Figures
3.21 BUC11 mRNA expression analysis in testis (normal and cancer) tissues . 101
3.22 BUC11 mRNA expression analysis in diverse cancer tissues . . . . . . . 102
3.23 Alignment of BUC9 nucleotide sequence with the sequencing result for
the larger PCR product . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
3.24 Alignment of BUC9 nucleotide sequence with the sequencing result for
the smaller PCR product . . . . . . . . . . . . . . . . . . . . . . . . . . 106
3.25 BUC9 two potential splice variants mRNA and predicted protein sequences107
3.26 BUC11 mRNA expression in human breast cancer cell lines by quantita-
tive RT-PCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
3.27 BUC11 mRNA expression in human normal tissues by quantitative RT-PCR109
3.28 BUC11 mRNA expression in human melanoma tissues by quantitative
RT-PCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
3.29 BUC11 mRNA expression in human protaste tissues by quantitative RT-
PCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
3.30 Average expression stability values of control genes . . . . . . . . . . . . 112
3.31 BUC11 mRNA expression in paired normal and tumour breast tissues by
quantitative RT-PCR, sorted according to the age of patients at diagnosis . 113
3.32 BUC11 mRNA expression in paired normal and tumour breast tissues by
quantitative RT-PCR, sorted according to the stage of the tumour tissues . 114
3.33 BUC11 mRNA expression in paired normal and tumour breast tissues by
quantitative RT-PCR, sorted according to the grade of the tumour tissues . 115
3.34 BUC11 mRNA expression in paired normal and tumour breast tissues by
quantitative RT-PCR, sorted according to the HER2 expression status of
the tumour tissues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
4.1 Binding strength of rabbit anti-BUC11 polyclonal antibody to BUC11
peptide by ELISA (1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
4.2 Binding strength of rabbit anti-BUC11 polyclonal antibody to BUC11
peptide by ELISA (2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
4.3 Western Blot of human breast cancer cell line MDA231 . . . . . . . . . . 141
4.4 Western Blot of breast cancer cell lines and ALC cell lines . . . . . . . . 142
4.5 Immunofluorescence assay for BUC11 protein expression and localisa-
tion analyses in human cell lines . . . . . . . . . . . . . . . . . . . . . . 145
4.6 Immunofluorescence assay for BUC11 protein expression and localisa-
tion analyses in human breast cancer cell lines . . . . . . . . . . . . . . . 146
4.7 Immunohistochemical staining for BUC11 protein expression in multiple
normal tissue microarrays (1) . . . . . . . . . . . . . . . . . . . . . . . . 149
4.8 Immunohistochemical staining for BUC11 protein expression in multiple
normal tissue microarrays (2) . . . . . . . . . . . . . . . . . . . . . . . . 150
4.9 Immunohistochemical staining for BUC11 protein expression in multiple
normal tissue microarrays (3) . . . . . . . . . . . . . . . . . . . . . . . . 151
ix
List of Figures
4.10 Immunohistochemical staining for BUC11 protein expression in multiple
normal tissue microarrays (4) . . . . . . . . . . . . . . . . . . . . . . . . 152
4.11 Immunohistochemical staining for BUC11 protein expression in multiple
breast tissue microarrays . . . . . . . . . . . . . . . . . . . . . . . . . . 153
4.12 Immunohistochemical staining for BUC11 protein expression in breast
fresh frozen sections . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
4.13 Immunohistochemical staining for BUC11 protein expression in prostate
cancer fresh frozen sections . . . . . . . . . . . . . . . . . . . . . . . . . 155
5.1 Diagram of the construction of the plasmid pBudCE4.1/BUC11 . . . . . 169
5.2 Agarose gel electrophoresis of pBudCE4.1/BUC11 clones after double
digestion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 170
5.3 Alignment of BUC11 nucleotide sequence with the sequencing result for
one of the positive pBudCE4.1/BUC11 clones . . . . . . . . . . . . . . . 170
5.4 Quantitative RT-PCR analysis of BUC11 transfection in ALC cells . . . . 172
5.5 Quantitative RT-PCR analysis of BUC11 silencing in MDA231 cells . . . 173
5.6 Proliferation assay following BUC11 transfection . . . . . . . . . . . . . 174
5.7 Proliferation assay following BUC11 silencing . . . . . . . . . . . . . . 175
5.8 Validation of the microarray data by quantitative RT-PCR . . . . . . . . . 181
5.9 Comparison of BUC11 mRNA expression with MT2A mRNA expression
in paired normal and tumour breast tissues by quantitative RT-PCR . . . . 182
5.10 Microarray upregulated gene network build in the software Ingenuity
Pathways Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183
5.11 Focus on the microarray upregulated gene network build in the software
Ingenuity Pathways Analysis (1) . . . . . . . . . . . . . . . . . . . . . . 184
5.12 Focus on the microarray upregulated gene network build in the software
Ingenuity Pathways Analysis (2) . . . . . . . . . . . . . . . . . . . . . . 185
5.13 Microarray downregulated gene network build in the software Ingenuity
Pathways Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 186
5.14 Focus on the microarray downregulated gene network build in the soft-
ware Ingenuity Pathways Analysis (1) . . . . . . . . . . . . . . . . . . . 187
5.15 Focus on the microarray downregulated gene network build in the soft-
ware Ingenuity Pathways Analysis (2) . . . . . . . . . . . . . . . . . . . 188
x
List of Tables
1.1 Examples of tumour antigens classified into five categories . . . . . . . . 10
1.2 Rare familial cancer syndromes and genes associated with breast cancer
susceptibility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
1.3 The five clinically relevant molecular subgroups of breast cancer . . . . . 29
2.1 Cell lines and their description . . . . . . . . . . . . . . . . . . . . . . . 56
2.2 Primers used for PCR of BUC genes, NY-BR-1 gene and reference genes 58
2.3 Primers used for PCR of genes screened in the BUC11 gene knockdown
study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
2.4 Sequences of siRNAs used for transfection in the gene knockdown study . 69
3.1 Nucleotide and predicted protein sequence similarity of BUC6 to nu-
cleotide and protein sequences previously deposited in the GenBank database 88
3.2 Nucleotide and predicted protein sequence similarity of BUC9 to nu-
cleotide and protein sequences previously deposited in the GenBank database 89
3.3 Nucleotide and predicted protein sequence similarity of BUC10 to nu-
cleotide and protein sequences previously deposited in the GenBank database 90
3.4 Nucleotide and predicted protein sequence similarity of BUC11 to nu-
cleotide and protein sequences previously deposited in the GenBank database 91
3.5 BUC6 mRNA expression analysis by quantitative RT-PCR . . . . . . . . 96
3.6 Summary table of the exhaustive mRNA analysis of the BUC genes . . . 98
4.1 BUC11 predicted protein sequence similarity to protein sequences previ-
ously deposited in the GenBank database . . . . . . . . . . . . . . . . . 130
4.2 BUC11 predicted protein (amino acids 49-67) sequence similarity to Homo
sapiens protein sequences previously deposited in the GenBank database
(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
4.3 BUC11 predicted protein (amino acids 49-67) sequence similarity to Homo
sapiens protein sequences previously deposited in the GenBank database
(2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
4.4 BUC11 predicted protein (amino acids 49-67) sequence similarity to Homo
sapiens protein sequences previously deposited in the GenBank database
(3) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
xi
List of Tables
4.5 BUC11 predicted protein (amino acids 49-67) sequence similarity to Homo
sapiens protein sequences previously deposited in the GenBank database
(4) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
4.6 Known function of Homo sapiens proteins which sequences deposited in
the GenBank database are similar to peptide 49-67 of BUC11 predicted
protein (1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
4.7 Known function of Homo sapiens proteins which sequences deposited in
the GenBank database are similar to peptide 49-67 of BUC11 predicted
protein (2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
4.8 PSORT analysis of BUC11 predicted protein sequence . . . . . . . . . . 136
4.9 PROSITE analysis of BUC11 predicted protein sequence . . . . . . . . . 137
4.10 BUC11 peptide sequence (7-19) similarity to protein sequences previ-
ously deposited in the GenBank database . . . . . . . . . . . . . . . . . 139
4.11 Statistical analysis of cases showing negative BUC11 staining versus any
positive BUC11 cytoplasmic protein expression . . . . . . . . . . . . . . 157
4.12 Statistical analysis of cases showing negative BUC11 staining versus weak
BUC11 cytoplasmic protein expression . . . . . . . . . . . . . . . . . . 157
4.13 Statistical analysis of cases showing negative BUC11 staining versus moderate-
strong BUC11 cytoplasmic protein expression . . . . . . . . . . . . . . . 158
4.14 Statistical analysis of cases showing negative BUC11 nuclear staining
versus any positive BUC11 nuclear protein expression . . . . . . . . . . . 158
4.15 Statistical analysis of cases showing low BUC11 nuclear staining versus
BUC11 nuclear protein expression . . . . . . . . . . . . . . . . . . . . . 159
5.1 Cell cycle analysis by flow cytometry of BUC11 siRNA-transfected MDA231
cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176
5.2 Top 10 most upregulated genes in the microarray analysis . . . . . . . . . 177
5.3 Top 10 most downregulated genes in the microarray analysis . . . . . . . 178
xii
Abbreviations
AICD Activation-induced cell death
ANN Artificial neural network
APC Antigen-presenting cell
BAGE B melanoma antigen
BCR-ABL Breakpoint cluster region/Abelson
BLAST Basic local alignment search tool
bp Base pair
BRCA Breast cancer susceptibility
BUC Breast-associated UniGene clusters
CDK Cyclin-dependent kinase
CDKN Cyclin-dependent kinase inhibitor
cDNA Complementary deoxyribonucleic acid
CEA Carcinoembryonic antigen
CML Chronic myeloid leukaemia
CpG Cytosine and guanine separated by a phosphate
CT Cancer testis
CTL Cytotoxic T lymphocytes
DC Dendritic cell
DCIS Ductal carcinoma in situ
DISC Disabled infectious single cycle
DNA Deoxyribonucleic acid
EBV Epstein-Barr virus
EGF Epidermal growth factor
ELISA Enzyme-linked immunosorbent assay
ER Estrogen receptor
EST Expressed sequence tag
FACS Fluorescent-activated cell sorting
FCS Foetal calf serum
FDA Food and drug administration
FITC Fluorescein isothicyanate
GAGE G antigen
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
xiii
Abbreviations
GM-CSF Granulocyte macrophage-colony stimulating factor
HAGE Helicase antigen
HCV Hepatitis c virus
HER2 Human epithelial growth factor receptor 2
HHV8 Human herpesvirus 8
HPRT1 Hypoxanthine guanine phosphoribosyl transferase 1
HRP Horse radish peroxidase
HPV Human papillomavirus
HSP Heat shock protein
HSV Herpes simplex virus
HTLV Human T cell leukemia virus
Id Idiotype
IFA Incomplete Freund’s adjuvant
IFN Interferon
Ig Immunoglobulin
IHC Immunohistochemistry
IL Interleukin
kDa Kilodalton
L Ligand
LCIS Luminal carcinoma in situ
LDLR Low density lipid receptor
LPS Lipopolysaccharide
MAGE Melanoma antigen
MALDI Matrix-assisted laser desorption/ionisation
MHC Major histocompatibility complex
MIC MHC class I-related chain
miRNA microribonucleic acid
MLP Multiple layer perceptron
mRNA messenger ribonucleic acid
NK Natural killer cell
NKG2D Natural killer cell activating receptor
NPI Nottingham Prognostic Index
NY-ESO-1 New York esophageal squamous cell carcinoma antigen
PBMC Peripheral blood mononuclear cell
PBS Phosphate buffer saline
PDGF Platelet-derived growth factor
PI Propidium iodide
Poly I.C Polyinosinic polycytidylic acid
PR Progesterone receptor
PSA Prostate-specific antigen
xiv
Abbreviations
PSMA Prostate-specific membrane antigen
Rb Retinoblastoma
RNA Ribonucleic acid
RP Ribosomal protein
RT Room temperature
RT-PCR Reverse transcriptase-polymerase chain reaction
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
SELDI Surface-enhanced laser desorption/ionisation
SEREX Serological analysis of recombinant tumour cDNA expression
libraries
siRNA Small interfering ribonucleic acid
TAA Tumour-associated antigen
TBP TATA box binding protein
TCR T cell receptor
TGF Transforming growth factor
Th T helper lymphocytes
TLR Toll-like receptor
TMA Tissue microarray
TNF Tumour necrosis factor
Treg Regulatory T cell
UK United Kingdom
ULPB UL16-binding proteins
USA United States of America
UV Ultraviolet
VEGF Vascular endothelial growth factor
xv
Abstract
An improved and individualised breast cancer care can be pursued with the use of tu-
mour markers that are associated with risk assessment, diagnosis, prognosis, prediction
of treatment outcome, monitoring of the disease and development of novel therapies. As
such, this study proposed to characterise and evaluate the potential for the management
of breast cancer of four novel unpublished breast-associated genes, the breast-associated
UniGene clusters (BUC6, BUC9, BUC10 and BUC11), which were identified in our lab-
oratory by database mining. The first aspect of this research project was to undertake
extensive in silico analysis and in vitro expression analysis for all genes using sequencing
and RT-PCR based assays on a variety of tissues of normal and cancerous origin in order
to further select the most promising candidates for potential use in cancer care. In light
of all the data collected, the work was subsequently focused on the BUC11 gene. Since
BUC11 mRNA was found to be expressed at very low levels in normal tissues except in
some non-essential tissues where it is expressed at a higher level, BUC11 was not consid-
ered a cancer testis antigen. BUC11 mRNA was also found at high levels in all testicular
cancer tissues tested as well as in a quarter of prostate cancer tissues tested and at lower
levels in a small proportion of melanomas, and thus BUC11 was not considered to be a
tumour-specific gene. Quantitative RT-PCR analysis of a large panel of normal/cancer
breast tissues has demonstrated that up to 97% of all tissues expressed BUC11 mRNA
and 60.6% of patients over-expressed BUC11 mRNA. Immunoassays performed with the
custom-made anti-BUC11 antibody showed that BUC11 protein was preferentially found
in the epithelial luminal type of malignant breast cells however no evidence was found
to link BUC11 protein with breast tumour formation, state or progression of the disease.
Therefore, the study also aimed to elucidate the molecular pathways that BUC11 may be
involved in. Using a combination of in vitro gene silencing/induction based experiments
and gene chip microarray technology, BUC11 was shown to potentially have a function
in pathways controlling the proliferation of cells. The data obtained on the BUC11 gene
during the course of this study provided a rationale to further investigate the potential
immunogenicity of its protein in a transgenic mouse model however preliminary exper-
iments did not lead to any conclusive data. Collectively, this study demonstrated the
expression analysis of a novel gene set which can potentially have clinical utility for sev-
eral cancers, especially the most promising candidate BUC11, and which require further
investigation.
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Chapter 1
Introduction
“Cancer is a word, not a sentence”
(John Diamond, British broadcaster and journalist, who died of throat cancer in 2001)
I have chosen this simple but meaningful quote, which has been used worldwide by physi-
cians, charities and others, because it exposes that cancer is not necessarily a fatality as
with appropriate care people can survive cancer.
1.1 Cancer: an overview
1.1.1 Cancer is a class of diseases which has a multifactorial, multi-
step causation
Cancer is a worldwide health concern that can affect anyone at any age. Worryingly
one in three people will be diagnosed with cancer in their lifetime and one in four will
die (Quinn et al., 2001). According to the World Health Organisation, 7.9 million peo-
ple died from cancer in the world in 2007, representing 13% of all worldwide deaths
(http://www.who.int, 2009). It has been projected that cancer will cause approximately
12 million deaths in 2030. Almost any tissue of the body can be affected and the most
common cancers worldwide for both men and women are lung, stomach, liver, colon and
breast cancers.
The term “cancer” refers to a group of diseases, with over 100 types reported. Car-
cinomas represent approximately 85% of all cancers and originate from epithelial cells
whereas sarcomas develop from mesodermal cells such as those found in bone and mus-
cle and adenocarcinomas from glandular tissue such as the one found in breast. A cancer
cell arises from an abnormal cell that has accumulated and sustained multiple defects in
its DNA. Then, daughter cancer cells multiply in an unregulated manner, passing on these
defects and aggregate in a mass called tumour. Abnormal cancer cells also have the abil-
ity to invade and destroy the surrounding healthy tissue. From the original site, cancer
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cells can eventually spread to other parts of the body (metastasis) via the bloodstream or
the lymphatic system causing further damage by compromising tissue functions. Surpris-
ingly, the immune system which has a role in identifying and killing tumour cells does not
always eliminate the abnormal cells. Sir Frank Macfarlane Burnet introduced the concept
of immunological surveillance (or immunosurveillance) in the early seventies. In his the-
ory, the normal immune system is able to detect and destroy newly mutated cells, however
some of them can bypass this surveillance, thus causing cancer by growing and spreading
(Burnet, 1970). This theory was supported by the observation of spontaneous tumour
regressions (Hoption Cann, 2002). Cancer immunoediting also demonstrates immuno-
surveillance as this process was shown to have two antagonistic functions in immuno-
competent hosts: to recognise and eliminate nascent transformed cells thus protecting the
host against tumour progression and to assist a tumour that has reduced immunogenicity
to grow and escape destruction by the immune system (Dunn et al., 2002; Dunn et al.,
2005).
In 2000, Hanahan and Weinberg described six common features of all cancer types
(Figure 1.1). The six hallmarks of cancer, vital for the process of carcinogenesis are:
growth signal autonomy, evasion of growth inhibitory signals, evasion of apoptosis, un-
limited replicative potential, the formation of new blood vessels (angiogenesis), invasion
and metastasis (Hanahan and Weinberg, 2000). Researchers are studying and targeting
each of these hallmarks to develop novel therapies for cancer patients.
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Figure 1.1: The six hallmarks of cancer.
This figure was taken from Hanahan and Weinberg (2000).
Cancers are genetic diseases at the cellular level. The majority of mutations responsi-
ble for carcinogenesis are somatic, as opposed to inherited. Inherited mutations (germline
mutations) have occurred in the sperm or egg cells of the parents. Continuous or fre-
quent exposure of DNA to carcinogens allows mutations to accumulate, increasing the
chances that these mutations will eventually lead to cancer and explains the fact that the
risk of developing cancer increases with age. Many factors contribute to carcinogene-
sis, whether they are endogenous (hereditary mutations, hormonal balance, strength of
the immune system, by-products of the metabolism or errors during DNA replication) or
exogenous (diet, reproductive life, exposure to carcinogens such as chemicals, Ultra Vi-
olet (UV) rays or viruses). Epidemiologic studies revealed that the four most important
factors influencing transformation are the environment, smoking, diet and reproductive
life. UV rays and chemicals can induce direct or indirect DNA mutations, for instance
exposure to UVB radiation from the sun has been linked to melanoma (form of skin can-
cer) whereas hormones are not mutagenic but they can promote cell proliferation. Also,
sexually transmitted viruses can promote cancer, for example, it is generally accepted
that virtually all cervical cancers are positive for human papillomaviruses which cause
the disease. Perhaps the most recognisable risk factor for a particular cancer is smoking,
with approximately 81 carcinogens known to be present in cigarette smoke (Smith et al.,
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2003). In addition, chronic inflammation, such as ulcers, has been shown to play a role in
the development of up to 5% of all cancers. Some physiological factors that contribute to
the development of cancer comprise of mutagenic oxygen radicals (by-products of aero-
bic metabolism) and mutations caused by error-prone polymerases during the normal cell
processes of DNA replication or repair.
1.1.2 Oncogenes and tumour suppressor genes
Mutations acquired and sustained by a cell affect the regulation of its cell cycle and
normal cellular processes during the development of the malignant cell phenotype, such
as cell proliferation and survival, through the multi-step process of activation of proto-
oncogenes into oncogenes and inactivation of tumour suppressor genes. In the model of
tumour development by succession of clonal expansions that follows a Darwinian model
of evolution, a cell that acquired and sustained activation of one oncogene or inactivation
of one tumour suppressor gene gives rise to daughter cells that have growth and survival
advantages thus proliferate greater than the neighbouring cells in the tissue. In that domi-
nating clonal population, one cell will acquire an additional oncogene activated or tumour
suppressor gene inactivated, thus gaining a further advantage for independent growth. It
is believed that cancer progression can be explained by a sequence of four to six clonal
expansions.
1.1.2.1 Oncogenes
Oncogenes (viral or cellular) are a class of growth-promoting genes involved in the
pathogenesis of cancer, with more than 100 identified to date. Almost all oncogenes
are the mutated forms of normal, pre-existing cellular genes called proto-oncogenes that
have been activated either through retrovirus acquisition or somatic mutation. The pro-
tein product of an oncogene is either produced in higher quantities than normal or has a
dramatically increased activity.
In the early 1970s, following animal work, the hypothesis that tumour viruses were re-
sponsible for initiating all human cancers led to extensive research on retrovirus-associated
oncogenes and notably the discovery of the Sarcoma (Src) oncogene induced by the Rous
retrovirus and found in colon cancer (Martin, 1970; Martin, 2004). Retroviruses need the
host cellular mechanisms for energy and synthesis of new viral particals. The RNA of the
virus is reverse-transcribed into DNA before being randomly integrated into the host cell
genome. Over generations, viruses can acquire coding regions of the host cellular genes
into their own RNA, resulting in the creation of oncogenes. For instance, the Rous Sar-
coma Virus has integrated into its RNA a truncated form of the cellular proto-oncogene
c-src. The viral oncogenes are transcribed in virus-infected cells under the control of the
viral transcriptional promoter, independently to cellular signals that used to regulate the
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proto-oncogenes and the resulting over-expression of the oncogenes promotes unregu-
lated growth of the cells.
Using transfection experiments (DNA from chemically transformed cells introduced
in normal cells), another type of oncogene was discovered that did not originate from
viral infection but from somatic mutation in proto-oncogenes, either spontaneously or
through exposure to endogenous or exogenous carcinogens. Somatic mutations affect the
structure of the protein encoded by the oncogene or induce over-expression of the normal
protein if the mutation occurred in the gene promoter region.
Taken together, the proteins encoded by oncogenes are involved at different levels
in growth factor signal transduction pathways and include growth factors, growth factor
receptors, intracellular signal transducers and transcription factors. During the course
of tumour progression, activation of oncogenes, along with the inactivation of tumour
suppressor genes, allows tumour cells to evade the growth inhibitory signals secreted by
the surrounding normal cells thus acquiring growth signal autonomy and uncontrollable
proliferation (Bertram, 2000). For example, the over-expression of the mutated form of
the platelet-derived growth factor (PDGF) receptor and the constitutive activation of the
epidermal growth factor receptor (EGFR) have been linked to uncontrolled proliferation
of human glioma cells through an autocrine activation (Westermark et al., 1995) and
androgen-independent prostate cancer cells (Fong et al., 1992), respectively. Also, the
human epithelial growth factor receptor 2 (HER2), which has a role in signal transduction
pathways leading to cell growth and differentiation, was found to be over-expressed in
up to 25% of breast tumours and correlated with a worse prognosis for patients (Menard
et al., 2001; Slamon et al., 1989). Constitutive activation of signalling pathways result
in a high proliferative state of cells and perhaps the most cited example of intracellu-
lar signal inducers is the proto-oncogene RAS protein, a small GTPase, found in 20 to
25% of human tumours (Downward, 2003). In these tumours, cells acquire the neoplastic
phenotype through the deregulation of RAS signalling pathways involved in cell growth
and proliferation. Scholl and colleagues have demonstrated that transformation of mouse
cells, by transfecting them in vitro with the Ras gene, is observed only following the
immortalisation of the cells prior to the experiment (Scholl et al., 2005); therefore Ras-
induced malignant transformation can only occur with the involvement to the process of
many other genes, acting altogether. Also, the constitutive and overexpression of the tran-
scription factor c-Myc protein, due to chromosomal translocation, is responsible for the
improper increase in transcription of Myc-regulated genes. This results in expression of
proteins such as cyclins A and E which control the progression of cells through the cell
cycle which then force tumour cells to divide uncontrollably (Ponzielli et al., 2005).
1.1.2.2 Tumour suppressor genes
Tumour suppressor genes have an “anti-oncogenic” role and are involved in the con-
trol (limitation) of cell growth, cell survival and in DNA repair. Unrepaired genetic
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changes in tumour suppressor genes lead to their inactivation, thus promoting survival
of transforming cells and favouring progression of a malignant cell phenotype. The num-
ber of inactivated tumour suppressor genes in the genomes of human cancer cells is far
greater than the number of activated oncogenes. According to Knudson’s two-hit hypoth-
esis, individuals are predisposed to cancer through the inheritance of a germline mutation
in one allele of a tumour suppressor gene followed by the mutation in the second allele of
that tumour suppressor gene during their life (Knudson, 1971). This hypothesis however
only explains familial (inherited) forms of cancers as, in the case of sporadic forms of
the disease, individuals can acquire subsequent mutations in both alleles of the tumour
suppressor genes during their life or they can have an allelic loss followed by a mutation
of the second allele. Other than mutation, the function of tumour suppressor genes can
also be decreased or lost by epigenetic phenomenons (Esteller et al., 2001) like promoter
methylation which is frequently found in Wilm’s tumours (Wagner et al., 2002). Perhaps
the most characterised tumour suppressor genes to date are the p53 and retinoblastoma
(Rb) genes (Figure 1.2).
Retinoblastoma is a very treatable cancer developing in the cells of the retina and is
the most common ocular malignancy in children. The disease results from either the ge-
netic form or the non-genetic form (55% cases diagnosed with the latter). Defects in the
Rb gene can either be inherited from a parent or is the result of somatic mutations during
the development of the foetus. The nuclear protein encoded by the Rb gene (RB) controls
the entry of cells into the S phase (DNA replication). Mutations in the Rb gene affect the
struture of RB, compromising the interactions of the protein with the complex of tran-
scription factors (E2F/DP). Under normal conditions, if RB is hypophosphorylated it will
bind and inactivate E2F/DP. Defects in genes encoding proteins that normally control RB
phosphorylation are also responsible for indirectly inactivating RB which then can not
bind the E2F/DP transcription complex. Consequently, the activity of this complex is
never repressed, the control over the cell cycle at the S phase entry is lost and cells can
proliferate in an unrestricted manner. Overexpression of D-type cyclins, amplification of
cyclin-dependent kinases 4 and 6 (CDK4, CDK6) and inactivation of cyclin-dependent
kinase inhibitor p16 (CDKN2 gene) have all been associated with a decreased or lost
function of the RB protein (Lukas et al., 1995).
A tumour suppressor gene, which is a close “associate” of the Rb gene and has a
very important role in regulating the stability of the genome (DNA repair mechanisms),
replicative senescence, premature senescence and apoptosis, is the p53 gene (Bertram,
2000). The P53 protein, also referred as “guardian of the genome”, is activated when
DNA defects are detected and induces an arrest of the cell cycle and/or apoptosis so that
the errors in the genome are not passed on to daughter cells. In response to stress stimuli,
activated P53 induces an increase of the cyclin-dependent kinase inhibitor 1A, CDKN1A
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(p21) expression level. The protein encoded by the p21 gene blocks the progression of the
cell cycle at the G1 phase by binding and inhibiting the activity of various cyclin-CDK
kinase activities (Bearss et al., 2002). Over 70% of all human cancers have their p53
pathway inactivated and also present mutations in some genes upstream or downstream
to this pathway (Levine, 1997). Inactivation of the tumour suppressor gene p53 is the
result of mutations which cause changes in the protein structure, preventing the formation
of hydrogen bonds between the DNA and P53 (Cho et al., 1994). Inactivation of p53
pathway contributes to the progression of tumour development through evasion of apop-
tosis and uncontrolled cell growth.
Figure 1.2: The mammalian cell cycle.
Normal growth and division of a mammalian cell are controlled by the processes of the
cell cycle which is divided into four phases: G1, S (replication of DNA), G2 and M (mi-
tosis). A fifth phase, G0 (not represented in the figure), is the state of nonproliferating
cells that left the active cell cycle during G1. Progression through the cycle is rigorously
guided by the activity of diverse molecules such as cyclins (Cyc), cyclin-dependent pro-
tein kinases (CDK) and the tumour suppressor gene retinoblastoma (Rb). Taken from
Andrietta et al., 2001.
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1.1.3 Tumour-associated antigens
The accumulation of activated proto-oncogenes and inactivated tumour suppressor
genes in a tumour cell has inevitably an effect on the expression of other genes involved in
the same pathways or upstream and downstream to these pathways; the proteins of these
affected genes are classified as Tumour Associated Antigens (TAA). The first human tu-
mour antigen identified, called MAGE-1, was isolated from a melanoma patient by van
der Bruggen and colleagues in 1991 (van der Bruggen et al., 1991). They used a genetic
approach in which constructed cDNA expression libraries from the melanoma tissue of a
patient were transfected into target cells and then these target cells presented the antigen
on the cell surface and any antigens that were able to induce an antigen-specific immune
response were identified. Since the early nineties, many tumour antigens, recognised by
T cells and capable of inducing a tumour-specific T cell response, have been identified
in many different cancers by three approaches (Miles et al., 2006): genetic, biochemical
and “reverse immunology”. These include techniques such as the serological analysis of
recombinant tumour cDNA expression libraries (SEREX) (Li et al., 2004; Miles et al.,
2007) and mass spectrometry (Matharoo-Ball et al., 2007). The TAA can be classified
into 5 main groups (Table 1.1): cancer testis antigens, antigens overexpressed in tumours,
differentiation antigens, tumour antigens resulting from mutations such as fusion proteins
and viral antigens. The characteristics that make a TAA an ideal target for the develop-
ment of novel anti-cancer strategies include: to be solely or mainly expressed by tumour
cells, to be vital to the tumour and to be immunogenic.
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Table 1.1: Examples of tumour antigens classified into five categories.
1.1.4 The immune system: first line of defense against cancer
As stated previously, Burnet described in 1970 the concept of immune surveillance
in which he hypothesised that the immune system can recognise cancer cells and act to
stop their growth or prevent the formation of tumours (Burnet, 1970). The hypothesis
has been long-discredited for many years until the mid-nineties when many studies on
tumour immunology have fueled this assumption with the discovery of specialised cells
of the immune system involved in this concept.
1.1.4.1 Innate immune system
The innate immune system, also referred as the “inbuilt immune protection”, act
rapidly upon infection of the body by external agents such as bacteria, fungi or viruses.
The cells of the innate immune system circulate continuously and destroy almost imme-
diately the pathogens upon encountering them. The innate immune system is constituted
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of many types of cells that can bind to surface molecules “instinctively” recognised as
foreign, displayed by the infectious agents or by the infected cells (Janeway, 1991). The
most prominent players are natural killer cells (NK) and phagocytic cells (dendritic cells,
macrophages), originating from lymphoid progenitor cells and myeloid progenitor cells
respectively. Phagocytic cells engulf and lyse the foreign agents or infected cells whereas
natural killer cells release cytotoxic granules which lyse the targets. Phagocytic cells can
distinguish “self” (the body’s own healthy cells) from “non-self” (the pathogens or in-
fected cells) through the Toll-like receptors (TLR) that they express (Kopp and Medzhitov,
2003). These receptors bind to a variety of ligands whose patterns are common to most
foreign agents, for example, double-stranded RNA (TLR3), unmethylated CpG DNA mo-
tifs (TLR9), peptidoglycans and lipoproteins (TLR2). Upon binding, the cells become
activated and release signalling molecules (cytokines) to recruit other immune cells in
order to increase the intensity of the response to the infection. If this first line of defense
requires help during an infection, these cytokines can activate antigen-presenting cells
(APC) belonging to the adaptive immune system which release co-stimulatory molecules
that further engage other components of adaptive immunity.
This co-operation between the innate immune system and the adaptive immune sys-
tem can also be observed in the case of cancer. The immune cells of the innate system
are the first to “sense the danger” at the tumour site and alert the adaptive immune sys-
tem. The mechanisms by which these cells can detect tumour cells are still unclear but
are most likely linked to biological signals of dying cells (Shi et al., 2003) or transformed
cells (Biassoni, 2008). The combination of activation of oncogenes, inactivation of tu-
mour suppressor genes and expression of tumour antigens in a cell result in biological
characteristics that can be recognised and targeted as “abnormal” by the immune cells.
Stressed cells release molecules like heat shock proteins (HSP) which are ligands to TLR
(Balogh et al., 2009). Furthermore, tumour cells developing under the stressful condi-
tion of hypoxia (environment deprived from oxygen supply) express specifically certain
surface molecules such as the UL16-binding proteins (ULBPs), which are major histo-
compatibility complex (MHC) class I-related molecules (MICs), and which are ligands to
the natural killer cell activating receptor NKG2D/DAP10 (Sutherland et al., 2001). Ac-
tivated NK cells then release the cytokine called interferon-gamma (IFN-γ) which has
several roles in the immune system. It can target directly the cancer cells by either block-
ing important mechanisms required for the progression of the tumour or cause them to
produce cytokines to recruit other immune cells, or indirectly by provoking the matu-
ration of phagocytic cells which then secrete the cytokine Interleukin-12 (IL-12) that
further activates specific cells of the adaptive immune system, namely cytotoxic T lym-
phocytes (Degli-Esposti and Smyth, 2005). Other receptors present on the cell surface of
NK cells are the Killer Inhibitory Receptors (KIR) and C-type lectin-like receptors which
specifically bind to MHC class I molecules, found on almost every nucleated cell of the
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body, and induce self-tolerance; however, it also allows the escape from immune detec-
tion of tumour cells that have acquired down-regulation of the expression of MHC class
I molecules (Moretta et al., 1996; Restifo et al., 1993). Approximately 90% of the ani-
mal species rely on the innate (nonspecific) immune system alone for protection against
pathogens whereas the rest of the animal kingdom possess the adaptive immune system
(antigen specific) as well.
1.1.4.2 Adaptive immune system
Dendritic cells (DC) are the most studied APC of the immune system as they ef-
ficiently mediate the collaboration between the innate and the adaptive immune path-
ways. Immature dendritic cells derived from hematopoietic bone marrow progenitor
cells migrate to different tissues throughout the body via the blood. Dendritic cells en-
gulf antigens, process them internally and present fragments of these on MHC class II
molecules (found only on APC) as well as MHC class I molecules to lymphocytes. Den-
dritic cells become mature by up-regulating the expression of MHC molecules and co-
stimulatory cell surface receptors (B7, CD40). Once activated, they migrate to lymph
nodes where they encounter helper T cells and cytotoxic T cells (CTL). The process
of “co-conditioning” of DCs and T cells takes place in the presence of IFN when the
co-stimulatory proteins of DCs, CD40 and B7, bind respectively to the co-stimulatory
molecules CD40 ligand (CD40L) and CD28 expressed on the cell surface of T cells
(Ridge et al., 1998). Mature dendritic cells produce diverse cytokines such as IL-12
to further activate T cells and they present antigens (in the form of peptides) on their
MHC molecules to T cell receptors (TCR) in order to initiate specific immune responses.
The adaptive immune system comprised two types of immune responses: humoral and
cellular. An overview of the humoral and cellular arms of the immune system is given in
Figure 1.3.
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Figure 1.3: Overview of the humoral and cellular arms of the immune system.
Taken from Weinberg (2007).
The main components of the humoral immune system are the B cells. They are lym-
phocytes that, upon stimulation by activated helper T cells, proliferate and differentiate
into plasma cells. These plasma cells then secrete antibodies that recognise TAA present
on tumour cells and help in the killing of the target cells. B cells act also as antigen-
presenting cells thus activating T cells and making them produce cytokines which are
important molecules for the initiation and maintenance of the humoral immune response
by B cells. On the other hand, the main players of the cellular immune system are the T
cells: helper T cells, CTLs and regulatory T cells. CTLs express the glycoprotein CD8
on their cell surface (CD4-/CD8+) whereas helper T cells can be divided into two groups:
T helper 1 lymphocytes and T helper 2 lymphocytes. These cells are known respectively
CD4+ Th1 cells and CD4+ Th2 cells and express the glycoprotein CD4 on their cell sur-
face (CD4+/CD8-). CD4+ Th2 cells are the mediators of the humoral immune response
(Th2) whereas CD4+ Th1 cells mediate the stimulation of CD8+ T cells.
T cells originate from lymphoid progenitors in the bone marrow. All T cells are
initially double-negative (CD4-/CD8-) then develop into double-positive (CD4+/CD8+,
low expression). The latter then become either CD4+/CD8- cells upon positive selection
through the interaction TCR/MHC class II molecules with self-antigens or CD4-/CD8+
upon positive selection through the interaction TCR/MHC class I molecules with self-
antigens (Fink and Bevan, 1978). Then, these selected T cells that have shown capability
of binding to MHC molecules undergo a negative selection: the ones that react to self-
antigens are removed in order to avoid the development of autoimmune diseases (Surh
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and Sprent, 1994). In the lymph nodes, mature DCs interact with CD4+ Th1 cells through
cytokines, co-stimulatory molecules and MHC molecules presenting tumour-derived pep-
tides. Then, activated CD4+ Th1 cells stimulate CD8+ T cells to become CTLs. Activated
CTLs then recognise MHC class I antigen and peptide and destroy the antigen-bearing tu-
mour cells by releasing cytotoxic granules such as perforins which pierce the tumour cell
membrane or triggering apoptosis through death receptors (Figure 1.4). According to
several studies, the activity of CD4+ Th1 cells and CD8+ T cells appears to be crucial to
the generation of a potent anti-tumour immune response.
Figure 1.4: Anti-tumour responses mediated by CD4+ and CD8+ T cells.
Carcinoembryonic antigen (CEA) induces anti-tumour responses which are mediated by
CD4+ and CD8+ T cells. (a) Tumour-derived CEA proteins and peptides are shed and
(b) taken up by antigen-presenting cells (c) which process the antigen into small peptidic
fragments (d) and presents these peptides to CD8+ T cells via their MHC class I molecules
(e) and to CD4+ T cells via their MHC class II molecules. (f) This leads to the release of
cytokines such as IL-2 which further activated CD8+ T cells. (g) Activated CD8+ T cells
(CTL) target antigen-bearing tumour cells (h) by releasing perforins for tumour cell lysis
or by inducing apoptosis of the tumour cells via Fas/FasL receptors. Taken from Ho¨rig et
al., 2000.
1.1.5 Tumour evasion: immunological tolerance to cancer cells
The fact that patients are diagnosed everyday with growing malignant tumours demon-
strates that the immune system of these cancer patients has somehow failed to detect tu-
mour cells and generate an efficient immune response to kill them before the cancer is
diagnosed. The tumour can bypass detection and elimination by the immune system as
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a consequence of either deficiencies associated with the immune system or resourceful
escape mechanisms from the tumour cells.
Down-regulation of cell surface molecules is an important mechanism for tumour cells
to become less immunogenic. Tumour cells, especially metastatic cells and those found
in cancers with an unfavourable prognosis, often show down-regulation or even loss of
expression of MHC class I molecules (Gudmundsdottir et al., 2000). Tumour cells hav-
ing less MHC class I molecules on their cell surface increase their chances of avoiding
detection by CTLs and to bias the immune system towards a humoral immune response,
which in most studies has been shown to be incapable of destroying cancer cells. The
decrease or loss of expression of MHC class I molecules, detected in approximately 16
to 50% of human solid tumours (Khong and Restifo, 2002), can be due to mutations
(beta2-microglobulin, alpha chain, transcription factors), post-translational modifications
(glycosylation), inhibitory mechanisms in their transport system or viruses (Benitez et
al., 1998; Garcia-Lora et al., 2003; Paschen et al., 2003). Several studies with murine
models have shown the importance of a normal or high level (transfected) of expression
of MHC class I molecules to induce tumour regression (Tanaka et al., 1985; Ali et al.,
2002; Ahmad et al., 2004). An event closely related to the down-regulation of MHC class
I molecules is the processing of TAA which can be disregulated by mutations affecting
genes involved in immunoproteasome processing (LMP2, LMP7) or genes involved in
the transport of TAA; thus the tumour cell presents a reduced amount of antigenic pep-
tides to cells of the immune system; hence favouring its escape from immunosurveillance
(Lehmann et al., 2000).
The decrease of expression of B7 co-stimulatory molecules can also benefit tumour
development. In vivo and in vitro transfection studies have shown that a strong immune
response by CTL, as well as tumour regression can be achieved when tumour cells express
high levels of B7-1 molecules (Bueler and Mulligan, 1996; Heuer et al., 1996). On the
other hand, expression or up-regulation of other molecules on the tumour cell surface can
be advantageous to the tumour. For example, the receptor FasL, a member of the Tumour
Necrosis Factor (TNF)-receptor family, when binding to its receptor Fas (present on lym-
phocytes), activates a death signaling pathway leading to apoptosis of the immune cells
(Hahne et al., 1996; O’Connell et al., 1999). Moreover, it has been shown that tumour
cells can become resistant to cytotoxic cell-mediated lysis by decreasing their capability
of binding perforins (Lehmann et al., 2000), producing the serine protease inhibitor PI9
which acts against the pro-apoptotic molecule granzyme B (Medema et al., 2001) or pro-
ducing the anti-apoptotic transcription factor NF-kappaB in response to stress induced by
chemotherapeutic drugs (Baldwin, 2001).
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Other mechanisms of tumour escape are associated with the immune system itself.
Immunocompromised individuals, such as HIV-infected patients or individuals having a
weak immune system like elderly people, do not have fully effective defenses against can-
cer and thus are at a higher risk of developing a tumour. The CTL associated molecule
4 (CTLA-4) binds B7 molecules with a higher affinity than the receptor CD28, caus-
ing a decrease in proliferation of activated T lymphocytes (Carreno et al., 2000). Also,
the secretion of immunosuppressive cytokines at the tumour site by different types of T
lymphocytes (CD4+ Th2 cells, Treg cells) can auto-inactivate these cells. For instance, in
1998, Asselin-Paturel and colleagues reported the production of IL-10 by CD4+ Th2 cells
in non-small cell lung tumours (Asselin-Paturel et al., 1998). Also, Treg cells can inhibit
the activity of CTL by releasing the cytokines IL-10 and/or Tumour Growth Factor (TGF)
(Von Boehmer, 2005). Several studies have demonstrated that the activity of Treg cells at
the tumour site is detrimental to the antigen-specific anti-tumour immune response, thus
beneficial to the development of the tumour (Curiel et al., 2004; Kawaida et al., 2005).
Moreover, in 2002, Maher and colleagues discussed the process of Activation-Induced
Cell Death (AICD) and its role in immune privilege. AICD controls immune system
homeostasis by inducing apoptosis through Fas-FasL interactions, however tumour cells
resistant to the effect of AICD can exploit this by expressing FasL on their cell surface
and “counterattacking” T cells (Maher et al., 2002). In conclusion, the list of all the de-
scribed mechanisms of tumour escape here is non-exhaustive and cancer researchers are
trying to gain a better understanding of the complexity of the processes involved in the
confrontation between tumour cells and immune cells, in an attempt to develop more tar-
geted anti-tumour therapies such as cancer vaccines.
1.1.6 Cancer vaccines: boosting the immune system to break im-
mune tolerance to cancer
For many years, researchers have exploited the capability of the immune system to
detect antigens and destroy antigen-bearing tumour cells in order to develop therapeu-
tic cancer vaccines to boost immunosurveillance. Two preventive vaccines for cancers
caused by viruses (human papillomavirus, hepatitis B virus) have been approved by the
Food and Drug Administration (FDA) however, to date, no therapeutic vaccine for cancer
has been authorised. These vaccines are only available to patients through clinical trials,
which are essential to thoroughly test the safety and efficacy of the treatments. Where
possible, vaccines are studied using animal models prior to clinical trials in humans and
the lack of approved cancer vaccines for immunotherapies shows the challenging nature
of the design of cancer vaccines for treatment compared to those used for prevention
(Rosenberg et al., 2004). Therapeutic cancer vaccines must demonstrate two required
criteria for validation: they must induce specific immune responses targeting the tumour
and these responses must “defeat” the mechanisms employed by tumour cells to escape
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recognition. Many tumour antigens have been discovered, as described earlier, and their
T-cell epitopes represent a source of potential new targets for inclusion in cancer vaccines.
Cancer immunotherapy comprises three main categories which will be discussed: active
immunotherapy, adoptive immunotherapy and passive immunotherapy.
1.1.6.1 Active immunotherapy
Active immunotherapy consists of several types of vaccines which will be consid-
ered: whole cell vaccines, heat shock protein vaccines, peptide vaccines, dendritic cell
vaccines, DNA vaccines and viral vector based vaccines.
Whole cell vaccines were the first type of therapeutic cancer vaccine studied. They
contain tumour cells taken from the cancer patient (autologous) or tumour cells from an-
other cancer patient (allogeneic) which have been irradiated prior to injection into the
patient together with an immunologic adjuvant. Before administration, these cells can
be engineered to express a small molecule (hapten), designed to elicit an immune re-
sponse when attached to a protein (Berd, 2001) or, to enhance T cell activity, the tumour
cells can be cultured in cytokine-supplemented media such as IL-2, IL-6 or Granulocyte
Monocyte-Colony Stimulating Factor (GM-CSF) (Zhang et al., 2005) or transfected to
express co-stimulatory molecules and cytokines (Ali et al., 2000). This type of vaccine
has proved to be partially effective, with generally 10-30% of cancer patients presenting a
regressive tumour following immunotherapy (Weber et al., 2000). For example, in clini-
cal trials, 20 to 30% of the cancer (melanoma or kidney) patients injected with autologous
tumour cells genetically modified to produce diverse cytokines (IL-2, IL-7, IFN-gamma
or GM-CSF) have shown partial or complete response to the treatment (Parmiani et al.,
2000).
Heat shock protein vaccines consist of a mixture of adjuvants that are naturally pro-
duced by mammals, called heat shock proteins (HSP96, HSP70, HSP90, HSP110, grp170),
which chaperone antigenic peptides to APC and thus improve the generation of anti-
tumour immune responses (Srivastava et al., 1998; Binder et al., 2004). In clinical trials
using autologous HSP96 vaccines, these adjuvants were proven to be non-toxic and to
induce anti-tumour specific CTL responses in approximately 50% of the cancer patients
(Janetzki et al., 2000).
Peptides vaccines are developed according to identified immunogenic epitopes de-
rived from TAA which are presented by APC to CTL in the context of MHC class I
molecules. The first clinical trials using peptide vaccines were performed on melanoma
patients using differentiation antigens (MelanA/MART-1, gp100, tyrosinase) or CT anti-
gens (MAGE-1, MAGE-3). For example, a vaccine based on a MAGE-3 derived-peptide
allowed the complete regression of melanomas in 28% of the patients treated, whereas
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only 11% patients treated with a vaccine based on a MAGE-1 derived-peptide show re-
mission (Marchand et al., 1999) and a vaccine composed of MART-1 derived peptides,
administrated with Incomplete Freund’s Adjuvant (IFA), induced a peptide-specific CTL
response, but a clinical response was only observed when IL-2 was co-administrated with
this peptide vaccine (Rosenberg et al., 1998). Also, a vaccine combining the CT anti-
gen NY-ESO-1, considered the most immunogenic tumour antigen discovered to date,
and GM-CSF promotes a peptide-specific CTL response and consequently regression of
some metastases in 60% of the melanoma patients tested (Jager et al., 2000). Not only
melanoma but other cancers have been targeted with Breakpoint cluster region/Abelson
(BCR/ABL)-derived, HER2-derived and Ras-derived peptides for chronic myeloid leuka-
emia (CML) (Pinilla-Ibartz et al., 2000), breast cancer (Knutson et al., 2001) and pan-
creatic adenocarcinoma (Gjertsen et al., 2001), respectively. The choice of adjuvant and
the dosage given to patients are important criteria to consider when designing peptide
vaccines. Moreover, many immunological studies focus on the generation of immune
responses through the enhanced activity of CD4+ T cells directed towards MHC class II
peptides and not just CTL (Rojas et al., 2005; Mathieu et al., 2007) and some vaccines are
composed of both MHC class I and MHC class II peptides (Zeng et al., 2002). Other stud-
ies have focused on developing vaccine delivery systems using nano-particles (Kalkanidis
et al., 2006), CpG oligonucleotides as adjuvant (Haining et al., 2008) or liposomes (Al-
tin and Parish, 2006). During inflammatory responses and chronic autoimmune diseases,
endogenous epitopes from released self antigens can re-direct existing immune responses
whereby these epitopes become the focus targets of the immune attack, this detrimental
phenomenon is called epitope (determinant) spreading (Vanderlugt et al., 1998). Epi-
tope spreading was shown to be an important process for a peptide vaccine strategy to be
successful. Epitope spreading occurs when the T cell response, following vaccination of
patients, is not specific to the peptide from the vaccine but targets also multiple epitopes
derived from the TAA present in the vaccine or even a completely different TAA. This
phenomenon was observed in breast cancer patients that were given a single HER2/neu
peptide vaccine (Mittendorf et al., 2006). Another important factor in the development
of an efficient peptide vaccine is CTL avidity which is dependent on the concentration of
the antigen. If the dose of peptide in the vaccine is too high, this may cause the inhibition
of CTL proliferation (Alexander-Miller et al., 1996). High avidity CTL recognise the
antigen-derived peptide at low doses whereas low avidity CTL only recognises the pep-
tide when present at high density (Snyder et al., 2003). Peptide-based vaccines present
many advantages compared to other vaccines, such as the low cost and simplicity of pro-
duction as well as easy monitoring of immune responses. Also, using rapid molecular or
immunohistochemical techniques, patients likely to be responsive to the treatment, that is
to say who express the TAA of interest, can be selected.
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Dendritic cell vaccines are based on the administration to cancer patients of autolo-
gous DC that have been cultured in vitro with cytokines such as GM-CSF or IL-4 (Siena
et al., 1995) and in the presence of antigenic peptides (Takahashi et al., 2003), tumour
cell lysates (Tamir et al., 2007) in order to specifically activate T cell responses against
the tumour cells. It has been reported that 50% of melanoma patients treated with autol-
ogous DC loaded with either MART-1 (Palucka et al., 2006), tyrosinase (Schreurs et al.,
2000) or gp100-derived peptides (Linette et al., 2005) have tested positive for antigen-
specific CTL responses. Similarly, in another clinical trial, some melanoma patients in
advanced stage IV of the disease showed specific CTL responses and tumour regressions
following injection of autologous DC loaded with a MAGE-3 peptide (Godelaine et al.,
2003). Engineered dendritic cells include those transfected with mRNA isolated from tu-
mour cells (Kyte and Gaudernack, 2006) or with vectors encoding TAA cDNA sequences
(Chan et al., 2004) and a cytokine cDNA sequence (Fu et al., 2008) or those modified to
produce DC maturating/activating agents such as CD40L (Lapteva et al., 2007) or IL-12
(Vujanovic et al., 2006).
DNA vaccines are not based on peptides derived from tumour antigens but on the
whole sequence of the TAA. This has the advantage of presenting the full spectrum of
antigenic MHC class I and class II molecules from one TAA. The DNA vaccines can
also present CpG oligonucleotide sequences, cytokine sequences or co-stimulatory se-
quences to enhance the immunogenic potential of the targeted antigen-presenting cells
(Leitner et al., 1999). In animals, the DNA can be injected intramuscularly with a syringe
and then transported in the blood to other parts of the body where it will mostly induce
a Th1-orientated immune response. Alternatively the DNA can be introduced subcuta-
neously with a gene gun when coated on gold bullets. It is then taken up by dendritic
cells of the epidermis, which migrate to the regional lymph nodes and induce primarily
a Th2-orientated immune response (Weiss et al., 2002). Unfortunately, studies to date
have shown only poor immune responses generated following DNA immunisation. How-
ever, the prime-boost strategy (Woodland, 2004) has already shown promising results,
for example with the use of electroporation (Buchan et al., 2005). Finally, viral vector
vaccines for cancer immunotherapy have considerable potential due to infectious mech-
anisms that produce the “danger signals” required to overcome tumour tolerance. Many
different types of viral vectors have been used in animal models and in clinical trials
such as Herpes simplex viruses, retroviruses, lentiviruses, poxviruses, adenoviruses and
alphaviruses. Examples of recombinant viral vectors include those encoding TAA (PSA,
CEA) or others encoding cytokines (GM-CSF) (Aarts et al., 2002). Many studies aiming
to develop viral vector-based immunotherapies have used disabled infectious single cycle-
Herpes simplex virus (DISC-HSV) in murine tumour models (Rees et al., 2002; Ahmad
et al., 2005). Ali and colleagues have shown regression of the tumour in up to 70% of
mice which have been injected directly into the tumour with a DISC/HSV/GM-CSF vec-
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tor (Ali et al., 2002; Ali et al., 2004). The limitations of viral vector vaccines are the
patient’s own antibodies directed against viruses that the immune system has previously
encountered. The viral antigens, being more immunogenic than the TAA of interest, are
recognised and targetted by existing antibodies. It is unlikely that any given viral vector
could be injected more than once because of its ability to elicite neutralising antibody.
1.1.6.2 Adoptive immunotherapy
Adoptive immunotherapy consists of the isolation of autologous or allogeneic tu-
mour infiltrating cells, supporting their proliferation in vitro and their re-introduction
in the patient in large numbers in order to enhance the anti-tumour activity of immune
cells. Allogeneic adoptive immunotherapy has proven very useful in treating leukaemias
(June, 2007) whereas autologous adoptive immunotherapy is more applicable to solid tu-
mours such as melanoma; for instance, up to 50% of patients treated with lymphoablative
chemotherapy followed by vaccination with polyclonal T cell lines composed of tumour
specific CD4+ and CD8+ T cells have shown anti-tumour responses (Dudley et al., 2002;
Dudley et al., 2005). Finally, autologous T cells can be transfected in vitro with TAA-
specific TCR genes such as MART-1 (Benlalam et al., 2007), gp100 (Morgan et al., 2003)
or NY-ESO-1 (Kronig et al., 2009) and form in vivo an important population of T cells
specific to the TAA of interest leading to potentially more substantial clinical responses
in cancer patients and regression of their tumours.
1.1.6.3 Passive immunotherapy
Passive immunotherapy is based on the use of tumour antigen-specific monoclonal
antibodies (mAb). Monoclonal antibodies are monospecific, that is to say they will only
recognise one specific antigen and are produced by clones derived from one single par-
ent B cell. Importantly, many mAbs have been approved by the FDA as targeted cancer
therapeutics. In 2007, the FDA approved, among others, the humanised mAb Cetuximab
(produced by Imclone) targeting the EGFR in colorectal cancer, the humanised mAb Be-
vacizumab (produced by Genentech) targeting the Vascular Endothelial Growth Factor
(VEGF) also for use in colorectal cancer and the humanised mAb Trastuzumab (pro-
duced by Genentech) targeting HER2 in breast cancer. Researchers are studying highly
expressed tumour cell surface proteins in order to design novel mAbs to target these TAA
in diverse cancers. The mechanisms of action of mAb either involves antibody opsonisa-
tion, which is the process of specific binding of the mAb to its surface tumour antigen that
signal to phagocytic cells to ingest and destroy the target tumour cell, or the binding of
mAb to growth factor receptors present on the surface of some tumour cells, which blocks
the activity of these receptors (required for the survival of these tumours) and triggers the
death of the tumour cell by apoptosis (Viani et al., 2007). Studies are currently being
undertaken to develop novel mAb conjugated to another molecule in order to enhance
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the efficacy of conventional mAb. For instance, two antibody-radioisotype combinations,
90Y-Ibritumumab tiuxetan and 131I-Tositumomab, have been approved to date (Sharkey
et al., 2009). Other molecules used for labelling mAb include various toxins such as the
anti-B4-blocked ricin targeting CD5 (Kreitman, 2001) or cytotoxic drugs such as gem-
tuzumab ozogamicin which has been approved for cancer therapy (Ricart and Tolcher,
2007). Another type of antibody-based vaccines is based on the use of anti-idiotypic
(Id) mAb. These antibodies possess three-dimensional immunogenic regions (idiotopes)
which mimic the structures and functions of tumour antigens and thus serve as substitute
antigens in the induction of specific antitumour immunity in active immunotherapy. The
murine anti-Id mAb 6D12 mimics a specific epitope of HER2 (Mohanty et al., 2007) and
the anti-Id mAb 1E10 has induced anti-tumour response in models of primary breast can-
cer and melanoma (Diaz et al., 2009).
1.1.7 Cancer stem cells
It is now well recognised that tumour cells arise from normal cells that have increas-
ingly acquired neoplastic phenotypes due to the accumulation of unrepaired changes in-
volving the activation of proto-oncogenes into oncogenes and the inactivation of tumour
suppressor genes. The course of tumour progression follows the process of successive
clonal expansions in accordance to a Darwinian evolution of favouring the proliferation
of daughter cells that have inherited an advantageous mutation. However, the increasing
knowledge on stem cells and cancer stem cells challenges the whole model of multi-step
tumour progression. Stem cells’ main characteristics are their state of differentiation (less
differentiated than non stem cell progeny), their self-renewing capability (some descen-
dant cells remain stem cells), their ability to migrate to other tissues and their important
unlimited ability to proliferate. According to the claims of many studies, a tumour ap-
pears to be composed of very few tumour stem cells and of a majority divided between
progenitor cells (intermediates) and fully differentiated descendants which have limited
proliferative potential in vivo. Therefore, it has been hypothesised that the tumour pro-
gression model actually takes place within the minority population of tumour stem cells.
This theory is supported by several facts: the self-renewal capability of stem cells offers
an extended window of time for mutations to take place; the turnover rate of fully dif-
ferentiated cells driven by the Hayflick limit which explains that fully differentiated cells
cannot divide indefinitely due to the telomeres reaching a critical length (Hayflick, 1965)
and that it takes at least several months for an accumulation of mutations leading to a
malignant phenotype; cancer cells that have been found tumorigenic present on their cell
surface proteins that are characteristic of the normal stem cells of the tissue where the
tumour originated and finally fast growing tumours contain more stem cell-like cells than
slow growing tumours.
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The first evidence of the existence of tumour stem cells came from a study on Acute
Myelogenous Leukemia (AML) cells (Bonnet and Dick, 1997). Then, in 2003, Al-
Hajj and colleagues prepared breast cancer cells from tumours and, using fluorescent-
activated cell sorting (FACS), have enriched a subpopulation of cells, representing 12%
of the whole cell population, that were cell surface antigens CD24 low and CD44 high.
Afterwards, several hundred of these isolated cells successfully seeded new tumours
following injection in immunocompromised mice, whereas approximately 20,000 cells
from the major cell population failed to do so (Al-Hajj et al., 2003). It became evi-
dent that only very few cells within a tumour were tumourigenic and the rest consisted
of cells having limited capability for in vivo proliferation. Comparable results to those
obtained in the study of Al-Hajj and colleagues have since been obtained in various tu-
mours such as brain tumours (Singh et al., 2003) and prostate tumours (Collins et al.,
2005). In 2005, Collins and colleagues identified and characterised a subpopulation of
tumorigenic prostate cancer stem cells isolated from human prostate tumours which are
CD44+/alpha2beta1integrinHigh/CD133+, self-renewing and able to give rise to differen-
tiated cells. These cells were isolated using the mentioned markers and similar tech-
niques that are used in the isolation of normal prostate stem cells such as colony forming
assays, immunofluorescence staining of target cells and invasion activity assay in Ma-
trigel (Collins et al., 2005). More recently and using similar methods, Engelmann and
colleagues have isolated from the breast cancer cell line MCF-7 a breast cancer stem cell-
like subpopulation that expressed the tumour antigen MUC1, which led them to reach the
conclusion that these breast cancer stem cells would be good targets for MUC1-directed
immunotherapy (Engelmann et al., 2008). Indeed, cancer stem cells represent interesting
targets for anti-cancer therapies. Researchers aim to develop novel drugs that specifically
target and induce the death of cancer stem cells, which are essential for the proliferation
of the solid tumour, thus regression of the tumour would be gradually observed and the
risk of metastasis and recurrence of the disease would be reduced. Other methods for
cancer therapy would include promoting differentiation of the cancer stem cells, inducing
removal of cancer stem cells and targeting cancer stem cell-specific antigens. The discov-
ery of the latter is likely to be important in order to develop novel polyvalent anti-tumour
vaccine strategies (Morrison et al., 2008).
1.2 Breast cancer
1.2.1 Breast cancer statistics
Breast cancer is a family of diseases with a high profile. The World Health Organisa-
tion stated that breast cancer accounted for 519,000 deaths worldwide in 2004, classifying
it in fifth place in the list of types of cancer responsible for the overall cancer mortality
(http://www.who.int, 2009). Although breast cancer is a disease associated with women
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of all ages, carcinoma of the male breast can occur and accounts for less than 1% of all
cases diagnosed. Consequently, little information is available in the literature on research
studies involving male patients. According to the latest statistics given by Cancer Re-
search UK, breast cancer is the most common cancer affecting women in the UK, with
45,660 new cases diagnosed in 2005. Breast cancer is the most commonly diagnosed
cancer in British young women (under the age of 35 years old), with very few cases of
patients being in their teens or early twenties. However, the majority of women diagnosed
each year in the UK are post-menopausal. Current estimations suggest that the lifetime
risk for women to have this disease is 1 in 9 and 11,990 women died in 2007 from breast
cancer in the UK alone. The five-year survival rate is 80% nowadays and by comparison
only half of the women diagnosed with breast cancer in the seventies survived the disease
beyond five years (http://info.cancerresearchuk.org, 2009).
As shown in Figure 1.5, the incidence rate for age-standardised British females has
increased by 57% between 1981 and 2005 while the mortality rates for the same group
have decreased by 36% in the last 20 years. The number of breast cancer cases diagnosed
is higher in the developed world than in Asia and Africa (http://info.cancerresearchuk.org,
2009). The number of patients diagnosed with breast cancer has been steadily increas-
ing not only in the UK but in other economically developed countries as well, and if this
pattern continues globally it has been estimated that by 2010 there will be approximately
1.5 million new cases (Parkin et al., 2005). This increase can be mainly attributed to im-
proved and increased screening and an increasingly aging population, along with research
into earlier disease detection. Furthermore, improvements in detection and treatment of
breast cancer have meant that the age-standardised mortality rate has been steadily declin-
ing since 1989 in the economically developed countries. However, despite this progress,
large numbers of women are still either being diagnosed with late stage disease or go on
to develop metastases and end up dying from their disease.
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Figure 1.5: Age standardized (European) incidence and mortality rates, female breast
cancer, Great Britain, 1975-2004.
Taken from Cancer Research UK (2009) at http://www.cancerresearchuk.org.
1.2.2 Epidemiology of breast cancer
As previously mentioned, the majority of breast cancer cases are diagnosed in women
over 50 years old, this indicates that the risk of developing breast cancer increases with
age. Routine screening of breast cancer within the UK is achieved by undertaking mam-
mograms on women aged 50 to 70 years old as this age group has shown the highest
number of cases of breast cancer diagnosed. Also, women who carry genetic predisposi-
tions or are exposed to other risk factors such as those outline in Table ?? have a higher
risk of developing breast cancer. Risk factors associated with the family history of breast
cancer in relatives, especially first degree of relationship and multiple cases on one side
of the family, are strongly linked to an increased risk of developing breast cancer (Evans
and Howell, 2007). In developed countries, these hereditary factors only make up to a
quarter of all factors to breast cancer susceptibility (Key et al., 2001), the remaining three-
quarters are environmental, physiological and lifestyle-related. Prolonged exposure to the
hormones oestrogen and progesterone linked to early menstruations, late menopause, oral
contraceptive pills and hormone replacement therapies have been strongly associated with
an increased risk of developing breast cancer (Travis and Key, 2003).
Other physiological factors that have been linked to breast cancer development in-
clude previous breast cancer (Chen et al., 1999), certain types of benign (nonprolifera-
tive) breast lumps (Byrne et al., 2000), high body mass index (BMI), high mammographic
breast density (Vachon et al., 2007) and taller individuals (van den Brandt et al., 2000).
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Higher BMI is associated with lower breast cancer incidence for pre-menopausal women,
however higher BMI and weight gain before the menopause strongly increase the risk
of developing breast cancer in post-menopausal women who don’t use postmenopausal
hormones (Huang et al., 1997). Weight gain can be linked to hormonal changes or diet.
Another dietary risk factor for breast cancer is excessive alcohol consumption (Holmes
and Willett, 2004). Exercise is another lifestyle risk factor being investigated (Leitzmann
et al., 2008). An important environmental factor that increases the risk of breast can-
cer is the long-term exposure to radiation (Berrington de Gonzalez and Darby, 2004).
On the other hand, reproductive risk factors (linked to hormonal mechanisms) that have
a protective effect against the development of breast cancer include higher BMI in pre-
menopausal women, early first pregnancy, number of children and breast-feeding (Evans
and Howell, 2007). Furthermore, vitamin D, calcium, isothiocyanates, soy and marine n-3
fatty acids are among other dietary factors which appear to be beneficial in the prevention
of breast cancer through an increase in the protective mechanism of lipid peroxidation-
induced apoptosis (Gago-Dominguez et al., 2007). Phyto-oestrogens might also be useful
in the chemoprevention and treatment of breast cancer (Limer and Speirs, 2004).
1.2.3 Etiology of breast cancer
In 5 to 10% of all breast cancer cases, patients diagnosed have inherited from their par-
ents one or several gene mutations that predispose to the disease. The genes BReast
CAncer susceptibility 1 and 2 (BRCA1 and BRCA2), p53 and the Cowden disease gene
PTEN/MMAC1 are tumour suppressor genes and their ineffective mutated forms have
been linked to a high risk of developing breast cancer (Ellisen and Haber, 1998). BRCA1
and BRCA2 are “high risk” breast cancer susceptibility genes, identified in the 1990’s
(Miki et al., 1994; Wooster et al., 1995). These genes are involved in repairing DNA
damage whereas their mutated versions are responsible for about 80% of the familial
breast cancers and 5-6% of all breast cancers (Greene, 1997). Most cases of familial
breast cancer actually carry inherited defects in at least one of the “moderate risk” or
“low risk” genes. CHEK2, a cell cycle checkpoint regulator and putative tumour suppres-
sor gene, has been identified as a moderate-risk gene and carrying an inherited alteration
in this gene may double the risk of a woman developing breast cancer (CHEK2 Breast
Cancer Case-Control Consortium, 2004; Vahteristo et al., 2002).
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Table 1.2: Rare familial cancer syndromes and genes associated with breast cancer sus-
ceptibility.
Taken from Laversin et al., 2008.
The majority of breast cancers develops sporadically (no familial history), often due
to somatic mutations or incorrectly regulated genes in the breast cells (Lerebours and
Lidereau, 2002; Ross et al., 2003; Widschwendter and Jones, 2002). Over-expression of
oncogenic epidermal growth factor receptors (EGFR, HER2, ERBB3, ERBB4) and intra-
cellular signaling molecules (c-Src, h-Ras) and inactivation of tumour suppressor genes
such as cell cycle regulators (RB1, p53) are frequently found in sporadic cases of breast
cancer. Also, over-expression of the EMSY gene, whose protein acts on BRCA2 protein,
has been identified in many sporadic breast cancers and demonstrates the possibility of
interlinked breast cancer pathways between the inherited and sporadic forms of the dis-
ease (Hughes-Davies et al., 2003). As a conclusion, the predisposition to breast cancer
for a woman is determined by the inheritance of different penetrance gene variants which
may weaken the cell’s defence mechanisms against carcinogens and the accumulation of
unrepaired somatic mutations.
1.2.4 Pathological types and molecular classification of breast cancer
1.2.4.1 Pathological types
Breast tissue is a complex structure formed by an outer myoepithelial/basal layer, an
inner luminal epithelial layer and non-epithelial components (fibroblasts, lymphocytes,
endothelial cells, adipocytes, neurons and myocytes). In the breast, cancer develops from
cells in the glands that produce milk or ducts that deliver milk to the nipples. Can-
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cer Research UK provides an important source of information on the different types
of breast cancer which will be looked at in this section (http://www.cancerhelp.org.uk,
2009). There are five main histological types of breast cancer: ductal carcinoma in situ
(DCIS), lobular carcinoma in situ (LCIS, 10% cases diagnosed, more common in pre-
menopausal women), invasive ductal breast cancer (70-80% cases diagnosed) (Robison
et al., 2004), invasive lobular breast cancer and inflammatory breast cancer (1-2% cases
diagnosed). From the original site, breast cancer cells can eventually metastasise to other
parts of the body, the most common being bone (Theriault and Hortobagyi, 1992). Other
rare types of breast cancer include Paget’s disease (1-2% cases diagnosed), breast can-
cer in men, medullary breast cancer (5% cases diagnosed), mucinous breast cancer (2%
cases diagnosed) and tubular breast cancer (1% cases diagnosed). DCIS and LCIS are
characterised by some cells inside the ducts and the lobes respectively that have become
cancerous but have not invaded the surrounding healthy breast tissue. However, in some
cases, if these carcinoma in situ are left untreated they might develop into invasive breast
carcinoma in the future. The factors influencing the transition of breast carcinoma in situ
to invasive breast carcinoma are still mainly unknown, however it appears that changes
in the microenvironment play an important role in the process (Schnitt, 2009). In inflam-
matory breast cancer, the cancerous cells have invaded lymph ducts present in the breast
which then can not drain properly excess tissue fluid, creating a localised inflammation.
Figure 1.6 shows the current model of tumorigenesis in the breast tissue.
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Figure 1.6: Hypothetical model of breast tumour progression.
A duct of the breast tissue is made of a basement membrane and layers of luminal ep-
ithelial cells and myoepithelial cells. The stroma surrounding the duct is composed of
various endothelial cells, fibroblasts, myofibroblasts and leukocytes. Ductal carcinoma
in situ (DCIS) comprises of genetically and phenotypically altered myoepithelial cells
which have decreased in number and a degraded basement membrane. Furthermore, cell
populations such as stromal fibroblasts, myofibroblasts, endothelial cells and lympho-
cytes have increased in number. In the case of invasive breast carcinoma, the basement
membrane as well as the myoepithelial cell population have been lost and the malignant
tumour cells have invaded the surrounding healthy tissue and potentially metastasised to
other tissues and organs. Taken from Polyak (2007).
1.2.4.2 Molecular profiling of breast cancer
Breast tumours exhibit a characteristic cellular and molecular heterogeneity (Sorlie et al.,
2001) and it is globally accepted that the molecular differences among cancers are re-
sponsible for the different clinical courses in patients with histologically similar tumours
(Pusztai et al., 2007). An increasingly more accurate molecular classification of breast
tumours into subtypes has been developed since the beginning of the century through
the extensive use of DNA microarrays (Perou et al., 2000; Sorlie et al., 2001; Sorlie et
al., 2003). The definitive 5 clinically relevant molecular subgroups to date are listed in
Table 1.3. In 2005, using tissue microarray (TMA) technology and hierarchical clus-
tering methodology with 1,076 cases of invasive breast cancer, Abd El-Rehim and col-
leagues have uncovered 5 groups with distinct patterns of protein expression from a large
panel of well-characterised commercially available biomarkers which illustrated the bi-
ological heterogeneity of breast cancer. Further analysis using multiple layer perceptron
(MLP)-artificial neural network (ANN) analysis identified 2 large groups based on their
expression of luminal epithelial cell phenotypic characteristics, hormone receptor pos-
itivity, absence of basal epithelial phenotype characteristics and lack of HER2 protein
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overexpression. Two other groups were defined by high HER2 positivity and negative
or weak hormone receptors expression. The fifth group was identified by strong basal
epithelial characteristics, p53 positivity, absence of hormone receptors and weak to low
luminal epithelial cytokeratin expression. According to the authors, this classification,
which is not yet accepted in clinical practice, provides information for revision of the cur-
rent traditional classification systems for breast cancer (Abd El-Rehim et al., 2005). In
2008, Meijnen and colleagues have successfully categorised DCIS into two main groups
and five subgroups using six published molecular markers defining breast cancer subtypes
and a histological approach based on immunohistochemistry (Meijnen et al., 2008).
Table 1.3: The five clinically relevant molecular subgroups of breast cancer.
In the case of HER2, ”-” means ”not over-expressed” and ”+” means ”over-expressed”.
1.2.5 Detection of breast cancer
1.2.5.1 Breast self-examination
Breast awareness is the non-invasive, physical self-examination of the breasts in order to
detect any symptoms of breast cancer such as a lump. This has proven effective in de-
tecting tumour mass and is advised to all women, especially those not included in the UK
breast cancer screening programme. Upon observation of breast abnormalities, women
have an appointment with their General Practitioner (GP) who will firstly physically ex-
amine the breasts then recommend further clinical tests if judged necessary.
1.2.5.2 Imaging
In the UK, national breast cancer screening applies to all women aged 50 to 70 years old.
These women, who are in an age group considered at higher risk of developing breast
cancer, are invited every 3 years to undertake an X-ray of the breasts (mammogram). By
2012, the age group for the screening programme will have changed to 47-73 years old
(http://www.cancerhelp.org.uk, 2009). Mammograms are also recommended to women
of any age showing breast cancer symptoms identified by their GPs. Breast cancer can
be detected at an early stage with mammograms. DCIS is nowadays more frequently
detectable in the breast due to an increasing use of mammography that allows identifica-
tion of typical microcalcification patterns (Kessar et al., 2002) whereas in situ or invasive
lobular carcinomas cannot be detected on a mammogram. Lobular carcinomas are often
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defined by a thickened part of the breast tissue instead of a defined lump, making lobular
carcinomas more difficult and longer to diagnose than ductal carcinomas. Most women
who have no obvious lump in their breast have what is termed carcinoma in situ because
tumour cells have not yet proliferated in the surrounding healthy tissue. Like many other
medical tests, mammograms are not 100% accurate and false positives (calcification due
to non-cancerous changes in the tissue) as well as false negatives occasionally occur.
A breast ultrasound scan is another imaging method for breast cancer screening.
Younger women, who have denser breast tissues which is not recommended for mam-
mography, can be screened for breast cancer using other imaging methods for example
a breast ultrasound scan and an Magnetic Resonance Imaging (MRI) scan. Breast ultra-
sound scans are also used to assess if a detected lump is solid (tumour) or contains fluid
(cyst) and MRI scans are also used to determine the surgical options for women diagnosed
with lobular breast carcinoma. Knutson and Steiner have reviewed the usefulness of non-
invasive methods traditionally used for breast cancer screening and reported that MRI
scans have high false-positive rates and are costly; therefore they should not be used for
general screening but as an alternative test if mammography failed (Knutson and Steiner,
2007).
Mammograms, ultrasound scans and MRI scans are non-invasive screening methods
and according to the results of these tests, removal of cells or tissues for microscopic
pathological examination of biopsy material might be carried out afterwards. The types
of biopsy include, from the less to the more invasive methods, needle aspiration, needle
(core) biopsy and surgical biopsy. Traditionally, nipple duct fluid and periductal nee-
dle aspiration are examined cytologically for the diagnosis of breast cancer (King et al.,
1983). LCIS is usually diagnosed with definite proof by biopsy and cytological analysis.
For some years, screening programmes have raised concerns about overdiagnosing
breast carcinoma in situ, but not invasive breast carcinoma. Detecting breast carcinoma in
situ that, if left untouched, was not going to develop into an invasive disease or detecting
false positive exposes women to overtreatment, with the associated potential trauma and
toxic side effects.
1.2.5.3 Genetic testing
Patients with a family history of breast cancer with known mutations in the genes
BRCA1 and BRCA2 can be screened for these mutations to determine if they may benefit
from tailored screening and prevention methods, such as prophylactic mastectomy (com-
plete removal of the breast), which can reduce by 90% the incidence of breast cancer and
by 81% the risk of death by the disease in women who have a high-risk family history
(Hartmann et al., 1999). Direct sequencing (DS) distinguishes carriers from noncarriers
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however this method is expensive, time-consuming and subject to false negatives (Palma
et al., 2006). In high-risk families with no known inherited mutations, individuals with
mutated BRCA genes can be also identified by this genetic test. However no other ge-
netic breast cancer susceptibility tests are currently available to patients with a familial
history of breast cancer. Research is focusing on the discovery of more frequently found
moderate-risk and low-risk susceptibility genes in order to develop novel multiple-gene
screening test that would be clinically available in the future for patients with or without
a family history of the disease (Thompson et al., 2008).
1.2.6 Diagnosis and prognosis of breast cancer
Diagnosis and prognosis are two very important interventions in breast cancer man-
agement and, as stated by Hu and colleagues (2005), early diagnosis of breast cancer is
far more important than any therapy.
1.2.6.1 Diagnosis and staging
Once the cancer has been detected in the breast, it is staged using the globally recog-
nised and standardised TNM cancer staging system which was primarily developed by
Pierre Denoix between 1943 and 1952. Staging is very important in the decision-making
process for best breast cancer treatment regime. This takes into account the histological
characteristics of the malignant cells such as size of the tumour, spread to lymph nodes
and spread to other organs. There are four main stages (http://www.cancerhelp.org.uk,
2009): stage I (tumour up to 2cm, no lymph nodes affected and no evidence of spread
beyond the breast), stage II (tumour between 2cm and 5cm and/or lymph nodes in armpit
affected and no evidence of spread beyond armpit), stage III (tumour more than 5cm,
lymph nodes in armpit affected but no evidence of spread beyond armpit) and stage IV
(tumour of any size, lymph nodes in armpit often affected and where the cancer has spread
to other parts of the body). In addition, tumour cells are traditionally tested for hormonal
receptors (ER, PR) and the growth factor receptor HER2 to determine if patients may
benefit from tailored hormone therapies or molecular therapies, which will be discussed
later on.
1.2.6.2 Prognosis
Galea and colleagues, in 1982, developed and further validated the Nottingham prog-
nostic index (NPI) for prognosis for breast cancer patients who show a primary, operable
cancer (Galea et al., 1992). It is used in Europe and is based on histopathological features
including tumour size, histological grade and lymph node status (Yu et al., 2004). The
aggressiveness of the invasive breast cancers is indicated by determining the histological
grade of the tumour with the Elston and Ellis method which assesses tubule formation,
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mitochondrial index and nuclear pleomorphism (variability in size and shape of cells and
their nuclei) (Elston and Ellis, 2002). Grades are classified into three types: grade 1
(low grade, slow growing cells), grade 2 (intermediate grade) and grade 3 (high grade,
fast growing cells). High grade tumour cells are more aggressively proliferating than low
grade tumour cells and patients with grade 3 tumour cells are given a worse prognosis.
DCIS cells can also be graded to determine the likeliness of the localised disease to be-
come invasive in the future.
Furthermore, the age of the patient, the tumour grade and hormone receptor status are
traditional characteristics that have been taken into account and incorporated into a pro-
gram that is available online for the prognosis of breast cancer (www.adjuvantonline.com).
Adjuvant online can predict 10 year recurrence of the cancer and overall survival of breast
cancer patients by considering the predicted response to adjuvant chemotherapy (Ravdin
et al., 2001). Grading the tumour is useful to predict the breast cancer patient’s outcome,
thus determining the best treatment options according to the aggressiveness of the disease.
However, traditional prognostic means remain an indication of the patient’s outcome and
are not 100% reliable.
1.2.7 Therapies for breast cancer
Following the process of detection, diagnosis and prognosis of the breast cancer, clin-
icians will determine the best options to offer a tailored treatment to the patient. Each of
the five different histological types of breast cancer requires a specific mix of treatments.
Most women diagnosed with LCIS will not develop a malignant breast cancer so pa-
tients will usually not receive any treatments, not even surgery. They will be given regular
monitoring in order to watch for an eventual progression of the disease into an invasive
type that would then require an early intervention. Patients diagnosed with DCIS have a
greater chance of developing invasive carcinoma than those diagnosed with LCIS (Fen-
timan, 2001) so the affected tissue is removed either by mastectomy (followed by breast
reconstruction) or, in most cases, by conservative surgery (wide local excision) if the area
affected is not too large. Surgery is usually followed by a course of radiotherapy in order
to kill any remaining abnormal cells. If the DCIS or LCIS cells are tested positive for
hormone receptors, a course of hormone therapy could also be given to the patient to try
and prevent the formation of invasive breast cancer. Anastrozole is a hormone therapy
currently used in a trial (IBIS 2) to assess its efficacy in preventing the development of
breast cancer in women which have a higher than average risk, especially those diagnosed
with LCIS or DCIS. Another study called GLACIER aims at the identification of genes in
blood samples that increases the risk for women to develop LCIS and that could be used
in a screening test for healthy women (http://www.cancerhelp.org.uk/trials, 2009).
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Invasive ductal and lobular breast cancers are treated the same way, tailored accord-
ing to the results of the diagnostic and prognostic tests of the individual: surgery usu-
ally followed by radiotherapy and chemotherapy or surgery usually followed by the less
toxic hormone therapies if the tumour tested positive for ER/PR or molecular therapies
if the tumour tested positive for HER2/EGFR. Alternatively, patients may be subjected
to a combination of all these treatments. Inflammatory breast cancer is caused by lymph
channels that are blocked in the breast, therefore neoadjuvant chemotherapy is given to
reduce the swelling before surgery (local excision or mastectomy) is performed. In re-
gards to late stage invasive breast cancers which have metastasised to other organs (not
just lymph nodes), patients are considered almost incurable and therapies are carried out
with the intention to extend the patient’s life by decreasing tumour burden and palliating
the symptoms. All breast cancer patients with any tumour type will be given follow up
appointments after their course of treatment has ended to be monitored for their response
to therapies and for early detection if recurrence of the disease was to occur. Five years
post-treatment was shown to be the critical time period for relapse and is therefore used
in assessing survival rates of breast cancer.
Oestrogen, essential for the development of the breast tissues, can promote breast
cancer so a course of hormone therapy can be added for patients who have tumour cells
testing positive for a high number of oestrogen receptors. Tamoxifen is a compound that
competes with oestrogen for the oestrogen receptor thus inhibiting the effect of oestro-
gen as a growth factor for cancer cells (Ward, 1973). According to many trials, tamox-
ifen greatly diminishes the risk of a recurrent cancer and improves the overall survival
for women by 10 years (Wishart et al., 2002). The decline of the breast cancer age-
standardised mortality rate at the end of the last century is partly due to the continuous
extensive distribution of tamoxifen. Other hormonal therapies include progestogens (ar-
tificial progesterone) and aromatase inhibitors (given to postmenopausal women only),
both block the production of oestrogen. For women with ER/PR negative tumours who
cannot receive hormonal therapy, a course of chemotherapy would be advised for them.
Chemotherapy can also be suggested to premenopausal women who have ER positive tu-
mours. A combination of drugs is usually given during the course of the treatment and it
includes the use of an anthracycline (DNA intercalating agent causing free radical dam-
age of the ribose thus preventing cell division).
Approximately 25% of patients diagnosed with breast cancer present a high level of
HER2 receptors on their tumours. HER2 positive tumours are ER and PR negative and
present a more aggressive phenotype than the HER2 negative ones therefore patients have
a poorer prognosis. HER2 positive patients can be treated with trastuzumab or lapatinib.
Trastuzumab (HerceptinTM), manufactured by Genentech, is a humanised monoclonal
antibody directed against the growth factor receptor HER2. Lapatinib (TykerbTM), manu-
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factued by GlaxoSmithKline, is a small-molecule inhibitor of the growth factor receptors
HER2 and EGFR. Trastuzumab and lapatinib, both molecular therapies, were the only
two targeted breast cancer therapeutics approved in 2007 and, to date, no immunother-
apy for breast cancer has been approved. A UK phase I clinical trial is currently being
conducted using a novel DNA-based vaccine called polyHER2neu for immunotherapy of
metastasised breast cancer, with the aim of activating the immune system to recognise and
kill the antigen-bearing breast cancer cells (http://www.cancerhelp.org.uk/trials, 2009).
Breast cancer patients diagnosed with triple negative tumours (ER negative, PR nega-
tive, HER2 not overexpressed) have a really poor prognosis since these will not respond to
homornal therapies (tamoxifen, aromatase inhibitors) or targeted therapies (trastuzumab,
lapatinib) and can only be treated with chemotherapies. Many studies are currently focus-
ing on the molecular characteristics of the tumour cells of this group of patients in order
to develop alternative targeted therapies (Irvin and Carey, 2008).
1.3 Towards personalised management of breast cancer
For the last 20 years, major breakthroughs in breast cancer research have resulted in
improvements in the management of the disease which in turn has led to a steadily declin-
ing female age-standardised mortality rate (currently 34%, Cancer Research UK, Figure
1.5) and a steadily increasing female age-standardised incidence rate (13%, Cancer Re-
search UK, Figure 1.5). However, despite this important progress, a late stage diagnosis or
an unforseen development of metastases still ultimately claim the lives of large numbers
of women. Early diagnosis is key to survival and is more significant than any treatment
(Hu et al., 2005). Up to 70% of breast cancer patients will have a recurrent disease fol-
lowing treatment (Chatterjee and Zetter, 2005) and Cancer Research UK communicated
that out of all female breast cancer cases diagnosed in the UK in 2006 around 20% would
not survive beyond five years (Cancer Research UK, 2009). These statistics highlight the
limitations of accepted prognostic tools in predicting recurrence of the disease. Conse-
quently, in a significant number of breast cancer cases, women are over-treated as they
are given aggressive therapies in which associated side effects actually outweigh benefits
(Chia et al., 2001). Also, the major draw backs of a number of current therapies, such as
chemotherapy and hormonal therapy, are undeniably the inefficacy and toxicity of treat-
ments.
As previously mentioned, the majority of breast cancers arise sporadically from mu-
tated or inadequately regulated genes in the breast cells. Breast cancer is described in the
literature as a clinically heterogeneous and complex disease and, in the last ten years, re-
searchers have used high-throughput technologies such as DNA microarrays to refine the
classification of subtypes of breast tumours according to their molecular profiles (Perou
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et al., 2000; Sorlie et al., 2001; Sorlie et al., 2003). The study of the differences in gene
expression allows the identification of novel biomarkers which provide alternative, more
reliable factors for the diagnosis, prognosis and therapy of breast cancer. The ultimate
goal is the development of therapy-specific tests for the noninvasive screening of breast
cancer patients at the clinic in order to provide an effective, personalised management of
the disease.
A biomarker can be DNA-based, RNA-based or protein-based, used on its own or in
a panel with others. The utility of the marker, the magnitude of effects (none, weak, mod-
erate, strong), the analysis of the reliability of the marker, any technical issues (assay),
any analytical issues (cutoff points, test/validation sets and multivariate analysis) and any
trial design issues (appropriate patient population) are considered in the process of ap-
proval of any new breast cancer biomarkers for clinical use (Henry and Hayes, 2006).
Very few biomarkers for breast cancer have been clinically validated so far, mainly due to
low number of samples studied, inconsistent results and the long time duration between
the discovery and validation processes (Ludwig and Weinstein, 2005).
For the last ten years or so, high throughput “omic” technologies such as genomics
and proteomics have been extensively used in the identification of breast cancer specific
biomarkers. Thanks to the sequencing of the human genome, completed at the beginning
of the century (Venter et al., 2001), large amounts of information have been obtained and
are readily available in public databases. Microarray technology is an automated high-
throughput technique that uses this information. The array can be a small chip (glass or
silicon) or microscopic beads on which thousands of different DNA oligonucleotides or
protein molecules (probes) have been fixed in an orderly approach at specific locations
and whole human genome chips are commonly used nowadays. In DNA microarrays, the
target sample (cDNA or cRNA from control or test samples) is hybridised to the probes,
the interaction between the two is measured using fluorescence-based detection then the
large amount of data generated is statistically analysed using bioinformatics. Researchers
use DNA microarrays to quickly study the changes in expression levels between tumour
and normal counterpart samples from breast cancer patients or between treated and con-
trol cells with the aim to discover novel biomarkers. Protein binding microarrays are
useful in the study of protein interactions and for the discovery of novel drug targets and
antibody microarrays are widely used to identify proteins in a given cell lysate.
Recent techniques to study the proteome also include protein mass spectrometry. It is
used to compare the levels of protein expression between samples from healthy and can-
cer patients with the objective of discovering breast cancer associated biomarkers for
diagnosis, prognosis and prediction of treatment outcome. The samples used can in-
clude serum, urine and tissue lysates. Ideally, lysates are produced from tissues that have
been laser microdissected beforehand in the case of heterogeneous tumours like the breast
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ones. Laser-capture microdissection is the process of isolating a pure, morphologically
distinct cell population from a tissue section which is naturally made of heterogeneous
types of cells (Emmert-Buck et al., 1996); thus allowing a more targeted and accurate
analysis of the samples by proteomic or genomic means. MALDI (matrix-assisted laser
desorption/ionization mass spectrometry) and SELDI (surface-enhanced laser desorp-
tion/ionization mass spectrometry) technologies have been extensively used for biomarker
discovery in the last few years (Laronga and Drake, 2007; Garrisi et al., 2008; Matharoo-
Ball et al., 2007). The protein or peptide (tryptically digested proteins) profiles, combined
with downstream bioinformatics analysis using relevant links and database interrogation,
allows ions of high importance to be identified (Lancashire et al., 2009).
An expressed sequence tag (EST) is a short nucleotide sequence produced from randomly
selected cDNA clones (Adams et al., 1991) and a gene is usually represented by several
ESTs. The identification of human-specific ESTs has increased dramatically following
the completion of the human genome project. The number of ESTs of a given gene in a
given library reflects the level of expression of the gene in the tissue or cell line which
the library derived from. It is possible to mine databases, where the expression patterns
of the studied genes in normal tissues and tumour tissues can be found, with the single
objective of identifying in silico breast cancer related genes.
In 1995, Sahin and colleagues have developed SEREX, a novel serological approach to
identify TAA that are able to induce humoral immune responses, which is based on the im-
munoscreening of cDNA expression libraries from tumour samples with sera from cancer
patients (Sahin et al., 1995). This technique has been successfully used in the identifica-
tion of TAA from various tumour types. For example, NY-ESO-1 was discovered using
an oesophageal cancer cDNA library (Jager et al., 2000) and, in our laboratory, T21 and
MTA1 were identified using prostate cancer cDNA libraries (Assudani et al., 2006; Miles
et al., 2007; Li et al., 2008).
1.3.1 Breast cancer biomarkers for screening and diagnosis
Hereditary breast cancer biomarkers have previously been discussed (section 1.2.3
Etiology of breast cancer). Around 80% of all the familial breast cancers and around 5 to
6% of all breast cancer cases diagnosed will show mutations in the BRCA1 and BRCA2
genes (Greene, 1997). Therefore, women with a family history of breast cancer will be
advised by clinicians to be screened for these mutations by direct sequencing (DS). The
test is unfortunately expensive, time-consuming (Palma et al., 2006) and can give false
negative results. To date, no other genetic breast cancer susceptibility tests using other
high-risk genes for familial breast cancer are clinically available. However, several re-
cent studies have reported that women diagnosed with breast cancer, who have a strong
family history of breast cancer not linked to mutated BRCA1 or BRCA2, have mutations
in ataxia telangiectasia mutated (ATM), BRCA1 interacting protein C-terminal helicase
1 (BRIP1) and partner and localiser of BRCA2 (PALB2) significantly more frequently
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than the control women who were healthy, with or without a strong cancer family his-
tory (Renwick et al., 2006; Seal et al., 2006; Rahman et al., 2006; Erkko et al., 2007).
ATM is a cell cycle checkpoint kinase which regulates the activity of many proteins in-
cluding the tumour suppressor protein p53 and the checkpoint-like protein CHK2. Walsh
and colleagues stated that around 5% of breast cancer patients with a strong family his-
tory of breast cancer, who have been tested positive for wild type BRCA1 and BRCA2,
have mutations in the p53 and CHK2 genes (Walsh et al., 2006). Therefore, it has been
acknowledged that genetic testing for the mutations of these genes should be made avail-
able to women with a strong family history of breast cancer who have tested negative for
mutations in BRCA1 and BRCA2.
To date, no biomarker has been validated for clinical use in breast cancer risk assess-
ment and diagnosis, and some candidate biomarkers for screening failed the validation
process as they showed a high false-positive rate. A breast cancer biomarker has to be
very specific and be detectable through minimally invasive and cost effective techniques
to be desirable for risk assessment and diagnosis (Ludwig and Weinstein, 2005). For the
diagnosis of breast cancer, relatively non-invasive samples such as nipple duct fluid and
periductal needle aspiration have been traditionally examined for abnormal cells (King
et al., 1983). Using patient’s blood in molecular-based protocols for the detection of
specific biomarkers is thought to be nowadays the best minimally invasive way to detect
breast cancer (Levenson, 2007). The MUC1 glycoproteins (epitopes CA15-3, CA27-29)
are components of cell-cell junctions in the breast and have been shown to be helpful in
the detection of primary breast cancer (Gion et al., 1999). Cytokeratins of intermediate
filaments have been used successfully for testing for early breast cancer in several studies,
however their lack of sensitivity meant they cannot be validated for clinical use (Eskeli-
nen et al., 1994). Mammaglobin is a protein specific to the breast tissue whose detection
in serum or urine samples, measured by an ELISA assay, can indicate the presence of mi-
crometastases in peripheral blood, lymph nodes and bone marrow of patients and could
therefore be useful in the diagnosis of breast cancer (O’Brien et al., 2002). Biomarkers
that can also be used to distinguish between patients with early stage breast cancer and
healthy individuals have been identified in serum and nipple duct fluid using SELDI (Li
et al., 2002; Sauter et al., 2002).
1.3.2 Breast cancer biomarkers for prognosis and prediction of treat-
ment outcome
Personalised management of breast cancer involves biomarker-guided therapy options
in order to prevent unnecessary treatments and overtreatment of patients and to ensure
high treatment success rate and reduced costs (Strand et al., 2006).
Few biomarkers have been widely accepted and are routinely used for prediction of re-
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sponse to therapy and in the prognosis of breast cancer. Some of the biomarkers which
are indicative of a poor prognosis are: overexpression of HER2 (Bieche et al., 1999),
absence of ER (Bezwoda et al., 1991), inactivated P53/PTEN (Borresen-Dale, 2003; De-
powski et al., 2001), RhoC (Kleer et al., 2002), c-myc (Deming et al., 2000), loss of
expression of E-cadherin (Yoshida et al., 2001), matrix metalloproteases (Egeblad and
Werb, 2002), Ep-CAM (Gastl et al., 2000), hTERT (Bieche et al., 2000), a modified form
of cyclin-E (Keyomarsi et al., 2002), loss of expression of the tumour suppressor gene
maspin (Maass et al., 2002) and mutated BRCA1 (Robson et al., 2004). Some of the
biomarkers which play an important role in predicting the response to therapy are: HER2
whose expression levels can indicate the benefits of treating breast cancer patients with
trastuzamab (Hunt and Keyomarsi, 2005), ER/PR whose expression makes tumours sen-
sitive to treatments (Tamoxifen and aromatase inhibitors) (James et al., 2007), PS2 which
is linked to ER presence hence suggestive of a good response to hormonal therapy (Ar-
davanis et al., 1997), Bcl-2 whose expression indicates increased survival with hormonal
treatments (Yang et al., 2003), MDR1 which is associated with resistance to chemother-
apy (Trock et al., 1997), BRCA1 whose absence means tumour cells are more sensitive
to chemotherapy and the presence of which makes tumour cells more sensitive to antimi-
crotubule agents (James et al., 2007), Glutathione S-transferase whose over-expression is
associated with multi-drug resistance (Batist et al., 1986) and mutated p53 which is asso-
ciated with resistance to hormonal, adjuvant, neoadjuvant and combination chemotherapy
(Bottini et al., 2000; Daidone et al., 1999; Geisler et al., 2001 and Montero et al., 2001).
Also, high levels of the protein CA15-3 in the serum of breast cancer patients undergoing
chemotherapy is usually indicative of a weak response to the treatment (Al-azawi et al.,
2006).
Widely available and recognised, yet expensive tests for prediction of treatment out-
come and prognosis of breast cancer comprise the Mammaprint (a gene microarray-based
test from Agendia BV), Oncotype DX (a quantitative-Polymerase Chain Reaction-based
test from Genomic Health Inc) and Mammostrat (an immunohistochemistry-based test
from Applied Genomics Inc) tests. It is thought that these microarray gene expres-
sion profilers have the same efficacy for the prediction of breast cancer outcome and
response to therapies as the traditional clinical breast cancer biomarkers (Eden et al.,
2004). Mammaprint is used to categorise breast cancer patients (lymph-node negative,
ER positive or negative tumours) who have only received surgery as treatment in a low or
a high risk group for distant recurrence of the disease (van de Vijver et al., 2002; van ’t
Veer et al., 2002). Oncotype DX is used to test patients (lymph-node negative, ER pos-
itive tumours), who received surgery and tamoxifen, for prediction of cancer recurrence
and to determine if they would benefit from certain types of chemotherapy (Cronin et al.,
2004; Paik et al., 2004). Mammostrat is used to predict the risk (high, moderate or low)
of breast cancer patients (lymph-node negative, ER positive tumours), who received only
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surgery as treatment, to develop distant metastasis regardless of chemotherapy regimens
(Ring et al., 2006).
1.3.3 Breast cancer biomarkers for treatment
Hormonal therapies such as tamoxifen or aromatase inhibitors (Cristofanilli and Hor-
tobagyi, 2002) and the monoclonal antibody trastuzumab (McKeage and Perry, 2002) are
well accepted therapies as mentioned previously. The re-introduction of maspin expres-
sion (Maass et al., 2002) or wild type-p53 expression (Liu et al., 1995) are potential treat-
ments for breast cancer; and EpCAM, cyclin E, the platelet-derived growth factor (PDGF)
and Flk-1 (a growth factor receptor) are potential targets for immunotherapies (Ariad et
al., 1991; Gastl et al., 2000; Hasan and Jayson, 2001; Hunt and Keyomarsi, 2005). Cancer
cell growth can be inhibited in around 90% of breast cancer patients tested positive for the
vitamin D receptor (nuclear steroid hormone receptor) when tumour cells are treated with
the vitamin D analogue 1a,25-(OH)2D3 (Friedrich et al., 1998). Wu and colleagues stated
that receptor selective retinoids, which have a role in growth inhibition and induction of
apoptosis, could be used in novel therapies for breast cancer patients whose tumour tested
positive for these but negative for ER (Wu et al., 2002). Also, ligands for the peroxisome
proliferator-activated receptor (PPAR), such as the natural prostaglandin 15-deoxy-delta-
12,14-prostaglandin J2 (PGJ2) and the synthetic anti-diabetic thiazolidenediones trogli-
tazone (TGZ), could be of interest for use in novel therapies targeting breast cancer cell
growth (Pignatelli et al., 2001). Another receptor which could be a good candidate for
therapy is the growth receptor flk-1. It has been shown that when flk-1 mRNA molecules
are cleaved by ribozymes the growth rate of microvasculature endothelial cells decreases,
making flk-1 a potential target in novel strategies against angiogenesis (Hasan and Jayson,
2001). In 2004, Castelli and colleagues stated that heat shock proteins which are potential
biomarkers for breast cancer treatment due to their ability to chaperone tumour antigens,
especially MHC peptides, could be an effective way of developing a vaccine strategy to
break immune tolerance to these protein targets, thus inducing specific regression of the
tumour (Castelli et al., 2004).
1.3.4 Breast cancer biomarkers for monitoring the disease
The majority of deaths from breast cancer are due to the spread of metastases to other
organs and the development of secondary tumours compromising the function of these
organs. Therefore, it is of prime importance to detect metastasis and to monitor the dis-
ease following primary treatment. Serum or urine from breast cancer patients can be used
in an ELISA assay to detect the presence of the protein mammaglobin which would in-
dicate that breast tumour cells have spread through peripheral blood and lymph nodes to
other parts of the body (O’Brien et al., 2002). Ep-CAM and HER2 are also indicators of
micrometastases in peripheral blood and bone marrow of breast cancer patients (Gastl et
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al., 2000; Andersen et al., 1995); and urokinase-type plasminogen activator (PAl-1 and
PAl-2) and cathepsins B and L are biomarkers for breast cancer recurrence (Borstnar et
al., 2002; Foekens et al., 1998).
1.4 Rationale and outline of the study
The development of novel cancer vaccines for immunotherapy, as well as novel diag-
nostic or prognostic tools, is based on the discovery and validation of TAA. For this pur-
pose and as previously mentioned, EST database mining is one strategy thus has been used
to identify potential tumour-specific antigens. Using this method, novel breast-associated
genes (Breast-associated UniGene Clusters or BUC) have recently been discovered in our
laboratory by limiting the search criteria to genes present in human normal breast and/or
breast cancer tissues or cell lines but not in human normal tissues or organs except testis,
ovary and placenta. Upon further characterisation using molecular techniques, four in-
teresting and potential TAA, namely BUC6, BUC9, BUC10 and BUC11, were selected
for further study (personal communication with Dr Li). This research project proposed to
characterise the BUC genes in order to determine their potential applications in diagnosis,
prognosis or therapy for cancer, particularly for breast carcinoma. Firstly, the full gene
sequences of the four BUC genes had to be obtained to determine the similarities shared
with published genes and a comprehensive mRNA expression analysis had been carried
out in various invasive and non-invasive histological subtypes of breast cancer, benign
breast tumours, breast cancer cell lines, other malignancies (melanoma, prostate cancer)
and normal tissues. The gene which demonstrated promising expression patterns was
then further characterised at the protein level using various immunoassays with diverse
normal and tumour tissues. Furthermore, the study incorporated preliminary research
into the biological functions of this gene and its potential involvement in carcinogenesis
and/or tumour progression using gene expression induction experiments, gene expression
knockdown experiments and microarrays. Finally, it was intended to evaluate the im-
munogenicity of the gene product in a HLA transgenic mouse model.
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Materials and Methods
2.1 General laboratory consumables and equipments
2.1.1 Reagents
Reagents were stored as per manufacturer instructions and used before the expiry date.
Culture media Supplier
Dulbecco’s Modified Eagle Medium (DMEM) BioWhittaker Europe
Eagle’s minimal essential medium (EMEM) BioWhittaker Europe
RPMI 1640 medium (RPMI) BioWhittaker Europe
McCoy’s medium Invitrogen
OPTI-MEM Gibco Life Technologies
CTL media Cellular Technology
Supplements to culture media Supplier
Foetal calf serum (FCS) BioWhittaker Europe
4-(2-hydroxyethyl)-1-piperazine-
-ethanesulfonic acid (HEPES) BioWhittaker Europe
Fungizone Promega
Geneticin (G418) Promega
L-glutamine BioWhittaker Europe
Non essential amino-acids (NEAA) BioWhittaker Europe
Penicillin/Streptomycin BioWhittaker Europe
2-mercaptoethanol Sigma
Other cell culture reagents Supplier
Dimethyl sulfoxide (DMSO) Sigma
Incomplete Freund’s adjuvant (IFA) Sigma
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Lipopolysaccharide (LPS) Sigma
Murine GM-CSF PeproTech EC
Murine IL-2 PeproTech EC
Phosphate buffer saline (PBS) BioWhittaker Europe
Polyinosinic polycytidylic acid (Poly I.C)llllll Sigma
Staphylococcus aureus
enterotoxin B (SEB) Sigma
Trypan blue Sigma
Trypsin/Versene BioWhittaker Europe
Chemical reagents Supplier
Acetic acid Fisher Scientific
Acetone Acros Organics
Acetonitrile Fisher Scientific
Acrylamide-bis Geneflow
Agar Oxoid Ltd
Agarose Bioline
Alpha-chymotrypsin Sigma
Ammonium bicarbonate Sigma
Ammonium Persulphate National Diagnostics
Ampicillin Sigma
Anhydrous ethanol Sigma
Aprotinin Sigma
Aza-deoxycytidine (AZAC) Sigma
BioTaqTMDNA polymerase Bioline
Bovine serum albumin (BSA) ICN Biomedicals
Bromophenol blue sodium salt Promega
Calcium Chloride (CaCl2) Sigma
Chloroform BDH
Chromium-51 Amersham Biosciences
Citric acid Sigma
Dextran sulphate Sigma
Dithiothreitol (DTT) Sigma
DNA ladder (1Kb plus) Gibco Life Technologies
Deoxyribonucleotide triphosphate (dNTP) Bioline
DPX mountant Sigma
Embedding compound Bright Instrument
Ethanol BDH
Ethidium bromide Sigma
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Ethyldiamine tetraacetic acid (EDTA) Sigma
4x ProtoGel Resolving Buffer National Diagnostics
Fluorescent mounting media Dako
Gills haematoxylin solution Sigma
Glacial acetic acid Fisher Scientific
Glucose Sigma
Glutaraldehyde Sigma
Glycerol Sigma
Goat serum Sigma
Gold microcarriers (1.0µm) Bio-Rad
Harris haematoxylin solution Sigma
Hydrochloric acid (HCl) Fisher Scientific
Hydrogen peroxide (H2O2) Sigma
INTERFERinTM Polyplus Transfection
Isopropanol Sigma
Isoton Beckman-Coulter
Liquid nitrogen BOC
Lipofectamine 2000 Invitrogen
Marvel Premier Brands
Magnesium chloride (MgCl2) Fischer Scientific or Promega
Methanol Acros Organics
NANOpure Diamond distilled water Barnstead
Nitrogen (gas) Air Liquide
N,N,N’,N’-tetramethyl-
ethylenediamine (TEMED) National Diagnostics
Octyl-beta-d-glucopyranoside (OGP) Sigma
Orange G Sigma
Paraformaldehyde Sigma
Phenol/Chloroform/Isoamyl alcohol Sigma
Phosphate buffer saline (PBS) (1X) BioWhittaker Europe
Phosphate buffer saline (PBS) (Tablets) Oxoid
PhusionTMHF buffer Finnzymes
PhusionTMDNA polymerase Finnzymes
Poly vinyl pyrrolidone (PVP) Sigma
Ponceau S solution Sigma
Potassium acetate (KOAc) Sigma
Potassium ferricyanide (K3Fe(CN)6) Sigma
Potassium ferrocyanide (K4Fe(CN)6) Sigma
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Propidium iodide (PI) Sigma
Precision Plus Protein
WesternC standard Bio-Rad
ProtoGel Resolving Buffer National Diagnostics
ProtoGel Stacking Buffer National Diagnostics
Rabbit liver powder Sigma
Restriction enzymes Promega or New England Biolabs
Ribonuclease (RNase) Qiagen
RNA-STAT 60 Biogenesis
Scintillation fluid Packard
Silane Sigma
Sodium azide (NaN3) Sigma
Sodium chloride (NaCl) Fischer Scientific
Sodium citrate Sigma
Sodium dodecyl sulphate (SDS) Sigma
Sodium hydroxide (NaOH) Fischer Scientific
Sodium phosphate dibasic (Na2HPO4) Sigma
Sodium phosphate monobasic (NaH2PO4) Sigma
Spermidine Sigma
Substrate solution (for ELISA) R&D Systems
Sulfuric acid (H2SO4) Sigma
SYBR R©green supermix Bio-Rad
Trifluoroacetic acid Acros Organics
Trichostatin A (TSA) Sigma
Tris Fischer Scientific
Tris-HCl (1.5M), pH 6.8 or pH 8.8 Geneflow
Tritiated (3H)-thymidine Amersham Biosciences
Trizma base Sigma
Trypsin Gold, Mass Spectrometry grade Promega
Tryptone Oxoid Ltd
Tween 20 Sigma
2-methylbutane (Isopentane) Acros Organics
Ultra Pure 10x Tris/Glycine
electrophoresis grade buffer National Diagnostics
Ultra Pure 10x Tris/Glycine/SDS electro-
-phoresis grade buffer National Diagnostics
Urea Sigma
Vitamin E Sigma
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Xylene Acros Organics
Yeast extracts Oxoid Ltd
ZeocinTM Invitrogen
Immunochemical reagents Supplier
Rabbit anti-BUC11 antibody Pacific Immunology
BUC11 peptide to which Rabbit
anti-BUC11 antibody has been raised Pacific Immunology
Swine anti-rabbit Immunoglobulin G
(IgG)-Fluorescein
IsoThioCyanate (FITC) DAKO
Swine anti-rabbit IgG-HorseRadish Pero-
-xidase (HRP) DAKO
Goat anti-rabbit IgG biotinylatedlllllllllllll DAKO
Polyclonal rabbit IgG isotype control AbD serotec
Streptavidin conjugated HRP AbD serotec
DRAQ5TM Biostatus
Plasmids Supplier
pBudCE4.1 and pCRII-blunt-TOPOllllllll Invitrogen
pMACS Kk.Tag(N) Miltenyi Biotec
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Kits Supplier
ABC and DAB kits Vector Laboratories
Cell line Nucleofector R©Kit V Amaxa
DNA isolation kit Biological Industries
Dc Protein Assay kit Bio-Rad
ECL Western Blotting reagents Amersham Biosciences
M-MLV (Moloney Murine Leukemia
Virus) Reverse Transcriptase kit Promega
Mouse CD4: Dynabeads mouse CD4llllllll Dynal
Mouse CD8: Dynabeads mouse CD8 Dynal
Mouse IFNγ Development Module R&D Systems
ELISpot Blue color Module R&D Systems
RNAeasy MiniKit Qiagen
Kit for immunoprecipitation with
µMACSTMProtein G MicroBeadslllllllllllll Miltenyi Biotec
Kit for selecting cotransfected cells
with pMACS vector Miltenyi Biotec
Kit for isolating mouse leukocytes
(Pan T Cell Isolation Kit) Miltenyi Biotec
T4 ligase kit Promega
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2.1.2 Equipment
Glassware
Pyrex glassware was washed in teepol, rinsed twice in distilled water and autoclaved.
Disposable equipment and plastic-ware Supplier
BD microlance 3 needles (0.5ml, 1ml) Becton Dickenson
Bijou tubes (7ml) Sterilin
Cell scrapers TPP
Culture slides (8 chambers) BD Falcon
Cryovials (1.2ml) TPP
ELISA plates (96-well) Costar
ELISPOT plates(96-well) Millipore
Eppendorf tubes (0.5ml, 1.5ml) Sarstedt
FACS tubes Elkay
Filter tips (10µl, 200µl, 1ml) Sarstedt
Flat bottom culture dishes(6-, 24-, 96-well) Sarstedt
Gel blotting papers Whatman
Hyperfilm ECL films Amersham
Luma-Plate 96 Packard
96-well plate harvester filters Perkin Elmer
Nitrocellulose membranes GE Healthcare
Pasteur pipettes (plastic) Sarstedt
PCR tubes Axygen Scientific
Petri dishes (plastic) Sarstedt
Real-Time PCR tubes (100µl) Corbett Research
Round bottom culture dishes (96-well) Sarstedt
Scalpels Swann-Morton
Screw top tubes (15ml, 50ml) Sarstedt
Serological pipettes (5ml, 10ml, 25ml) Sarstedt
Syringes (10ml) Becton Dickenson
Tefzel tubing Bio-Rad
Tips (20µl, 200µl, 1ml) Sarstedt
Tissue culture flasks (T25, T75, T175) Sarstedt
Universal tubes (20ml) Sterilin
0.2µm filters Sartorius
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Equipment Supplier
Centrifuge, microcentrifuge MSE
Class II safety cabinets Walker
Cold room Polysec
Confocal microscope Leica
Cryostat (Leica CM 1900) Leica
Distilled water system (ddH2O) Barnstead
Drying cabinet Scientific Laboratory Supplies
Dynabeads separation unit Dynal
Electrophoresis gel tanks Bio-Rad
Flow cytometer (Coulter Epics XL.MCL) Beckman-Coulter
Fridge Denley
Glass cuvette for spectrophotometer Hellma
Helios gene gun Bio-Rad
Hypercassette Amersham Biosciences
ImmunoSpot R©Analyzer Cellular Technology
Microscope Nikon
Microwave Matsui
-20◦C freezer Lec
-80◦C freezer Sanyo
Nanodrop ND1000 microspectrophotometer Nanodrop Technologies
96-well plate harvester Packard
96-well plate reader Tecan
NucleofectorTM Amaxa
Orbital shaker Stuart
Progene thermal cycler (for conventional PCR) Techne
Power packs Bio-Rad
ICycler iQ Multicolor Real-Time
PCR Detection System Bio-Rad
Rotor-Gene 6000 Corbett Research
Refrigerated microcentrifuge Hettich Zentrifugen
Semi-dry transfer apparatus Bio-Rad
Sonicator VWR
Spectrophotometer (SP Bio) Sanyo
37◦C, 5% CO2 incubator Forma Scientific
Top count scintillation counter Packard
Tubing prep station Bio-Rad
UNO-Thermoblock Biometra
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UV spectrophotometer Sanyo
UV transilluminator Ultra Violet Products
Water baths Grant instruments
2.1.3 Buffers
Buffers for bacterial cell culture:
LB broth LB Agar
5g NaCl 5g NaCl
10g tryptone 10g tryptone
5g yeast extracts 5g yeast extracts
pH adjusted to 7.0 with NaOH 15g agar
Completed to 1,000ml with ddH2O pH adjusted to 7.0 with NaOH
Autoclaved Completed to 1000ml with ddH2O
Autoclaved
Buffers for DNA extraction from bacterial cell culture:
GTE solution 1% SDS/0.2M NaOH solution
50mM glucose 100µl NaOH (10M)
25mM Tris-HCl (pH 8.0) 500µl 10% SDS
10mM EDTA 4.4ml ddH2O
KOAc solution
60ml 5M KOAc
11.5ml glacial acetic acid
28.5ml ddH2O
Buffers for tissue culture:
Trypan blue White cell counting solution
Dilute the purchased 0.4% solution Dilute 100% acetic acid to a 0.6%
to 0.1% v/v in PBS v/v solution in PBS
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Buffers for flow cytometry and confocal microscopy:
FACS buffer Solution to permeabilise cells
0.1% w/v BSA Dilute 4% paraformaldehyde solution (kept at 4◦C)
0.02% w/v NaN3 to 1% v/v in PBS
1x PBS
Solution to fix cells
70% v/v ethanol in PBS
Buffers for immunohistochemistry:
Primary antibody solution Secondary antibody solution
(frozen sections) (frozen sections)
2µg/ml rabbit anti-BUC11 antibody 2µg/ml goat anti-rabbit IgG-biotin
5% (v/v) goat serum 1.5% (v/v) goat serum
Completed to final volume with PBS Completed to final volume with PBS
2µg/ml Polyclonal rabbit IgG
isotype control
5% (v/v) goat serum
Completed to final volume with PBS
Primary antibody solution Secondary antibody solution
(paraffin-embedded sections) (paraffin-embedded sections)
10µg/ml rabbit anti-BUC11 antibody 3.8µg/ml goat anti-rabbit IgG-biotin
5% (v/v) goat serum 1.5% (v/v) goat serum
Completed to final volume with PBS Completed to final volume with PBS
ABC reagent (working solution) DAB reagent(working solution)
2.5ml PBS 2.5ml ddH2O
1 drop reagent A 1 drop buffer
1 drop reagent B 2 drops DAB
1 drop H2O2 30%
Citrate buffer
27ml 0.01M citric acid
123ml 0.1M sodium citrate
Completed to 1,500ml with ddH2O
pH to 6.0
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Buffers for Enzyme-Linked ImmunoSorbent Assay (ELISA):
Wash buffer Blocking agent
0.05% (v/v) Tween 20 in PBS 3% (w/v) Marvel in PBS
Primary antibody solution Secondary antibody solution
serial dilutions of rabbit anti-BUC11 1:1000 dilution of Swine anti-rabbit
antibody made in blocking agent IgG-HRP in blocking agent
Substrate solution Stop solution
1 volume colour reagent A 2.5M H2SO4
1 volume colour reagent B
Buffers for Mass Spectrometry:
Lysis buffer for MALDI analysis
9.5M Urea
2% (w/v) DTT
1% (w/v) OGP
Aliquoted and stored at -80◦C
Buffers for Enzyme-Linked ImmunoSorbent SPOT (ELISPOT):
Buffer for Pan T Cell Isolation Capture Antibody working solution
0.5% BSA For each 96 well plate: 2 aliquots
2mM EDTA of Capture Antibody Concentrate
Completed to final volume with Completed to final volume
PBS pH 7.2 and degassed of 10ml with PBS
Wash Buffer Blocking Buffer
0.05% Tween 20 in PBS 1% BSA
5% sucrose
Completed to final volume in PBS
Reagent Diluent Detection Antibody working solution
1% BSA in PBS For each 96 well plate: 2 aliquots
pH 7.2-7.4, filtered of Detection Antibody Concentrate
Completed to final volume
of 10ml with PBS
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Streptavidin-AP working solution
For each 96 well plate:
167µl of Streptavidin-AP
Completed to final volume
of 10ml in Reagent Diluent
Buffers for Agarose gel electrophoresis or Western Blotting:
50x TAE Orange G DNA loading buffer
242g Tris 12.5mg orange G powder
57.1ml glacial acetic acid 1.5ml glycerol
100ml 0.5M EDTA (pH 8.0) Completed to 5ml with ddH2O
Make up to 1000ml with ddH2O
Dilute 1:50 in ddH2O
for working solution
Ammonium Persulphate (APS) Reducing sample buffer
100mg in 1ml of distilled water 2.5 ml of 0.5M Tris-HCl pH 6.8
Fresh frozen (-80◦C) into aliquots 0.4g of 2% w/v SDS
2ml of 10% v/v Glycerol
200mg of 1% w/v DTT
0.04g of 0.2% w/v Bromophenol
blue
Make up to 20ml with ddH2O
Running buffer Transfer buffer
100ml of Ultra Pure 10x Tris/Glycine/SDS 100ml Ultra Pure 10x
Tris/Glycine
(0.25M Tris, 1.92M Glycine, 1%SDS) (0.25M Tris, 1.92M Glycine)
Make up to 1000ml with ddH2O 200ml of methanol
(0.025M Tris, 0.192M Glycine, 0.1% SDS) Make up to 1000ml with ddH2O
(0.025M Tris, 0.192M Glycine)
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Tris Buffer Saline (TBS) TBS-Tween 20 (TBST)
5x stock 500µl of Tween 20
12.11g of Trizma base Make up to 1000ml with TBS
146.1g of NaCl
Make up to 1000ml with ddH2O
Adjust pH to 7.5
Dilute 1:5 in ddH2O for
working solution
TBS-Tween 20-Marvel ECL chemiluminescence reagent
2.5g of Marvel 1 volume of solution A
250µl of Tween 20 1 volume of solution B
50ml of TBST
Primary antibody solutions Secondary antibody solutions
1:500 dilution of rabbit 1:2,500 dilution of Swine
anti-BUC11 antibody (1mg/ml) anti-rabbit IgG-HRP (0.76mg/ml)
in TBS-Tween 20-Marvel in TBS-Tween 20-Marvel
1:1,000 dilution of rabbit 1:5,000 dilution of
IgG isotype control (2mg/ml) Streptavidin conjugated HRP
in TBS-Tween 20-Marvel (1mg/ml) in TBS-Tween 20-Marvel
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2.1.4 Gels
Agarose gel:
1.5% agarose gel (small) 1.5% agarose gel (medium)
0.75g of agarose 2.25g of agarose
50ml of 1x TAE 150ml of 1x TAE
5µl of Ethidium bromide 15µl of Ethidium bromide
Protein gel:
15% resolving gel 4% stacking gel
To prepare 2 gels: To prepare 2 gels:
7.5ml of Protogel 1.04ml of Protogel
3.74ml of resolving gel buffer 2ml of stacking gel buffer
3.5ml of ddH2O 4.88ml of ddH2O
150µl of APS 40µl of APS
15µl of TEMED 8µl of TEMED
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2.1.5 Primary culture media
Culture media were prepared and used within one month. Complete BM-DC medium
was prepared fresh, just before use.
Bone-Marrow Dendritic cell T cell medium:
(BM-DC) medium: 500ml of RPMI
500ml of RPMI 10% (v/v) of FCS
5% (v/v) of FCS 2mM of L-glutamine
2mM of L-glutamine 20mM of HEPES
10mM of HEPES 50µM of 2-mercaptoethanol
50µM of 2-mercaptoethanol 50U/ml of Penicillin/Streptomycin
25U/ml of Penicillin/Streptomycin 0.25µg/ml of Fungizone
0.25µg/ml of Fungizone
Complete BM-DC medium:
BM-DC medium
1ng/ml mGM-CSF
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2.1.6 Cell lines and their media
The cell lines and their corresponding culture media used in this project are outlined
in Table 2.1.
Table 2.1: Cell lines and their description.
The cell line MDA435 was known as a breast cancer cell line until recently. That is why
it was used as such during this study and appeared as such in Chapter 3. In their study
published in 2007, Rae and colleagues concluded that the stocks of MDA435 cells are,
without any doubt, all derived from the melanoma cell line M14 (Rae et al., 2007).
2.2 Methods
2.2.1 Expression analysis
2.2.1.1 RNA extraction and cDNA synthesis
Dr. R. Ferris (USA) and Prof. D. Schadendorff (Germany) kindly provided the samples
of head and neck carcinoma and the samples of melanoma, respectively. Dr. Aija Line
(Latvia) kindly provided the samples of colon, gastric and breast carcinoma mRNA (with
patient-matched normal tissue mRNA). Dr A. Gritzapis (Greece) generously provided a
total of 218 frozen breast tissues which correspond to paired normal and tumour tissues
from 109 breast cancer patients. The mRNA samples from normal tissues were purchased
from Clontech (UK). The mRNAs from human cell lines were extracted from cells cul-
tured at the laboratory (see Table 2.1).
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Total RNAs were isolated from various cell lines and tissues using RNA STAT-60TM
according to the manufacturer’s protocol. For extracting RNA from frozen tissues, the
tissue was grounded in liquid nitrogen in a Class II safety cabinet using a mortar and
pestle to a powder which was then homogenised in 1ml of RNA STAT-60TM, transferred
to a 1.5ml Eppendorf tube and stored at room temperature (RT) for 5 minutes. For ex-
tracting RNA from cell lines, suspension cells were pelleted at 1,500rpm for 3 minutes
and lysed in a Class II safety cabinet with 1ml RNA STAT-60TM. For adherent cells, 1ml
RNA STAT-60TMwas directly added to the culture vessel to lyse them. The homogenate
was then transferred to a 1.5ml Eppendorf tube and stored at room temperature (RT) for
5 minutes. Then, under a fume hood, 0.2ml of chloroform was added to the homogenate
and the tube was shaken vigorously by hand for 60 seconds and left at RT for 3 minutes.
The samples were centrifuged at 14,000rpm for 15 minutes at 4◦C. The colourless up-
per aqueous phase which contained the RNA was transferred to a fresh 1.5ml Eppendorf
tube, mixed with 0.5ml of isopropanol and the tube was stored at RT for 8 minutes. The
samples were centrifuged at 12,000rpm for 10 minutes at 4◦C. The supernatant was dis-
carded and the white pellet was washed with 1ml 75% ethanol. The RNA pellet was dried
under the fume hood and re-suspended in double-distilled water (ddH2O) by passing it
few times through the pipette tip. The concentration and purity of the isolated RNA was
measured with a UV spectrophotometer. Samples were diluted 1:100 in ddH2O and ab-
sorbance was measured at 260nm and 280nm.
Total RNA was reverse transcribed into cDNA using M-MLV RT following manu-
facturer’s instructions. The reverse transcription was either carried out with Oligo(dT)15
primers (Promega, UK) or random primers (Promega, UK). Random primers were the
primers of choice when the cDNA was going to be used in quantitative RT-PCR assay
screening several reference genes. The cDNA synthesis using Oligo(dT)15 primers was
carried out as follows. In a 0.5ml Eppendorf tube, 2µg of total RNA (or all the RNA
solution if less than 2µg available) was mixed with 1µl of Oligo(dT)15 primer solution
and ddH2O was added to make the final volume to 10µl. The tube was heated in a thermal
block at 70◦C for 5 minutes, immediately cooled on ice and briefly spun in a microcen-
tifuge. The following mix of components was added to the tube at RT: 5µl of 5X M-MLV
RT buffer (Promega, UK), 1µl of dNTP (12.5mM of each dATP, dTTP, dGTP and dCTP),
0.7µl of RNasin R©ribonuclease inhibitor (Promega, UK), 1µl of M-MLV RT and 7.3µl of
ddH2O. The tube was gently mixed and incubated in a waterbath at 39.2◦C for 80 minutes.
The tube was then heated in a thermal block at 95◦C for 5 minutes. The cDNA was cooled
on ice, spun briefly and stored at -20◦C. The cDNA synthesis using random primers was
carried out as follows. In a 0.5ml Eppendorf tube, 2µg of total RNA (or all the RNA
solution if less than 2µg available) was mixed with 0.5µl of random primer solution and
ddH2O was added to make the final volume to 10µl. The tube was heated in a thermal
block at 70◦C for 5 minutes, immediately cooled on ice and briefly spun in a microcen-
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tifuge. The following mix of components was added to the tube at RT: 5µl of 5X M-MLV
RT buffer (Promega, UK), 1µl of dNTP (12.5mM), 0.7µl of RNasin R©ribonuclease in-
hibitor (Promega, UK), 1µl of M-MLV RT and 7.3µl of ddH2O. The tube was gently
mixed and incubated in a waterbath at 37◦C for 60 minutes. The tube was heated in a
thermal block at 95◦C for 5 minutes and then immediately cooled on ice, spun briefly and
stored at -20◦C.
2.2.1.2 Primers for Polymerase Chain Reaction (PCR)
Primer sequences were either taken from literature when available or designed to
cover two different exons in the sequence to eliminate amplification of trace amounts
of genomic DNA in the cDNA samples where possible. Some of the primers were de-
signed to generate PCR products of under 250 base pairs (bp) in size to optimise the
quantitative RT-PCR. Primer design was carried out with the assistance of the Primer3
program (http://biotools.umassmed.edu/bioapps/primer3www.cgi).
The primers were supplied by Eurofins MWG Operon (UK). The name, the sequences,
the temperature of annealing (Ta) and the extension time of all the primers used in this
study are listed in Table 2.2 and Table 2.3.
Table 2.2: Primers used for PCR of BUC genes, NY-BR-1 gene and reference genes.
The DNA polymerase used for non- or semi-quantitative RT-PCR with all these primers
was the BioTaq DNA polymerase. The number of cycles used for non- or semi-
quantitative RT-PCR was 30. “Ta” is the temperature of annealing in degree Cel-
sius. “Time” is the time of the extension step during the PCR, in seconds (s). The
primers “BUC11 FR3R3” were used for the semi-quantitative and quantitative RT-PCR of
hCG25653 gene and designed just after the protein-coding region. The primers “BUC11
FR4R4” were also used for the quantitative RT-PCR of hCG25653 gene and designed
within the protein-coding region. “BUC11 F5R5” primers were designed to flank the
coding region of hCG25653 gene and used for the cloning in the mammalian expres-
sion vector pBudCE4.1. Each “BUC11 F5R5” primer has 4 common bases “TCA” at
their 5’ end then the forward primer has the recognition site for the restriction enzyme
SalI (GˆTCGAC) and the reverse primer has the recognition site for the enzyme XbaI
(TˆCTAGA).
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Table 2.3: Primers used for PCR of genes screened in the BUC11 gene knockdown study.
“Ta” is the temperature of annealing in degree Celsius. “Time” is the time of the extension
step during the PCR, in seconds (s).
2.2.1.3 Semi-quantitative Polymerase Chain Reaction
The non- or semi-quantitative RT-PCR reaction was performed in the Techne Pro-
gene PCR machine using either the BIOTAQTMDNA Polymerase or the PhusionTMHigh-
Fidelity DNA Polymerase. The RNA extracted from cell lines and tissues were pre-
screened for the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
GAPDH was then used to normalise the mRNA levels between the samples.
For each reaction with the BIOTAQTMDNA Polymerase, thermocycling was done in
a final volume of 25µl containing 1µl of template cDNA (or 1µl of ddH2O for nega-
tive control), 2.5µl of the buffer for the polymerase, 0.75µl of MgCl2, 0.4µl of dNTPs
(12.5mM of each dATP, dTTP, dGTP and dCTP), 1µl of gene-specific forward primer, 1µl
of gene-specific reverse primer (20mM), 0.125µl of polymerase and 18.225µl of ddH2O.
The cycling conditions were as follows: melting step at 95◦C for 3 minutes, (denaturation
at 94◦C for 1 minute, annealing at primer-specific Ta for 1 minute, extension at 72◦C for
primer-specific time) x appropriate number of cycles, final extension step at 72◦C for 5
minutes and 4◦C forever.
For each reaction with the PhusionTMHigh-Fidelity DNA Polymerase, thermocycling
was done in a final volume of 50µl containing 1.5µl of template cDNA (or 1.5µl of ddH2O
for negative control), 10µl of Phusion buffer HF, 1µl of dNTPs (12.5mM of each dATP,
dTTP, dGTP and dCTP), 1µl of gene-specific forward primer, 1µl of gene-specific reverse
primer (20mM), 0.5µl of polymerase and 35µl of ddH2O. The cycling conditions were as
follows: melting step at 98◦C for 30 seconds, (denaturation at 98◦C for 10 seconds, an-
nealing at primer-specific Ta + 3◦C for 20 seconds, extension at 72◦C for primer-specific
time) x appropriate number of cycles, final extension step at 72◦C for 5 minutes and 4◦C
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forever.
2.2.1.4 Agarose gel electrophoresis
15µl minimum of the final PCR products were mixed with 5µl of 5X DNA loading
buffer Orange G and subsequently size separated on 1.5% (m/v) agarose Tris-Acetate-
EDTA (TAE) gel. The gel was prepared by repeated heating in a microwave and con-
tained 0.0001% (v/v) of ethidium bromide for band visualisation. To approximate the
size of the PCR products on electrophoresis, the samples were run along with 0.1µg of
DNA ladder 1Kb Plus. The electrophoresis runs were conducted at 100 volts for 1 hour
and 30 minutes to 2 hours. The PCR products were visualised under UV light.
2.2.1.5 Quantitative Polymerase Chain Reaction
The standard curve was prepared by serial dilution of cDNA from a sample (tissue
or cell line) known to express well the gene of interest: undiluted sample, 1/10, 1/100,
1/1,000 and 1/10,000. The RT-Q-PCR reactions were performed in the i Cycler Q Multi-
color Real Time PCR detection system (Bio-rad, USA) and later on in the study in the new
Rotor-Gene 6000 (Corbett Research, UK), using iQTMSYBR R©Green Supermix. Dupli-
cates were carried out for each tissue or cell line to test. Thermocycling for each reaction
was done in a final volume of 12.5µl containing 0.5µl of template or standard, 6.25µl of
SYBR R©Green Supermix, 0.5µl of gene-specific forward primer, 0.5µl of gene-specific
reverse primer and 4.75µl of ddH2O. In each experiment, 6 “no template” controls have
been included to ensure no contamination has occurred and also to indicate the degree of
amplification due to primer dimers. The cycling conditions were as follows: melting step
at 95◦C for 3 minutes, (denaturation at 95◦C for 30 seconds, annealing at primer-specific
Ta for 30 seconds, extension at 72◦C for primer-specific time) x 45 cycles. Finally, a
melting (dissociation) curve was acquired by slowly ramping the temperature from Ta to
95◦C by 1◦C increment.
The fluorescence of each sample was measured at the end of annealing step or ex-
tension step and at the end of each cycle in the case of the dissociation curve. The Ct
value, which corresponds to the number of cycles at which the reaction crosses a thresh-
old value (fluorescence exceeds the background level), was calculated by the software so
as the standard curve. Following completion of the quantitative RT-PCR reaction, the Ct
value for each sample and the standard curve were recorded. The standard curve method
was used for the quantification of the results as follows. The standard quantity (SQ) mean
for the gene of interest was divided by the SQ mean of the housekeeping gene which
resulted in the normalised mRNA expression of the gene of interest in the tissues or cell
lines.
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Assuming that primer efficiencies are similar for the genes studied, the standard curve
can be omitted from the assay, allowing more samples to be screened. The comparative Ct
method is therefore used for the quantification of the results. Following completion of the
quantitative RT-PCR that did not include a standard curve, the analysis of the results was
carried out using the comparative Ct method, also known as the 2−[delta][delta]Ct method,
where [delta][delta]Ct=[delta]Ct,sample-[delta]Ct,reference Here, [delta]Ct,sample is the Ct
value for any sample normalised to the housekeeping gene and [delta]Ct,reference is the Ct
value for the calibrator also normalised to the housekeeping gene. The result is given as
a relative gene expression level of the gene of interest in the tissues or cell lines.
2.2.1.6 Cell lysate preparation
Cells, from cell lines cultured in the laboratory, were harvested and washed twice in ice
cold PBS at 1,500rpm for 3 minutes at 4◦C. Depending on the size of the pellets, cells
were re-suspended in either 50µl or 100µl of ddH2O for lysis and transferred to Eppendorf
tubes. The lysates were kept on ice for 10 minutes, sonicated for 1 minute, placed on a
rotating wheel in a cold room for 30 minutes, left on ice again for 30 minutes and finally
centrifuged at 14,000rpm for 30 minutes at 4◦C. Supernatants were transferred to fresh
Eppendorf tubes and stored at -80◦C until analysis (protein assay and SDS-PAGE) and
further use (Western Blotting, Immunoassays, etc.).
2.2.1.7 Protein assay
The protein concentration in the lysates was measured by performing a Bio-Rad Dc pro-
tein assay in a 96-well plate according to the manufacturer’s protocol. Briefly, the protein
standard was made of BSA diluted in ddH2O (buffer used for lysis of cells) in serial dilu-
tion, from 1.5mg/ml to 0.22mg/ml. 20µl of reagent S was added to each ml of reagent A.
25µl of reagent A (+S) was added to 5µl of samples (each sample run in duplicate) and
200µl of reagent B was then added to each well. The plate was wrapped in foil and the
reaction was left to develop for 15 minutes at RT. Finally, the plate was read at 750nm on
a Tecan 96-well plate reader.
2.2.1.8 Sodium Dodecyl Sulphate PolyAcrylamide Gel Electrophoresis (SDS-PAGE)
Protein samples were defrosted and diluted in reducing sample buffer at a ratio 3:1. The
proteins were denatured by boiling the samples at 95◦C for 5 minutes in a thermal block.
Samples (about 30µg) were loaded to individual wells of the acrylamide gel placed in the
electrophoresis chamber, along with biotinylated protein marker. The gel (100cm2) was
run at 100 volts (V) through the 4% stacking gel and at 150V through the 15% resolving
gel.
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2.2.1.9 Semi-Dry Western Blotting
Proteins, separated by size by SDS-PAGE, were then transferred at 13V for 30 minutes
onto a nitrocellulose membrane using a semi-dry transfer unit according to the manufac-
turer’s protocol. The membrane was then stained with Ponceau S and cut into the ap-
propriate pieces for immunoprobing. The membrane was washed 3 times in TBS-Tween
20 to remove Ponceau S and blocked overnight in TBS-Tween 20-Marvel, on an orbital
shaker in a cold room.
The peptide block was prepared by mixing the desired amount of primary antibody with
5 fold (by weight) excess of peptide, as follows. 20µg of antibody was gently mixed to
100µg of peptide, all diluted in TBS-Tween 20-Marvel to make up 500µl, and left at RT
for 30 minutes to 2 hours prior adding the pre-incubated antibody/blocking peptide to
9,500µl of TBS-Tween 20-Marvel.
The membrane was washed 3 times for 15 minutes in TBS-Tween 20 at RT on an orbital
shaker. The primary antibody solution (see Materials) was added to the membrane which
was incubated for 3 hours on an orbital shaker at RT. Then, the membrane was washed
3 times for 15 minutes in TBS-Tween 20 at RT on an orbital shaker. The secondary an-
tibody solution (see Materials) was added to the membrane which was incubated for 2
hours at RT on an orbital shaker. The membrane was then washed 4 times for 15 minutes
in TBS-Tween 20 at RT on an orbital shaker, revealed with ECL Western Blotting kit
reagents and the luminescence was detected on Hyperfilm ECL films in a dark room.
2.2.1.10 Fluorescent activated cell sorting (FACS)
The following protocol was used for staining the DNA for cell cycle analysis. Briefly,
72 hours after transfection experiment, adherent cells were trypsinised, transferred to
FACS tubes and washed twice with FACS buffer for 3 minutes at 1,500rpm at 4◦C. The
supernatant was discarded and the pellet resuspended gently in the FACS buffer remaining
in the tube. The tubes were placed on ice and 1ml ice cold 70% ethanol was mixed in
order to fix the cells. Then, the cells were washed twice in FACS buffer as before and the
pellet was resuspended in 1ml FACS buffer with 1µl of Rnase solution (100mg/ml) and
50µl of Propidium Iodide solution (1mg/ml). The tubes were incubated at 37◦C for 20
minutes and placed on ice while performing the FACS analysis on the flow cytometer.
2.2.1.11 Enzyme-Linked ImmunoSorbent Assay (ELISA)
The following protocol corresponds to the heterologous, non-competitive, solid-phase
ELISA. Briefly, BUC11 peptide (to which Rabbit anti-BUC11 antibody has been raised,
1mg/ml stock solution) was diluted in PBS in serial dilution. 200µl of peptide dilu-
tions was added to the 96-well plate. The dilutions used were: 1:50 (20µg/ml), 1:100
(10µg/ml), 1:200 (5µg/ml), 1:400 (2.5µg/ml), 1:800 (1.25µg/ml), 1:1,600 (0.625µg/ml)
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and 1:3,200 (0.3125µg/ml). A blank without any peptide was added. The plate was
wrapped in foil and incubated at 4◦C overnight. Then, the antigen solution was discarded
by inversion in the sink and the wells washed 3 times with wash buffer. The plate was
dried by inversion onto absorbent paper. 200µl of blocking agent was added to each well
and the plate, wrapped in foil, was incubated for 3 hours at RT to block excess protein
binding sites. The wells were washed as before 3 times with wash buffer and dried again.
Rabbit anti-BUC11 antibody (3mg/ml, stock solution) was diluted in blocking agent in se-
rial dilution. 100µl of antibody dilutions was added to the 96-well plate (duplicate wells).
The dilutions used were: 1:2,500 (400ng/ml), 1:3,333 (300ng/ml), 1:5,000 (200ng/ml),
1:10,000 (100ng), 1:20,000 (50ng/ml) and 1:100,000 (10ng/ml). The plate was wrapped
in foil and incubated for 2 hours at RT. The wells were washed 4 times with wash buffer
as before. 100µl of swine anti-rabbit IgG-HRP solution was added to the wells and the
plate, wrapped in foil, was incubated for 2 hours at RT. The wells were washed 4 times
with wash buffer as before, 100µl of substrate solution was added to them and the plate,
wrapped in foil, was incubated for 10 to 30 minutes, until an appropriate blue colour de-
veloped. The reaction was stopped with 50µl of stop solution. Finally, the plate was read
at 450nm on a Tecan 96-well plate reader.
A second ELISA was subsequently performed, using the same protocol but with the
following dilutions of antibody and peptide. The peptide dilutions used were: 1:500
(2µg/ml), 1:1,000 (1µg/ml), 1:2,000 (0.5µg/ml), 1:4,000 (0.25µg/ml), 1:8,000 (0.125µg/-
ml), 1:16,000 (0.0625µg/ml) and 1:32,000 (0.03125µg/ml). The antibody dilutions used
were: 1:25,000 (40ng/ml), 1:100,000 (10ng/ml), 1:200,000 (5ng/ml), 1:400,000 (2.5ng/-
ml), 1:800,000 (1.25ng/ml) and 1:1,600,000 (0.63ng/ml).
2.2.1.12 Immunofluorescence
Briefly, 300µl of culture media containing 1.7x104 adherent cells were plated in each
chamber of 8-chamber slides and incubated overnight at 37◦C. The media was removed
and the cells were washed twice with cold FACS buffer very gently, by pipetting on the
side of the chamber. The cells were permeabilised with 100µl/chamber of 1% (w/v)
paraformaldehyde for 10 minutes at RT, washed twice as before and then fixed with
100µl/chamber of ice cold 70% ethanol for 10 minutes at RT. Rabbit anti-BUC11 an-
tibody was used at a concentration of 0.005µg of antibody per 1µl of FACS buffer. The
peptide block was prepared by mixing 5µg of antibody to 100µg of peptide, all diluted in
FACS buffer. 100µl of primary antibody solution and peptide block solution was added
to designated chambers and the slides were incubated on ice for 45 minutes. Then, cells
were washed twice as before and 100µl of swine anti-rabbit IgG-FITC (0.005µg of an-
tibody per 1µl of FACS buffer) was added to the appropriate chambers. The slides were
incubated on ice, in the dark, for 30 minutes. Cells were then washed 3 times with FACS
buffer and the slides were dried at 37◦C. Before the slides were dried, in some experi-
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ments, DRAQ5TM(far-red fluorescent DNA dye) was added to the corresponding cham-
bers as follow: 125µl of PBS mixed with 0.25µl of neat DRAQ5TMwas added to each
chamber, incubated at 37◦C for 3 minutes then removed. The slides were mounted with
fluorescent mounting media and left at 4◦C for 3 hours to overnight. Finally, slides were
studied under a confocal microscope. The laser (blue light) of the microscope excites the
FITC molecules which consequently emit a visible green light.
2.2.1.13 Immunohistochemistry
Paraffin-embedded multiple normal and tumour tissue microarrays (BN241, BN242
and BR242) were purchased from US Biomax. Frozen melanoma tissue sections were
kindly provided by Prof. D. Schadendorff (Germany). Frozen prostate tissues were kindly
provided by clinicians at Nottingham City Hospital (Nottingham, UK) and were sectioned
in our laboratory. Frozen sections were stored at -80◦C and the paraffin-embedded tissue
microarrays at RT, until immunohistochemistry assays were performed.
Dr A. Gritzapis (Greece) kindly provided a total of 218 frozen breast tissues which
correspond to paired normal and tumour tissues from 109 breast cancer patients. All these
tissues were mounted and sectioned as follows. Firstly, glass slides for sectioning were
prepared with the following protocol. In a fume cupboard, slides were immersed in a
bath of acetone for 5 minutes, in a bath of 2% (v/v) silane in acetone for 5 minutes and,
after draining, in a different bath of acetone for 5 minutes. The slides were left to dry
in the fume cupboard and stored at RT. The tissues were defrosted, quickly mounted in
mounting liquid on cardboard pieces and re-frozen in liquid nitrogen. Mounted tissues
were stored at -80◦C until further use. In a cryostat, with the temperature of the blade set
at -29◦C and the temperature of the chamber set at -19◦C, tissue sections of 7µm were
applied on the glass slides. The slides were left at RT overnight. For mass spectrometry
analysis using Matrix-assisted laser desorption/ionization (MALDI), about 10 sections
(7µm) of each breast tissue were transferred into a 1.5ml Eppendorf tube and mixed with
100µl of lysis buffer, by pipetting up and down several times. The sample was sonicated
for 30 seconds, vortexed for 30 seconds and stored at -80◦C until further use. To fix the
sections, the slides were immersed in a mix of 50% (v/v) methanol and 50% (v/v) ace-
tone for 5 minutes at RT. The fixed sections were then frozen at -80◦C until assayed by
immunohistochemistry.
Antigen retrieval was performed on paraffin-embedded tissue microarrays as follows.
The slides were baked for 2 hours at 60◦C to melt the wax. The wax was then removed
in a bath of xylene for 5 minutes followed by a different bath of xylene for 5 minutes.
The sections were re-hydrated in graded ethanol (100%, 100% and 70% (v/v), each for
3 minutes) and rinsed in running tap water for 15 minutes. Citrate buffer was heated in
the microwave for 10 minutes on full power or until boiling. The slides were added to the
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near boiling citrate buffer which was further heated in the microwave on full power for
10 minutes. Slides were then rinsed in the running tap water for 15 minutes and finally
rinsed with ddH2O.
At this step, immunohistochemistry for both frozen tissues and paraffin-embedded tissues
follows the same protocol. Frozen sections were taken out of the -80◦C freezer, left to
adjust to RT and placed in a bath of 1X PBS for 5 minutes. 0.3% (v/v) H2O2 diluted in
1X PBS was added to the tissue sections for 5 minutes. Tissues were then rinsed with 1X
PBS and placed in a bath of 1X PBS for 5 minutes. 10% (v/v) goat serum (made from
the species of the secondary antibody) diluted in 1X PBS was then added to block the
sections for 20 minutes. The excess of serum was then shaken off and the sections were
carefully blotted around. The primary antibody solution (see Materials) was added to the
tissues and the slides were incubated overnight at 4◦C. The staining of tissue sections with
rabbit IgG isotype control and of sections from the same tissue (on a different slide) with
anti-BUC11 antibody was always carried out at the same time. Tissues were then rinsed
with 1X PBS and placed in a bath of 1X PBS for 5 minutes. The secondary antibody
solution (see Materials) was added to the tissues and the slides were incubated at RT for
30 minutes. Meanwhile, ABC reagent was made up and left to stand 30 minutes. Tissues
were then rinsed with 1X PBS and placed in a bath of 1X PBS for 5 minutes. The wash
step was repeated once more. The ABC reagent was added to the tissues and left to react
for 30 minutes at RT with the bound secondary antibodies. The slides were then washed
twice as before and the DAB reagent was added onto the slides. The reagent was left to
react with the ABC reagent until a suitable brown colour developed, then the slides were
immediately rinsed in running tap water for 2.5 minutes and in ddH2O for 2.5 minutes.
Paraffin-embedded sections and frozen sections were finally counterstained respectively
for 15 seconds in Gills haematoxylin solution and for 10 seconds in Harris haematoxylin
solution. Tissues were then rinsed in running tap water and fixed consecutively, in a fume
cupboard, in graded ethanol (70% 1 minute, 100% 1 minute, 100% 2 minutes, (v/v))
and in two different bath of xylene for 1 minute each. Slides were mounted with DPX
mountant and a glass cover slip then left to air-dry for several hours. Fixed and mounted
sections were subsequently stored at RT. Tissue staining was observed under the micro-
scope. The scoring of the stained sections was not evaluated by a pathologist.
2.2.2 Cloning of BUC11
PCR products were either cloned into the mammalian expression vector pBudCE4.1
or into pCRII-blunt-TOPO vector following the manufacturer’s protocol.
2.2.2.1 DNA band extraction
Following electrophoresis, in order to use the amplified gene products for sequencing
or cloning into a vector, DNA was extracted and purified from the agarose using the DNA
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Isolation Kit according to the manufacturer’s protocol. Briefly, the agarose gel containing
the DNA was dissolved in the NaI solution for 5 minutes at 55◦C. Then, 30µl of glass
powder was mixed to the solution and incubated at RT for 5 minutes, mixing occasionally
during that time. The DNA bound to the glass powder was then washed three times with
the wash buffer. After centrifugation at 14,000rpm, the pellet was resuspended in 30µl of
ddH2O and incubated at 55◦C for 5 minutes. Following centrifugation at 14,000rpm for
45 seconds, the DNA in suspension within the supernatant was transferred to a fresh tube.
2.2.2.2 DNA ligation
Ligation of cDNA into the vectors was done using T4 ligase following the manufac-
turer’s recommendations. Briefly, 7µl of the enzyme-digested insert was added to 1µl
of the enzyme-double-digested plasmid with 1µl of T4 buffer and 1µl of T4 ligase for a
final volume of 10µl. Then, to complete the ligation process, the mixture was incubated
overnight at 4◦C.
2.2.2.3 Transformation into competent XL1-Blue E.coli cells and bulking up of the
plasmid
The ligated vector/gene product was used to transform XL1Blue cells (chemically
competent E.coli cells). 2µl of the reaction was added onto cells on ice and gently mixed
on ice for 10 minutes to 30 minutes. The cells were then heat shocked at 42◦C for 3
minutes in a waterbath and immediately transferred on ice. 250µl of LB Broth was added
at RT to the cells which were then shaken horizontally at 200rpm, 37◦C for 1 hour. 150µl
and 50µl of culture were subsequently spread onto two LB agar plates containing the re-
quired antibiotic (either 50µg/ml of ampicillin or 30µg/ml of zeocin, depending on the
antibiotic resistance gene expressed by the plasmid of interest) and plates were incubated
at 37◦C overnight in the incubator. The following day, plates were checked for growth of
vector positive colonies.
2.2.2.4 Enzyme digestion
Briefly, PCR products were digested either with one or two restriction enzymes to
generate overhangs for the ligation process. The restriction enzymes used depended on
the cDNA sequences to be cloned and on the recognition sites available in the multiple
cloning sites of the plasmids. The separate digestion of pCRII-blunt-TOPO and gene-
specific PCR products prior to ligation or the digestion, following cloning, of positive
colonies vector pCRII-blunt-TOPO/gene of interest with the restriction enzyme EcoRI
was carried out as follows. For each reaction, 0.1µg of plasmid DNA was mixed with
1µl of restriction enzyme buffer (H), 0.1µl of BSA (10µg/µl), the appropriate amount of
ddH2O to a final volume of 9.75µl and 0.25µl of EcoRI enzyme. The mix was incubated
2 hours in a waterbath at 37◦C. The digested products were then loaded on an agarose
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gel for electrophoresis as described previously. The separate digestion of pBudCE4.1 and
BUC11-specific PCR products prior to ligation or the digestion, following cloning, of
positive colonies vector pBudCE4.1/BUC11 using the two restriction enzymes SalI and
XbaI was done as follow. For each reaction, 3µl of plasmid DNA was mixed with 0.5µl
of restriction enzyme buffer (D), 0.5µl of BSA, 0.5µl of SalI enzyme and 0.5µl of XbaI
enzyme. The mix was incubated 2 hours in a waterbath at 37◦C. For one tube, the restric-
tion enzymes have been replaced with ddH2O to include a negative control. The digested
products were then loaded on an agarose gel for electrophoresis as described previously.
2.2.2.5 DNA isolation and sequencing
Each picked colony which has grown on the LB agar plate is immersed into 3ml of LB
broth containing antibiotic (concentrations as before) and incubated shaking overnight
at 37◦C. The following day, 1.5ml of culture was centrifuged at room temperature at
14,000rpm for 5 minutes. All the following centrifugations are performed under the same
conditions. The supernatant was discarded, the pellet resuspended in 100µl cold GTE
and incubated 5 minutes on ice. Then 200µl of 1% SDS/0.2M NaOH solution was added
and the tube incubated 5 minutes on ice. Afterwards, 150µl of Potassium acetate (KOAc)
solution was mixed and the tube was incubated 5 minutes on ice. The tube was cen-
trifuged, the supernatant was collected in a fresh tube and the pellet discarded. 800µl of
the bottom layer chloroform/isoamyl alcohol was added and the tube vortexed. Then the
tube was centrifuged and the upper layer was collected in a fresh tube and 1ml of 100%
molecular grade ethanol was added. The tube was then incubated at room temperature for
15 minutes and centrifuged. The supernatant was discarded and the pellet washed with
500µl of 70% molecular grade ethanol. The tube was centrifuged and the pellet was air
dried for 30 minutes on the bench. Finally the pellet was resuspended in 30µl to 50µl
ddH2O with 1µl RNase. The concentration and purity of the isolated DNA was measured
with a spectrophotometer. Samples were diluted 1:100 in ddH2O and absorbance was
measured at 260nm and 280nm. The purified PCR products were sent to MWG Biotech
for sequencing (Value read).
The sequencing for the BUC genes was carried out using PCR products obtained with
the following protocol. For each reaction with the PhusionTMHigh-Fidelity DNA Poly-
merase, thermocycling was done in a final volume of 50µl containing 1.5µl of BR13
(breast cancer tissue) DNA (or 1.5µl of ddH2O for negative control), 10µl of Phusion
buffer HF, 1µl of dNTPs, 1µl of BUC6 forward primer, 1µl of BUC9 reverse primer
(20mM), 0.5µl of polymerase and 35µl of ddH2O. The cycling conditions for the re-
actions was as follow: 98◦C 30 seconds, (98◦C 10 seconds, 62◦C 20 seconds, 72◦C 1
minute) x 40 cycles, 72◦C 5 minute, 4◦C forever. This protocol was repeated in the same
way for BUC9 forward primer with BUC10 reverse primer and BUC10 forward primer
with BUC11 reverse primer. The PCR products were loaded on an agarose gel and, after
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electrophoresis, PCR products were isolated as described previously. The purified PCR
products were sent to MWG Biotech for sequencing (Value read). The sequencing results
were aligned in SPIDEY alignment tool (http://www.ncbi.nlm.nih.gov/spidey/) against
genomic DNA.
2.2.3 Gene induction or silencing
2.2.3.1 DNA transfection
Electroporation was the method of choice to transiently transfect cells as the experi-
ments using Lipofectamine 2000 were proven unsuccessful. The transfection was carried
out using the Amaxa R©Cell line Nucleofector R©Kit V for K562 cells as per the man-
ufacturer’s instructions. Briefly, 1x106 of non-adherent ALC cells used per reaction
were centrifuged at 1,000rpm for 10 minutes. The pellet was resuspended in 100µl of
Nucleofector R©Solution V at RT and mixed with the required amount of plasmid DNA:
pKKN2 with either pBudCE4.1/- or pBudCE4.1/BUC11, to a ratio of 1:2.5. The sam-
ple was then transferred into an Amaxa certified cuvette which was closed with a cap
and inserted into the cuvette holder of the NucleofectorTM. When the program for the
electroporation has finished, 500µl of pre-warmed culture medium (no antibiotics) was
added to the cells which were then immediately transferred using the provided plastic
pipette to a well of a 6-well plate containing pre-warmed culture medium. When neces-
sary, zeocin (50µg/ml) was added to the culture medium 48 hours following transfection.
The following day, cells were harvested for expression analysis at different time points
using MACSelect Microbeads and MS columns according to the manufaturer’s protocol.
Briefly, the transfected cells were centrifuged at 1,000rpm for 10 minutes and the pellet
was resuspended in 320µl of the degassed, pre-cooled PBE solution. The cells were then
magnetically labelled by incubating them with 80µl of MACSelect Microbeads on ice
for 15 minutes (final volume adjusted to 2ml with PBE). The MS column was placed in
the magnetic field of a suitable MAC separator and prepared by rinsing with 500µl of
PBE. All of the cell suspension was then added to the column and unlabelled cells were
collected in a fresh tube. The column was washed 4 times with 500µl of PBE with the
unlabelled fraction being collected. The column was then removed from the separator
and place in a suitable collection tube. Either 1ml of PBE or culture medium, depending
on the subsequent use of the cells, was added onto the column and the transfected cells
were immediately flushed out by firmly applying the supplied plunger.
2.2.3.2 Small interfering RNA (siRNA) transfection
The siRNA specific for BUC6 and BUC11 were designed using the online tool from
Ambion siRNA Target Finder (http://www.ambion.com/techlib/misc/siRNA finder). The
siRNA were purchased from Eurogentec (Table 2.4). The transfection of breast cancer
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cell lines SK-BR3-V(-) and MDA231 with gene-specific siRNA was carried out using
INTERFERinTMsiRNA transfection reagent. Cells were plated out at a density of 5x104
cells per well in a 24 well plate in complete medium the day before transfection and
placed in an incubator (37◦C, 5% CO2). The experiment was performed on duplicate
wells. Each experiment comprised cells with gene-specific siRNA, cells with negative
control siRNA, cells with INTERFERinTMalone and cells alone. For each set of two
wells, the procedure was as follow: 2.5µl (40µM) of gene-specific siRNA (or negative
control siRNA) was added to 250µl of OptiMEM R©I Reduced Serum medium and the
tube was vortexed. 5µl of INTERFERinTMwas added and the tube was vortexed for 10
seconds. The mix was then incubated 10 minutes at RT. While incubating, the media
from wells was removed and 100µl of fresh complete media was added to each well.
After incubation, 100µl of INTERFERinTM/siRNA mix was added to wells giving a final
volume of 200µl, during this process the plate was gently rocked to ensure good coverage
of the well. The cells were then placed in the incubator (37◦C, 5% CO2). After 6 hours
incubation, 500µl of fresh complete medium was added to each well. After 24 hours, the
cells were ready to be tested for gene knockdown. RNAs from cells were harvested at
24 hours (and at 48 hours and 72 hours when performing a time course) using the RNA
STAT-60TMmethod as described previously. RNA was reverse transcribed into cDNA
and the gene expression was measured using quantitative RT-PCR as outlined previously.
The Ct values for BUC6 or BUC11 were normalised to those of GAPDH. The Ct value
obtained from cells with gene specific siRNA was compared to the Ct value obtained from
cells with INTERFERinTMalone which indicated the level of specific gene knockdown.
Table 2.4: Sequences of siRNAs used for transfection in the gene knockdown study.
The siRNA specific for BUC6 and BUC11 were designed using the online tool from
Ambion siRNA Target Finder (http://www.ambion.com/techlib/misc/siRNA finder). The
siRNA were purchased from Eurogentec. The sense and antisense strands were annealed.
2.2.3.3 Proliferation assay
Transfected MDA231 cells or ALC cells were used in a tritiated thymidine-based
proliferation assay. Tritiated thymidine was added to the cells (final concentration of
0.037MBq/ml) and incubated at 37◦C in a 5% CO2 incubator for 18 hours. Then, cells
were harvested onto a 96-well filter plate (Luma-Plate 96) with the harvester. After the
plate was dried in an oven for about 2 hours, each well was covered with 40µl of scin-
tillation fluid. The radioactivity, in counts per minute for each well, was detected in a
Top-count scintillation counter.
69
Chapter 2. Materials and Methods 2.2
2.2.3.4 Affymetrix GeneChip R©Microarray
The expression analysis of MDA231 siRNA-transfected cells was carried out using the
GeneChip R© Human Genome U133 Plus 2.0 Array and the NASC Affymetrix service pro-
vided by the University of Nottingham, Sutton Bonington Campus, Loughrough (infor-
mation on the methodology they used is available at http://affymetrix.arabidopsis.info/).
The experiment was conducted in duplicates for both BUC11 siRNA-transfected cells and
negative control siRNA-transfected cells. The quantity and purity of the RNA extracted
from the cells were assessed using a Nanodrop ND1000 microspectrophotometer. For
each array, at least 5µg of highly pure RNA was required. The NASC Affymetrix ser-
vice checked the quality of the RNA provided, using the Agilent Bioanalyzer, when the
samples were received to ensure there was no degradation during transport and then they
check again when cRNA has been made prior to fragmentation and hybridisation.
2.2.4 Animals and immunisation
2.2.4.1 Animals
Double transgenic C57BL/6 HLA-A2.1/-DR1 (HHDII-DR1) mice were received as a
generous gift from Dr. F. Lemonnier (Institut Pasteur, Paris, France). HHDII-DR1 mating
positive mice were maintained inbred by making sure they have a common F0 ancestor.
Animals were bred at Nottingham Trent University animal house according to the Home
Office Codes of Practice for the housing and care of animals.
2.2.4.2 DNA bullets and DNA immunisation
The expression vectors pBudCE4.1/- (control) and pBudCE4.1/BUC11 were coated
respectively onto 1µm gold microcarriers according to the manufacturer’s instructions.
Briefly, 18µg of plasmid DNA was mixed with 200µl of 0.05M spermidine containing
0.0083g of gold by sonicating for a few seconds. During sonication, 200µl of 1M CaCl2
was added drop wise then the tube was incubated at RT for 10 minutes. The mixture
was washed three times in anhydrous ethanol and resuspended in 1ml of 0.025mg/ml
PVP. Whilst sonicating, the mixture was loaded into a dried Tefzel tubing and left to
stand in a Tubing Prep Station for 30 minutes. The dry ethanol was removed using a
syringe and the tubing was spinned for 5 minutes with the nitrogen. The dried tubing was
then removed from the station and cut into small pieces using a guillotine. These DNA
bullets were stored at 4◦C. Each HHDDII-DR1 mouse was either immunised with one
gold bullet using a Helios gene gun or intra-muscularly in both legs with 25µl of RPMI
medium (no G418, no FCS) containing 25µg of naked plasmid DNA either pBudCE4.1/-
or pBudCE4.1/BUC11 in each leg. Three rounds of immunisation for the immunisation
with the gene gun and 2 rounds of immunisation for the immunisation intra-muscularly
were carried out on the same animals at 7-day intervals.
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2.2.5 Cytotoxicity assay, proliferation assay and Enzyme-Linked Im-
munoSorbent SPOT (ELISPOT) in mice
2.2.5.1 Generation of murine BM-DC
The protocol for the preparation of murine dendritic cells was adapted from the one
provided by Inaba and colleagues (Inaba et al., 1992). Briefly, the hind limbs of the mouse
were harvested and the muscles and knuckles were removed using a scalpel. The bones
were then flushed with BM-DC media, the cells were washed, resuspended in 2ml of BM-
DC media and counted in 0.6% (v/v) acetic acid and 0.1% (v/v) Trypan blue. Cells were
then plated in a 24-well plate at 0.5x106 cells per well per ml of BM-DC media which
contains 1ng/ml of murine GM-CSF. The BM-DC were pulsed with either 25µg of cell
lysate per well (ALC/pBudCE4.1/BUC11 as the relevant gene or ALC/pBudCE4.1/- as
a negative control or ALC/pBudCE4.1/HAGE as an irrelevant gene) or 12.5µg of pep-
tide per well (BUC11 specific-peptide or HAGE specific-peptide as an irrelevant peptide)
which were pre-incubated with the BUC11 antibody for 10 minutes at 37◦C in a 5% CO2
incubator. After incubation of the plate for 6 hours in the incubator, 1µl of LPS per well
was added to induce complete maturation and the plate was incubated overnight in the in-
cubator. The following day, the BM-DC were scraped with a plastic tip and centrifuged at
at 1,500rpm for 3 minutes at 4◦C. The pellet was resuspended in 1ml of BM-DC medium,
12.5µl of Poly I.C was added and BM-DC were incubated 4 hours at 37◦C in a 5% CO2
incubator prior their use in Enzyme-Linked ImmunoSorbent SPOT (ELISPOT) or in pro-
liferation assay. Poly I.C is a synthetic Polyinosinic polycytidylic acid dsRNA which
induces the production of IFNγ.
2.2.5.2 Isolation of murine leukocytes
Spleens were harvested from immunised mice and a naive mouse seven days after the
last immunisation and the cells were flushed out with T cell medium in sterile condition.
Some T cells were cultured without isolation for use in proliferation assays. These were
cultured in T cell medium containing vitamin E (1µl/ml of culture medium) and 10µl
(1mg/ml) per well of either BUC11 relevant peptide or T21 irrelevant peptide (in vitro
re-stimulation). Three days later, 25U of IL-2 was added per well to the culture medium.
The isolation of mouse leucocytes was done using the Pan T Cell Isolation Kit in ac-
cordance to the manufacturer’s instructions. Briefly, following cell count, cells freshly
isolated from spleens were spun down at 1,500rpm for 10 minutes at 4◦C. The pelleted
cells were resuspended in the buffer solution and the Biotin-AbCocktail was added up
to 10µl per 1x107 cells. The mix was incubated for 10 minutes at 4◦C. Then, the buffer
solution (30µl per 1x107 cells) and the anti-biotin microbeads (19µl per 1x107 cells) were
added and the mix was incubated for 15 minutes at 4◦C. Cells were washed with 6ml of
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buffer and centrifuged at 1,500rpm for 10 minutes at 4◦C. The pellet was resuspended in
500µl of buffer and the cell suspension was applied to a MS column that was placed in the
magnetic field of a MACS separator and prepared by rinsing with 500µl of buffer. The
unlabelled cells were collected and represented the enriched T cell fraction. The column
was then washed 3 times with 500µl of buffer and the effluent was collected in the same
tube of the previous step. The total effluent was centrifuged at 1,500rpm for 10 minutes
at 4◦C and the cells were counted in 0.1% (v/v) Trypan blue. Cells were then plated out
in a 24 well-plate at 3x106 cells per ml per well in T cell medium and incubated overnight
at 37◦C in a 5% CO2 incubator.
2.2.5.3 Proliferation assay for murine T cells
BM-DC were prepared as described before and counted in 0.1% (v/v) Trypan blue.
The T cells used in this assay were the T cells restimulated in vitro with relevant (BUC11)
and irrelevant (T21) peptides, prepared as described before and counted in 0.1% (v/v) Try-
pan blue. The ratio 10 T cells for every BM-DC was used so 100µl of T cells suspension
(5x105 cells/ml of culture medium) and 100µl of BM-DC suspension (5x104 cells/ml of
culture medium) were plated per well. The co-cultured cells were incubated 48 hours
at 37◦C in a 5% CO2 incubator. Tritiated thymidine was then added to each well (final
concentration of 0.037MBq/ml) and the plate was incubated for 18 hours at 37◦C in a 5%
CO2 incubator. Cells were harvested using a 96-well harvester onto a 96-well filter plate
(Luma-Plate 96) and the plate was dried in an oven for 2 hours. Then, 40µl of scintillation
fluid was added to each well and the radioactivity was measured in counts per minute for
each well in a Top-count scintillation counter.
2.2.5.4 ELISPOT
The IFNγ ELISPOT was carried out using the Mouse IFNγ ELISPOT Development
Module according to the manufacturer’s instructions. A 96-well plate was coated with
100µl of the diluted capture antibody, sealed with the lid and incubated at 4◦C overnight.
The plate was washed 3 times with 200µl of wash buffer per well then inverted on a
clean paper towel. The membranes were blocked with 200µl of blocking buffer per well.
The plate was covered with foil paper and incubated for 2 hours at RT. Meanwhile, the T
cells prepared as outlined before were harvested, counted and resuspended in CTL culture
medium containing glutamine. The plate was rinsed with CTL culture medium and the
wells were immediately filled with 100µl of the T cell suspensions. As a control, some
T cells were contionned with Staphylococcus aureus enterotoxin B (SEB promotes TH2
cell polarisation). The plate was incubated for about 2 hours at 37◦C in a 5% CO2 in-
cubator (until the incubation of BM-DC described before has finished). The BM-DC are
counted and plated at 100µl per well of the 96-well plate. The ratio used was 10 T cells
for every BM-DC. The plate was incubated for 24 hours at 37◦C in a 5% CO2 incubator.
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The plate was washed 4 times with wash buffer as described before then the 100µl of di-
luted detection antibody was added per well. The plate was covered with the lid and foil
paper and incubated overnight at 4◦C. The plate was washed 3 times with wash buffer as
described before and 100µl of diluted Streptavidin-AP was added per well. The plate was
then cover in foil paper and incubated for 2 hours at RT. The plate was washed 3 times
with wash buffer as described before, rinsed with ddH2O and inverted on a clean paper
towel. Then, 100µl of BCIP/NBT solution was added per well, the plate was covered with
the lid and foil paper and incubated in the dark for 30 minutes at RT. The plate was then
rinsed once with ddH2O, inverted on a clean paper towel and left to dry at 37◦C. Once the
plate was dry, it was stored at RT prior to analysis in the ImmunoSpot R©Analyzer.
2.2.5.5 Chromium release cytotoxicity assay
For this assay, the T cells used were prepared as described before but have not been
re-stimulated in vitro and the targets used were ALC/pBudCE4.1/BUC11 cells as relevant
targets, ALC/pBudCE4.1/- cells as negative control and ALC/pBudCE4.1/HAGE cells as
irrelevant targets. The ratio used was 100 T cells for every ALC cell. ALC cells were
counted in 0.1% (v/v) Trypan blue and centrifuged at 1,500rpm for 3 minutes. The pellet
was resuspended in residual medium, 56µl of Chromium-51 was added (final concentra-
tion of 1.85MBq/ml) and the tubes were incubated in the waterbath at 37◦C for 1 hour.
T cells were counted in 0.1% (v/v) Trypan blue and resuspended in T cell medium to
a concentration of 2.5x106 cells/ml. After incubation, ALC cells were washed in 10ml
of T cell medium and incubated for another hour in the waterbath at 37◦C. ALC cells
were then washed as before, counted and resuspended to a final concentration of 2.5x104
cells/ml in T cell medium. T cells and ALC cells were co-plated at 100µl per well (200µl
final volume per well). The “maximum release” wells were prepared by mixing 70µl of
T cell medium with 100µl of ALC cell suspension and 30µl of 1% SDS solution. The
“spontaneous release” wells were prepared by mixing 100µl of T cell medium with 100µl
of ALC cell suspension. The plate was incubated for 4 hours at 37◦C in a 5% CO2 in-
cubator. Then, 50µl of each well was replated onto a 96-well filter plate (Luma-Plate
96) in the same order and this plate was incubated in an oven at 37◦C to dry overnight.
The radioactivity was then measured in counts per minute (CPM) per well in a Top-
count scintillation counter. The percentage of specific cytotoxicity was determined using
the following equation: percentage of cytotoxicity = (CPM experimental release - CPM
spontaneous release)/(CPM maximum release - CPM spontaneous release).
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BUC Family Identification and mRNA
Expression Analysis
3.1 Introduction
3.1.1 The importance of breast cancer-associated markers
The most common cancer for women in the UK is breast cancer, with around 46,000 new
cases diagnosed each year (Cancer Research UK, 2008). The majority of breast cancers
develop sporadically, often due to mutations or incorrectly regulated genes in the breast
cells (Lerebours and Lidereau, 2002; Ross et al., 2003; Widschwendter and Jones, 2002).
Over the last ten years, from a better understanding of the complexicity of breast cancer
and major developments in genomics and proteomics using high-throughput technologies,
alternative, more trustworthy factors, called biomarkers, for the clinical management of
breast cancer patients have emerged. General opinion is that biomarkers can bring more
accurate and sensitive tools to the clinical settings than conventional approved histopatho-
logical parameters. A biomarker can be DNA-based, RNA-based or protein-based and
can be used individually or in combination with other biomarkers. As stated by Ludwig
and Weinstein (2005), the process of clinical validation for most of the candidate breast
cancer biomarkers is only starting and almost none of them have been integrated into the
formal TNM staging system. The low number of validated biomarkers for breast cancer
is the consequence of often inconsistent results, too few patients’ samples taken for stud-
ies and the enormous time it takes to validate any new medical innovation (Ludwig and
Weinstein, 2005).
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To move towards individualised and improved breast cancer care, there is a need for
tumour markers that are associated with risk assessment, diagnosis, prognosis, prediction
of treatment outcome, monitoring of the disease and development of novel therapies. The
complete human genome has been sequenced and mapped in the Human Genome Project,
launched in 1990. Following its completion, a large volume of information has been
obtained and deposited into publicly available databases. This resource of information
opened the door for researchers to understand the function of our 20,000-25,000 protein-
coding genes and to cancer genomics/proteomics with the comparison of the genomes
and proteomes of a normal cell and of a cancer cell of a given tissue.
The main methods for biomarker discovery are expression profiling by gene microar-
rays, proteomics and Expressed Sequence Tag (EST) database search. Microarray tech-
nology can be defined as an automated high-throughput technique for the analysis of
thousands of different DNA sequences or proteins fixed to a really small chip of glass or
silicon. Proteomics is the use of protein mass spectrometry to analyse and draw compar-
isons between protein sets of interest e.g. all proteins found in a breast cancer sample
versus all proteins found in a normal breast sample. It can be combined with bioinfor-
matics to determine relevant links and database interrogation in order to identify those
proteins (Lancashire et al., 2009). One of the proteomics techniques which has been used
to identify breast cancer biomarkers is MALDI (Laronga and Drake, 2007). ESTs are
generally short sequences produced from randomly selected cDNA clones and very often
reflect the transcriptional and functional activity of the tissue/cell line which they were
derived from. The presence or absence of ESTs in different libraries provides information
about the organ, cell type, or tumour specificity of expressed genes. A gene is usually rep-
resented by several ESTs. The more ESTs of the same gene is found in a given library the
more the gene is expressed in the tissue which the library derived from. Several studies
have focused on the search for cancer related genes by whole genome in silico subtraction
using EST entries.
3.1.2 The discovery of the breast-associated UniGene clusters family
The National Center for Biology Information (NCBI) website provides the UniGene
system (http://www.ncbi.nlm.nih.gov/sites/entrez?db=unigene) (Figure 3.1) to automat-
ically divide the collection of all DNA sequences available (GenBank database) into a
non-redundant set of gene-oriented “clusters”. The information provided for each Uni-
Gene cluster include the ESTs of one gene, the tissues of origin and the chromosome map
location.
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Figure 3.1: UniGene Homepage.
The UniGene Homepage shows the list of Species and their respective UniGene En-
tries. Each entry is a group of transcript sequences which originate from the same gene
or expressed pseudogene and gives information such as gene expression, gene location
and protein similarities (http://www.ncbi.nlm.nih.gov/sites/entrez?db=unigene, January
2009)
Previously in our laboratory, Dr Geng Li mined the UniGene database with the objec-
tive to identify new breast-associated genes, limiting his search to ESTs which originate
from human normal breast and/or breast cancer tissues or cell lines but not from nor-
mal tissues or organs except testis, ovary and placenta (personal communication with Dr
Li). He subsequently selected 228 breast-associated UniGene clusters (BUC1-228) and
used RT-PCR to validate the expression patterns. According to preliminary work, four
BUC genes (BUC6, BUC9, BUC10 and BUC11) were found highly expressed in normal
breast, breast cancer and testes tissues but not in other normal tissues. In order to evaluate
the potential of BUC6, BUC9, BUC10 and BUC11 for the management of breast cancer
patients, this project was undertaken firstly to obtain the full sequence of the genes and
determine their similarity with published genes and subsequently to conduct an exhaus-
tive mRNA expression analysis. Gene expression was investigated using conventional
RT-PCR. Afterwards, the expression patterns obtained with conventional RT-PCR were
validated and further investigated using quantitative RT-PCR. The samples used in the
study were from various normal breast tissues, breast cancer tissues, breast cancer cell
lines, malignancies (e.g. melanoma and prostate cancer) and normal tissues. Some cancer
tissues used were provided with patient-matched normal tissues and all material collected
had full ethical approval granted.
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3.2 Results
3.2.1 Characterisation of the full length mRNA sequences of the BUC
family
The Basic Local Alignment Search Tool (BLAST) is a program available on the NCBI
website (http://blast.ncbi.nlm.nih.gov/Blast.cgi) that identifies regions of local similarity
between sequences, comparing nucleotide or protein sequences of interest to sequences
deposited within databases. The program gives the statistical significance of matches and
is very helpful in the identification of novel sequences or members of gene families and
in the studies of the relationship between sequences such as function or evolution. The
mRNA sequences of the ESTs BUC6, BUC9, BUC10 and BUC11, formatted in FASTA,
were uploaded in the option ”BLAST Human Sequences” of the ”BLAST Assembled
Genomes” found on the BLAST Homepage. The BLAST results indicated that all four
ESTs appear to be located on the human chromosome 10.
In order to determine the precise location on the human chromosome 10 of the ESTs
BUC6, BUC9, BUC10 and BUC11 and unlock information on their identity (e.g. gene
homologies), a powerful alignment program called Spidey (Figure 3.2) was used.
Figure 3.2: Spidey Homepage.
Spidey is a mRNA-to-genomic alignment program invented by Sarah Wheelan and lo-
cated on the NCBI website. The program allows the alignment of mRNA sequences
of interest against the genomic sequence, regardless of intron size, using two align-
ment tools: BLAST and Dot View. It can also perform interspecies alignments
(http://www.ncbi.nlm.nih.gov/spidey/index.html, January 2009).
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Spidey is a program that can be found on the NCBI website (http://www.ncbi.nlm.nih.
gov/spidey/index.html). The purpose of the program is to align mRNA sequences of
interest against the genomic sequence, regardless of intron size, using two alignment
tools: BLAST and Dot View. The input for Spidey are a unique genomic sequence and
a set of mRNA accession numbers or sequences in FASTA format. The data is anal-
ysed one mRNA sequence at a time. Briefly, a high-stringency BLAST against the ge-
nomic sequence is firstly performed for each mRNA sequence and the alignments are
sorted by score. Then, another BLAST search is performed with the entire mRNA and
a high-scoring, non-overlapping subset of the alignments is created. The percent iden-
tity per exon is finally determined, as well as the number of gaps per exon, the overall
percent identity, the percent coverage of the mRNA, the number of splice donor sites,
the presence of an aligning or non-aligning poly(A) tail, the acceptor sites for each
exon and the occurence of a mRNA that has a 5’ or 3’ end (or both) that does not
align to the genomic sequence. The program can also perform interspecies alignments
(http://www.ncbi.nlm.nih.gov/spidey/spideydoc.html).
The mRNA sequences, formatted in FASTA, of the ESTs BUC6, BUC9, BUC10 and
BUC11 were aligned against the genomic Human DNA sequence from clone RP11-20F24
on chromosome 10p11.21-12.1. This region contains the 3’ end of the NY-BR-1 gene for
breast cancer antigen NY-BR-1, two novel genes, a pseudogene similar to part of ATP8A2
(ATPase, aminophospholipid transporter-like, Class I, type 8A, member 2), a novel pseu-
dogene and a vomeronasal receptor pseudogene, complete sequence (GenBank accession
number AL157387.9, information from NCBI website, updated on the 6th May 2008).
When an “All Databases” search is performed on the NCBI website using the accession
number for this genomic sequence, two gene entries can be found: ANKRD30A which is
the Homo sapiens ankyrin repeat domain 30A (mRNA of 4405 base-pairs, validated pro-
tein coding), also known as the breast cancer antigen NY-BR-1 (Jager et al., 2001) and the
unpublished gene hCG25653 (LOC646360, mRNA of 653 base-pairs, predicted protein
coding) located next on the chromosome. As shown in Figure 3.3, the BUC sequences
don’t overlap and they are aligned on this part of the chromosome, which strongly sug-
gested that the BUC genes may be related.
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Figure 3.3: Spidey alignment of the BUC original mRNA sequences against genomic Hu-
man DNA sequence from clone RP11-20F24 on chromosome 10p11.21-12.1.
The mRNA sequences of BUC6, BUC9, BUC10 and BUC11, in FASTA format, were
aligned in Spidey alignment tool against the genomic Human DNA sequence from clone
RP11-20F24 on chromosome 10p11.21-12.1. Following the alignment, it became appar-
ent that the sequences are not overlapping and that they are aligned one after another on
this part of the chromosome.
The ESTs, as stated previously, are incomplete sequences of expressed genes, there-
fore it was decided to amplify and sequence the full length of the mRNA molecules be-
tween BUC6 and BUC11. The sequencing was carried out using PCR products obtained
with the following protocol. The following primers were designed especially for this se-
quencing: BUC69 forward and reverse primers as well as BUC910 forward and reverse
primers. BUC69 forward primer anneals in the 3’ end of BUC6 sequence and BUC69
reverse primer anneals in the 5’ end of BUC9 sequence. BUC910 forward primer an-
neals in the 3’ end of BUC9 sequence and BUC910 reverse primer anneals in the 5’
end of BUC10 sequence. Briefly, for each reaction with the PhusionTM High-Fidelity
DNA Polymerase, thermocycling was done in a final volume of 50µl containing 1.5µl of
BR13 (breast cancer tissue) cDNA (or 1.5µl of double distilled water for negative con-
trol), 10µl of Phusion buffer HF, 1µl of dNTPs, 1µl of BUC69 forward primer, 1µl of
BUC69 reverse primer, 0.5µl of polymerase and 35µl of double distilled water. The cy-
cling conditions for the reactions was as follow: 98◦C 30sec, (98◦C 10sec, 58◦C 30sec,
72◦C 1min) x 40 cycles, 72◦C 7min, 4◦C hold. This protocol was repeated in the same
way for BUC910 forward primer with BUC910 reverse primer, for BUC9 forward primer
with BUC11 reverse primer, for BUC69 forward primer with BUC910 reverse primer and
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for BUC69 forward primer with BUC11 reverse primer. The PCR products were loaded
on an agarose gel and after electrophoresis PCR products were isolated as described in
Chapter 2. The purified PCR products were used for a second round of PCR amplification
and the purified products were sent to MWG Biotech (UK) for sequencing (Value read).
The sequencing results were aligned in Spidey against the genomic DNA corresponding
to Human DNA sequence from clone RP11-20F24 on chromosome 10p11.21-12.1 (Gen-
Bank accession number AL157387.9). The overlapping sequences were merged together
to create one single sequence of the “BUC gene” which was re-aligned against the same
genomic DNA sequence (Figure 3.4). The figure shows the “BUC gene” mRNA sequence
to be 5,764 base-pair-long and located on chromosome 10.
Figure 3.4: Spidey alignment of the BUC sequencing results against genomic Human
DNA sequence from clone RP11-20F24 on chromosome 10p11.21-12.1.
After sequencing, the mRNA sequences of BUC6, BUC9, BUC10 and BUC11, in FASTA
format, were aligned in Spidey alignment tool against the genomic Human DNA sequence
from clone RP11-20F24 on chromosome 10p11.21-12.1. The overlapping sequences
were merged together and the single sequence “BUC gene” was re-aligned against the
same genomic DNA sequence which resulted in this figure. The “BUC genes” are ex-
pressed as a mRNA sequence of 5,764 base-pair-long which does not include any obvious
protein coding frame.
Following sequencing and analysis, the nucleotide sequence of each BUC gene was
uploaded on the Translator tool of the JustBio website in order to get the predicted protein
sequence (http://www.justbio.com/translator/index.php). The nucleotide sequences for
BUC6, BUC9, BUC10 and BUC11 can be found, respectively, in Figure 3.5, Figure 3.7,
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Figure 3.9 and Figure 3.11 and the predicted protein sequences for BUC6, BUC9, BUC10
and BUC11 can be found, respectively, in Figure 3.6, Figure 3.8, Figure 3.10 and Figure
3.12.
Figure 3.5: BUC6 nucleotide sequence.
This is the full mRNA sequence for BUC6, obtained following sequencing and alignments
in Spidey alignment tool. The mRNA sequence is 2,420 base-pair-long.
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Figure 3.6: BUC6 predicted protein sequence.
The nucleotide sequence was translated into a protein sequence using the Translator tool
of the JustBio website (http://www.justbio.com/translator/index.php). The translation was
carried out in 3 phases from 5’ end of nucleotide sequence, using the standard genetic
code. Stars represent stop codons.
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Figure 3.7: BUC9 nucleotide sequence.
This is the full mRNA sequence for BUC9, obtained following sequencing and alignments
in Spidey alignment tool. The mRNA sequence is 771 base-pair-long.
Figure 3.8: BUC9 predicted protein sequence.
The nucleotide sequence was translated into a protein sequence using the Translator tool
of the JustBio website (http://www.justbio.com/translator/index.php). The translation was
carried out in 3 phases from 5’ end of nucleotide sequence, using the standard genetic
code. Stars represent stop codons.
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Figure 3.9: BUC10 nucleotide sequence.
This is the full mRNA sequence for BUC10, obtained following sequencing and align-
ments in Spidey alignment tool. The mRNA sequence is 1,921 base-pair-long.
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Figure 3.10: BUC10 predicted protein sequence.
The nucleotide sequence was translated into a protein sequence using the Translator tool
of the JustBio website (http://www.justbio.com/translator/index.php). The translation was
carried out in 3 phases from 5’ end of nucleotide sequence, using the standard genetic
code. Stars represent stop codons.
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Figure 3.11: BUC11 nucleotide sequence.
This is the full mRNA sequence for BUC11, obtained following sequencing and align-
ments in Spidey alignment tool. The mRNA sequence is 652 base-pair-long.
Figure 3.12: BUC11 predicted protein sequence.
The nucleotide sequence was translated into a protein sequence using the Translator tool
of the JustBio website (http://www.justbio.com/translator/index.php). The translation was
carried out in 3 phases from 5’ end of nucleotide sequence, using the standard genetic
code. Stars represent stop codons.
The nucleotide sequences as well as the predicted protein sequences were compared to
database entries in order to ascertain whether or not the identified BUC genes had already
been published or were novel. The sequences were uploaded on the BLAST search page
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). For the nucleotide sequences, the blastn (some-
what similar sequences) program was used with the options: “all GenBank+EMBL+DDBJ
+PDB sequences (but no EST, STS, GSS,environmental samples or phase 0, 1 or 2 HTGS
sequences)” and the search set “Nucleotide collection (nr/nt)”. For the predicted protein
sequences, the blastp (protein-protein BLAST) program was used with the options: “All
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non-redundant GenBank CDS translations+PDB+SwissProt+PIR+PRF excluding envi-
ronmental samples from WGS projects” and the search set “Non-redundant protein se-
quences (nr)”. The top 3 most significant search results for the similarity of the BUC
nucleotide sequences to other entries in the database and the top 2 most significant search
results for the similarity of the BUC predicted protein sequences to other entries in the
database have been compiled in Table 3.1, Table 3.2, Table 3.3 and Table 3.4 for BUC6,
BUC9, BUC10 and BUC11 respectively.
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Nucleotide similarity (GenBank accession number)
Description
Query
coverage
Maximum
identity
Human DNA sequence from clone RP11-20F24 on chro-
mosome 10p11.21-12.1 Contains the 3’ end of the NY-
BR-1 gene for breast cancer antigen NY-BR-1, two novel
genes, a pseudogene similar to part of ATP8A2 (ATPase,
aminophospholipid transporter-like, Class I, type 8A, mem-
ber 2), a novel pseudogene and a vomeronasal receptor
pseudogene, complete sequence (AL157387.9)
100% 100%
MACACA MULATTA BAC clone CH250-103G5 from
chromosome unknown, complete sequence (AC209749.3)
92% 96%
MACACA MULATTA BAC clone CH250-14B20 from
chromosome unknown, complete sequence (AC205191.3)
68% 96%
Phase 1 Protein similarity (GenBank accession number)
Description
Query
coverage
Maximum
identity
unnamed protein product [Homo sapiens] (BAC85788.1) 70/807 77%
PREDICTED: hypothetical protein isoform 2 [Pan
troglodytes] (XP 515750.2)
70/807 72%
Phase 2 Protein similarity (GenBank accession number)
Description
Query
coverage
Maximum
identity
LAMA5 protein [Homo sapiens] (AAH85017.1) 43/807 76%
hCG2042294 [Homo sapiens] (EAW95054.1) 46/807 69%
Phase 3 Protein similarity (GenBank accession number)
Description
Query
coverage
Maximum
identity
LAG1 longevity assurance homolog 5 (S. cerevisiae), iso-
form CRA a [Homo sapiens] (EAW58131.1)
84/807 70%
unnamed protein product [Macaca fascicularis]
(BAE89454.1)
83/807 75%
Table 3.1: Nucleotide and predicted protein sequence similarity of BUC6 to nucleotide
and protein sequences previously deposited in the GenBank database.
The nucleotide sequence was uploaded in blastn and the predicted protein sequence was
uploaded in blastp (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The top 3 most significant
search results for the nucleotide sequence and the top 2 most significant search results for
each of the 3 phases of translated protein sequence are shown. The Query Coverage in the
Protein Similarity section is shown as the number of amino acids of the query matching
the amino acids of the database entries/total number of amino acids of the query.
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Nucleotide similarity (GenBank accession number)
Description
Query
coverage
Maximum
identity
Human DNA sequence from clone RP11-20F24 on chro-
mosome 10p11.21-12.1 Contains the 3’ end of the NY-
BR-1 gene for breast cancer antigen NY-BR-1, two novel
genes, a pseudogene similar to part of ATP8A2 (ATPase,
aminophospholipid transporter-like, Class I, type 8A, mem-
ber 2), a novel pseudogene and a vomeronasal receptor
pseudogene, complete sequence (AL157387.9)
100% 100%
Human DNA sequence from clone RP11-467D10 on chro-
mosome 13 Contains part of the ATP8A2 gene for AT-
Pase, aminophospholipid transporter-like, Class I, type 8A,
member 2 (ML-1 protein (IB, ATP, ML-1, ATPIB, DK-
FZP434B1913)) and a novel pseudogene, complete se-
quence (AL157366.12)
88% 87%
Homo sapiens cDNA clone IMAGE:9052749
(BC144229.1)
32% 91%
Phase 1 Protein similarity (GenBank accession number)
Description
Query
coverage
Maximum
identity
hCG1789874 [Homo sapiens] (EAW85905.1) 113/258 100%
rCG52191 [Rattus norvegicus] (EDL85250.1) 43/258 81%
Phase 3 Protein similarity (GenBank accession number)
Description
Query
coverage
Maximum
identity
PREDICTED: similar to ATPase, aminophospholipid trans-
porter (APLT) [Rattus norvegicus] (XP 223390.4)
42/257 42%
hypothetical protein IL0605 [Idiomarina loihiensis L2TR]
(YP 154995.1)
51/257 39%
Table 3.2: Nucleotide and predicted protein sequence similarity of BUC9 to nucleotide
and protein sequences previously deposited in the GenBank database.
The nucleotide sequence was uploaded in blastn and the predicted protein sequence was
uploaded in blastp (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The top 3 most significant
search results for the nucleotide sequence and the top 2 most significant search results
for phase 1 and phase 3 of translated protein sequence are shown. Search for phase 2
did not result in any significant similarity to any known protein sequences. The Query
Coverage in the Protein Similarity section is shown as the number of amino acids of the
query matching the amino acids of the database entries/total number of amino acids of
the query.
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Nucleotide similarity (GenBank accession number)
Description
Query
coverage
Maximum
identity
Human DNA sequence from clone RP11-20F24 on chro-
mosome 10p11.21-12.1 Contains the 3’ end of the NY-
BR-1 gene for breast cancer antigen NY-BR-1, two novel
genes, a pseudogene similar to part of ATP8A2 (ATPase,
aminophospholipid transporter-like, Class I, type 8A, mem-
ber 2), a novel pseudogene and a vomeronasal receptor
pseudogene, complete sequence (AL157387.9)
100% 100%
MACACA MULATTA BAC clone CH250-14B20 from
chromosome unknown, complete sequence (AC205191.3)
100% 92%
MACACA MULATTA BAC clone CH250-103G5 from
chromosome unknown, complete sequence (AC209749.3)
100% 92%
Phase 1 Protein similarity (GenBank accession number)
Description
Query
coverage
Maximum
identity
unnamed protein product [Homo sapiens] (BAH13866.1) 39/641 82%
PREDICTED: ATPase, aminophospholipid transporter-like,
Class I, type 8A, member 2 isoform 1 [Macaca mulatta]
(XP 001092554.1)
39/641 82%
Table 3.3: Nucleotide and predicted protein sequence similarity of BUC10 to nucleotide
and protein sequences previously deposited in the GenBank database.
The nucleotide sequence was uploaded in blastn and the predicted protein sequence was
uploaded in blastp (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The top 3 most significant
search results for the nucleotide sequence and the top 2 most significant search results for
phase 1 of translated protein sequence are shown. Searches for phases 2 and 3 did not
result in any significant similarity to any known protein sequences. The Query Coverage
in the Protein Similarity section is shown as the number of amino acids of the query
matching the amino acids of the database entries/total number of amino acids of the query.
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Nucleotide similarity (GenBank accession number)
Description
Query
coverage
Maximum
identity
PREDICTED: Homo sapiens hCG25653 (LOC646360),
mRNA (XM 001724231.1)
100% 99%
PREDICTED: Homo sapiens hCG25653 (LOC646360),
mRNA (XM 944750.2)
100% 99%
PREDICTED: Homo sapiens hCG25653 (LOC646360),
mRNA (XM 933553.2)
100% 99%
Phase 1 Protein similarity (GenBank accession number)
Description
Query
coverage
Maximum
identity
PREDICTED: ATPase, aminophospholipid transporter-like,
Class I, type 8A, member 2 isoform 2 [Macaca mulatta]
(XP 001092668.1)
34/218 55%
PREDICTED: ATPase, aminophospholipid transporter-like,
Class I, type 8A, member 2 isoform 1 [Macaca mulatta]
(XP 001092554.1)
34/218 55%
Phase 2 Protein similarity (GenBank accession number)
Description
Query
coverage
Maximum
identity
PREDICTED: similar to hCG25653 [Homo sapiens]
(XP 938646.1)
75/218 100%
PREDICTED: T32E20.19 [Arabidopsis thaliana]
(AC020646 27)
101/218 27%
Phase 3 Protein similarity (GenBank accession number)
Description
Query
coverage
Maximum
identity
hCG25653, isoform CRA a [Homo sapiens] (EAW85902.1) 30/217 100%
Table 3.4: Nucleotide and predicted protein sequence similarity of BUC11 to nucleotide
and protein sequences previously deposited in the GenBank database.
The nucleotide sequence was uploaded in blastn and the predicted protein sequence was
uploaded in blastp (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The top 3 most significant
search results for the nucleotide sequence and the top 2 most significant search results for
each of the 3 phases of translated protein sequence are shown. There was only one search
result for phase 3. The Query Coverage in the Protein Similarity section is shown as the
number of amino acids of the query matching the amino acids of the database entries/total
number of amino acids of the query.
To summarise, the common first hit for BUC6, BUC9 and BUC10 nucleotide se-
quences is, as expected, the genomic Human DNA sequence from clone RP11-20F24
on chromosome 10p11.21-12.1 (GenBank accession number AL157387.9). As shown
in Table 3.1, BUC6 nucleotide sequence is highly similar to clone CH250-103G5 and
clone CH250-14B20, both DNA isolated from the blood cells of a healthy rhesus mon-
key (Macaca mulatta). Also, BUC6 predicted protein sequence has weak similarities
with the human laminin alpha 5 (LAMA5), an extracellular glycoprotein. Most impor-
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tantly, BUC6 sequence matches the 3’ end of the NY-BR-1 gene but not in the coding
region (intron). Regarding BUC9, its nucleotide sequence is strongly similar to a hu-
man DNA sequence on chromosome 13 and weakly similar to an uncharacterised human
cDNA clone. BUC9 predicted protein sequence is quite similar to the predicted protein
hCG1789874. As for BUC6 nucleotide sequence, BUC10 nucleotide sequence is highly
similar to CH250-103G5 and clone CH250-14B20 of the rhesus monkey. BUC10 pro-
tein sequence is weakly similar to a human unnamed protein product. More interestingly,
99% of BUC11 nucleotide sequence matches the complete mRNA sequence of the un-
published human-specific gene hCG25653 (mentioned earlier), as shown in Figure 3.13.
The predicted BUC11 protein (phase 2 of translation) is 100% homologous to the pre-
dicted protein of the gene hCG25653 (75 amino-acid-long). It is important to mention
that the sequencing results for BUC11 (data not shown) originally matched only up to
47% of hCG25653 gene sequence, with 100% sequence coverage. However, just after
sequencing of the BUC genes and some mRNA expression analysis, specific primers for
the coding region of hCG25653 were designed and used to amplidy cDNA for cloning
into an expression vector (Chapter 5). Only one PCR product was obtained so it was con-
cluded that the sequencing results of BUC11 included artifact sequences such as genomic.
Therefore, the correct nucleotide sequence of BUC11 (652bp) shown here without the ar-
tifacts matched up to 99% hCG25653 nucleotide sequence thus the predicted protein for
BUC11 and the predicted protein of hCG25653 are identical. The two nucleotide differ-
ence is due to artifacts included in the original sequencing.
To conclude, the ”BUC gene” mRNA sequence is composed, at its 5’ end of the full
BUC6 nucleotide sequence in the 3’ end of the NY-BR-1 gene, but in the non-coding
region, and, at its 3’ end, of the BUC11 nucleotide sequence which 99% of it corresponds
to the mRNA sequence of the gene hCG25653. A final Spidey alignment result of the
mRNA sequences for the BUC genes, the NY-BR-1 gene and the hCG25653 gene against
the genomic Human DNA sequence from clone RP11-20F24 on chromosome 10p11.21-
12.1 is presented in Figure 3.14.
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Figure 3.13: hCG25653 mRNA and predicted protein sequences.
The GenBank accession number is XM 001724231.1. The complete mRNA sequence
of the gene hCG25653 is 653 base-pair-long. The coding region is predicted to start at
nucleotide 95 and end at nucleotide 322. The predicted protein sequence is 75 amino-
acid-long. The nucleotides highlighted in red shows the differences between hCG25653
mRNA sequence and BUC11 mRNA sequence. In BUC11 mRNA sequence, the first
nucleotide highlighted was found a Thymine and the last nucleotide is not present.
Figure 3.14: Spidey alignment of the BUC, NY-BR-1 and hCG25653 mRNA sequences.
After sequencing and BLAST analysis, the mRNA sequences of BUC6, BUC9, BUC10
and BUC11, along with the mRNA sequences of NY-BR-1 and hCG25653 genes, in
FASTA format, were aligned in Spidey alignment tool against the genomic Human DNA
sequence from clone RP11-20F24 on chromosome 10p11.21-12.1.
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3.2.2 mRNA expression analysis of the BUC family
As stated previously, Dr Geng Li has mined the UniGene database for ESTs from
normal breast, and/or breast cancer tissues or cell lines but not from normal essential tis-
sues or organs except testis, ovary and placenta. Prior to this project, Dr Geng Li used
both semi-quantitative and quantitative Real-Time RT-PCR to analyse the expression pat-
terns of the 228 BUC genes selected in a panel of RNAs from normal, malignant tissues
and breast tumour cell lines. Out of the 228 BUC genes, BUC6, BUC9, BUC10 and
BUC11 were validated and further selected because of their high expression in breast
cancer, normal breast and testes but not in other normal tissues. The semi-quantitative
and quantitative Real-Time RT-PCR results from his own study (personal communication
with Dr Li) are summarised in Figure 3.15, Table 3.5 and Figure 3.16. The reference
gene GAPDH was used to normalise the mRNA levels between the samples. Briefly, the
semi-quantitative RT-PCR results indicated that BUC6 was not expressed in 21 different
normal foetal and adult tissues including brain, lung, liver and peripheral blood mononu-
clear cells (PBMC) but highly expressed in normal breast tissues, testis cancer tissues,
breast cancer tissues and one breast cancer cell line (T47D). Moreover, the analysis of
the results of the quantitative Real-Time RT-PCR performed with BUC6 primers on a
RNA panel derived from various normal and tumour specimens revealed very low levels
of BUC6 mRNA in normal tissues except testis tissues. BUC6 mRNA expression level
in all breast cancer tissues tested was high with, as an example, BUC6 mRNA level in
Br4 that was found to be 131,072 times the BUC6 mRNA level detected in liver. Using
semi-quantitative RT-PCR, a similar pattern of mRNA expression for BUC9, BUC10 and
BUC11 was uncovered. BUC9 and BUC10 mRNA were highly expressed in the normal
testis tissue and all the breast cancer tissues tested. BUC9 and BUC10 mRNA were not
expressed in brain, heart, liver and lung however they were found at a low level in PBMC.
BUC11 mRNA was not expressed in the normal tissues tested, including the one testis
tissue used. However, it was expressed in 3 out of 4 breast cancer tissues tested.
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Figure 3.15: BUC6 mRNA expression analysis by semi-quantitative RT-PCR.
BUC6 mRNA expression analysis in a panel of normal tissues, breast cancer tissues and
one breast cancer cell line. The housekeeping gene GAPDH was used to normalise the
mRNA levels between the samples. The top left and top right pictures show GAPDH and
BUC6 mRNA expression in a panel of normal tissues. The picture in the middle shows
BUC6 mRNA expression in four normal breast tissues (Nb1-4), in one normal testis tissue
(TS3) and one breast cancer tissue (Br9). The bottom left picture shows BUC6 mRNA
expression in four normal tissues (brain, trachea, kidney and lung), two cancer testis tis-
sues (TS2 and TS3), one breast cancer cell line (T47D) and two breast cancer tissues (Br3
and Br5). The bottom right picture shows BUC6 mRNA expression in five normal tissues
(placenta5, placenta6, ovary, muscle and peripheral blood mononuclear cells (PBMC))
and five breast cancer tissues (Br7, BR8, Br9, Br10 and Br3).
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Table 3.5: BUC6 mRNA expression analysis by quantitative RT-PCR.
BUC6 mRNA expression analysis in a panel of normal tissues, breast cancer tissues and
one breast cancer cell line. The samples used include 6 essential normal tissues (brain,
lung, trachea, heart, liver and kidney), 3 normal testis tissues (TS2-4), 3 testis cancer tis-
sues (TS5-7), 4 breast cancer tissues (Br1-4) and one breast cancer cell line (T47D). The
analysis of the results was carried out using the comparative Ct method. The reference
gene GAPDH was used to normalise changes in specific gene expression. The last col-
umn shows the normalised level of BUC6 mRNA expression in the tissues and cell line,
relative to its expression level in normal liver (reference tissue).
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Figure 3.16: BUC9, BUC10 and BUC11 mRNA expression analysis by semi-quantitative
RT-PCR.
BUC9, BUC10 and BUC11 mRNA expression analysis in a panel of normal tissues and
breast cancer tissues. The reference gene GAPDH was used to normalise the mRNA lev-
els between the samples. The samples used include seven normal tissues (brain, heart,
kidney, liver, lung, peripheral blood mononuclear cells (PBMC) and testes) and four
breast cancer tissues (Br2, Br3, Br9 and Br10).
As illustrated, Dr Geng Li has studied the four BUC genes mRNA expression patterns
in a variety of normal and tumour specimens prior to this project however a more thorough
analysis was required before considering that one or more BUC genes could be of interest
for breast cancer management. The BUC genes potential for diagnosis, therapy (gene
therapy or immunotherapy) and detection of metastatic breast cancer cells (in peripheral
blood or lymph nodes of patients) depends partly on the restricted expression patterns
of the genes in certain tissues. As stated before, ideally, they must not be expressed in
essential normal tissues and must be highly expressed and up-regulated in tumour tissues
compared to normal counterpart tissues. Consequently, the mRNA expression analysis of
BUC6, BUC9, BUC10 and BUC11 was conducted using a large number of normal tissue
RNAs (purchased) and tumour tissue RNAs of varied origins (generous donations of col-
laborators). The results of the parallel study of the full length BUC sequences and their
similarities with known genes or proteins (results shown in section 3.2.1) justified that
the mRNA expression study became gradually focused on BUC11 and thus explains the
larger number of analysis carried out on BUC11 compared to BUC6, BUC9 and BUC10.
Non-, semi-quantitative and quantitative RT-PCR were performed with the primers and
conditions detailed in Chapter 2.
Briefly, 2µg of RNA (or entire sample if the RNA concentration was low) and Oligo(dT)15
or random primers were used to generate cDNA by reverse-transcription. Following com-
pletion of the semi-quantitative RT-PCR reaction, products were loaded and run on a 1.5%
agarose gel. The housekeeping gene GAPDH was used to normalise the mRNA levels
between the samples. Following completion of the quantitative RT-PCR reaction, the Ct
value for each sample and the standard curve were generated. The standard quantity (SQ)
mean for the BUC gene was divided by the SQ mean of the housekeeping gene GAPDH
which resulted in the normalised mRNA expression of the BUC gene in the tissues. The
summary of the mRNA expression analysis, conducted during the project and prior to
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the project by Dr Geng Li, for all the BUC genes is presented in Table 3.6. Examples
of the results obtained in the non- or semi-quantitative RT-PCR analysis are presented in
Figure 3.17, Figure 3.18, Figure 3.19, Figure 3.20, Figure 3.21 and Figure 3.22. These
experiments are semi-quantitative as cDNA concentrations have been adjusted to ensure
a similar copy number for GAPDH, except the ones presented in Figure 3.17 and (B) of
Figure 3.22.
Normal tissues BUC6 BUC9 BUC10 BUC11
Panel of essential tissues 0/22 0/6 6/14 0/6
Placenta 0/3 1/1 1/1 0/1
Breast 4/4 2/2 nd 1/1
Testes 6/6 1/1 nd 3/3
Stomach nd 2/4 nd 0/4
Colon nd nd nd nd
Oesophagus nd 4/4 nd 0/3
Kidney nd nd nd 0/4
PBMC 0/1 1/1 1/1 0/6
Cancer tissues BUC6 BUC9 BUC10 BUC11
Melanoma 7/7 7/7 7/7 0/7
Mesothelioma nd nd nd 0/8
Breast 9/9 6/9 10/11 10/11
Testes nd nd nd 3/3
Stomach 3/3 2/4 5/5 0/4
Colon 2/2 nd nd nd
Oesophagus nd 4/4 4/5 0/3
Kidney nd nd nd 0/4
Head and Neck nd nd 6/8 nd
Breast cell lines 4/5 4/7 4/5 1/5
Table 3.6: Summary table of the exhaustive mRNA analysis of the BUC genes.
This table sums up the results from the intensive mRNA expression analysis of all BUC
genes, using the non- or semi-quantitative and quantitative RT-PCR techniques. It illus-
trates the number of individual tissues showing positive expression, for each of the genes
of interest. “nd” means “not determined”. RNA samples from gastric tissues (cancer and
normal), colon tissues (cancer and normal) and breast tissues (cancer and normal, differ-
ent stages) have been provided by Dr. Aija Line from the Latvian University Biomedical
Centre (Latvia). The tissues are paired cancer and normal counterpart, each pair from the
same patient. Oesophageal and kidney tissues were also provided as pairs. PBMC: pe-
ripheral blood mononuclear cells. Breast cancer cell lines: SKBR3, MDAP3, MDA435,
T47D, BR293, MDA231 and MDA468.
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Figure 3.17: BUC9 mRNA expression analysis in breast cancer tissues and cell lines.
BUC9 mRNA expression analysis in breast cancer tissues and cell lines by semi-
quantitative RT-PCR. The housekeeping gene GAPDH was used to normalise the mRNA
levels between the samples. Lanes: (1) to (8) Breast cancer tissues: (1) BR11, (2) BR12,
(3) BR13, (4) BR15, (5) BR16, (6) BR19, (7) BR25, (8) BR28. (9) to (12): breast cancer
cell lines: (9) MDAP3, (10) MDA435, (11) T47D, (12) BR293. (13) Negative control,
(14) DNA ladder. Bands were present at approximately 500 base pairs which correspond
to the expected size (495 base pairs) of the target for the BUC9 primers used. This work
was undertaken by Julieta De Silva (BSc student).
Figure 3.18: BUC9 mRNA expression analysis in normal tissues.
BUC9 mRNA expression analysis in normal tissues by semi-quantitative RT-PCR. The
housekeeping gene GAPDH was used to normalise the mRNA levels between the sam-
ples. Lanes: (1) Brain, (2) Skeletal muscle, (3) Kidney, (4) Placenta, (5) Heart, (6) Testis,
(7) Lung, (8) Liver, (9) Breast 1, (10) Breast 2, (11) Negative control, (12) DNA ladder.
Bands were present at approximately 500 base pairs which correspond to the expected
size (495 base pairs) of the target for the BUC9 primers used. This work was undertaken
by Julieta De Silva (BSc student).
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Figure 3.19: BUC11 mRNA expression analysis in normal tissues.
BUC11 mRNA expression analysis in normal tissues by semi-quantitative RT-PCR. The
housekeeping gene GAPDH was used to normalise the mRNA levels between the sam-
ples. Figure (A) lanes: (1) DNA ladder, (2) Negative control, (3) Breast, (4) Heart, (5)
Testis, (6) Liver, (7) Prostate, (8) Brain, (9) Uterus, (10) Spleen, (11) Skeletal muscle,
(12) Lung, (13) Kidney, (14) Placenta, (15) DNA ladder. Figure (B) lanes: (1) DNA
ladder, (2) Negative control, (3) Fetal brain, (4) Fetal liver, (5) Trachea, (6) Thyroid, (7)
Spinal cord, (8) Salivary gland, (9) Thymus, (10) DNA ladder. Bands were present at
approximately 200 base pairs which correspond to the expected size (197 base pairs) of
the target for the BUC11 primers used.
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Figure 3.20: BUC11 mRNA expression analysis in breast cancer tissues and cell lines.
BUC11 mRNA expression analysis in breast cancer tissues and cell lines by semi-
quantitative RT-PCR. The housekeeping gene GAPDH was used to normalise the mRNA
levels between the samples. Figure (A) lanes: (1) DNA ladder, (2) Negative control,
(3) to (8) cell lines: (3) T47D, (4) MDA231, (5) MDA468, (6) BR293, (7) MCF7, (8)
MDAP3, (9) to (14) tissues: (9) BR2, (10) BR15, (11) BR19, (12) BR11, (13) BR20, (14)
BR13, (15) DNA ladder. Figure (B) lanes: (1) DNA ladder, (2) Negative control, (3) to
(7) tissues: (3) BR25, (4) BR26, (5) BR27, (6) BR9, (7) BR12. Bands were present at
approximately 200 base pairs which correspond to the expected size (197 base pairs) of
the target for the BUC11 primers used.
Figure 3.21: BUC11 mRNA expression analysis in testis (normal and cancer) tissues.
BUC11 mRNA expression analysis in in testis (normal and cancer) tissues by semi-
quantitative RT-PCR. The housekeeping gene GAPDH was used to normalise the mRNA
levels between the samples. Lanes: (1) DNA ladder, (2) Negative control, (3) to (5)
testicular cancer tissues: (3) TS2, (4) TS3, (5) TS4, (6) to (7) normal testis tissues: (6)
TS6, (7) TS7, (8) DNA ladder. Bands were present at approximately 200 base pairs which
correspond to the expected size (197 base pairs) of the target for the BUC11 primers used.
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Figure 3.22: BUC11 mRNA expression analysis in diverse cancer tissues.
BUC11 mRNA expression analysis in diverse cancer tissues by semi-quantitative RT-
PCR. The housekeeping gene GAPDH was used to normalise the mRNA levels between
the samples. Figure (A) lanes: (1) DNA ladder, (2) Negative control, (3) to (10) Mesothe-
lioma tissues: (3) Meso1, (4) Meso2, (5) Meso3, (6) Meso4, (7) Meso5, (8) Meso6, (9)
Meso7, (10) Meso8. Figure (B) lanes: (1) DNA ladder, (2) Negative control, (3) to (12)
Melanoma samples 1 to 10, (13) DNA ladder. Figure (C) lanes: (1) DNA ladder, (2) Neg-
ative control, (3) to (10) Gastric paired normal (N) and cancer (T) tissues: (3) BN2, (4)
BT2, (5) BN4, (6) BT4, (7) BN5, (8) BT5, (9) BN6, (10) BT6. Figure (D) lanes: (1) DNA
ladder, (2) Negative control, (3) to (10) Kidney paired normal (N) and cancer (T) tissues:
(3) KN1, (4) KT1, (5) KN2, (6) KT2, (7) KN10, (8) KT10, (9) KN12, (10) KT12. Figure
(E) lanes: (1) DNA ladder, (2) Negative control, (3) to (8) Oesophageal paired normal
(N) and cancer (T) tissues: (3) EN1, (4) ET1, (5) EN3, (6) ET3, (7) EN4, (8) ET4.
A more detailed account of the results (Table 3.6) for each individual gene of interest,
completing the analysis undertaken by Dr Geng Li prior to this project, is given in the
following paragraph. Following semi-quantitative RT-PCR, it was found that BUC6 is
expressed in all the melanoma samples tested. BUC6 mRNA is expressed in all of the
breast cancer cell lines tested (SKBR3, T47D, MDA468 and MDA231) except BR293,
with levels of expression varying from one cell line to another. The quantitative RT-PCR
analysis revealed that BUC6 mRNA expression is significantly higher in breast cancer,
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when compared to expression in gastric and colon (normal and cancer) samples tested.
As seen in Figure 3.17, the two gene products observed during semi-quantitative RT-PCR
analysis suggests that BUC9 mRNA may exist as two splice variants in breast cancer
tissues and cell lines tested positive except for the breast cancer cell lines MDAP3 and
SKBR3. BUC9 mRNA is expressed in 6 out of 9 breast cancer tissues and in the breast
cancer cell lines MDAP3, T47D, SKBR3 and MDA231 but not MDA435, BR293 and
MDA468. As seen in Figure 3.18, BUC9 mRNA expression was positive only in the fol-
lowing normal tissues: placenta, testis and breast. The results suggest that BUC9 may
exist as two splice variants in testis and breast tissues but as a single spliced mRNA
in placenta. However, another semi-quantitative RT-PCR experiment (figure not shown)
brought to light that BUC9 mRNA is also expressed in all the tested paired oesophageal
normal and cancer tissues, with a similar level. BUC9 mRNA is expressed in 2 paired
gastric normal and cancer tissues out of 4, with BUC9 overexpressed in normal compared
to cancer tissue. Both gastric and oesophageal tissues only expressed the longest splice
variant.
Comparable to BUC6 analysis, the melanoma samples all tested positive for the ex-
pression of BUC9 mRNA as well as BUC10 mRNA. BUC10 mRNA molecules were
found in all the breast cancer cell lines tested (SKBR3, T47D, MDA468 and MDA231)
with the exception of BR293. BUC10 mRNA expression was proved to be detectable in
6 out of 14 essential normal tissues. BUC10 mRNA was also tested positive in all gastric
cancer tissues, breast cancer tissues, oesophageal cancer tissues and head and neck (nor-
mal and cancer) tissues tested, using quantitative RT-PCR. BUC10 mRNA is expressed
at different levels in all the samples tested and to a much weaker extend in breast cancer
than seen in the other cancer and normal tissues (figure not shown). Following semi-
quantitative RT-PCR analysis, it appears that BUC11 mRNA is only expressed in the
breast cancer cell line T47D (Figure 3.20) and is found in about 90% of the breast cancer
tissues tested. Figure 3.21 shows that all testis (normal and cancer) tissues tested posi-
tive for BUC11 mRNA. Only breast and testis tissues tested positive for BUC11 mRNA
molecules (Figure 3.19). This observation was validated using quantitative RT-PCR (fig-
ure not shown) showing that BUC11 mRNA is not expressed or is at very low levels
in the normal tissues tested (heart, liver, prostate, brain, uterus, spleen, skeletal muscle,
lung, kidney, placenta, trachea, thyroid, spinal cord, salivary gland, thymus and periph-
eral blood mononuclear cell). BUC11 mRNA is expressed at similar levels in the normal
testis and testicular cancer tissues tested. Quantitative RT-PCR using specific BUC11
primers also revealed that BUC11 mRNA is expressed at widely different levels in the
10 breast cancer samples tested with apparent higher levels in early stages of the dis-
ease when compared to later stages. In the normal counterpart tissue, BUC11 mRNA
expression follows the same trend. Furthermore, the more sensitive technique of quan-
titative RT-PCR proved that BUC11 mRNA is not only expressed in the breast cancer
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cell line T47D but also at low level in the breast cancer cell line MDA231 which was
not detected using semi-quantitative RT-PCR. BUC11 mRNA was undetectable in the 6
different samples of peripheral blood mononuclear cells tested (figure not shown) nor in
any of the diverse cancer tissues tested (mesothelioma, melanoma, gastric cancer, kidney
cancer and oesophageal cancer) as seen in Figure 3.22.
As discussed earlier, BUC9 mRNA expression studies showed either one or two PCR
products depending on the tissue type. From this observation, it was concluded that BUC9
might exist as two mRNA splice variants in some tissue types but as a single spliced
mRNA in others. This was investigated further by cloning the two PCR products for se-
quencing. Briefly, following RT-PCR with the breast cancer sample BR15 cDNA, the gel
extracted and purified upper band (about 500 base pairs) and lower band (about 400 base
pairs) were individually cloned into pCRII-blunt-TOPO (Invitrogen) vectors and XL1B
cells were transformed and cultured. After DNA Miniprep and EcoRI restriction digest,
positive clones for BUC9 genes were sent for sequencing to MWG Biotech (UK). The se-
quences were then aligned to the original BUC9 sequence using the JustBio Aligner tool
(http://www.justbio.com). The data, presented in Figure 3.23 and Figure 3.24, clearly
shows that the smaller PCR product lacks 103 base pairs which are present in the larger
PCR product. This finding confirms that BUC9 mRNA molecules can at least be spliced
into two different molecules, depending on the tissue of origin. As shown in Figure 3.25,
the predicted protein sequences for both splice variants have been generated using the
Translator tool of the JustBio website (http://www.justbio.com/translator/index.php) and
potential polypeptides uploaded in a protein-protein BLAST (http://blast.ncbi.nlm.nih.gov
/Blast.cgi) using the same conditions as previously mentioned. No significant similarity
was found with human nor mouse proteins when database searches were performed.
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Figure 3.23: Alignment of BUC9 nucleotide sequence with the sequencing result for the
larger PCR product.
“BUC9” is the reference nucleotide sequence for BUC9 and “8H1M13Forward” is
the sequencing result of the approximate 500 base pair PCR product, following semi-
quantitative RT-PCR using cDNA from a breast cancer tissue that tested positive for the
two potential BUC9 splice variants. The two sequences perfectly align and prove the
specificity of the PCR product sequenced.
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Figure 3.24: Alignment of BUC9 nucleotide sequence with the sequencing result for the
smaller PCR product.
“BUC9” is the reference nucleotide sequence for BUC9 and “4LM13Forward” is the
sequencing result of the approximate 400 base pair PCR product, following semi-
quantitative RT-PCR using cDNA from a breast cancer tissue tested positive for the two
potential BUC9 splice variants. The two sequences align except that the sequencing result
is missing 103 base pairs which are present in the reference, suggesting that the shorter
PCR product is a splice variant of the original gene and is not a result of contamination
or artifact.
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Figure 3.25: BUC9 two potential splice variants mRNA and predicted protein sequences.
The nucleotide sequence was translated into a protein sequence using the Translator tool
of the JustBio website (http://www.justbio.com/translator/index.php). The translation was
carried out in one phase from the first ATG of the nucleotide sequence, using the stan-
dard genetic code. Stars represent stop codons. The polypeptide highlighted in blue (65
amino acids) is common to both splice variants predicted protein sequences. The se-
quence highlighted in green is another potential polypeptide for each splice variant which
has a unique amino acid sequence. For the longest splice variant, the polypeptide in green
is 57 amino-acid-long whereas the polypeptide in green for the shortest splice variant is
50 amino-acid-long.
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3.2.3 Focus on BUC11 mRNA expression analysis
Based on the data collected for BUC11 compared to the data obtained for the other
BUC genes so far (section 3.2.2), BUC11 was identified as being the most promising
gene of the BUC family. Further work presented in this thesis was consequently fo-
cused on this gene and primarily on a more thorough mRNA expression analysis. In our
study, we designed specific primers to hCG25653 gene for use in conventional RT-PCR
and other specific primers for use in quantitative RT-PCR. Some experiments were con-
ducted on normal tissue RNAs (purchased from Clontech, UK), melanoma tissue RNAs
(generously donated by Prof. D. Schadendorff, Germany), prostate tissue RNAs (gener-
ously donated by Nottingham City Hospital, UK) and RNA from breast cancer cell lines
cultured in the laboratory. Quantitative Real-Time RT-PCR was the method of choice
because it is less time consuming, more specific and more sensitive (especially when low
levels of mRNA are obtained from tissues gained through different collaborations) com-
pared to semi-quantitative RT-PCR. Briefly, 2µg of RNA (or entire sample if the RNA
concentration was low) and Oligo(dT)15 or random primers were used to generate cDNA
by reverse-transcription. The quantitative RT-PCR was performed as described in Chap-
ter 2. The housekeeping gene GAPDH was used to normalise changes in specific gene
expression. Following completion of the quantitative RT-PCR reaction, the analysis of
the results was carried out using the comparative Ct method. The graphs showing the
relative gene expression levels of BUC11 in the breast cancer cell lines, the normal tis-
sues, the melanoma tissues and the prostate tissues are presented, respectively, in Figure
3.26, Figure 3.27, Figure 3.28 and Figure 3.29 (the Ct values can be found in Appendix I).
Figure 3.26: BUC11 mRNA expression in human breast cancer cell lines by quantitative
RT-PCR.
Quantitative RT-PCR analysis was carried out on 7 breast cancer cell lines. The graph
shows the normalised level of BUC11 mRNA expression in the cell lines, relative to its
expression level in T47D, arbitrarily set as 1.
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Figure 3.27: BUC11 mRNA expression in human normal tissues by quantitative RT-PCR.
Quantitative RT-PCR analysis was carried out on a panel of 20 normal tissues. The graph
shows the normalised level of BUC11 mRNA expression in the tissues, relative to its
expression level in testis tissue, arbitrarily set as 1.
Figure 3.28: BUC11 mRNA expression in human melanoma tissues by quantitative RT-
PCR.
Quantitative RT-PCR analysis was carried out on 26 melanoma tissues. The clinical infor-
mation for these samples is unknown. The graph shows the normalised level of BUC11
mRNA expression in the tissues, relative to its expression level in normal testis tissue,
arbitrarily set as 1.
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Figure 3.29: BUC11 mRNA expression in human prostate tissues by quantitative RT-
PCR.
Quantitative RT-PCR analysis was carried out on 3 known benign prostate tissues, 6
known malignant prostate tissues and 7 prostate tissues of unknown tumour type. The
graph shows the normalised level of BUC11 mRNA expression in the tissues, relative to
its expression level in normal prostate tissue, arbitrarily set as 1.
As shown in Figure 3.26, BUC11 mRNA was only detected in 2 out of 7 breast cancer
cell lines tested. BUC11 mRNA is found at a higher level in T47D compared to MDA231.
It can not be observed on the graph but extremely low levels of BUC11 mRNA were de-
tected in MCF7, SKBR3 and MDAP3 cells, with relative gene expression respectively
0.0009, 0.0009 and 0.0004. With semi-quantitative RT-PCR, BUC11 mRNA was found
only in breast and testis tissues. Quantitative RT-PCR also gave a high level of BUC11
mRNA in these two tissues but low levels were also found in other normal tissues (Figure
3.27), however the expression in these compared to the expression in testis and placenta
is negligible. Only 3 out of 26 melanoma patients tested positive for BUC11 mRNA how-
ever the level in these patients compared to the level in normal testis tissue is again very
low (Figure 3.28). Finally, as shown in Figure 3.29, BUC11 mRNA was found expressed
in 5 out of 16 prostate tissues tested (1 normal prostate tissue, 3 malignant tumour tis-
sues and 1 unknown tumour type tissues), with high levels in tumour when compared to
the level in normal prostate. Also, none of the known benign tissues expressed BUC11
mRNA.
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In order to assess the potential of BUC11 for the care of breast cancer patients, a
large scale study was conducted on cDNA from patients where matched breast cancer
tissues and normal breast tissues had been obtained. Dr Angelos Gritzapis (The Cancer
Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece)
made available a total of 218 frozen breast tissues which correspond to paired normal and
tumour tissues from 109 patients (a list of the tissues can be found in Appendix II). The
clinical information provided include, for each patient, the age at diagnosis of the disease,
the stage of the tumour, the grade of the tumour and the HER2 receptor expression status
of the tumour. Briefly, RNA was extracted from frozen tissues using liquid nitrogen, a
mortar, a pestle and RNA-STAT 60 under a class II safety cabinet. Reverse-transcription
using random primers was carried out on 2µg of RNA and cDNA was used in quantitative
RT-PCR. It is noteworthy that three different control genes were used: GAPDH, hypox-
anthine ribosyltransferase (HPRT1) and TATA-box-binding protein (TBP). In quantitative
RT-PCR analysis, a internal control gene has to be used to correct expression data for dif-
ferences between samples in the quality of the RNA used, the quantity of the RNA used
and the efficiency of the RT. As suggested by Jacques de Kok and colleagues (2005),
a lot of studies wrongly use a single reference gene for normalisation even if no gold
standard control gene has been characterised to date for use with clinical tumour samples
(de Kok et al., 2005). They compared 13 frequently used reference genes in cancer re-
search (large ribosomal protein, b-actin, cyclophilin A, GAPDH, phosphoglycerokinase
1, b-2-microglobin, b-glucuronidase, HPRT1, TBP, transferrin receptor, porphobilinogen
deaminase, ATP synthase 6 and 18S ribosomal RNA) and came to the conclusion that,
for normalisation, the use of the mean expression of several reference genes is the best
substitute to the use of a single control gene. However they found out that HPRT1 is the
best out of all of the tested genes and can alternatively be used on its own.
Following quantitative RT-PCR, the geNorm VBA applet for Microsoft Excel (free
download at http://medgen.ugent.be/genorm/) was used to determine the most stable con-
trol genes from GAPDH, HPRT1 and TBP in the panel of breast tissues tested. As stated
in the user manual, the tool allows the calculation of “the gene expression stability mea-
sure M for a reference gene as the average pairwise variation V for that gene with all
other tested reference genes. Stepwise exclusion of the gene with the highest M value
allows ranking of the tested genes according to their expression stability”. Vandesom-
pele and colleagues (2002) give an account of the calculations and principles in their
paper published in Genome Biology under the title “Accurate normalization of real-time
quantitative RT-PCR data by geometric averaging of multiple internal reference genes”.
The result of the calculation of the average expression stability values of control genes is
given in Figure 3.30. HPRT1 and TBP were determined as the most stable genes therefore
the mean of their Ct values were used for the determination of relative gene expressions
in the analysis carried out using the comparative Ct method. The data were plotted on
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four graphs using Prism version 3.03. Each graph shows the normalised level of BUC11
mRNA expression in the normal tissue, relative to its expression level in the tumour tissue
on the Y axis and one of the clinical information of the X axis, either the age of patients at
diagnosis, the grade of the tumour, the stage of the tumour or the HER2 expression status
of the tumour tissues.
Figure 3.30: Average expression stability values of control genes.
The most stable reference genes from a set of tested genes in the panel of cDNA from
the paired normal and tumour breast tissues were determined using the software geNorm
(http://medgen.ugent.be/genorm/).
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Figure 3.31: BUC11 mRNA expression in paired normal and tumour breast tissues by
quantitative RT-PCR, sorted according to the age of patients at diagnosis.
Quantitative RT-PCR analysis was carried out on the cDNA panel of paired normal and
tumour breast tissues. The analysis of the results was carried out using the comparative
Ct method. The control genes HPRT1 and TBP were used for normalisation. The graph
shows the normalised level of BUC11 mRNA expression in the normal tissue, relative to
its expression level in the tumour tissue. The values above 1 represent the patients whose
BUC11 mRNA expression is upregulated in the tumour tissue compared to the normal
counterpart tissue. The values below 1 represent the patients where BUC11 mRNA ex-
pression is downregulated in the tumour tissue compared to the normal counterpart tissue.
The average for each group is given by the horizontal line.
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Figure 3.32: BUC11 mRNA expression in paired normal and tumour breast tissues by
quantitative RT-PCR, sorted according to the stage of the tumour tissues.
Quantitative RT-PCR analysis was carried out on the cDNA panel of paired normal and
tumour breast tissues. The analysis of the results was carried out using the comparative
Ct method. The control genes HPRT1 and TBP were used for normalisation. The graph
shows the normalised level of BUC11 mRNA expression in the normal tissue, relative to
its expression level in the tumour tissue. The values above 1 represent the patients whose
BUC11 mRNA expression is upregulated in the tumour tissue compared to the normal
counterpart tissue. The values below 1 represent the patients where BUC11 mRNA ex-
pression is downregulated in the tumour tissue compared to the normal counterpart tissue.
The average for each group is given by the horizontal line. Stage I: the tumour is less than
2cm, the lymph nodes in the armpit are not affected and the cancer has not spread. Stage
IIa: the tumour is less than 2cm, the lymph nodes in the armpit are affected and the can-
cer has not spread. Stage IIb: the tumour is less than 5cm, the lymph nodes in the armpit
are affected and the cancer has not spread. Stage III&IIIa:the tumour is more than 5cm,
the lymph nodes in the armpit are affected and the cancer has not spread. Stage IV: the
tumour can be any size, the lymph nodes may or may not be affected and the cancer has
metastasised to other parts of the body.
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Figure 3.33: BUC11 mRNA expression in paired normal and tumour breast tissues by
quantitative RT-PCR, sorted according to the grade of the tumour tissues.
Quantitative RT-PCR analysis was carried out on the cDNA panel of paired normal and
tumour breast tissues. The analysis of the results was carried out using the comparative
Ct method. The control genes HPRT1 and TBP were used for normalisation. The graph
shows the normalised level of BUC11 mRNA expression in the normal tissue, relative to
its expression level in the tumour tissue. The values above 1 represent the patients whose
BUC11 mRNA expression is upregulated in the tumour tissue compared to the normal
counterpart tissue. The values below 1 represent the patients where BUC11 mRNA ex-
pression is downregulated in the tumour tissue compared to the normal counterpart tissue.
The average for each group is given by the horizontal line. Grade I: slow growing tumour
cells, Grade II: intermediate growing tumour cells , Grade III: fast growing tumour cells.
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Figure 3.34: BUC11 mRNA expression in paired normal and tumour breast tissues by
quantitative RT-PCR, sorted according to the HER2 expression status of the tumour tis-
sues.
Quantitative RT-PCR analysis was carried out on the cDNA panel of paired normal and
tumour breast tissues. The analysis of the results was carried out using the comparative
Ct method. The control genes HPRT1 and TBP were used for normalisation. The graph
shows the normalised level of BUC11 mRNA expression in the normal tissue, relative to
its expression level in the tumour tissue. The values above 1 represent the patients whose
BUC11 mRNA expression is upregulated in the tumour tissue compared to the normal
counterpart tissue. The values below 1 represent the patients where BUC11 mRNA ex-
pression is downregulated in the tumour tissue compared to the normal counterpart tissue.
The average for each group is given by the horizontal line. N: negative, 1: dim positive,
2: intermediate positive, 3: highly positive.
First of all, it is worth noting that almost all breast cancer patients expressed BUC11
mRNA in the normal and tumour tissues except three patients who did express BUC11
mRNA in the normal breast tissue but no expression was found in the tumour tissue. The
first patient was 71 years old with the tumour at stage III, of grade II and did not express
HER2. The second patient was 40 years old with the tumour at stage II, of grade II and
highly expressed HER2. The third patient was 45 years old with the tumour at stage III,
of grade II and did not express HER2. The regulation (down- or up-) of BUC11 mRNA
expression is not linked to the age of the patient at diagnosis (Figure 3.31). Similarly, as
shown in Figure 3.32, the data analysed according to the stage of the tumour indicated
that BUC11 mRNA levels do not specifically vary with the advancement of the disease
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and does not follow any trend. Furthermore, the BUC11 mRNA levels in tissues is not
connected to the expression status of the HER2 receptor (Figure 3.34). Finally, BUC11
mRNA expression levels appeared to be unrelated to the grade of the breast tumours
(Figure 3.33).
3.3 Discussion
The BUC genes are novel breast-associated genes recently identified in our lab by
mining EST databases, on the basis of their specific expression spectrum including testis,
normal breast and breast cancer tissue. In this chapter, the aims were to obtain the full
length sequence of the BUC genes and determine the clinical relevance of the BUC genes
by investigating their expression spectrum at the mRNA level, before making further con-
sideration on the potential applications of these genes. Genes which expression is limited
to non vital organs such as breast and testis are targets for immunotherapeutic strategies.
These aims have been achieved in that interesting expression analysis data have been ob-
tained for all the BUC genes.
In this study, following exhaustive sequencing of the BUC genes, it was shown that
all the sequences are mapping to chromosome 10p1121.12.1. The sequencing results re-
vealed that, in fact, BUC6 mRNA sequence, which form exon 1 of the “BUC gene”, is
part of the 3’ end of NY-BR-1 gene, away from the coding region. Furthermore, exons 10
to 14 of the “BUC gene” forms the entire sequence of BUC11 and 99% of this sequence
matches perfectly the mRNA sequence of the unpublished (hypothetical coding protein)
gene hCG25653, which is next to NY-BR-1 on the chromosome. NY-BR-1 is a tumour
antigen identified by SEREX (serological analysis of recombinant cDNA expression li-
braries) (Jager et al., 2001). Using RT-PCR, Jager and colleagues found that NY-BR-1
mRNA is present solely in the ductal epithelium of the breast, prostate, prostate cancer
(32%) and testis (Jager et al., 2001 and 2005). NY-BR-1 was expressed in 70% of all
tested breast cancer tissues in the study published by Jager and Knuth in 2005 (Jager
and Knuth, 2005). During the research on NY-BR-1 expression at the protein level con-
ducted by Jager, Seil and colleagues in 2007, it was found that NY-BR-1 is present in
the epithelia of ducts and acini of the mammary gland and that all other normal tissues,
including testis, did not express the protein. The expression was more frequent in duc-
tal carcinomas in situ and/or the intraductal component of invasive carcinomas than in
invasive carcinomas. The majority of the breast cancer cell lines tested expressed only
low NY-BR-1 levels and the NY-BR-1 protein was found localised to the cytoplasm and
the cell membrane. Researchers came to the conclusion that NY-BR-1 is a differentiation
antigen of the mammary gland with potential use for diagnosis and immunotherapy of
breast cancer (Jager et al., 2007 and Seil et al., 2007). Jager and others identified two
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HLA-A2 restricted NY-BR-1 peptides which are CD8+ T cell specific and naturally pro-
cessed (Jager et al., 2005 and Wang et al., 2006). These findings support the idea of using
NY-BR-1 for antigen-based therapy of HLA-A2 positive breast cancer patients whose
tumours express NY-BR-1. Furthermore, in 2007, Theurillat and colleagues studied the
co-expression of NY-BR-1 with HLA class I antigens in a tissue microarray. About 15%
of primary breast tumours and 6% of distant metastases highly co-expressed NY-BR-1
and HLA class I, suggesting that about 10% of breast cancer patients could receive T-
cell-based immunotherapy (Theurillat et al., 2007). In the same study, they interestingly
uncovered that NY-BR-1 expression was more frequent in grade I than in grade II or
grade III breast cancers and it was correlated with estrogen receptor expression and in-
versely correlated with HER2-status and EGFR expression (Theurillat et al., 2007). Also,
NY-BR-1 expression is more frequent in lymph node-negative primary carcinomas and is
lost with tumor progression (Varga et al., 2006). In 2008, Theurillat and colleagues pub-
lished a study stating that NY-BR-1 protein can not be detected in testis and prostate even
if mRNA can be detected in prostate, prostate cancer and testis as previous published
work demonstrated. They also found NY-BR-1 mRNA expression in primary spermato-
cytes, in 2% of prostate carcinomas and 70% of primary breast carcinomas and normal
breast epithelium, with strong correlation to its protein expression. Interestingly, they
hypothesised that, because of NY-BR-1 restricted expression to sex-related organs, the 4
estrogen response elements (ERE)-like sequences nearby the promoter region, the strong
co-expression of ER alpha and NY-BR-1 (mRNA and protein levels) and the important
decrease of NY-BR-1 expression in recurrences after treatment with tamoxifen, ER alpha
may control NY-BR-1 transcription (Theurillat et al., 2008).
The nucleotide and protein BLAST results for the four BUC genes indicated that no
significant homology to any known genes or proteins was found, except in the case of
BUC11 with its similarity to hCG25653. Nevertheless, it is known that the production
of a particular mRNA molecule is not always associated with the assembly of the corre-
sponding amino acid sequence. Many gene sequences which are not transcribed into pro-
teins are non-coding RNA transcripts (ncRNA) and the complex tertiary structure of these
non-coding RNA transcripts give them structural, catalytic or regulatory functions (Szy-
manski et al., 2003). However, as previously mentioned, BUC11 generates a predicted
protein with homology to hCG25653. The predicted protein could be of immunothera-
peutic interest if it is proven that the gene product is actually produced and has a vital role
in breast cancer cells.
Preliminary RT-PCR results (personal communication with Dr. Li) appeared promis-
ing therefore mRNA expression analyses were undertaken in our study for all the BUC
genes. RT-PCR has been widely recognised as the most sensitive tool available for mRNA
detection and quantitation. It is generally assumed that the absence of detectable RT-PCR
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products in one given tissue implies a level of expression lower than 0.1% when com-
pared to the counterpart tissue (cancerous versus normal) (Boel et al., 1995). Most of
the mRNA expression analysis has been carried out using conventional, non- or semi-
quantitative RT-PCR depending on the experiment. However, the issue with conventional
RT-PCR is that the intensity of the signal is not necessarily directly proportional to the
amount of DNA being amplified, however sensitivity can be increased with the correct
optimisation of the PCR conditions. The strategy was also to include quantitative RT-
PCR, which was developed over the last few years and has the advantage of being highly
quantitative and reliable and is now the preferred method to measure changes in gene ex-
pression. This study has confirmed that quantitative RT-PCR is more reliable and sensitive
for mRNA expression analysis than conventional RT-PCR. Quantitative RT-PCR allows
a quantitative analysis and can detect very low levels of expression (with a low amount
of sample i.e. 0.5µl) that can not be seen on an agarose gel electrophoresis loaded with
the product from conventional RT-PCR thus leading to an inaccurate interpretation of the
results.
Genes which are tissue-specific manifest an expression profile restricted to certain
tissue types (e.g. reproductive tissues) and are supervised by rigorous and specific tran-
scriptional control mechanisms. It is through preferential activation or silencing of tissue-
specific genes that cell differentiation mechanisms take place in multi-cellular eukaryotes.
Differentiated cells then show their individual phenotypic characters and their roles in the
organism. A strictly restricted expression spectrum, especially to non vital tissues such
as breast, is of particular interest for immunotherapeutic strategies because the normal
vital tissues would not be affected by the treatments. After the reproductive years, the
breast is not essential hence unintended destruction of normal breast tissues of breast can-
cer patients through novel therapies should have negligible consequences. To determine
whether the BUC genes display an appropriate expression profile, various invasive and
non-invasive histological subtypes of breast cancer, breast cancer cell lines, malignancies
(e.g. melanoma and mesothelioma) and normal tissues were used for the mRNA expres-
sion studies. It is worth noting that, as explained in Chapter 2, MDA435 cell line was used
in the study of the expression of the BUC genes in breast cancer cell lines before it was
known that MDA435 is actually a melanoma cell line as stated in a recent publication in
the journal Breast Cancer Research and Treatment in 2007, entitled “MDA-MB-435 cells
are derived from M14 Melanoma cells–a loss for breast cancer, but a boon for melanoma
research” (Rae et al., 2007).
In the preliminary studies using RT-PCR (personal communication with Dr. Li), the
BUC6 gene demonstrated a specific expression pattern restricted mainly to normal testis
and breast tissues. However, traces of expression in PBMC and placenta were also found.
BUC6 mRNA was found expressed in normal breast (100%), breast cancer tissues (89%)
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and testis tissues (100%). BUC6 mRNA was also found expressed in the breast cancer
cell line T47D. Interestingly, low expression of BUC6 was found in mesothelioma tissues
(50%) and mesothelioma cell lines (75%). In this study, BUC6 mRNA expression was
observed in all the melanoma samples tested. However, the level of expression for each
individual sample was not ascertained as the RT-PCR was non-quantitative. This data
suggests that BUC6 is not only expressed in breast cancer and mesothelioma but also is
highly expressed in melanoma. Therefore, due to its high occurrence in breast cancer,
melanoma and mesothelioma, BUC6 could be of interest as a biomarker for these types
of cancer hence further investigations should be carried out. Mesothelioma is a rare can-
cer almost always caused by exposure to asbestos and as a result the most common site of
development is the lungs. Current therapies have proven unsuccessful and as a result the
median survival time after diagnosis of the malignant form is 6 to 12 months. Therefore,
novel mesothelioma associated biomarkers could be of high interest for the development
of more effective therapies. BUC6 was expressed in breast cancer cell lines with high
levels in T47D (which confirmed the result in preliminary studies) and SKBR3, slightly
lower level in MDA231 and at a low level in MDA468. BR293 does not express BUC6
mRNA and this might be due to transcriptional silencing in this particular cell line.
Gene silencing is a common process that can occur under normal conditions at some
point during the development by, for instance, the downregulation caused by transacting
factors, the deactivation of tissue-specific promoter or by silencer regulatory molecules.
Mutations of the cis and trans-regulatory elements are responsible for changes in the gene
expression profile in cancerous cells compared to normal cells i.e. for the reduction of
level of transcription thus the loss of cell differentiation. Moreover, other mechanisms
can be responsible for the change of expression. For instance, promoter hypermethyla-
tion through methylation of the CpG islands is associated with transcriptional silencing
(Ohtani-Fujita et al., 1993). Also, under in vitro conditions, cell lines divide more rapidly
than the cells from their tissues of origin and it was demonstrated that the observed gene
expression differences comprise an up-regulation of genes that have a role in proliferation
(Perou et al., 1999). Sandberg and Ernberg (2005) showed that in cell lines the tissue-
specific up-regulation of genes is generally lost and observed that within cell lines which
originated from the same tumour type, large variations in the expression of tumour and
tissue-specific genes can be found (Sandberg and Ernberg, 2005). Therefore, studies stat-
ing the percentage of cell lines expressing the gene of interest do not necessarily reflect
the percentage of patients who may express the gene. Finally, BUC6 mRNA expression
was analysed using quantitative RT-PCR in some gastric tissues (normal and cancer),
colon tissues (normal and cancer) and breast cancer tissues. BUC6 mRNA expression
was significantly higher (at least 80 times) in the breast cancer samples than in the gastric
and colon samples, however the low number of samples used should moderate this affir-
mation. Therefore, it is suggested that at least 10 more samples for each type of cancers
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should be used to repeat this experiment. The level of expression of BUC6 mRNA in vital
tissues remains to be confirmed.
In the preliminary studies using RT-PCR (personal communication with Dr Li), BUC9
mRNA was not present in vital tissues, was expressed at very low level in PBMC and was
highly expressed in testis and breast cancer tissues. Two gene products were observed
in breast cancer and testis tissues but only one gene product was shown in PBMC. This
data was confirmed in this study as BUC9 mRNA expression was only found in placenta,
testis and breast when tested in a panel of 9 normal tissues. The two PCR products only
observed for testis and breast suggest that BUC9 may exist as a splice variant in these
tissues. The two PCR products were true findings and not a result of artifact or contami-
nation. Alternative splicing occurs in at least 30% of human genes and is defined as the
re-arrangement of exons of the pre-mRNA (transcribed from the same gene) in alterna-
tive manners. These mRNAs can then code for proteins which functions can differ a lot
or not at all. The presence and/or level of a specific variant in a specific tissue may be an
indication of disease state. The two forms of the gene were found highly expressed in all
the breast cancer tissues tested except for BR16 which exhibits a low level of expression
for both forms.
BUC9 splice variants were also observed in the breast cancer cell lines T47D (high
level), MDA468 (low level) and MDA231 (low level). On the other hand, the breast can-
cer cell lines MDAP3 and SKBR3 only exhibit one variant of the gene (largest variant).
The splicing occurs in the middle of the longest BUC9 mRNA sequence, with 103 base
pairs missing. All oesophageal paired normal and cancer tissues tested expressed BUC9
mRNA, with a high level in the majority of the samples. Two out of four paired normal
and gastric cancer tissues expressed the longest variant of BUC9, with BU9 mRNA level
being significantly higher in normal compared to tumour tissues. As a conclusion, BUC9
is expressed in normal oesophageal and gastric normal tissues therefore this gene is less
desirable as a target for immunotherapy because of the possible toxic side effects. All
the melanoma samples tested present the longest variant of BUC9. The data collected so
far suggest that the shortest BUC9 variant is only expressed in the majority but not all of
the normal breast tissues, breast cancer tissues, breast cancer cell lines and normal testis
tissues. Therefore, this particular variant could be a target in immunotherapies which will
only affect these non-essential tissues and not the vital organs. However, the expression
in testicular cancer tissues has to be ascertained and expression of the variant in other can-
cers tested to confirm the restriction of expression of this variant. The BLAST analysis of
the predicted proteins of both variants did not show any significant homology to known
proteins.
In the preliminary studies using RT-PCR (personal communication with Dr. Li),
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BUC10 mRNA expression pattern is comparable to BUC9 mRNA expression that is to
say PBMC expressed very low levels of BUC10 mRNA whereas testis and breast cancer
tissues expressed high levels of BUC10 mRNA. However, in the case of BUC10, only one
gene product was shown. The results of the present study showed that BUC10 mRNA is
highly expressed in melanoma. Furthermore, regarding expression in breast cancer cell
lines, BUC10 mRNA is expressed at very low level in most of the breast cancer cell lines
tested (T47D, MDA468, and MDA231) with the exception of the high level of expres-
sion found in SKBR3 cells. BUC10 mRNA is expressed at lower level in breast cancer
cell lines and tissues than in normal tissues, gastric cancer, oesophageal cancer and head
and neck paired normal and cancer tissues. Higher expression in normal tissues (includ-
ing adrenal, thyroid and PBMC) than in breast cancer tissues is a drawback to consider
using BUC10 in immunotherapies. However, further experiments can be undertaken to
determine if BUC10 is suitable as a target for immunotherapies for any of the gastric,
oesophageal and head and neck cancers.
Preliminary studies on BUC11 mRNA expression (personal communication with Dr.
Li) suggested that BUC11 mRNA is not expressed in the following normal tissues: brain,
heart, kidney, liver, PBMC and testis. Moreover, BUC11 mRNA was found expressed
in breast cancer tissues, with two gene products visible on agarose gel electrophoresis.
The conventional RT-PCR results show that BUC11 mRNA is expressed in normal testis
and breast tissues but not in any of the other 17 normal tissues tested which includes vital
organs and not in any of the PBMC samples tested. BUC11 mRNA is highly expressed in
breast cancer tissues (90% positive so far) but the majority of the breast cancer cell lines
tested did not express BUC11 mRNA and only a low BUC11 level was found in T47D.
All the testis cancer and normal tissues tested expressed similar levels of BUC11 mRNA.
BUC11 mRNA was not detectable using conventional RT-PCR in any of the mesothe-
lioma samples, melanoma samples, gastric (paired normal and cancer) tissues, kidney
(paired normal and cancer) tissues and oesophageal (paired normal and cancer) tissues.
Using quantitative RT-PCR, the expression pattern obtained by conventional RT-PCR
was confirmed and further investigated. Quantitative RT-PCR results corroborated the
finding that normal and testis cancer tissues present similar levels of BUC11 expression
however more samples would be required to have a better knowledge of the expression
levels in these tissues.
High levels of BUC11 mRNA in normal breast and testis tissues were found, with
higher expression in breast compared to testes, however expression was also detected in
other normal tissues due to the higher sensitivity of the quantitative RT-PCR compared
to the conventional RT-PCR. The level of expression in these other normal tissues such
as brain and heart compared to the level of expression in testis and placenta is extremely
low. Therefore, one can conclude that BUC11 mRNA expression is limited to non vital
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organs, making BUC11 a potential attractive vaccine target. The testis are an immuno-
priviledged organ that is to say the antigen coded by any of the BUC genes would not be
expressed on the surface of testicular cells in conjunction with MHC class I (spermato-
gonia lack MHC) therefore would not elicit an immune response. However, the normal
breast tissues could be affected by the treatment but immune responses directed against
normal breast cells would have similar effects to complete surgical removal of the breast.
Furthermore, the level BUC11 mRNA expression confirmed in placenta suggests that
pregnant women would not be able to receive immunotherapies that use BUC11.
Regarding the breast cancer cell lines, quantitative RT-PCR results confirmed the con-
ventional RT-PCR data but also showed that a detectable but lower level of BUC11 mRNA
in MDA231 than in T47D exists. The lack or the extremely low level of expression in
most of the cell lines could be explained by transcriptional silencing as mentioned before.
Also, the administration of 5-azacytidine (Taylor and Jones, 1982) a DNA-demethylating
agent, to a breast cancer cell line that does not expressed BUC11 could potentially restore
the gene expression but only in the case of BUC11 promoter hypermethylation. The result
interestingly correlates with a published study in which the majority of the breast cancer
cell lines tested expressed only low NY-BR-1 levels (Seil et al., 2007).
Using quantitative RT-PCR, BUC11 mRNA was found to be expressed in 25% of all
prostate tissues tested. The analysis established for the first time the positive expression
of BUC11 mRNA in prostate tumour tissues. The levels were high in tumour tissues (ma-
lignant and unknown tumour type) when compared to the level found in normal prostate
during the expression analysis of normal tissues. BUC11 mRNA was not detected in the
known benign tissues. The low number of tissues tested and also the lack of information
on most of the prostate tumour samples (7 out of 16) suggest that the study would need
to be repeated on a larger scale in order to confirm the pattern of BUC11 expression seen
in prostate tissues. This is necessary prior to determining if BUC11 could be of interest
in the management of prostate cancer. In published studies, NY-BR-1 mRNA was found
expressed in up to 32% of prostate cancers, sporadically expressed in normal prostate
tissues (Jager et al., 2005), however NY-BR-1 protein could not be detected in prostate
samples (Theurillat et al., 2008). The mammary gland (along with the ovary and uterus)
in females and the testis in males (along with the prostate gland) are human reproductive
tissues and the most important target tissues of sex steroid hormones which include es-
trogen, progesterone and androgen (Gao et al., 2002). These hormones exert their roles
in the target tissues via their specific intracellular receptors which are part of the nuclear
receptor family and function as transcription factors to regulate the target gene expression
(McKenna et al., 1999). Tumours of the human reproductive tissues (male and female)
have been linked to the abnormal expression or function of the sex steroid hormone re-
ceptors and the abnormal functioning (or expression) and mutations of these receptors has
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been linked to resistance to hormonal therapies for breast and prostate cancers (Gao et al.,
2002). One can conclude that BUC11 could be a differentiation antigen (regulated by sex
steroid hormones) of the breast and testis if antigenicity of its protein is established and if
its protein expression correlates strongly with the expression of hormones receptors such
as ER-alpha (Theurillat et al., 2008).
Regarding mRNA expression of BUC11 in melanoma, only 11.5% of patients (un-
known clinical information) tested were positive for a very low level of expression when
compared to the level in normal testes. The levels in melanoma samples had to be com-
pared to the level in testes because no “normal skin” samples were available for this
study. It would be interesting to determine whether the 3 positively tested melanoma
samples have a common clinical feature such as stage of the disease in order to speculate
on the role of BUC11 mRNA in these tumour cells at a certain point of the develop-
ment of the disease. This result proves that BUC11 mRNA expression is actually not
restricted to tumours of the breast, the testes or the prostate however the low mRNA lev-
els in melanoma samples and the low number of patients positive for mRNA molecules
indicate that BUC11 might not be of interest for skin cancer.
Since it appears irrelevant to therapeutically target or exploit a gene expressed in low
abundance or in a low number of patients, an accurate quantification of BUC11 in breast
cancer tissues was thought indispensable to provide information on the significance of
BUC11 for the management of patients. Furthermore, the hypothesis that BUC11 might
be upregulated in the early stages of breast cancer and downregulated at later stages had
to be challenged with expression analysis in a large panel of tissues from all stages and
grades. A number of normal breast tissues were also tested for the expression of BUC11
to determine if the silencing of gene expression observed in 10% of breast cancer tissues
is linked to cancer mechanisms or to normal molecular or cellular mechanisms. For this
purpose, cDNA from paired normal and tumour tissues from 109 breast cancer patients
were utilised for quantitative RT-PCR analysis, along with primers for BUC11 and the
control genes GAPDH, HPRT1 and TBP. Since the choice of the best control genes for a
given panel of cDNA samples using quantitative RT-PCR is essential, the geNorm VBA
applet for Microsoft Excel (free download at http://medgen.ugent.be/genorm/) was ap-
plied to select HPRT1 and TBP as the most stable control genes for this study. The results
were sorted according to the clinical information provided by Dr Angelos Gritzapis (The
Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens,
Greece): age at diagnosis, stage of the tumour, grade of the tumour and HER2-status,
but the clinical information made available for this study was restricted. In order to fur-
ther classify the samples and have a more refined BUC11 expression pattern, it would
have been of interest to know the status of other biomarkers (e.g. ER, PR, p53 muta-
tion), the method used to determine the stage and grade of the tumour, the cut off point in
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determining the HER2 status as well as the distance in the breast between the extracted
tumour tissues and their normal counterparts. Unfortunately, as the tissues were harvested
recently (less than 5 years ago), the follow-up of patients (survival, tumour recurrence,
distance metastasis formation) was not available and did therefore not allow the prognos-
tic potential of BUC11 to be determined.
The tissues used in this study have not been laser-capture microdissected and the
distance between the harvested tumour and normal tissue is unknown and it is very pos-
sible that the tumour tissue contained some normal cells and vice versa, therefore, the
gene expression of BUC11 might have been diluted. It is well-known that breast tissue
is heterogeneous and that the use of whole heterogeneous tissues in molecular analyt-
ical techniques such as quantitative RT-PCR poses the problem of interpretation of the
data because the true genomic state of a given cell population (disease or normal) can
only be ascertained using a very pure cell population (Espina et al., 2006). Laser-capture
microdissection can overcome this issue and is the process of isolating a pure, morpho-
logically distinct cell population from a tissue section, cytological preparation or live cell
culture which is made, by nature, of heterogeneous types of cells (Emmert-Buck et al.,
1996). Recently, Walton and colleagues showed for the first time upregulation of the ex-
pression of the gene ERbeta in prostate tumours which have been laser microdissected
(Walton et al., 2009). Consequently, one can doubt that the results obtained in this study
show the true biological profile of the disease and disease-free cells, however the data
should still provide some clues towards the understanding of BUC11 mRNA expression
pattern in breast tissues. In these breast samples, BUC11 mRNA is expressed at widely
varying levels. It was observed that 60.6% of patients had BUC11 mRNA expression
upregulated in their tumour when compared to BUC11 mRNA expression in the matched
normal adjacent breast tissue. It appears that, in almost half of the breast cancer patients
tested in this study, molecular control mechanisms downregulated the transcription of
BUC11 gene in the tumour cells during the process of tumorigenesis. Transcriptional si-
lencing (BUC11 mRNA molecules not detectable) was found in the tumour tissue but not
in the normal matched tissue of 3 patients, representing only about 3% of the total number
of patients tested. The age group, stage of the tumour and HER2-status of these 3 patients
did not seem to be significant and only one clinical factor, the grade (II), appeared to show
a trend with the expression of BUC11 (increased in grade II and decreased in grade III).
In these patients, it appears that BUC11 gene expression was repressed during tumori-
genesis. The transcriptional silencing observed can not be due to mutagenic inactivation
because the patients express BUC11 mRNA expression in their normal breast tissue, how-
ever it may be explained by hypermethylation mechanisms, which has been reported in
various human tumours. In this study, BUC11 mRNA regulation could not be correlated
with the age of the patient at diagnosis, thus it is likely that age has no effect on the ex-
pression of BUC11 in breast tissues. In women, a naturally-occurring fall of oestrogen
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levels leads to the menopause. As menopausal status is usually linked to the age of an
individual (although premature menopause can happen), one can then hypothesize that
oestrogen levels do not have a direct effect on the regulation of BUC11 expression in
breast tissues.
HER2 is an epidermal growth factor receptor which is over-expressed in up to 30%
of breast cancers and is an important prognostic factor as it is associated with aggressive
phenotype of the tumour, non-responsiveness to hormonal treatment and reduced sensi-
tivity to conventional chemotherapies (Slamon et al., 1989). In this study, BUC11 mRNA
expression and HER2-status did not correlate, thus it appears that HER2 and BUC11 are
not co-expressed to the same levels in breast tissues. The stage of the breast cancer is a di-
agnostic factor and the grade of the tumour is a factor of aggressiveness, thus prognosis. It
is worth noting that histological grade has a very subjective prognostic value as suggested
by Volpi and colleagues in 2004 (Volpi et al., 2004). Some tumours are categorised by
clinicians as grade II only because the results of its three components (tubule formation,
nuclear pleomorphism and mitotic count) do not clearly fall in the category of grade I or
grade III. In these samples, BUC11 mRNA levels did not significantly follow any pattern
regarding the progression or the aggressiveness of the disease. It is worth noting that the
distribution of patients in the different categories of clinical information about the tumour
is unbalanced. For instance, there is a low number of these patients tested for a grade I
tumour compared to the number of patients whose tumours are of grade II and III. Simi-
larly, few patients have been diagnosed with a stage I, III or IV tumour compared to the
patients who had a stage II disease. Before ruling out BUC11 as a good candidate for
diagnosis and prognosis of breast cancer, a comparison of BUC11 expression in breast
tumour tissues with the expression of other genes recognised as biomarkers for breast
cancer prognosis and diagnosis would be necessary.
In light of all the mRNA expression data collected for BUC11, this gene was identified
as being the most promising of the BUC gene family. Cancer/testis (CT) antigens are
tumour antigens with an expression in normal tissues confined to male germ cells in
the testis but not in adult somatic tissues (with the exception of ovary and placenta in
some cases) hence BUC6, BUC9, BUC10 and BUC11 genes do not fall into the category
of CT antigens. BUC11 is highly expressed in breast and testis tissues and found at
high levels in up to 97% of the breast cancer tissues tested. The tissue specificity of
BUC11 expression profile provides rationale to consider BUC11 as a tissue-specific gene
involved in the differentiation of breast and testis tissues. BUC11 is a potential target for
vaccine strategies however most of the therapeutic relevance of the BUC11 breast and
testis-associated gene relies on the study of the protein encoded by this gene. It is of
prime importance to confirm that the hypothetical protein is produced using an antibody
specific to this antigen in immunoassays.
126
Chapter 4
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4.1 Introduction
The BUC family comprises novel unpublished breast-associated genes identified by min-
ing databases in our laboratory. Their respective mRNA expression levels in a variety of
tissues of normal and cancerous origin were thoroughly characterised in this study using
RT-PCR based assays. Out of all of the results obtained, BUC11 gene appeared to be
a promising candidate for breast cancer management. BUC11 mRNA was found to be
highly expressed in breast and testis tissues (normal and tumour) and high mRNA levels
were obtained in up to 97% of breast cancer cases. However, all the information gath-
ered previoulsy on BUC11 is restricted to the messenger RNA level and the therapeutic
applicability of BUC11 depends on proof that the BUC11 protein is naturally produced
by the cells and, if present, that BUC11 protein expression patterns show relevance to
the management of the disease. BUC11 could potentially be a target for novel molecular
therapies or for immunotherapies and it could also be a marker for diagnosis or prognosis
of breast cancer. For instance, for an antigen to be effective as a target in T-cell-based
immunotherapies, it has to be co-expressed with HLA class I antigens (Theurillat et al.,
2007). In addition, there have been many reports of non-protein-coding RNA that might
have important regulatory roles in cells which can be assessed by specific gene knock-
down experiments (Huttenhofer et al., 2005).
Quantification of a gene at both the mRNA and protein levels is therefore of prime
importance in order to gain a comprehensive view of the mechanisms controlling gene
expression. Whether mRNA and protein levels correlates or not can provide valuable in-
formation on how the cell regulates the expression of the gene of interest (Greenbaum et
al., 2003). Therefore, it was necessary in the present study to corroborate mRNA quan-
titation (Chapter 3) with protein quantitation. The later was performed using immunoas-
says with the custom-made anti-BUC11 monospecific polyclonal antibody. Firstly, in-
formation regarding the sequence of BUC11 predicted protein was obtained by means of
database mining to highlight any similarities with known proteins, potential roles, subcel-
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lular localisations and post-translational modifications. Secondly, anti-BUC11 antibody
was used in a series of immunoassays in order to determine the expression of BUC11
protein, to characterise its expression patterns in diverse normal and tumour tissues and
to compare protein levels with mRNA levels previously obtained. These assays included
immunoblotting, immunofluorescence and immunohistochemistry.
4.2 Results
4.2.1 Data mining with BUC11 predicted protein sequence
As shown in Chapter 3, the BUC11 mRNA sequence shares 99% similarity with
hCG25653 mRNA sequence and the 2 nucleotide difference is due to errors in sequenc-
ing. For this research programme, hCG25653 mRNA and hCG25653 predicted protein
will be referred as BUC11 mRNA and BUC11 predicted protein respectively.
The predicted protein sequence of BUC11 gene was compared to database entries by
a blastp (protein-protein BLAST) search (http://blast.ncbi.nlm.nih.gov/Blast.cgi). When
the blastp search was undertaken using “all species”, only one entry was found and this
correspond to hCG25653 predicted protein sequence (Table 4.1). This result suggested
that BUC11 predicted protein sequence does not significantly match any other deposited
protein sequences in the database. However, when the blastp search was applied using the
option “Homo sapiens only”, surprisingly additional entries were shown (Table 4.1). All
entries, apart from the expected hCG25653 predicted protein, belong to the Baculoviral
IAP repeat-containing protein 4 (XIAP). The matched amino acids between the two pro-
teins are found in the region 49-67 of BUC11 predicted protein. XIAP is a chromosome
X-linked protein; it binds to tumour necrosis factor receptor-associated factors TRAF1
and TRAF2, inhibits the cell-death associated proteases caspase-3 and caspase-7 and in-
hibits apoptosis induced by menadione (causes oxidative stress) and interleukin-1 beta
converting enzyme (ICE, also known as caspase-1) (Entrez Gene, NCBI). Studies have
highlighted the interest in targeting XIAP protein for the treatment of breast cancer (Lee
and Cho, 2008; Choi et al., 2008; Aird et al., 2008). For instance, Hong and colleagues
showed that suppression of a protein (p34SE-1) that normally protects XIAP from be-
ing degraded and which is highly expressed in breast cancer tissues induces apoptosis,
making this protein a target in the development of novel breast cancer treatments (Hong
et al., 2009). Also, some clinical trials for the treatment of cancer are ongoing using an
antisense oligonucleotide against XIAP mRNA (Tamm, 2008). The blastp search was re-
peated with another species, Mus musculus, and the sequence of the mouse equivalent for
human XIAP, Xiap (90.9% protein sequence similarity between XIAP human and Xiap
mouse), was the only significant match to BUC11 predicted protein sequence, within the
same region 49-67 (Table 4.1). Following this analysis, another narrowing blastp search
was generated by comparing the region 49-67 of BUC11 predicted protein against all de-
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posited sequences for Homo sapiens proteins. The entries are shown in Tables 4.2, 4.3,
4.4 and 4.5. This not only resulted in hCG25653 and XIAP as significant hits but also
other proteins, with varying percentage and regions of similarity. Tables 4.6 and 4.7 show
the role, if known, of these proteins. The proteins XIAP and BIRC8 inhibits apoptosis
(Schimmer et al., 2006; Lagace et al., 2001) and the proteins CAPRIN2 and PPP2R1A
inhibits cell growth (Aerbajinai et al. 2004; Lin et al., 2006). The proteins FGD3, PKN2,
DNAH2 and PLEKHH3 are associated with the structure of the cell (Entrez Gene, 2009;
Schmidt et al., 2007; Chapelin et al., 1997). Interestingly, JMJD3 has been linked with
metastatic prostate cancer, CHRM3 with invasive migration of melanomas, the lack of
MAP2K7 with resistance to treatment of colon cancer cells and FUT4 as well as MLL2
with cancer cell growth (Xiang et al., 2007; Oppitz et al., 2008; Vasilevskaya et al., 2008;
Zhang et al., 2008; Mo et al., 2006).
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Table 4.1: BUC11 predicted protein sequence similarity to protein sequences previously
deposited in the GenBank database.
The predicted protein sequence of BUC11 was uploaded in the blastp tool
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Three searches were conducted: all species pro-
teins, Homo sapiens only proteins and Mus musculus only proteins. The significant search
results are shown. “Query coverage” gives the number of amino acids of the query match-
ing the amino acids of the database entries/total number of amino acids of the query.
“Amino acids” gives the region of BUC11 predicted protein.
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Table 4.2: BUC11 predicted protein (amino acids 49-67) sequence similarity to Homo
sapiens protein sequences previously deposited in the GenBank database (1).
The sequence of amino acids 49-67 of BUC11 predicted protein was uploaded in the
blastp tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The search was conducted on Homo
sapiens only proteins. The significant search results are shown. “Query coverage” gives
the number of amino acids of the query matching the amino acids of the database en-
tries/total number of amino acids of the query. “Amino acids” gives the region of BUC11
predicted protein.
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Table 4.3: BUC11 predicted protein (amino acids 49-67) sequence similarity to Homo
sapiens protein sequences previously deposited in the GenBank database (2).
The sequence of amino acids 49-67 of BUC11 predicted protein was uploaded in the
blastp tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The search was conducted on Homo
sapiens only proteins. The significant search results are shown. “Query coverage” gives
the number of amino acids of the query matching the amino acids of the database en-
tries/total number of amino acids of the query. “Amino acids” gives the region of BUC11
predicted protein.
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Table 4.4: BUC11 predicted protein (amino acids 49-67) sequence similarity to Homo
sapiens protein sequences previously deposited in the GenBank database (3).
The sequence of amino acids 49-67 of BUC11 predicted protein was uploaded in the
blastp tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The search was conducted on Homo
sapiens only proteins. The significant search results are shown.
Table 4.5: BUC11 predicted protein (amino acids 49-67) sequence similarity to Homo
sapiens protein sequences previously deposited in the GenBank database (4).
The sequence of amino acids 49-67 of BUC11 predicted protein was uploaded in the
blastp tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The search was conducted on Homo
sapiens only proteins. The significant search results are shown.
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Table 4.6: Known function of Homo sapiens proteins which sequences deposited in the
GenBank database are similar to peptide 49-67 of BUC11 predicted protein (1).
A blastp search (http://blast.ncbi.nlm.nih.gov/Blast.cgi) was carried out using the se-
quence of amino acids 49-67 of BUC11 predicted protein, on Homo sapiens only pro-
teins. The Gene ID and the published function(s) of the proteins which sequences were
found similar to amino acids 49-67 of BUC11 predicted protein are given.
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Table 4.7: Known function of Homo sapiens proteins which sequences deposited in the
GenBank database are similar to peptide 49-67 of BUC11 predicted protein (2).
A blastp search (http://blast.ncbi.nlm.nih.gov/Blast.cgi) was carried out using the se-
quence of amino acids 49-67 of BUC11 predicted protein, on Homo sapiens only pro-
teins. The Gene ID and the published function(s) of the proteins which sequences were
found similar to amino acids 49-67 of BUC11 predicted protein are given.
The in silico analysis of post-translational modifications, predicted motifs and struc-
ture of BUC11 predicted protein was carried out using internet-based tools. Firstly, the
BUC11 predicted amino acid sequence was uploaded in the program PSORT II which
predicts the possible localisations of the protein in cells by comparing the sequence
of interest with the different sequence characteristics of known protein sorting signals
(http://psort.ims.u-tokyo.ac.jp/form2.html). To enter the nucleus, proteins either have
nuclear localisation signal (NLS) or they are co-transported with a protein that has its
own NLS. In 1995, Hicks and Raikhel reviewed the three categories of NLSs (Hicks and
Raikhel, 1995). One category comprised pat4 (4 basic amino acids K or R; or 3 basic
amino acids, K or R followed by H or P) and pat7 (P followed within 3 residues by 3 K/R
residues out of 4) of SV40 large T antigen. Another category is the bipartite NLS which
is formed by 2 basic residues, 10 residue spacer and a region of at least 3 basic residues
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out of 5. It was found, as shown in Table 4.8, that BUC11 predicted protein has one pat4
NLS, corresponding to the amino acids 14-17. Furthermore, the protein content of basic
residues is slightly above 20% and the consensus NLS score equals the threshold. These
results suggests the possibility that the protein may localise to the nucleus. Additionaly,
the results obtained for Reinhardt’s method for both cytoplasmic/nuclear discrimination
and the k-NN prediction imply, with up to 56.5% confidence, that the protein is cyto-
plasmic. Therefore, it is possible that BUC11 predicted protein, if produced, is likely to
preferentially reside in the cytoplasm.
Table 4.8: PSORT analysis of BUC11 predicted protein sequence.
PSORT is a computer program (http://psort.ims.u-tokyo.ac.jp/form2.html) that predicts
the localisation of proteins in cells by comparing the protein sequences with the different
sequence characteristics of known protein sorting signals. Proteins where the NLS score
is equal to or above the 0.8 threshold are predicted to spend time in the nucleus. Proteins
which comprise of basic residues higher than 20% are predicted to be more nuclear than
cytoplasmic (nuclear proteins are rich in basic residues in general).
The sequence of BUC11 predicted protein was also analysed using the program PRO-
SITE (http://www.expasy.ch/prosite/) which compares protein sequences with patterns of
documented protein domains, protein families, functional sites and structural sites. The
search only revealed 4 matches, as seen in Table 4.9. The protein has 2 protein kinase C
phosphorylation sites (8-10 and 54-56), one tyrosine kinase phosphorylation site (17-24)
and one N-myristoylation site (50-55). The match for the N-myristoylation site is actually
in conflict with the data from the analysis with PSORT. It is known that N-myristoylation
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promotes protein-membrane and protein-protein interactions and that phosphorylation by
kinases is essential for the regulation of enzyme activity.
Table 4.9: PROSITE analysis of BUC11 predicted protein sequence.
PROSITE (http://www.expasy.ch/prosite/) compares the protein sequence with patterns
of documented protein domains, protein families, functional sites and structural sites.
In addition, the sequence of BUC11 predicted protein was uploaded into the program
Pfam (http://pfam.sanger.ac.uk/) which is a protein family database comprising sequence
alignments and hidden Markov models (HMMs). Pfam compares the sequence of the
protein of interest to protein domains in order to provide clues on the function of the
protein. Pfam analysis of BUC11 predicted protein did not produced any match with se-
quence alignments of the database or HMMs which exceeded the defined cut off value.
Further information on the predicted protein was obtained through the JustBio tool Prot-
Calc (http://www.justbio.com/protcalc/index.php) such as the amino acid composition,
the molecular weight (8724.36 Daltons) and the theoretical isoelectric point (pI, 9.91).
The predicted protein is quite small, with a molecular weight of about 8.7kDa. The theo-
retical pI of 9.91 implies that the protein is basic and rich in lysine (composing 17.33%).
The in silico software packages used in the BUC11 protein sequence analysis are only
predictors, therefore the interpretation and results generated should be used as guidance
only.
4.2.2 ELISA using anti-BUC11 antibody
To date, hCG25653 (BUC11) has not been the subject of any publication. hCG25653
has only been described in the databases as a protein-coding gene which RefSeq status
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&cmd=search&term=hCG25653, up-
dated 05/12/2008) is “model”, that is to say the sequence has not been curated and has
been derived from a whole-genome computational annotation pipeline. The predicted
coding region has 228bp which starts from base number 95 and finishes base number 322.
The protein (75 amino acids) is “predicted”(http://www.ncbi.nlm.nih.gov/entrez/viewer.fc
gi?val=XP 938646.1, updated 29/02/08). The protein sequence is given in Figure 3.13
(Chapter 3).
So far in this study, BUC11 has been detected at the messenger RNA level in various tis-
sues and cell lines. In order to investigate the possibility of BUC11 expression at the pro-
tein level, a polyclonal monospecific antibody was custom-made by Pacific Immunology
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(USA). The antibody was raised in rabbit against the following 13-amino acid peptide
(BUC117−19): PSKRLFFKKKRLC. Peptide chemists at Pacific Immunology analysed
the protein sequence and recommended the most immunogenic sequences, taking into ac-
count the characteristics of the predicted protein such as its hydrophobicity, hydrophilicity
and folding. However, it was possible that the selected peptide sequence (linear epitope)
would not correspond to an exposed region of the native protein. This particular peptide
sequence (BUC117−19) was selected after protein BLAST analysis (blastp, Homo sapi-
ens only, all non-redundant sequences, http://blast.ncbi.nlm.nih.gov/Blast.cgi) to assure
a minimal risk of cross-reaction with similar epitopes of non-targeted proteins. As ex-
pected, the peptide sequence was 100% homologous to a region of the BUC11 predicted
protein. The other matched proteins, matching 3 or more amino acids (minimum length
of binding site for antibody) of the 13-amino acid peptide and their molecular weight are
listed in Table 4.10. Western Blotting analysis could potentially show anti-BUC11 anti-
body binding to one or more of these hCG proteins of similar molecular weight to BUC11
protein instead of the targetted protein, however differences in the molecular weight and
hence the band observe on the Western Blot should provide evidence as to the identity of
the binding protein. In addition, anti-BUC11 antibody is polyclonal therefore it should
recognise a panel of different epitopes (11 epitopes of 3-amino acid long) from the 13-
amino acid peptide, increasing the chances of specifically binding to BUC11 protein and
not to the same epitopes on non-targetted proteins. The serum was affinity purified against
the peptide sequence thus the antibodies specific to the targetted protein (monospecific)
were isolated. An ELISA assay was performed to quantify peptide-specific antibody
present in the serum, flow-through and purified antibody samples.
138
Chapter 4. BUC11 Protein Expression Analysis 4.2
Table 4.10: BUC11 peptide sequence (7-19) similarity to protein sequences previously
deposited in the GenBank database.
The sequence of amino acids 7-19 of BUC11 predicted protein was uploaded into the
blastp tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The search was conducted on Homo
sapiens only proteins. The “matched sequences” are the matched amino acid sequences
of the proteins to the amino acid sequence of BUC11 peptide and only sequences of 3 or
more consecutive amino acids are shown.
Upon receiving and aliquoting rabbit anti-BUC11 polyclonal antibody and BUC11
peptide, an ELISA was carried out to test the binding strength of the antibodies to the
antigen (see Chapter 2). Briefly, the microtiter plate was coated with the peptide and the
unbound sites were blocked to avoid false positive results. Then, BUC11 antibody was
added to the wells followed by anti-rabbit IgG-HRP. The colored positive reaction was
measured at 450nm. As seen in Figure 4.1, the ideal concentration of BUC11 antibody
for the widest range of peptide concentration is 10ng/ml. The result of this ELISA was
confirmed by a second ELISA (Figure 4.2) although 40ng/ml of BUC11 antibody is more
appropriate for the concentration of peptide equal or below 0.25µg/ml.
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Figure 4.1: Binding strength of rabbit anti-BUC11 polyclonal antibody to BUC11 peptide
by ELISA (1).
ELISA was carried out using the dilutions of antigen given on the graph in µg/ml and
the dilutions of antibody given in the legend of the graph in ng/ml. Absorbances were
measured at 450nm. The results are shown as Absorbance(sample)-Absorbance(blank).
Figure 4.2: Binding strength of rabbit anti-BUC11 polyclonal antibody to BUC11 peptide
by ELISA (2).
ELISA was carried out using the dilutions of antigen given on the graph in µg/ml and
the dilutions of antibody given in the legend of the graph in ng/ml. Absorbances were
measured at 450nm. The results are shown as Absorbance(sample)-Absorbance(blank).
4.2.3 Western Blotting using anti-BUC11 antibody
The anti-BUC11 polyclonal antibody was validated using Semi-Dry Western Blotting
as described in Chapter 2. The antibody was used to probe a cell lysate produced from a
previously identified BUC11 mRNA-positive breast cancer cell line MDA231. The con-
trols for the experiment were “secondary antibody only”, “rabbit IgG antibody (isotype
control) with secondary antibody” and “peptide block”. As shown in Figure 4.3, a strong
band was observed on the developed membrane with a molecular weight in the region
of 15kDa and a weaker band in the region of 30kDa. The controls gave expected re-
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sults: the secondary antibody as well as the rabbit IgG isotype control did not show any
non-specific background staining and the BUC11 peptide (7-19) disrupted interactions
between the anti-BUC11 antibody and the BUC11 protein.
Figure 4.3: Western Blot of human breast cancer cell line MDA231.
Western Blotting was carried out by probing with anti-BUC11 antibody. The cell lysate
used was produced from the human breast cancer cell line MDA231 (positive for BUC11
mRNA expression). Results are from the same experiment. (1), (3) and (5): protein
marker. (2) MDA231 with primary and secondary antibodies, (4) MDA231 with rabbit
IgG isotype control and secondary antibody, and (6) MDA231 with peptide block.
Anti-BUC11 antibody was also used to probe cell lysates produced from human
breast cancer cell lines MDA468 (no BUC11 mRNA molecules detected, Chapter 3) and
MDAP3 (very low levels of BUC11 mRNA, Chapter 3) as well as on cell lysates pro-
duced from mouse lymphoma cell line ALC which was tested negative for BUC11 mRNA
expression and used for transfection with the recombinant plasmid pBudCE4.1/BUC11
(quantitative RT-PCR, cloning and transfection data are given in Chapter 5). Figure 4.4
shows that the two bands observed with the MDA231 cell lysate also appeared with
ALC/pBudCE4.1/BUC11 cell lysate, MDAP3 cell lysate and MDA468 cell lysate but
not with ALC/- cell lysate. Thus, ALC/pBudCE4.1/BUC11 cells transfected with the
construct plasmid pBudCE4.1/BUC11 seemed to successfully express BUC11 predicted
protein and the protein can be detected on the blot with anti-BUC11 antibody. However,
detection of BUC11 protein expression in MDA468 cells, similar to the expression found
in MDA231 cells, is unexpected as no mRNA molecules could be detected by quantitative
RT-PCR. This could be due to a very low number of target mRNA molecules present in
the sample and it is well documented that less than 10 (or 100) copies of target cDNA
per sample can only be quantified after optimisation of the assay (choice of master mix,
number of replicates and PCR machine conditions).
141
Chapter 4. BUC11 Protein Expression Analysis 4.2
Figure 4.4: Western Blot of breast cancer cell lines and ALC cell lines.
Western Blotting was carried out by probing with anti-BUC11 antibody. The cell lysates
used were produced from the human breast cancer cell line MDA231 (positive for BUC11
mRNA expression), the human breast cancer cell lines MDAP3 and MDA468 (nega-
tive for BUC11 mRNA expression), the untransfected mouse lymphoma cell line ALC
(negative for BUC11 mRNA expression) and the transfected ALC cell line with the re-
combinant plasmid pBudCE4.1/BUC11 (positive for BUC11 mRNA expression). Lanes
with protein marker: (1), (5), (9) and (13). Lanes with primary and secondary antibod-
ies: (2) MDA231, (3) ALC/-, (4) MDAP3, (10) ALC/pBudCE4.1/BUC11, (11) MDA231
and (12) MDA468. Lanes with secondary antibody only: (6) MDA231, (7) ALC/-, (8)
MDAP3, (14) ALC/pBudCE4.1/BUC11, (15) MDA231 and (16) MDA468.
The expected molecular weight of BUC11 predicted gene product is in the region of
8.7kDa. Two hypotheses were then proposed for the observed difference in mass in the
case of the stronger band: either anti-BUC11 antibody is preferentially binding another
protein other than the BUC11 gene product which could be in high abundance in the sam-
ple and could be one of those mentioned in Table 4.10, although the peptide block and
the blots with ALC/pBudCE4.1/BUC11 lysate contradict this affirmation, or anti-BUC11
antibody binds specifically to BUC11 protein which has post-translational modifications.
One has then to question if the same post-translational modifications can occur in cells
with or without detectable BUC11 mRNA, including cells engineered to produce the pro-
tein (ALC/pBudCE4.1/BUC11). The weaker band, in the region of 30kDa, which is
approximately twice the size of the protein(s) detected at 15kDa, could be due to protein
dimers even though the conditions for SDS-PAGE were denaturing (boiling in loading
buffer containing SDS and DTT). Under native conditions it is possible that BUC11 pro-
tein has the ability to build dimers and dimeric aggregates could actually be consolidated
following the denaturation process. In order to confirm this and reduce the formation of
dimers, the samples could be incubated with the powerful, irreversible reducing agent tris-
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(2-carboxyethyl)-phosphine (TCEP) to break disulfide bonds prior to SDS-PAGE (Bond-
Breaker TCEP solution, http://www.piercenet.com/products).
To investigate the true identity of the proteins bound to anti-BUC11 antibody on the
blots, cell lysates (ALC/- and MDA231) and anti-BUC11 antibody were used to immuno-
precipitate the proteins in columns purchased from Miltenyi Biotec (data not shown). The
eluted immunoprecipitates, along with non-immunoprecipitated (original) cell lysates,
were used in SDS-PAGE. One gel was kept for Western Blotting which showed, as ex-
pected, a band at 15 kDa in the lane loaded with the original MDA231 lysate and no
band in the lane loaded with the original ALC/- lysate. However, only non-specific, high
molecular weight bands, at approximately 50kDa, were visible in the lanes loaded with
the immunopurified MDA231 and ALC/- samples. Meanwhile, another gel was stained
with Comassie blue and after selection of several bands (at approximately 10kDa and
15kDa), proteins were extracted, digested with trypsin and spotted on a plate for MALDI
analysis. Further analysis of the peaks with LTQ mass spectrometer did not identify
BUC11 protein which is as expected due to the lack of visible band on the Western Blot
that is specific for the size of BUC11 protein. Future work is now required as it is crucial
to confirm that the proteins bound by the anti-BUC11 antibody in the Western Blotting
is the targeted BUC11 protein and is not another non-specific protein. This could be
achieved by 2D gel analysis, or other attempts at optimising the immunoprecipitation
protocol, followed by tryptic digestion and mass spectrometry.
4.2.4 Immunofluorescence using anti-BUC11 antibody
Several attempts were made using anti-BUC11 antibody for flow cytometry analysis,
however, these did not demonstrate BUC11 staining because the two rabbit IgG isotype
controls gave high levels of non-specific background staining. The shift in fluorescence
for the control samples was actually greater than the shift found for the test samples (data
not shown). This finding suggested that the rabbit IgG isotype controls were not suitable
for FACS analysis therefore no further FACS analysis was carried out to study BUC11
protein expression.
In order to determine the localisation pattern of BUC11 protein within cells, im-
munofluorescence experiments were performed. Briefly, human breast cancer cell lines
(positive for BUC11 mRNA) and a melanoma cell line (negative for BUC11 mRNA)
were grown in multi-chamber slides, permeabilised, fixed and stained with antibodies
(mentioned in Chapter 2) and the DNA dye DRAQ5TMand then observed using confocal
microscopy. High levels of BUC11 protein could be detected in MDA231 cells (pictures
B, C and F of Figure 4.5) but no protein was detectable in FM3 cells (picture H of Figure
4.5). None or extremely low non-specific background fluorescence was obtained in cells
stained with the secondary antibody only (pictures A, D and G of Figure 4.5) and with
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the rabbit IgG isotype control (picture E of Figure 4.5). In Figure 4.5 B and C, BUC11
proteins appeared to be localised in the cytoplasm. An accumulation of them appeared to
be located in the Golgi apparatus but this would need to be confirmed with future exper-
iments at a higher magnification and by using co-localisation with an antibody directed
against a Golgi-specific protein, such as the cellular trans-Golgi network membrane pro-
tein, golgin-87, to which the anti-human golgin-97 mouse monoclonal antibody (Sigma)
binds. However, when the staining was duplicated, there appeared to be same nuclear
staining for BUC11 (Figure 4.5, F). In correlation with the conflicting in silico analysis,
BUC11 could represent a protein translocated from one cellular compartment to another
upon activation. Additional work to confirm this would include subcellular fractionation
of cellular components followed by Western Blotting. Because of time constraints, this
aspect of the research could not be taken forward.
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Figure 4.5: Immunofluorescence assay for BUC11 protein expression and localisation
analyses in human cell lines.
Immunofluorescence assays were carried out using anti-BUC11 antibody on the human
breast cancer cell line MDA231 (positive for BUC11 mRNA) and the human melanoma
cell line FM3 (negative for BUC11 mRNA). Immunofluorescence was observed using
confocal microscopy in MDA231 cells (B), (C) and (F) but not in FM3 cells (H). Non-
specific secondary antibody staining was not observed for MDA231 cells (A and D) and
FM3 cells (G). Non-specific rabbit IgG isotype control staining was not observed for
MDA231 cells (E). Objective magnification: x40.
Staining of MDA231 cells and T47D cells is shown in Figure 4.6, where BUC11
protein is clearly localised in the cytoplasm and not in the nucleus; as the overlay picture
does not show any bright yellow colour in the nucleus, to be expected if BUC11 was also
localised in the nucleus (mixing of green colour of BUC11 staining with red colour of
DRAQ5TMstaining). The same result was found for T47D stained cells, which express
BUC11 mRNA (picture A, B and C of Figure 4.6). Without the overlay of staining,
Figure 4.6, A could be misleading and suggest that BUC11 is located in the nucleus.
Unexpectedly, BUC11 protein expression was found in the cytoplasm of MDA468 cells
(negative for BUC11 mRNA molecule under the limits of detection by the quantitative
RT-PCR), as shown in Figure 4.6. Also, MDAP3 cells seemed to express high levels of
BUC11 protein, whereas BUC11 mRNA levels were low following quantitative RT-PCR.
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This would suggest that the translation of mRNA to protein in MDAP3 cells is efficient or
that the protein is not easily degraded and remains intact within the cell for an extended
period of time. These results however correlate with the results obtained during Western
Blotting analysis.
Figure 4.6: Immunofluorescence assay for BUC11 protein expression and localisation
analyses in human breast cancer cell lines.
Immunofluorescence assay was carried out using anti-BUC11 antibody and
DRAQ5TMDNA dye on the human breast cancer cell lines MDA231, T47D (both
positive for BUC11 mRNA), MDAP3 and MDA468 (both negative for BUC11 mRNA).
Non-specific rabbit IgG isotype control staining was not observed for any of the cell lines
tested (pictures not shown). Objective magnification: x40. 2D-image processing was
carried out using the software Volocity version 4.3.2.
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4.2.5 Immunohistochemistry using anti-BUC11 antibody
As well as in vitro analysis of BUC11 protein expression in cell lines, the anti-BUC11
antibody was used for in vivo expression analysis of BUC11 protein in immunohisto-
chemical studies using a diverse array of normal and tumour tissue sections as described
in Chapter 2. Paraffin-embedded multiple normal tissue microarrays were purchased from
US Biomax (USA). Prior to antibody probing (anti-BUC11 antibody or isotype control)
the microarrays had to be subjected to an antigen retrieval process as described in Chap-
ter 2. Each slide was then stained in duplicate; one with anti-BUC11 antibody and the
other with isotype control antibody to determine any background staining (Figures 4.7 to
4.10). The BUC11 specific staining was then normalised using Mirax viewer software
package to take into account any background staining observed with the isotype control
antibody. At objective magnification x10, high levels of BUC11 protein expression were
observed in the cytoplasm of cells in testes, prostate, breast, ovary and uterus (Figure
4.7). Therefore, the protein expression in testis, breast, uterus and prostate tissues corre-
late with mRNA levels detected previously by quantitative RT-PCR (Chapter 3). Some
positive BUC11 protein staining was obtained in the brain, heart, skin, spleen and kidney
tissues however the isotype control also stained these tissues, to a weaker extent, which
suggests a certain degree of non-specific staining in these tissues (Figure 4.8). Previous
quantitative RT-PCR results showed low amounts of BUC11 mRNA molecules in brain,
heart and kidney but not in spleen. Similarly, positive BUC11 protein staining was ob-
served in the cytoplasm of cells in liver, lung, colon, intestine and stomach tissues (Figure
4.9). A weaker isotype control staining was obtained in liver, lung and colon and a sim-
ilar isotype control staining was found in intestine and stomach. Some BUC11 mRNA
expression was found previously in lung but not in liver, colon, intestine and stomach
tissues (quantitative RT-PCR). Therefore, BUC11 protein expression analysis matches
BUC11 mRNA expression analysis for lung, intestine and stomach tissues. Figure 4.10
demonstrates that the rabbit IgG isotype control and anti-BUC11 antibody produced the
same staining pattern on larynx, tonsil, oesophagus, pancreas and bladder tissue sections,
thus one can conclude that BUC11 protein cannot be visually detected in these tissues and
that this rabbit isotype control antibody is not suitable for in vivo immunohistochemical
staining on these particular tissues. The comparison of the protein and the mRNA levels
in these tissues has to be taken with caution because both analyses were not carried out
on tissues of the same origin.
Immunohistochemical staining on purchased paraffin embedded multiple breast (nor-
mal and tumour) tissue microarrays (US Biomax) was undertaken following the same
procedure. The stained sections were subjected to scanning, however the slide stained
with the isotype control antibody could not be analysed and the pictures were not suitable
for further image processing. This was due to a fault in mounting. Figure 4.11 demon-
strates high levels of BUC11 protein in the tumour cells of patients with invasive ductal
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carcinoma of grade II (A, B, C and D) and patients with invasive ductal carcinoma of
grade III (E and F). Positive staining was also observed in normal duct cells (G) although
to a lesser extent. These results correlate with the high levels of BUC11 mRNA expres-
sion previously observed in breast tissues by quantitative RT-PCR.
Cryostat sections taken from fresh frozen breast tissues (paired normal and tumour, gen-
erously donated by Dr A. Gritzapis), melanoma tissues (generously donated by Prof. D.
Schadendorff) and prostate tissues (collaboration with Nottingham City Hospital) were
prepared on silanised glass slides for immunohistochemical assays as described in Chap-
ter 2. These tissues had previously had RNA extracted from them and had been used to as-
sess BUC11 mRNA levels in quantitative RT-PCR analysis. Unfortunately, the melanoma
tissue sections taken were of poor quality and no useful information regarding BUC11
protein expression could be obtained following staining therefore the data is not pre-
sented. The tissue sections for breast and prostate are shown. Figure 4.12 shows stronger
staining of cells for all 3 patients, thus higher level of BUC11 protein expression was ob-
served in the breast tumour tissues compared to the normal breast tissues. To corroborate
these findings, all 3 patients were found to have BUC11 mRNA expression upregulated
in the tumour compared to the normal adjacent tissue. Figure 4.13 demonstrates that the
level of BUC11 protein expression in the malignant prostate tumour tissue Pr18 is higher
than in the malignant prostate tumour tissue 92/41. Positive staining correlated with the
detection of BUC11 mRNA in these two tissues and quantitative RT-PCR analysis also
showed that BUC11 mRNA level in Pr18 is approximately 3,000 fold higher than the
level in 92/41.
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Figure 4.7: Immunohistochemical staining for BUC11 protein expression in multiple nor-
mal tissue microarrays (1).
Positive staining obtained with anti-BUC11 antibody was observed in testes, prostate,
breast, ovary and uterus, when compared to the staining of the same tissues with rabbit
IgG isotype control. Tissue sections were scanned and image processing was carried out
using the software Mirax viewer. Objective magnification: x10.
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Figure 4.8: Immunohistochemical staining for BUC11 protein expression in multiple nor-
mal tissue microarrays (2).
Staining obtained with anti-BUC11 antibody was observed in brain, heart, spleen, skin
and kidney. Weaker staining obtained with the isotype control antibody was also ob-
served in these tissues. Tissue sections were scanned and image processing was carried
out using the software Mirax viewer. Objective magnification: x10.
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Figure 4.9: Immunohistochemical staining for BUC11 protein expression in multiple nor-
mal tissue microarrays (3).
Staining obtained with anti-BUC11 antibody was observed in liver, lung, colon, intestine
and stomach. Weaker to similar staining as shown with anti-BUC11 antibody was ob-
tained with the isotype control antibody in these tissues. Tissue sections were scanned
and image processing was carried out using the software Mirax viewer. Objective magni-
fication: x10.
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Figure 4.10: Immunohistochemical staining for BUC11 protein expression in multiple
normal tissue microarrays (4).
Staining obtained with anti-BUC11 antibody was observed in liver, lung, colon, intestine
and stomach. Similar staining obtained with the isotype control antibody was also ob-
served in these tissues. Tissue sections were scanned and image processing was carried
out using the software Mirax viewer. Objective magnification: x10.
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Figure 4.11: Immunohistochemical staining for BUC11 protein expression in multiple
breast tissue microarrays.
(A), (B), (C) and (D): breast cancer tissues from four different patients with invasive duc-
tal carcinoma of grade II. (E) and (F): breast cancer tissues from two different patients
with invasive ductal carcinoma of grade III. (G): cancer adjacent normal tissue of a dif-
ferent patient. Positive staining obtained with anti-BUC11 antibody was observed in all
these tissues when compared to the staining of the same tissues with rabbit IgG isotype
control. Pictures of stained tissue sections were taken with a camera attached to the mi-
croscope, under the same conditions. Objective magnification: x10.
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Figure 4.12: Immunohistochemical staining for BUC11 protein expression in breast
frozen sections.
Immunohistochemical assay was carried out on breast tumour tissue sections and nor-
mal counterpart tissue sections. The mRNA expression analysis of these tissues using
quantitative RT-PCR had been carried out. (A) 50-year-old breast cancer patient with
tumour diagnosed at stage I, grade II and negative HER2 expression. (B) 41-year-old
breast cancer patient with tumour diagnosed at stage IIIa, grade III and negative HER2
expression. (C) 52-year-old breast cancer patient with tumour diagnosed at stage I, grade
III and negative HER2 expression. Positive staining obtained with anti-BUC11 antibody
was observed in all these tissues, with greater intensity of staining in the tumour tissues
compared to the normal tissues. Pictures of stained tissue sections were taken with a
camera attached to the microscope, under the same conditions. Objective magnification:
x10.
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Figure 4.13: Immunohistochemical analysis for BUC11 protein expression in prostate
cancer frozen sections.
Immunohistochemical assay was carried out on malignant prostate carcinoma tissues
which tested positive for BUC11 mRNA expression using quantitative RT-PCR. Positive
staining obtained with anti-BUC11 antibody was observed in the tissues, when compared
to the staining of the same tissues with rabbit IgG isotype control. There was also greater
intensity of staining in Pr18 compared to Pr92/41. Pictures of stained tissue sections were
taken with a camera attached to the microscope, under the same conditions. Objective
magnification: x10.
Following encouraging preliminary results of tissue staining with anti-BUC11 anti-
body, a collaboration with Dr Des Powe (Department of Histopathology, Queen’s Medical
Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK) was undertaken.
Using anti-BUC11 antibody (stock provided at 10µg/ml by NTU), immunohistochemistry
(IHC) was performed by Dr Powe on formalin fixed paraffin embedded (FFPE) tissue mi-
croarray (TMA) blocks of breast carcinomas. The patient cohort comprised seven TMA
FFPE blocks constructed from consecutive primary operable invasive breast carcinomas
taken from patients involved in the Nottingham Tenovus Primary Breast Carcinoma Se-
ries between 1986 and 1993. This patient cohort has been extensively characterised and
contains at least 10 years follow up history with additional clinicopathology and cancer-
relevant biomarker data. Briefly, the BUC11 antibody concentration was optimised on
full face breast tumour excisional and TMA FFPE sections. Microwave heat antigen re-
trieval was carried out using 0.01M citrate (pH6) and a labelled streptavidin biotin IHC
technique used on a DakoCytomation (Denmark) TechMate autostainer. The optimal
working dilution of anti-BUC11 antibody for staining was determined to be 1:900 from
the stock provided. For scoring of the TMAs, the levels of cytoplasmic and nuclear stain-
ing intensity in malignant epithelium was determined using the H-score where intensity
was graded 0: no staining, 1: weak, 2: moderate, 3: strong staining. The association
between BUC11 and clinical outcome (survival, disease free interval and tumour recur-
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rence) was modelled using Kaplan-Meier plots and Cox regression hazards risk model
(SPSS software from SPSS Inc., USA). In addition, association between BUC11 and
other key markers of tumour relevance were investigated using a chi square test. A statis-
tical significance level of p≤0.05 was applied to the data.
In the TMA, BUC11 staining was detected at varying levels in the cytoplasm and
nuclei of breast cancer tissues. These findings corroborate previous observations and pro-
vide a clearer insight into the confocal results obtained previously; confocal localisation
of BUC11 appeared to generate contradicting results in duplicate experiments, localisa-
tion appeared to be cytoplasmic in one experiment and nuclear in subsequent experiments.
The IHC findings of dual localisation of BUC11 to the cytoplasm and nucleus in some tis-
sue cores suggests that the confocal findings were actually valid. One explanation could
be that BUC11 is a nuclear protein that is translocated to the cytoplasm following acti-
vation. The TMA staining was scored on 670 breast cancer cases and the distribution of
cytoplasmic staining was as follows: 81 patients scored 0 (12.1%), 199 patients scored
1 (29.7%), 250 patients scored 2 (37.3%) and 139 patients scored 3 (20.7%). The distri-
bution of nuclear staining was as follows: 205 patients positive (30.5%) and 467 patients
negative (69.5%). The H-score cutoff for low nuclear staining was 0-24 and the cutoff for
high nuclear protein expression was 25-300.
The results of the statistical analysis performed are presented in the following five
tables (Table 4.11, Table 4.12, Table 4.13, Table 4.14 and Table 4.15). To summarise,
no significant association was seen between BUC11 protein expression and, among oth-
ers (shown in the tables), ER and HER2 status, size of the tumour, grade of the tumour
and clinical outcome in this cohort of breast cancer patients. However, BUC11 protein
expression significantly correlated with the expression of the androgen receptor (AR),
the progesterone receptor (PgR), cytokeratins 18 and 19 (CK18 and CK19), the trans-
ferrin receptor CD71 and the transcription factors AP2 and YY1. Interestingly, these
results suggest that cytoplasmic BUC11 protein is found in endocrine hormonally posi-
tive luminal-type breast cancers.
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Table 4.11: Statistical analysis of cases showing negative BUC11 staining versus any
positive BUC11 cytoplasmic protein expression.
*The clinical outcome is defined with breast cancer specific survival (BCSS), disease free
interval (DFI), distant metastasis formation (DM) and tumour recurrence.
Table 4.12: Statistical analysis of cases showing negative BUC11 staining versus weak
BUC11 cytoplasmic protein expression.
Weak protein expression corresponds to H-score intensity=1. *The clinical outcome is
defined with breast cancer specific survival (BCSS), disease free interval (DFI), distant
metastasis formation (DM) and tumour recurrence.
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Table 4.13: Statistical analysis of cases showing negative BUC11 staining versus
moderate-strong BUC11 cytoplasmic protein expression.
Moderate-strong protein expression corresponds to H-score intensity=2&3. *The clini-
cal outcome is defined with breast cancer specific survival (BCSS), disease free interval
(DFI), distant metastasis formation (DM) and tumour recurrence.
Table 4.14: Statistical analysis of cases showing negative BUC11 nuclear staining versus
any positive BUC11 nuclear protein expression.
*The clinical outcome is defined with breast cancer specific survival (BCSS), disease free
interval (DFI), distant metastasis formation (DM) and tumour recurrence.
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Table 4.15: Statistical analysis of cases showing low BUC11 nuclear staining versus
BUC11 nuclear protein expression.
The H-score cutoff for low nuclear staining was 0-24 and the cutoff for high BUC11 nu-
clear protein expression was 25-300. *The clinical outcome is defined with breast cancer
specific survival (BCSS), disease free interval (DFI), distant metastasis formation (DM)
and tumour recurrence.
4.3 Discussion
The BUC11 gene, a member of the unpublished BUC family of novel breast-associated
genes found by database mining in our laboratory, was previously identified as a potential
candidate for breast cancer management based on the findings of an exhaustive analysis of
its mRNA expression pattern in diverse normal tissues, tumour tissues and cell lines. All
data obtained earlier were limited to the detection of BUC11 at the messenger RNA level,
however it has been shown in the literature that divergence between protein and RNA
levels is commonly found and can be due to factors, for examples the stability of RNA
molecules, the translation and post-translation associated regulatory processes as well as
protein degradation (Rogel et al., 1985; Chen et al., 2002). Consequently, investigation
as to whether the BUC11 mRNA is translated into protein was essential to establish its
possible clinical uses and the results of this research are presented in this chapter. The
main focuses of this chapter were, firstly, to mine databases for any information on the
BUC11 predicted protein sequence for examples sequence similarities, protein function
and structural features; secondly, to produce a custom-made anti-BUC11 antibody for
use in in vitro and in vivo immunoassays to determine whether or not BUC11 protein
is actually naturally produced and to elucidate its subcellular localisation and its protein
expression pattern in diverse cell lines and tissues. Finally, where possible, to compare
the protein expression pattern to the mRNA expression pattern obtained with RT-PCR
analyses.
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To determine the novelty of BUC11 protein, a thorough study of the predicted protein
sequence by database mining was conducted. Blast analyses demonstrated that BUC11
protein sequence has similarities with the sequences of the human and mouse chromo-
some X-linked protein respectively XIAP and Xiap. XIAP has been proven to have an
important role in inhibiting cell death and generated a great interest in the research com-
munity in studying it as a potential target for breast cancer therapies. This could be impor-
tant when deciphering a potential function of BUC11 protein. Other proteins which have
sequence similarities with BUC11 included an inhibitor of apoptosis (BIRC8), inhibitors
of cell growth (CAPRIN2 and PPP2R1A) and structural proteins (FGD3, PKN2, DNAH2
and PLEKHH3); also, several have been linked to cancer (JMJD3, CHRM3, MAP2K7,
FUT4 and MLL2). All the references used for the proteins cited above can be found in
the results section of this chapter. Based on the results of the BLAST alignments it can
be concluded that BUC11 is not 100% homologous to any previously published genes.
This maintains BUC11’s attractiveness as a breast cancer marker/target candidate. Addi-
tionaly, proteins demonstrating sequence similarities to BUC11 are all involved in some
way to cell growth or survival, thus providing additional support for the potential func-
tion of the BUC11 protein. In silico analyses of the BUC11 predicted protein sequence
suggested that the BUC11 protein could localised to the cytoplasm or nucleus. Also, the
protein was predicted to have a mass of 8.724kDa, to be basic and quite lysine-rich. The
search for structural or functional sites in BUC11 predicted protein sequence that would
provide clues on the potential role(s) of the protein did not give any similarity with known
functional sites or motifs.
In conclusion, the in silico analyses of BUC11 predicted protein did not prove infor-
mative. The lack of predicted functional motifs could be due to the small length of the
BUC11 protein (8.7kDa); or, more likely, that the BUC11 protein does not encode any
common functional motifs. It must be kept in mind that these in silico analysis tools
should only be used as a guide to the potential functions of a particular protein. More
comprehensive assays should always be performed to validate the predictions. For ab-
solute confirmation of BUC11 protein production, a monospecific BUC11 antibody was
custom produced. Upon receiving anti-BUC11 antibody, the affinity of the antibody for
the peptide to which it has been raised against was confirmed by ELISA. Following West-
ern Blotting of cell lysates with the BUC11 antibody, the blots showed that the antibody
binds to proteins with a mass in the range of 15kDa and to a weaker extend to proteins
with a mass in a range of 30kDa. These proteins were detected not only in lysates of cell
lines which have been previously shown to express BUC11 mRNA (MDA231, MDAP3
and ALC/pBudCE4.1/BUC11) but also in lysates of cells which have been previously
shown to not express any detectable BUC11 mRNA levels (MDA468). In order to de-
termine whether or not the 15kDa/30kDa bands observed on the blots were specific to
BUC11 protein, a control blot was performed; prior to addition of BUC11 antibody to
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the blot, BUC11 antibody was preincubated with BUC11 peptide that the antibody was
raised against. In theory if the band observed on the Western Blot is BUC11 specific then
it should be abolished by preincubation of the peptide and antibody. This binding was
abolished by preincubation informing that the products were BUC11 specific. Absolute
proof could be obtained by mass spectrometry analysis.
The difference in size observed between the predicted protein and the proteins de-
tected on the blots could well reflect post-translational modifications of BUC11 protein
even if these were not predicted in silico with the predicted protein sequence. Post-
translational modifications result in mass changes that can be detected during analysis
in which individual products of the same gene migrate to different locations on SDS-
PAGE or 2D-PAGE gels (Anderson and Anderson, 1998). Post-translational modifica-
tions include the addition of functional groups (e.g. biotinylation, glycosylation, phos-
phorylation), the addition of other peptides or proteins (e.g. ubiquitination) and structural
changes of the protein (proteolytic cleavage and disulfide bridges). Thus, the size of the
proteins detected (15kDa/30kDa) could be explained by the post-translational formation
of dimers due to addition of one BUC11 protein to another BUC11 protein, making the
proteins weakly detected in the region of 30kDa (possible quadrimers of BUC11 protein).
To test this hypothesis, important denaturation of the linked proteins would be necessary
to observe a change of location of the detected proteins on SDS-PAGE gels. It is also
possible that the difference in size is due to the addition of one (or several) functional
group or the addition of another protein (e.g. ubiquitin is 8.5kDda) and these modifica-
tions could be detected with the use of readily available kits such as the ones produced by
the company Sigma-Aldrich.
Confocal microscopy, which allows the detection of fluorescently labelled proteins,
was carried out to determine the subcellular localisation of BUC11 protein. Upon visu-
alisation, BUC11 protein was detected homogeneously in the cytoplasm of the positive
cells and it appears that, in some cases, proteins may also aggregate closely around the
nucleus. This finding correlated well with the in silico prediction as to cellular localisa-
tion of BUC11 protein. BUC11 protein was predicted to translocate to a different cellular
compartment upon activation.
BUC11 protein expression levels in T47D and MDA231 cells, as determined by confocal
microscopy, correlated with the BUC11 mRNA expression levels observed in the same
cell lines by quantitative RT-PCR. However, the high level of expression of BUC11 pro-
tein in MDAP3 cells does not correlate with the extremely low level of BUC11 mRNA
expression detected by quantitative RT-PCR. As mentioned earlier, there is no direct cor-
relation between mRNA expression and protein expression, emphasising the importance
of studying a gene of interest at the mRNA and protein expression levels. Lower lev-
els of mRNA molecules compared to proteins could be explained by an increase in gene
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transcription, low protein degradation rate and high protein stability. More surprisingly,
but correlating with the Western Blotting results, MDA468 cells showed good levels of
BUC11 protein expression whereas no mRNA molecules could be detected previously by
quantitative RT-PCR. One possible explanation on the divergence of mRNA and protein
expression is that RNA extraction for quantitative RT-PCR assays and immunofluores-
cence assays or cell lysates production for Western Blotting were not conducted at the
same time during the study therefore the number of passages and even batches of the cells
used were different and this could potentially have affected the gene copy number. Also,
another possible explanation is the limitations of mRNA molecules detected by quantita-
tive RT-PCR. The level of gene expression (mRNA and protein) always vary according
to the state (stressed, growing, etc.) and needs related to this particular state during the
life of a cell. The study should be repeated with RNA extraction (avoiding possible RNA
degradation thus loss of detectable mRNA molecules) and isolation of cells (for lysates
and fluorescence) from the same culture in order to provide a true and precise “snapshot”
of mRNA and protein expression at a given time in a given state of the cells. Also, the im-
munofluorescence assay should be repeated by including control chambers with peptide
block. Most of the research undertaken on breast cancer is carried out using breast cancer
cell lines as in vitro models. The majority of these cell lines were established from tumour
metastases and cell lines undergo genotypic and phenotypic changes with intensive cul-
ture. The accumulation of such changes ultimately means that these cell lines will differ
from the original characteristics of the tumours they were established from (Burdall et al.,
2003). Good alternatives to overcome these limitations include the use of recently estab-
lished cell lines from primary tumours or the more challenging primary cultures (Burdall
et al., 2003).
Hall and colleagues stated that studies focusing on gene expression in breast cancer
cell lines only partially reflect the gene expression in breast tissues (Hall et al., 1986). Im-
munohistochemistry is an in vivo assay that allows both the absolute presence of protein
to be determined as well as showing the subcellular localisation of the protein of interest.
It also has the advantages of showing which particular cell types in whole heterogeneous
tissues express the protein, which is something not possible in tissue lysates unless tis-
sues have been laser micro-dissected beforehand. A normal FFPE tissue microarray was
purchased from US Biomax and probed with BUC11 antibody. Varying levels of BUC11
protein were detected in these normal tissues, however one has to be cautious with these
findings due to the high level of background staining of the isotype control antibody after
optimisation. High levels of BUC11 protein were found in the hormone-dependent tis-
sues: breast, prostate, testes, ovary and uterus. This result correlated with the quantitative
RT-PCR data. Some additional vital tissues showed positive staining of BUC11 protein
too, but again high background staining with the isotype control antibody was also ob-
served. High levels of background staining were only problematic with the FFPE normal
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TMAs. This would suggest that more careful optimisation of the staining protocol on
these TMAs is required in the future. Also, the possible future use of monoclonal BUC11
antibody would reduce background staining. It is possible that DAB staining was left
longer on the sections stained with the isotype control compared to the sections stained
with anti-BUC11 antibody even if the experiment was undertaken with care. Also, pos-
itive staining of some tissues with the rabbit IgG isotype control suggests that either the
DAB staining should be left for a shorter period of time (reduce background staining to a
minimum) or more likely that this particular isotype is not suitable for the FFPE TMAs. If
high levels of BUC11 protein expression is confirmed in vital tissues then BUC11 might
not be considered for molecular therapies and immunotherapies where there could be se-
rious toxic effects as the normal tissues would also be targeted for destruction. High levels
of BUC11 protein expression were found in diverse breast tumour and matched normal
tissues, confirming the BUC11 mRNA pattern of expression observed previously by RT-
PCR. The positive staining obtained on the small cohort of fresh frozen tissues (breast and
prostate) correlated with the quantitative RT-PCR data generated with RNA isolated from
the same tissues. Furthermore, staining of the fresh frozen breast cancer tissues showed
very specific localisation of BUC11 protein in the glandular or ductal cells and not the
surrounding stroma or fatty tissue. Also, the staining observed in the fresh frozen normal
breast tissues is not as intense as in the cancer tissue and does not appear to be restricted
to glands but seems to be more heterogeneously diffused across the section.
In collaboration with Dr Powe, immunostaining was performed on FFPE TMA blocks
comprising 670 invasive breast carcinoma patients using anti-BUC11 antibody. This pro-
vided extensive information in the BUC11 protein expression pattern in a large cohort
of fully quality assured breast cancer samples. BUC11 protein expression was observed
in 87.9% of the cores on the TMA. This result correlates with both the semi-quantitative
and quantitative RT-PCR data previsouly obtained on BUC11 mRNA expression in breast
tumour tissues in which silencing of gene expression was observed in about 10% of
breast cancer cases. BUC11 protein was detected in varying levels in the cytoplasm,
with homogenous distribution, which is similar to the staining obtained previously with
anti-BUC11 antibody both using our IHC tissues and also using confocal microscopy.
Moreover, it was demonstrated that BUC11 protein expression was also detectable in
the nuclei of 30.5% of the tissues tested. In silico analyses of BUC11 predicted protein
sequence showed the possibility of BUC11 protein to be directed to the nucleus which
was not confirmed by confocal microscopy nor preliminary immunohistochemical stain-
ing in our laboratory. Ubiquitous cellular expression of BUC11 protein might reflect the
changing needs of the breast cell at the time of resection of the tumour. BUC11 pro-
tein does not appear to be present on the membrane of the cells, making it an unlikely
target for antibody-based therapies in breast cancer patients. BUC11 protein expression
was not found significantly associated with ER status, HER2 status, tumour size, tumour
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grade and clinical outcome. However BUC11 protein was positively correlated to ex-
pression of progesterone receptor (PgR), cytokeratin 18 (CK18), the transferrin receptor
CD71 and the transcription factors AP2 and YY1. Luminal-type breast cancers are usu-
ally classified by showing positive expression of ER and PgR (Loi, 2008); and CK18 has
been reported to be a marker for this type of breast cancers (Tang et al., 2006). Further-
more, CD71 might be associated with the growth of endocrine resistant phenotypes within
luminal-type breast cancers (Habashy et al., 2009). Finally, AP2 nuclear expression has
solely been found in epithelial and myoepithelial of normal and cancerous breast cells
(Pellikainen and Kosma, 2007) and YY1 has been associated with AP2 transcriptional
activity (Allouche et al., 2008). An interesting finding about BUC11 protein expression
and its potential role in breast cells was the fact that cytoplasmic and/or nuclear BUC11
protein was widely found in endocrine hormonally positive epithelial luminal-type breast
cancers. Therefore, BUC11 protein could potentially be considered as a novel luminal
epithelial marker and further confirmation studies on larger cohorts of patients need to be
performed.
Breast tissue is a complex structure formed by an outer myoepithelial/basal layer, an
inner luminal epithelial layer and non-epithelial components (fibroblasts, lymphocytes,
endothelial cells, adipocytes, neurons and myocytes). For the last ten years or so, distinc-
tive patterns of gene expression, obtained with DNA microarrays, have been widely used
in order to determine the most accurate molecular classification of breast tumours into
subtypes (Perou et al., 2000; Sorlie et al., 2001; Sorlie et al., 2003). The existence of at
least 5 clinically relevant molecular subgroups is known: luminal subtype A (ER+, PR+,
HER2-, 45% of breast cancer cases, better prognosis), luminal subtype B (ER+, PR+,
HER2-, Ki67≥10%, worse prognosis), HER2+ (ER-, PR-, HER2+, aggresive tumours),
basal subtype (ER-, PR-, HER2-, 15% of breast cancer cases, aggressive tumours) and
normal breast-like. It is of high importance to discover epithelial cell-type specific pro-
teins in order to increase knowledge on the multistep cancer formation and advancement
from normal cells to invasive breast carcinoma as well as to inform clinicians with re-
gard to novel diagnostic and prognostic markers of breast cancer (Jones et al., 2004; Loi,
2008). Furthermore, it is thought that breast cancer may arise from mammary epithelial
stem cells (Smith, 2002) and that quiescent cancer stem cells could be responsible for re-
sistance to therapy and recurrence of the disease (Reya et al., 2001). This theory is based
on the fact that most anti-cancer therapies such as chemotherapies target rapidly dividing
cells thus having no killing effect on resting cells like stem cells. Cells with stem cell-like
properties (quiescent, long life, high clonogenicity, self-replicating potential, plasticity
and drug resistance) have been found in various human tissues and cell lines; for exam-
ples normal breast (Stingl et al., 2005), breast cancer (Al-Hajj et al., 2003), human brain
tumours (Singh et al., 2003), prostate cancer (Collins et al., 2005), melanoma (Fang et al.,
2005), lung cancer (Ho et al., 2007), pancreatic cancer (Olempska et al., 2007), nasopha-
164
Chapter 4. BUC11 Protein Expression Analysis 4.3
ryngeal cancer (Wang et al., 2007) and thyroid cancer (Mitsutake et al., 2007). Farnie
and Clarke have provided evidence on the existence of breast cancer stem cells; in their
studies, they showed the possibility of enriching stem cell like and breast cancer initiating
populations through selection by the cell surface markers CD44+/CD24−, CD24 being
a marker associated with normal luminal epithelial cells (Farnie and Clarke, 2007). It
was also shown recently that MCF7 breast cancer cell line has a side population com-
prising cells that present biological characteristics of quiescent tumour stem cells and
which express the transmembrane glycoprotein MUC1, a potential immunotherapeutic
target; therefore, these tumour stem cells should also be targetted and destroyed during
immunotherapy (Engelmann et al., 2008). As a conclusion, novel breast cancer stem
cell-associated markers could represent potential targets for novel therapies to treat and
prevent recurrence of breast cancer. It would be interesting and of value to the current
study to determine whether or not BUC11 is expressed in breast cancer stem cells.
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BUC11 Functional Analysis
5.1 Introduction
Gene function analysis can be defined as the study of cellular changes due to varying lev-
els of expression of a gene of interest in order to uncover the biological function(s) that
a particular gene has in the targeted cells and the pathway(s) the gene might be involved
in. The analysis is based on the observation of specific effects on cell morphology, cell
proliferation or cell behaviour, generated after the induction of expression in cells that
do not normally express the gene of interest or after the repression of expression in cells
that normally express the gene of interest. Transfection of expression vectors into cells
and RNA interference-mediated gene silencing are extensively used as tools for research
in gene function studies and, more importantly, can be used in gene therapies for cancer
patients in order to replace defective tumour suppressor genes or inhibit the activity of
tumour oncogenes (Toloza et al., 2006; Takeshita and Ochiya, 2006; Huang et al., 2008).
Gene delivery, with vectors encoding a tumour antigen that has previously shown to be
immunogenic in in vitro and in vivo studies, can also be used to vaccinate patients, with
the objective of triggering a specific and strong immune response against tumour cells
expressing the tumour antigen.
Microarray technology is a way of undertaking functional analysis on a genome wide
scale and its popularity has increased dramatically over the last 10 years. Expression mi-
croarrays have been used to classify breast tumours (Perou et al., 2000; Sorlie et al., 2001;
Sorlie et al., 2003) and uncover genes involved in tumour development, progression and
recurrence of the disease. The genes identified can then be profiled and used to develop
diagnostic and prognostic tests. For example, MammaPrint is a 70-gene signature is-
sued from data analysis of microarrays containing 25,000 60-mer oligonucleotides (Glas
et al., 2006) and used by clinicians for predicting outcome of neoadjuvant chemother-
apy (Straver et al., 2009). Also, several gene expression profiles discovered by Kok and
colleagues can predict the progression of breast cancer in patients who received tamox-
ifen (Kok et al., 2009). Microarrays are also important for the discovery of targets for
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novel breast cancer therapies and the development of targeting drugs (Foekens et al.,
2008; Caldwell, 2007). For studies on a particular gene of interest, microarrays allow
researchers a snapshot of the entire genome of targeted cells according to the state of
cells and whether the gene of interest is up or downregulated with respect to a particular
question.
As BUC11 is an unpublished gene, no function for its predicted protein has been char-
acterised. Previously in this study, immunohistochemical analysis showed that BUC11
protein appears to be preferentially found in the epithelial luminal type of breast cells
(predominantly in the cytoplasm) however no evidence was found to link BUC11 protein
with breast tumour formation, state or progression. In this chapter, the aim was to pro-
vide evidence to support the hypothesis that BUC11 might be involved in carcinogenesis
and/or tumour progression and to elucidate some of the potential molecular pathways that
BUC11 may be involved in. In order to investigate the role(s) that BUC11 plays in the
cell, several experiments were conducted following “switching on” BUC11 expression in
mammalian cells, that do not normally express this gene and “switching off” BUC11 ex-
pression in mammalian cells by short interfering RNA (siRNA)-mediated gene silencing.
These experiments included proliferation assays, cell cycle analysis by flow cytometry
and microarray technology. Furthermore, conclusions on preliminary experiments (data
not shown) on the potential immunogenicity of BUC11 protein in a mouse model are
presented in this chapter.
5.2 Results
5.2.1 Cloning of BUC11 DNA into pBudCE4.1
The cloning of the full open reading frame of BUC11 into a mammalian expression
vector was necessary to carry out transfection of BUC11 DNA into mammalian cells that
do not normally express BUC11 mRNA. The murine lymphoma cell line (ALC), which is
stably transfected to express a HLA-A2 construct (containing neomycin resistance gene),
was chosen for this purpose and also for the eventual future use in a mouse tumour model
(not performed in this study). The mammalian expression vector pBudCE4.1 (Invitrogen)
includes the zeocin resistance gene and allows a high level of expression of genes in sta-
ble and transient studies in most mammalian cell types.
Briefly, the cDNA of the full open reading frame of BUC11 protein was amplified
using specifically designed flanking primers that also included the cutting sites for the re-
striction enzymes Sal I and Xba I found in the cytomegalovirus (CMV) multiple cloning
site of the pBudCE4.1 plasmid (Figure 5.1). Amplified BUC11 cDNA with flanking re-
striction enzyme sites and the pBudCE4.1 plasmid were double digested with the specific
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restriction enzymes, gel purified and ligated at 4◦C overnight. Ligation products were
used to transform chemically competent E.coli cells which were then plated on LB agar
plates containing the antibiotic zeocin. As shown in Figure 5.2, following selection of
clones subjected to restriction enzyme double digestion, positive clones that contained
BUC11 cDNA (300bp) were obtained. After purification, pBudCE4.1/BUC11 plasmids
were sequenced (MWG Biotech, UK) in order to confirm that the BUC11 sequence was
correct (Figure 5.3). The pBudCE4.1/BUC11 plasmid was subsequently used in the trans-
fection of ALC cells to determine any effects on cell proliferation and for immunogenicity
studies in MHC transgenic mice.
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Figure 5.1: Diagrammatic representation of the construction of the plasmid
pBudCE4.1/BUC11.
Specific primers were designed to amplify the full open reading frame of the BUC11
gene with the addition of the restriction enzyme cutting sites for Sal I and Xba I. Both
pBudCE4.1 vector and BUC11 cDNA were digested with the restriction enzymes Sal
I and Xba I. Following purification of desired digested products, BUC11 cDNA and
pBudCE4.1 were ligated.
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Figure 5.2: Agarose gel electrophoresis of pBudCE4.1/BUC11 clones after double diges-
tion.
Following double digestion of the selected clones with the restriction enzymes Sal I and
Xba I, DNA measuring 300bp could be detected in 8 out of 9 selected clones correspond-
ing to the expected size of cloned BUC11 cDNA.
Figure 5.3: Alignment of BUC11 nucleotide sequence with the sequencing result for one
of the positive pBudCE4.1/BUC11 clones.
”mRNABUC11original” is the reference nucleotide sequence for BUC11 and
”mRNApBud+BUC11sequenced” is the sequencing result of one of the positive
pBudCE4.1/BUC11 clones. The clone sequence presents the correct coding region for
BUC11 predicted protein. The start (ATG) and stop (TGA) codons are circled. There is a
deletion of an adenine in the clone 6 sequence at the start codon site but the reading frame
is not affected.
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5.2.2 Transfection of pBudCE4.1/BUC11 in mouse lymphoma cells
Following the successful cloning of BUC11, the pBudCE4.1/BUC11 plasmid was
used to transiently transfect, by electroporation, the murine lymphoma cell line (ALC)
which does not naturally express BUC11 mRNA. Attempts to create stable transfected
ALC cells using the transfection reagent Lipofectamine 2000 were unsuccessful. The
MACSelect - Transfected Cell Selection system (Miltenyi Biotec, Germany) enables a
quick magnetic enrichment of transfected cells, without the use of antibiotics. In this
study, a co-transfection methodology was chosen and carried out using the plasmid of
interest (pBudCE4.1/BUC11 or pBudCE4.1/- empty vector as control) and the purchased
plasmid pMACS Kk.II. The optimal co-transfection ratio of pMACS and the expression
vector of interest and the optimal selection time were determined following recommen-
dation from the manufacturer’s protocol. A time course (15 hours, 21 hours and 24
hours) was carried out on cells transfected with 3 different ratios (1:1.5, 1:2.5 and 1:5) of
pMACS:pBudCE4.1/- and pMACS:pBudCE4.1/BUC11.
According to quantitative RT-PCR analysis, BUC11 mRNA expression was detectable
in ALC/pBudCE4.1/BUC11 cells and not in the control cells 15 hours following trans-
fection. The highest BUC11 mRNA expressions were found in cells transfected with
the plasmid ratio 1:2.5. In these cells, the highest BUC11 mRNA expression was ob-
tained 21 hours following transfection and a decreased expression was observed after 24
hours due to the nature of a transient transfection without antibiotic selection (Figure
5.4). Therefore, in subsequent experiments, the selection of co-transfected cells using the
MACS Columns was carried out on cells transfected with the plasmid ratio 1:2.5 21 hours
following electroporation. In addition to the detection of BUC11 mRNA expression by
quantitative RT-PCR analysis, ALC/pBudCE4.1/- and ALC/pBudCE4.1/BUC11 lysates
were used for Western blotting analysis to demonstrate BUC11 at the protein level (data
shown in Chapter 4).
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Figure 5.4: Quantitative RT-PCR analysis of BUC11 transfection in ALC cells.
Following co-transfection with 3 different ratios of the plasmids pKKN2 and
pBudCE4.1/- (control) or pBudCE4.1/BUC11, RNAs from ALC cells were harvested at
three time points (no antibiotic added). The highest expression of BUC11 mRNA was
observed with the ratio 1:2.5. The relative BUC11 gene expressions following the tran-
sient transfection with the plasmid ratio 1:2.5 of the BUC11-negative mouse lymphoma
cell line are shown.
5.2.3 siRNA-mediated BUC11 gene silencing
BUC11 specific siRNA (targeting the coding region of BUC11 gene) was designed for
use in BUC11 gene silencing experiments on the BUC11 mRNA-expressing breast cancer
cell line MDA231. Attempts were made to transfect BUC11 siRNA in the breast cancer
cell line T47D first, which showed a higher BUC11 mRNA expression than MDA231
cells (data shown in chapter 3), but specific gene knockdown never reached more than
70% 24 hours following transfection (data not shown). It was later discovered, when
MDA231 cells were used instead, that specific BUC11 gene knockdown above 70% were
only obtained 48 hours following transfection. Briefly, MDA231 cells were plated in 24-
well plates the day before the transfection so that 60% confluence was reached. Cells
were then transfected with either BUC11 siRNA or negative control siRNA (Eurogentec,
Belgium) using the siRNA transfection reagent INTERFERinTM. A time course was car-
ried out to confirm the duration of specific BUC11 gene silencing: RNA was extracted
24, 48 and 72 hours following transfection for quantitative RT-PCR analysis. As seen in
Figure 5.5, BUC11 siRNA-specific decreased BUC11 mRNA expression was observed
24 hours following transfection, with an optimal silencing (above 70%) obtained after 48
hours. A decrease in gene silencing was found thereafter which reflects the transient na-
ture of siRNA-mediated gene knockdown. It was therefore decided to use the transfected
cells for subsequent experiments at the optimal time of 48 hours following transfection.
Neither negative control siRNA nor INTERFERin had a significant effect on BUC11
mRNA expression. Moreover, microscopic examination of transfected cells at different
time points did not show any obvious changes in cell morphology or cell adherence, how-
ever it was evident that cells transfected with BUC11 siRNA proliferated at a slower rate
than the control cells (images not shown).
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Figure 5.5: Quantitative RT-PCR analysis of BUC11 silencing in MDA231 cells.
A time course was carried out to determine the nature of BUC11 silencing overtime.
The percentages of BUC11 expression following the transient transfection with BUC11
specific siRNA of the BUC11-positive MDA231 breast cancer cell line are shown. The
highest percentage of BUC11 gene knockdown was observed 48 hours following trans-
fection. Gene silencing was considered successful when more than 70% gene knockdown
is observed.
In many cells, the production of interferon proteins is triggered in response to the
presence of double-stranded RNA (dsRNA) suggesting viral infection. It was previously
reported that in vitro transfection of cells with dsRNA such as the siRNA used in this
study can be responsible for an interferon-based response, altering not only the expres-
sion of interferon-responsive genes, but also the expression of the targeted gene of inter-
est. Quantitative RT-PCR analysis showing a reduction in the expression of the gene of
interest would therefore be misleading in the interpretation of non specific effects. For
instance, expression of both interferon-responsive genes 2’-5’-oligoadenylate synthase 1
(OAS1) and signal transducer and activator of transcription 1 (STAT1) were found to be
affected in mammalian cells transfected with siRNA (Fish and Kruithof, 2004; Ma et al.,
2005). In this study, OAS1 and STAT1 primers were used in quantitative RT-PCR anal-
ysis. No significant variations in the mRNA expression of these genes were observed,
suggesting that decreased expression of BUC11 mRNA obtained in this study was indeed
the result of specific BUC11 silencing by siRNA and not as a result of so called “off gene”
silencing (data not shown).
5.2.4 Proliferation assays
Proliferation assays were performed to determine the potential functional effects of
BUC11 in cell lines. Firstly, the BUC11-positive cell line MDA231, which was success-
fully used previously in siRNA-based gene knockdown studies, was again used in siRNA-
based gene knockdown studies and cell proliferation was measured. Secondly, a naturally
BUC11-negative cell line, ALC mouse lymphoma cell line, which has previously been
successfully transfected with the expression vector pBudCE4.1/BUC11, was also used
in the proliferation study. The proliferation assay was based on the incubation of cells
with 3H-thymidine. During each cell division, the cells incorporate radioactive thymidine
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into their DNA, thus the more proliferative the cells are the higher is the radioactivity of
the DNA, which can then be collected on a filter membrane and counted in a scintilla-
tion counter (counts per minute). In some instances, DNA or siRNA transfection effects
on mRNA expression can be measured as early as 6 hours following transfection, how-
ever, effects on protein production and function are not generally observed earlier than
48 hours following transfection. For this reason, proliferation assays were performed 48
hours or longer following transfection, usually at 2, 4 and 8 days after the transfection of
ALC/pBudCE4.1/BUC11 cells and ALC/pBudCE4.1/- cells (control). Figure 5.6 shows a
statistically significant increase in proliferation of the cells transfected with BUC11 gene
when compared with the cells transfected with the empty vector, both at 2 and 4 days.
On day 8, there was still a statistically significant difference, however this observation
requires caution because at this time point the cells had become confluent and the rate of
overall proliferation was reduced for both transfections (this can be observed visually and
by the drop in the proliferation rate as compared to days 2 and 4).
The effect of BUC11 gene silencing on the proliferation of MDA231 cells, test and
control cells were labelled with 3H-thymidine, 3 days, 7 days and 10 days following
siRNA transfection. Figure 5.7 shows a statistically significant decrease of proliferation
of the cells transfected with BUC11 siRNA when compared with the cells transfected
with negative control siRNA, both 3 days and 7 days after transfection. However, the pro-
liferation rate of the cells transfected with BUC11 siRNA had returned to a rate that was
very similar to the control cells, due mainly to the transient effect of siRNA transfection.
Figure 5.6: Proliferation assay following BUC11 transfection.
A time course was carried out to determine the rate of cell proliferation following transient
transfection of BUC11 mRNA-negative mouse lymphoma (ALC) cells with pBudCE4.1/-
and pBudCE4.1/BUC11. Zeocin was added to the media 48 hours following transfection.
Four replicates were used for each condition and each time point in this experiment. A
significant increase in proliferation of the BUC11-negative ALC cells was obtained 2
days after transfection with the vector expressing BUC11. *** p<0.001 represents the
statistical difference between ALC cells transfected with pBudCE4.1 empty vector and
those transfected with pBudCE4.1/BUC11 vector, determined by Student’s t-test.
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Figure 5.7: Proliferation assay following BUC11 silencing.
A time course was carried out to determine the rate of cell proliferation following tran-
sient transfection of BUC11 mRNA-positive MDA231 breast cancer cell line with BUC11
siRNA or negative control siRNA. Other controls included cells treated only with IN-
TERFERin and non-treated cells. Duplicates were used for each condition and each time
point in this experiment. A significant decrease in proliferation of the BUC11-positive
MDA231 cells was obtained 3 days after transfection with BUC11 siRNA. * p<0.05 and
** p<0.01 represent the statistical difference between MDA231 cells transfected with
negative control siRNA and those transfected with BUC11 siRNA, determined by Stu-
dent’s t-test.
5.2.5 Cell cycle analysis
The proliferation analysis suggested that BUC11 might have a role in a pathway in-
volved in the control of cell division. Uncontrolled cellular proliferation can result from
disorganisation of the cell cycle, therefore cell cycle analysis by propidium iodide (PI)
staining with flow cytometry (FACS) was carried out on the MDA231 breast cancer cell
line. Briefly, 72 hours following transfection with either control siRNA or BUC11 siRNA,
adherent cells were trypsinised, washed several times and fixed with cold ethanol. The
cells were washed, incubated with a mix of RNase and PI solutions and DNA fluores-
cence was measured by FACS. Table 5.1 shows the percentage of cells in each of the 3
phases of the cell cycle (G1, G2 and S) for both test and control cells. From these results
it appears that BUC11 gene silencing was responsible for an increase of cells in the G1
phase of the cell cycle with a comparable drop of the number of cells in the G2 and S
phases. Therefore, knockdown of BUC11 gene causes growth arrest in these cells, most
likely due to cell cycle inhibition at the G0-G1 checkpoint or G1/S checkpoint, poten-
tially due to BUC11 having an influence on the activity of G1 regulatory proteins. This
result correlates with the decrease of BUC11 gene silenced-MDA231 cell proliferation
observed and provides further evidence for a potential role of BUC11 in the regulation of
cell growth.
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Table 5.1: Cell cycle analysis by flow cytometry of BUC11 siRNA-transfected MDA231
cells.
”Control” cells are MDA231 cells transfected with negative control siRNA and ”BUC11
knockdown” cells are MDA231 cells transfected with BUC11 siRNA. Cells were stained
with propidium iodide 72 hours following transfection and measurement of DNA fluores-
cence was carried out by FACS. This experiment was carried out twice (n=2) with only
one replicate in each, the percentages are given as mean of both experiments. Analysis
of fluorescence using the software Cylchred gave the percentage of cells in each of the 3
phases of the cell cycle (G1, G2 and S) for both test and control cells.
5.2.6 Affymetrix GeneChip R©Microarray
As BUC11 is a novel unpublished gene, no information is available on the pathways
or cellular processes it is involved in. Following the observations made in the siRNA-
mediated BUC11 silencing experiments, analysis of the effects of BUC11 gene knock-
down on a wider scale, that is to say on the whole genome of MDA231 cells, was carried
out using Affymetrix GeneChip R© Microarray technology. Briefly, in the same experi-
ment, RNA was extracted from duplicates of control (control siRNA) and test (BUC11
siRNA) transfected MDA231 cells. Significant specific BUC11 gene silencing in the test
samples was confirmed by quantitative RT-PCR and the purity of the four RNA samples
was confirmed using a Nanodrop microspectrophotometer. The duplicate control and test
RNA samples were analysed at the Nottingham Arabidopsis Stock Centre (School of Bio-
sciences, University of Nottingham, Sutton Bonington Campus, Loughborough) on four
different GeneChip R©Human Genome U133 Plus 2.0 Arrays, which include more than
47,000 RNA transcripts (Affymetrix, USA).
Upon receiving the data, the gene expression profile data was plotted control versus
silenced. Regression analysis was conducted and the standard residual value determined
for each transcript spot. This was repeated for all replicates. The average and standard
deviation of standard residual values for each gene was calculated. Mean standard resid-
uals were ranked most negative to most positive. These values varied between -31.07
to 24.32 and the standard deviation values were within acceptable limits. Any genes
that had an average value above 2 were considered significantly upregulated in the test
samples compared to the control samples whereas any genes that had an average value
below -2 were considered significantly downregulated in the test samples compared to
the control samples. On the array, the U133 Plus 2.0 Probe set 237339 at was created
from the genes associated to the Genbank accession AI668620 which includes the gene
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hCG 25653 (BUC11)(http://www.genecards.org/cgi-bin/carddisp.pl?gene=hCG 25653).
The average value for the transcript representing BUC11 was -0.12 therefore the BUC11
gene is not significantly downregulated in this analysis.
The 10 most significantly upregulated genes and the 10 most significantly downreg-
ulated genes found in the microarray analysis are shown in Table 5.2 and Table 5.3 re-
spectively. The top 100 most upregulated genes (their average values range from 24 to
6.9) and the top 100 most downregulated genes (their average values range from -31 to
-7) were studied by searching relevant literature. It was possible to establish links be-
tween genes of the study based on information reported in the literature that they have a
direct effect on each other or that they have an indirect effect through a cascade of events
in the cell. Genes could also be grouped according to their biological function(s). The
list of the most upregulated genes is mainly composed of ribosomal proteins, heat shock
proteins, respiratory chain proteins, proteins involved in apoptotic pathways and proteins
involved in cell growth and protection of cell against hydrogen peroxide. The list of the
most downregulated genes is mainly composed of ribosomal proteins, metallothioneins,
angiogenic inducers and proteins involved in the cytoskeletal organisation, cell adhesion,
cell migration and cell proliferation.
Table 5.2: Top 10 most upregulated genes in the microarray analysis.
The 10 most upregulated genes in the BUC11 silenced-MDA231 breast cancer cells when
compared to the control cells found in the regression analysis of the microarray data are
shown. CLPTM1 stands for cleft lip and palate associated transmembrane protein 1.
“Average” is the average of standard residual values.
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Table 5.3: Top 10 most downregulated genes in the microarray analysis.
The 10 most downregulated genes in the BUC11 silenced-MDA231 breast cancer cells
when compared to the control cells found in the regression analysis of the microarray data
are shown. “Average” is the average of standard residual values.
The literature search of the top 100 significantly upregulated genes in MDA231 breast
cancer cells when BUC11 gene expression is knocked-down revealed a number of inter-
esting genes. As stated earlier, several ribosomal proteins were found. These include
ribosomal protein S2 (RPS2), ribosomal protein L15 (RPL15), ribosomal protein S19
(RPS19), ribosomal protein L13a (RPL13a), ribosomal protein L7a (RPL7a), ribosomal
protein S7 (RPS7) and mitochondrial ribosomal protein L11 (MRPL11). Several studies
have shown that the expression of some ribosomal proteins can be linked with the devel-
opment of prostate and colon cancer (Ohkia et al., 2004; Vaarala et al., 1998; Bee et al.,
2006; Pogue-Geile et al., 1991). Wang and colleagues showed that over-expression of
RPS2 might be involved in the development of prostate cancer and that RPL15 promotes
the proliferation of gastric cancer cells, making these proteins a good target for novel
cancer therapies (Wang et al., 2009; Wang et al., 2006). Loss of RPS19 expression was
associated with a decreased cell proliferation and an increase in apoptosis in a cell line
model of Diamond-Blackfan anemia (Miyake et al., 2008). On the other hand, RPL13a
and RPL7 expressions were associated with the induction of apoptosis by arresting cell
growth respectively in the G2/M phase and G1 phase of the cell cycle (Chen and Ioannou,
1999). Also, increased expression of RPS7 and of MRPL11 were shown to induce apop-
tosis and inhibit proliferation of cells (Chen et al., 2007; Dai et al., 2007). Two heat shock
(stress) proteins were also found in the most upregulated genes: Heat Shock 90kd protein
1 and Hsp89 alpha Delta-N and apoptosis can induce the accumulation of stress proteins
in cells. HSP90 is a good target for cancer therapies as it was shown to maintain, under
stress conditions, the functions of proteins associated with survival and proliferation of
cancer cells (Messaoudi et al., 2008). Several respiratory chain proteins were found in
the top 100 upregulated genes such as voltage-dependent anion channel 3 (VDAC3), mi-
tochondrial ubiquinone binding protein, uniquinol-cytochrome c reductase binding pro-
tein (UQCRB), NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 1 (NDUFA1),
NDUFS6, NDUFS5, NDUFB4, cytochrome c oxidases (COX7c, COX4, COX7B), ATP
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synthases (ATP5E and ATP5B). Mitochondria are essential cellular organelles for the pro-
duction of energy but also have functions in apoptosis. For example, VDAC3 was shown
to play an important role in mitochondria-mediated apoptosis (Shoshan-Barmatz et al.,
2006). Other interesting proteins found in the most upregulated genes that did not belong
to major protein groups include the mitochondrial carrier homolog 2 protein (MTCH2),
the glutathione peroxidase 1 protein (GPX1) and the cleft lip and palate associated trans-
membrane protein 1-like protein (CRR9). MTCH2 was found expressed in apoptotic cells
(Grinberg et al., 2005), CRR9 was associated with apoptosis in an ovarian cancer cell line
(Yamamoto et al., 2001) and overexpression of GPX1 was associated with delayed cell
growth and detoxification of hydrogen peroxide from cells (Faucher et al., 2003).
The literature search of the top 100 significantly downregulated genes in MDA231
breast cancer cells when BUC11 gene expression is knockdown also uncovered many in-
teresting genes. The ribosomal proteins L30 (RPL30) and S11 (RPS11) were found to be
amongst the 10 most downregulated genes. RPS11 was found downregulated in apoptotic
breast cancer cell lines such as MCF-7 (Nadano et al., 2001) and RPL30 was associated
with tumourigenesis in colon cancer (Jiang et al., 2008). Moreover, the following met-
allothioneins were found: MT2A, MT1F, MT-1E, MT-1X, MT-1H, MT1L and MT1G.
The family of metallothioneins is composed of at least 10 functional genes that encode
low molecular weight metal binding proteins that have been widely linked with prolif-
eration of breast cancer cells and have been associated with poorer prognosis in breast
cancer (Bay et al., 2006). Their functions include the maintenance of transition metal ion
homeostasis, redox balance, cell proliferation and apoptosis (Jin et al., 2004). In particu-
lar, MT2A has been associated with higher histological grade of breast cancer (Jin et al.,
2002). In this study, MT2A was found to be the most significantly downregulated gene.
Yang and colleagues stated that metallothionein genes are good targets for antisense ther-
apies in breast cancer (Yang et al., 2002). As previously mentioned, the top 100 most
downregulated genes included proteins involved in the cytoskeletal organisation, cell ad-
hesion, cell migration and cell proliferation such as actinin (alpha) 1 (ACTN1), syndecan
4 (SDC4), syndecan binding protein, clathrin (LCA, actin assembly role), actin gamma 1,
calponin 3 (CNN3, cytoskeleton-associated), tubulin beta 2, tropomyosin (actin-binding
protein), actin related protein 2/3 complex (PNAS-139), plasminogen activator urokinase
(PLAU) and ras homolog gene family member A (RHOA). Alpha-actinin was shown to
interact with syndecan 4 in the process of stabilisation of focal adhesions for cell survival
(Choi et al., 2008) and Urokinase-type plasminogen activator (PLAU) was associated
with breast cancer cell invasion (Hildenbrand and Schaaf, 2009). Syndecan 4 binds and
activates protein kinase C (PKC) alpha and was associated with RHOA in cell spreading
mechanisms (Thodeti et al., 2003). It was previously shown that PKC alpha promotes cell
survival and cell proliferation (Reyland, 2009). Thus, decreased expression of syndecan
4 would lead to decreased activity of PKC alpha, thus increased apoptosis. Also, lactate
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dehydrogenase A (LDHA) and cysteine-rich angiogenic inducer 61 (CYR61) were found
significantly downregulated in the BUC11 silenced-MDA231 cells. Lactate dehydroge-
nase has a role in angiogenesis (Koukourakis et al., 2003) and CYR61, also an angiogenic
inducer, is associated with integrins that play a role in RHOA-mediated cell proliferation
(Walsh et al., 2008). CYR61 expression was also associated with resistance to apoptosis
in the breast cancer cell line MCF-7 (Lin et al., 2004). Finally, the protein ubiquitin,
shown to have a role in labelling proteins for proteosomal degradation, in stabilisation of
other proteins and in apoptosis (Yang et al., 2009), was also found significantly downreg-
ulated in the microarray study.
In order to validate the changes in gene expression observed in the microarray anal-
ysis, primers were designed for 7 significantly upregulated genes (GPX1, RPS7, CRR9,
MRPL11, NDUFA1, COX7c and MTCH2) and 9 significantly downregulated genes (LDH
A, MT2A, RSP11, RPL30, RHOA, MT1F, CYR61). These genes were chosen according
to their rank order in the list of the most up- or down-regulated genes as well as their
interesting cell function(s). Quantitative RT-PCR analysis was carried out using the same
RNA samples that were sent for microarray analysis. As seen in Figure 5.8, 8 out of the 9
tested genes for downregulation in BUC11 silenced-MDA231 cells compared to control
cells and 4 out of the 7 tested genes for upregulation in BUC11 silenced-MDA231 cells
compared to control cells were validated (the Ct values can be found in Appendix III).
Overall, 75% of the genes tested showed the same change in expression observed in the
analysis of the microarray data. The change in gene expression for RPS11, RPS7, COX7c
and NDUFA1 did not correlate to the microarray analysis. For COX7c and NDUFA1, one
of the replicates did not correlate to the microarray data so the genes were not validated
whereas both replicates for the ribosomal proteins RPS7 and RPS11 did not correlate to
the microarray data.
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Figure 5.8: Validation of the microarray data by quantitative RT-PCR.
The 16 genes selected for validation that were found to be significantly upregulated or
downregulated in the analysis of the microarray data are shown. Primers were designed
and used in quantitative RT-PCR analysis using the same RNA samples sent to microarray
in order to confirm the change in gene expression between control and test samples. The
valued are given as mean of the duplicates. The change in gene expression for RPS11,
RPS7, COX7c and NDUFA1 did not correlate with the microarray analysis.
As stated previously, the metallothionein 2A was found to be the most downregulated
gene in the BUC11 silenced-MDA231 cells. Therefore, levels of MT2A expression and
levels of BUC11 expression might be controlled together by the same regulatory mecha-
nism according to the state of the breast cells. MT2A mRNA expression was measured
using quantitative RT-PCR in a panel of the breast tissues (paired normal and tumour tis-
sues) generously provided by Dr A. Gritzapis (Greece) and previously used in the quan-
titative RT-PCR analysis of BUC11 (Chapter 3). MT2A mRNA expression analysis was
carried out on cDNA from 23 patients which were selected so that the panel had a large
range of age, stage of the cancer, grade of the cancer and HER2 status. As seen in Figure
5.9, no significant correlation between BUC11 mRNA expression and MT2A mRNA ex-
pression was observed in these tissues. Only 10 patients out of 23 showed an increase in
mRNA expression for both BUC11 and MT2A in the tumour tissue compared to the nor-
mal tissue (patient numbers 78, 80, 64, 77, 63, 90, 60, 62, 84 and 67, grouped as group A).
No patients tested showed a decrease in mRNA expression for both genes. It was found
that 11 patients out of 23 showed an increase in MT2A mRNA expression and a decrease
in BUC11 mRNA expression in the tumour tissue compared to the normal tissue (patient
numbers 65, 76, 74, 83, 88, 89, 61, 86, 81, 75 and 87, grouped as group B). In particular,
patient 81 showed a silenced BUC11 mRNA expression and an above average increase
in MT2A mRNA expression in the tumour tissue compared to the normal tissue. Patient
59 showed decreased MT2A and increased BUC11 mRNA expressions and patient 79
showed an unchanged BUC11 and increased MT2A mRNA expressions, in the tumour
tissue compared to the normal tissue. In group A, 8 out of 10 patients were over 50 years
of age at the time of diagnosis whereas only for 4 out of 11 patients of group B were over
50 years of age. In group A, 9 out of 10 patients tested negative for overexpression of the
HER2 receptor in their tumour whereas 6 out of 11 patients tested negative in group B. In
181
Chapter 5. BUC11 Functional Analysis 5.2
group A, 6 out of 9 patients had a grade II tumour and 3 out of 9 patients had a grade III
tumour. In group B, 6 out of 10 patients had a grade II tumour and 4 out of 10 patients
had a grade III tumour. In group A, 2 out of 10 patients had a Stage I tumour and 8 out of
10 patients had a stage II tumour. In group B, 2 out of 10 patients had a Stage I tumour, 7
out of 10 patients had a stage II tumour and 1 out of 10 patients had a stage III tumour.
Figure 5.9: Comparison of BUC11 mRNA expression with MT2A mRNA expression in
paired normal and tumour breast tissues by quantitative RT-PCR.
Quantitative RT-PCR analysis was carried out on 23 patients (numbers) with paired nor-
mal (-) and tumour (+) tissues. No significant trend was found between BUC11 mRNA
expression and MT2A mRNA expression in these tissues.
Ingenuity Pathways Analysis is a software application made by Ingenuity R©systems
which allows researchers to quickly analyse experimental biological and chemical data
by building dynamic pathway models linked to the scientific literature. Pathways based
on the analysis of the microarray data obtained in this study have been built using this
software. For this purpose, the 926 significantly upregulated genes (averages range from
24.32 to 2) and the 592 significantly downregulated genes (averages range from -31.07
to -2) were selected however, as the number of genes that can be associated in one single
pathway analysis is limited to about 500, only the first 500 of each list were used.
Regarding the network build with the most upregulated genes of the microarray anal-
ysis (Figure 5.10, Figure 5.11 and Figure 5.12), several respiratory chain proteins were
found linked to each other. For instance, the respiratory chain transporter protein ATP5B
binds to YWHAG which is a protein associated with genomic instability that might pro-
mote tumourigenesis (Qi et al., 2007). Another protein mentioned earlier, the ion channel
protein VDAC3, binds to beta-actin (ACTB) which is important in cell shape, motility
and growth (Dormoy-Raclet et al., 2007) and could play a role in apoptosis (Tang et al.,
2006). Moreover, annexin ANXA2 binds to ACTB and was shown to be involved in
apoptosis of lung cancer cells (Huang et al., 2008), to have a role in the malignant phe-
notype of prostate cancer (Inokuchi et al., 2009) and to be associated with breast tumour
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invasion (Sharma et al., 2006). ACTB acts on the SWI/SNF related, matrix associated,
actin dependent regulator of chromatin (SMARCA4) which is an actin-dependent regula-
tor of chromatin and which loss of expression is associated with lung cancer development
(Reisman et al., 2003). The ribosomal proteins RPS9 and RPL31 bind to both ACTB and
the Ly1 antibody reactive homolog (mouse) (LYAR). LYAR is not well characterised to
date and its limited literature suggests metal ion and protein binding. Several heat shock
proteins (HSP90B1, HSP90AA1 and HSP90AB1) involved in stabilising proteins under
cellular stress and in cell survival to chemotherapy of acute myeloid leukemia cells when
overexpressed (Flandrinet al., 2008) and their interactions with each other are shown.
As seen in Figure 5.11 and Figure 5.12, several proteins indirectly act on Cyclin D1
(CCND1). CCND1 activity is essential for the cell cycle transition at G1/S and its over-
expression has been associated with cancer (Fu et al., 2008; Zhao et al., 2008; Shi et al.,
2008). Finally, the small nuclear ribonucleoprotein polypeptide E (SNRPE) is a contrib-
utor of oncogene-mediated reorganisation of the actin cytoskeleton and focal adhesions
(Klein et al., 2008).
Figure 5.10: Microarray upregulated gene network build in the software Ingenuity Path-
ways Analysis.
The analysis was carried out with the top 500 most upregulated genes, when BUC11 gene
expression is downregulated in MDA231 breast cancer cells, found during the analysis of
the microarray data. Some genes of the microarray analysis did not show any interaction
with other genes of the microarray analysis so they are not shown on this figure. The
software searches in the literature to build the network and to inform on the functions of
the proteins (network shapes) and the relationship between the proteins (network arrows).
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Figure 5.11: Focus on the microarray upregulated gene network build in the software
Ingenuity Pathways Analysis (1).
The software searches the literature to build the network and to inform on the functions of
the proteins (network shapes) and the relationship between the proteins (network arrows).
The proteins highly involved in the network such as LYAR, ANXA2, ACTB, CCND1,
YWHAG and HSP90 (B1, A5, AB1) are shown.
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Figure 5.12: Focus on the microarray upregulated gene network build in the software In-
genuity Pathways Analysis (2).
The software searches the literature to build the network and to inform on the functions
of the proteins (network shapes) and the relationship between the proteins (network ar-
rows). The proteins highly involved in the network such as CCND1, YWHAG, ATP5B
and HSP90 (B1, A5, AB1) are shown.
Regarding the network built with the most downregulated genes of the microarray
analysis (Figure 5.13, Figure 5.14 and Figure 5.15), the major histocompatibility com-
plex, class I antigen (HLA-B) was found to be associated with a number of proteins in
the network. Another important protein in the network is the catenin (cadherin-associated
protein), beta 1 (CTNNB1) which mediates cell adhesion, anchoring the actin cytoskele-
ton and was associated with tumour progression and metastasis (Goulioumis et al., 2008;
Gaujoux et al. 2008; Chen et al., 2005). The tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta polypeptide (YWHAZ) is another major player
in the network and acts on CTNNB1. It was found to be a marker of recurrence in breast
cancer (Frasor et al., 2006). YWHAZ binds to the previously mentioned angiogenic
inducer in breast cancer LDHA. RHOA, PLAU, SDC4 and CYR61 are other proteins
previously mentioned. Here in the network, it was shown that CYR61 indirectly acts on
PLAU whereas CTNNB1 directly acts on PLAU. SDC4 is indirectly linked to CYR61 and
CTNNB1. RHOA was found indirectly linked to CTNNB1. CTNNB1 is indirectly linked
to the previously mentioned ACTN1 and directly acts on cyclin D2 (CCND2). Methyla-
tion of cyclin D2 has been associated with 41% of breast cancers and has been linked to
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an increased cell proliferation (Euhus et al., 2008). Finally, the hypoxia inducible factor
1 alpha subunit (HIF1A) acts directly on LDHA and CTNNB1 and its overexpression
has been associated with tumour progression and poor outcome for breast cancer patients
(Kim et al., 2008).
Figure 5.13: Microarray downregulated gene network build in the software Ingenuity
Pathways Analysis.
The analysis was carried out with the top 500 most downregulated genes, when BUC11
gene expression is downregulated in MDA231 breast cancer cells, found during the anal-
ysis of the microarray data. Some genes of the microarray analysis did not show any
interaction with other genes of the microarray analysis so they are not shown on this fig-
ure. The software searches in the literature to build the network and to inform on the
functions of the proteins (network shapes) and the relationship between the proteins (net-
work arrows).
186
Chapter 5. BUC11 Functional Analysis 5.2
Figure 5.14: Focus on the microarray downregulated gene network build in the software
Ingenuity Pathways Analysis (1).
The software searches the literature to build the network and to inform on the functions of
the proteins (network shapes) and the relationship between the proteins (network arrows).
The proteins highly involved in the network such as HLA-B, CCND2 and PCNA.
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Figure 5.15: Focus on the microarray downregulated gene network build in the software
Ingenuity Pathways Analysis (2).
The software searches the literature to build the network and to inform on the functions of
the proteins (network shapes) and the relationship between the proteins (network arrows).
The proteins highly involved in the network such as YWHAZ, PLAU, SDC4, CYR61,
CTNNB1, ACTN1 and HIF1A.
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5.2.7 Preliminary studies on the immunogenicity of BUC11 protein
Conventional therapies (surgery, radiotherapy and chemotherapy) can prove success-
ful in the treatment of small and accessible tumours. However, these can be associated
with side effects, resistance to drugs and inefficacy to eliminate distant metastatic tu-
mours. Immunotherapy is an alternative therapy that can overcome these issues and is
based on targeting antigens of interest which ideal characteristics include: to be solely
or mainly expressed by tumour cells, to be vital to the tumour and to be immunogenic.
In the previous chapters, BUC11 was shown to be highly expressed in tumour cells and
not in vital normal tissues and seemed to have an essential role in tumour cell growth. It
was then of interest to find out whether BUC11 was immunogenic in view that it could
be used as a target. Antigen presenting cells such as dendritic cells ingest abnormal or
foreign cells and present the digested contents which are small peptides (18-22 amino
acids long) to other cellular components of the immune system via the Major histocom-
patibility complex (MHC) Class I molecules with the CD8+ T cell receptor or via the
MHC class II molecules with the CD4+ T cell receptor. Upon MHC class I presentation
to CD8+ T cells and with the help of IFN gamma, CD8+ T cells will be activated into
CTL. Upon MHC class II presentation to CD4+ T cells (helper T cells), CD4+ will also
be activated. Activated CTL will recognise the antigen-displaying tumour cell and kill it.
In order to have all this cascade of events, the participation of these three cell populations
is necessary in the majority of cases. The identification of class I and class II peptides that
can be used in vaccination-based therapies of HLA-A2 and HLA-DR1/DR4 cancer pa-
tients would demonstrate the immunogenic potential of BUC11 protein. For this purpose,
preliminary studies on the natural processing and the immunogenicity of peptides derived
from BUC11 protein were conducted using a DNA immunisation strategy of HHDII/DR1
double transgenic mice which rely on the human MHC molecules to present peptide; the
mice are knock-out for mouse MHC class I and II antigens.
At the time of this study, we did not have a mouse tumour model to study tumour
regression nor BUC11 overlapping peptides to test individually for immunogenicity. The
mammalian expression vector pBudCE4.1/BUC11 plasmid was used in this study to as-
certain that the whole BUC11 protein could induce a specific immune response by show-
ing that, in the immunised mice, BUC11-derived peptides are naturally endogenously
processed and presented by HLA molecules on the cell surface. Two methods of im-
munisation were tested in this study. The first method was the injection of gold-coated
pBudCE4.1/BUC11 plasmid DNA with a gene gun so that BUC11 protein is expressed
in the HHDII/DR1 mice (three rounds of gene gun immunisation at seven-day inter-
vals). The second method was the injection intramuscularly (IM) of pBudCE4.1/BUC11
plasmid DNA (two rounds of IM immunisation at seven-day intervals). In both cases,
other HHDII/DR1 mice were injected with the empty vector pBudCE4.1/- as controls.
Briefly, after the rounds of immunisation, splenocytes were harvested from the immu-
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nised mice. Meanwhile, BM-DC from naive mice were harvested and stimulated in
vitro with BUC11 peptide or an irrelevant peptide. In this study, the irrelevant peptide
chosen was HAGE, which is a CT antigen expressed in several human cancer types.
Then, the two cell populations were plated together. The CTL activity was assessed by
monitoring their ability to kill target cells and the release of IFN gamma. Also, pro-
liferation of T helper cells was measured by thymidine incorporation. BM-DC were
pulsed with either ALC/pBudCE4.1/BUC11 cell lysate, ALC/pBudCE4.1/HAGE cell
lysate, ALC/pBudCE4.1/- cell lysate, HAGE peptide or BUC11 peptide. Each of these
were individually mixed with BUC11 antibody before plating them with BM-DC cultures.
In the study, the CTL activity (the ability of T cells generated in immunised mice
against BUC11-derived peptides to specifically recognised and kill ALC/pBudCE4.1/BU-
C11 cells (HLA-A2 positive cells)) was measured by 15Cr release assay. ALC/pBudCE4.1
/BUC11 cells, ALC/pBudCE4.1/HAGE cells and ALC/pBudCE4.1/- cells were plated
with T cells generated and isolated from naive, control and test mice to determine the
specificity of the immune response. Preliminary results obtained after one experiment
were not found to be statistically significant, with large standard deviations. There was
generally more killing of ALC/pBudCE4.1/BUC11 cells compared to ALC/pBudCE4.1/
HAGE cells but this difference was not significant. Therefore, no peptide-specific cyto-
toxic response was achieved in this experiment (data not shown). This observation sug-
gests that none of the BUC11-derived peptides were naturally processed and presented on
HLA molecules to T cells in the immunised mice.
Also, the peptide-specific cytokine production (IFN gamma) was measured by ELISPOT.
Preliminary results obtained from three experiments showed that controls (T cells alone
and BM-DC alone) showed no significant difference in production of IFN gamma from
test mice (data not shown).
Finally, CD4+ cell proliferation was measured by 3H-thymidine incorporation assay (data
not shown). After one experiment, a significant difference in increased proliferation of
CD4+ cells in contact with BUC11 peptide compared to CD4+ cells in contact with the
irrelevant HAGE peptide was observed. This result was obtained for both test mice im-
munised by gene gun with pBudCE4.1/BUC11 plasmid DNA when compared with the
two control mice immunised by gene gun with pBudCE4.1/- plasmid DNA (p<0.05 for
mouse test 1 and p<0.01 for mouse test 2). Unfortunately, with the IM immunised mice,
CD4+ cells isolated from both test and control mice (no replicate due to death of one con-
trol mouse and one test mouse during the experiment) showed highly significant increase
of proliferation (respectively p<0.01 and p<0.001) when incubated with BUC11 peptide-
pulsed DC compared to incubation with HAGE peptide-pulsed DC. Furthermore, CD4+
cells isolated from the naive mouse used as negative control also showed a significant
increased in cell proliferation (p<0.001). These observations lead to the hypothesis that
gene gun immunisation with pBudCE4.1/BUC11 might have produced an immune re-
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sponse whereby BUC11-derived peptide(s) specifically primed CD4+ cells to proliferate
when cells were re-stimulated in vitro and that IM immunisation with pBudCE4.1/BUC11
was insufficient when used alone but stimulation in vitro was apparently sufficient to in-
duce a significant CD4+ cell proliferation in IM-immunised and naive mice.
5.3 Discussion
Previously, the structure and conserved domains of the unpublished BUC11 predicted
protein was studied by database mining and its localisation was shown by immunohisto-
chemistry. However, no conclusions could be drawn on the potential function of BUC11
in the cells from these studies. In this chapter, an attempt to provide information on the
role of BUC11 gene in the proliferation, morphology and behaviour of cells by conduct-
ing experiments based on the transfection or silencing of BUC11 was described.
The coding region for the 75 amino acid BUC11 protein (hCG25653 nucleotides 95 to
322) was successfully cloned into the mammalian expression vector pBudCE4.1. At this
point, which was early in the study (after sequencing of BUC genes and prior BUC11
protein analysis), it was clearly understood that the sequencing result of BUC11 included
artifact sequences which can be introduced during sequencing experiments. The correct
nucleotide sequence of BUC11 therefore matched the hCG25653 nucleotide sequence
thus the predicted protein is the same. The plasmid pBudCE4.1/BUC11 was then used to
transfect, by electroporation, a BUC11-negative mouse lymphoma (ALC) cell line which
was previously used in our laboratory for similar experiments. Quantitative RT-PCR anal-
ysis on the RNA extracted from transiently transfected cells demonstrated significant ex-
pression of BUC11 mRNA by these cells, as early as 15 hours following transfection.
Also, lysates of pBudCE4.1/BUC11-transfected ALC cells were used in a Western blot-
ting experiment and appeared to contain a protein specifically recognised by BUC11 an-
tibody (Chapter 4). These results demonstrated that BUC11 DNA has been successfully
transfected into cells that do not naturally express BUC11 and this cell line can be used
in further studies. It has previously been noted that mRNA and protein levels do not nec-
essarily correlate, therefore the transfection experiment should be repeated with a time
course and the levels of expression of BUC11 protein confirmed by confocal microscopy
using BUC11 specific antibody. Also, attempts to produce stably transfected cells were
unsuccessful in this study and further work should be undertaken to establish a cell line
with constitutive BUC11 expression.
Specific siRNA to the BUC11 protein coding region allowed a significant knockdown
of BUC11 mRNA expression in a BUC11-positive MDA231 human breast cancer cell
line, measured 48 hours following transient transfection by quantitative RT-PCR. Mor-
phological comparisons of BUC11 siRNA-transfected cells with control siRNA trans-
fected cells did not reveal any noticeable effects of BUC11 silencing on cell morphology,
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however cells appeared to proliferate slower when BUC11 expression was inhibited. The
observed decrease in the rate of proliferation was not linked to an interferon-based or
transfection reagent-based response but to a specific BUC11 siRNA-mediated response
to the knockdown of BUC11 mRNA expression. Similar to BUC11 DNA transfection
in ALC cells, the siRNA transfection experiment should be repeated with a longer time
course to establish the levels of mRNA expression by quantitative RT-PCR in parallel
to the confirmation of BUC11 knockdown at the protein level by immunofluorescence.
In this study, preliminary gene knockdown experiments were also carried out with BUC6
specific siRNAs but specific gene silencing following transfection into SKBR3 cells could
not be observed (data not shown).
Evasion of apoptosis and unregulated growth are two of the six hallmarks of cancer
(Hanahan and Weinberg, 2000). Upon confirmation of specific BUC11 gene induction
and repression obtained in targeted cells, proliferation assays using incorporation of 3H-
thymidine were carried out in order to determine whether BUC11 could have a role in the
proliferative pathways of the cell. A significant decrease in cell proliferation was shown in
BUC11-silenced cells whereas the reverse phenomenon was observed in BUC11-induced
cells. These correlating effects strongly suggested that BUC11 plays a role in pathways
controlling the proliferation of cells. However, the proliferation assays would need to be
successfully repeated several times in the future to absolutely confirm the findings. Also,
transfection of ALC cells should be repeated with the same time course (8 days) in order
to correlate the proliferation assay results with the levels of expression of BUC11 mRNA
and protein by quantitative RT-PCR and immunofluorescence and confirm the transient
nature of transfection without selection with antibiotics. Furthermore, as part of future
work, stably transfected ALC cells with pBudCE4.1/BUC11 plasmid should be used in
siRNA-mediated BUC11 silencing experiments to demonstrate decrease in cell prolifer-
ation by proliferation assays and in BUC11 protein expression by immunofluorescence.
This would confirm that the effects of BUC11 gene induction can be reversed by specific
gene knockdown. Also, for a more accurate comparison between the targeted cell lines,
BUC11 DNA transfection should be repeated into a BUC11-negative human breast can-
cer cell line. Finally, BUC11 induction and silencing experiments could be repeated in
the future in normal human breast cell lines, if available, to establish if the same effects
can be obtained in non-cancerous cells.
According to the findings of the cell cycle analysis carried out on BUC11-silenced
cells, BUC11 seems to play a role in a pathway involved in the regulation of cells at
the DNA damage G1/S checkpoint. Cells enter the G1 phase of the cell cycle once they
have received signals for cell division. According to intracellular and extracellular signals
at the G1/S checkpoint of the cell cycle, cells are directed either to die by apoptosis or
to undergo cell division. It is at this point that damaged cells undergo cell cycle arrest
192
Chapter 5. BUC11 Functional Analysis 5.3
while repair mechanisms help to restore a healthy state. Defects in cell cycle arrest at
the G1/S checkpoint has been linked to genome instability and tumourigenesis (Nojima,
2004). Therefore, BUC11 could be involved in a pathway regulating cell proliferation
which allows damaged or cancer cells to bypass surveillance mechanisms (checkpoints),
avoid cellular repairs and apoptosis and ultimately divide uncontrollably.
The effects of downregulating BUC11 mRNA expression were studied at the whole geno-
me level using Affymetrix GeneChip R©Microarray. Microarray technology has been
widely used for studies on the classification of breast cancer and on breast tumour devel-
opment and progression, following the completion of the Human Genome Project almost
10 years ago (Cooper, 2001). As expected, the genechips produced an overwhelming
amount of data so to make the data more manageable the top 100 most upregulated and
top 100 most downregulated genes when BUC11 mRNA expression is downregulated
were selected initially for analysis by searching the literature. Overall, when BUC11
gene is downregulated in MDA231 breast cancer cells, a significantly increased expres-
sion of genes associated with growth arrest and apoptosis and a significantly decreased
expression of genes associated with the cytoskeleton, cell migration, angiogenesis, cell
proliferation (especially metallothioneins) and cell survival were observed. These ob-
servations were confirmed by studying networks of the up- and down-regulated genes
respectively with the software application Ingenuity Pathways Analysis. This software
is a useful tool and provides a snapshot of the significant microarray findings in just two
networks, therefore adding weight in the hypothesis of pathways that BUC11 might be in-
volved in. It is worth noting that RNA microarrays do not reflect the proteome, as mRNA
and protein levels do not always correlate. A validation study on key genes found in the
microarray analysis was carried out and showed validity of the data although the exper-
iment should be repeated on a set of RNAs extracted from additional gene knockdown
experiments. To summarise, the microarray analysis of the whole genome of a breast
cancer cell line, in which BUC11 mRNA expression has been downregulated, correlated
with the cell proliferation analysis and highlighted genes that might be interacting, di-
rectly and indirectly, with BUC11 in cells. However, this microarray analysis did not
associate BUC11 with any particular pathway, and only provided insight into genes and
pathways to target in the future. Also, the experiment was only carried out with duplicates
and would need to be repeated with more replicates in order to obtain more statistically
significant data. Furthermore, the experiment should be extended to other breast cancer
cell lines expressing BUC11 and with cell lines transfected to express BUC11, in order to
compare different genomes.
Reverse immunology and transgenic mice expressing HLA molecules are used to
identify peptides from tumour antigens that are of interest in developing vaccination
strategies for tumour immunotherapies. For instance, Gritzapis and colleagues have
shown protection and therapeutic potentials of cytotoxic T lymphocyte (CTL) epitopes
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derived from the antigen HER2, when HER2 transgenic mice were immunised with a
HER2 vaccine (Gritzapis et al., 2006). Also, vaccination of breast cancer patients with a
mix of the same HER2 peptides and GM-CSF led to specific activation of naive and mem-
ory CD4+ and CD8+ T cells (Hueman et al., 2007). CD4+ T cells are now known to be
essential players in the induction and continuity of an immune response directed against
a tumour as well as being involved in tumour regression through apoptotic pathway ini-
tiation or IFN-mediated mechanisms (Assudani et al., 2007). Previously, our laboratory
used gene gun technology in the study of class I p53-derived peptides, which consists
in immunising mice with gold particles coated with a plasmid encoding the gene of in-
terest (Tuting, 1999). Immunisation with plasmid DNA has many advantages, including
the production of the protein of interest in vivo which can last for months, contrary to
direct injection of proteins which effects only last a few days. Unfortunately, prelimi-
nary studies on the immunogenicity of BUC11 protein provided inconclusive data. No
specific killing of ALC/pBudCE4.1/BUC11 cells by CTL and no specific production of
IFN gamma was observed. Specific CD4+ T cell proliferation was obtained following
gene gun immunisation however the non-specific proliferation of CD4+ T cells in the IM
study and naive mouse disproved the validity of the phenomenon due to immunisation
and not subsequent re-stimulation in vitro. The experiments would need to be repeated
in the future to assess the immunogenic potential of BUC11 protein and of individual
overlapping peptides which could form targets for antigen-specific vaccine or cell-based
therapy in breast cancer. Overlapping peptides of a antigen of interest are commonly used
in our laboratory to identify peptide targets that have low-to-moderate affinity with HLA
molecules, but nevertheless show immunogenic potential. DNA vaccine efficiency can be
improved by cloning the gene of interest together with cytokine genes or genes coding for
co-stimulatory molecules in the same plasmid (Guinn et al., 1999; Liu et al., 2004). The
expression vector pBudCE4.1 has two cloning sites and two independent promoters, thus
future cloning for immunogenicity studies using pBudCE4.1/BUC11 is possible. Another
potential immunisation strategy for future work could be the use of viral or bacterial vec-
tors which are widely used for gene delivering in both in vivo and in vitro immunological
studies and have been shown to increase the intensity of the immune response to antigens
(Aarts et al., 2002).
Genes that play a role in tumourigenesis and tumour progression (such as cell prolif-
eration) and which peptides derived from the proteins are able to induce a strong immune
response against the tumour cells and not the normal cells make appealing targets for
novel cancer therapies respectively gene therapy and tumour immunotherapy. In conclu-
sion, BUC11 appears to be involved in a proliferative pathway however further investiga-
tion is necessary to refine the role(s) of BUC11 in the breast cancer cells as well as in the
normal breast cells and to assess the immunogenic potential of BUC11 protein-derived
peptides.
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6.1 The BUC genes - novel breast-associated genes
Since the rapid development and use of new technologies in the last 20 years or so, con-
siderable advances in breast cancer research have been made possible. In accordance with
the latest statistical figures, these have in turn supported greater improvements in the tai-
lored management of patients, such as the exciting use of gene signatures for prediction
of treatment outcome and prognosis of breast cancer (van de Vijver et al., 2002; van ’t
Veer et al., 2002; Cronin et al., 2004; Paik et al., 2004; Ring et al., 2006). However,
despite the substantial amount of work being undertaken and the abundance of promising
results obtained in pre-clinical studies, very few biomarkers for the management of breast
cancer patients have shown significant utility in clinical trials and hence been approved
for use in humans. Thus, improvements still need to be made in all aspects of breast
cancer, from prevention to treatment of late-stage diseases (Thompson et al., 2008). Con-
ventionally, the treatment options available for breast cancer patients include surgery,
chemotherapy, radiotherapy, hormonal therapies and molecular targeted therapies, how-
ever, to date, no vaccine for immunotherapy has been approved. Also, not all patients can
receive hormonal or molecular therapies as demonstrated in the case of patients bearing
triple negative tumours (ER negative, PR negative, HER2 not overexpressed) who con-
sequently have an extremely poor prognosis and can only be referred for chemotherapy
and/or radiotherapy with their respective toxic side effects. Therefore, the identification
and validation of novel, highly specific antigens for breast cancer, which could be used
to develop novel targeted treatment strategies, is of prime importance for many research
groups. Ideally, following screening of the antigens presented by the tumour cells, a
patient would receive a personalised combination of surgery to remove the tumour mass
and targeted immunotherapy to boost the immune system to overcome tumour escape and
seek and kill invasive, metastatic and cancer stem cells, the latter thought to be involved
in the recurrent nature of the disease (Morrison et al., 2008). This tailored management
would therefore spare breast cancer patients from the burden, unspecificity and associated
toxic side effects of chemotherapy and radiotherapy as well as improve the success rate
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and reduce the cost of treatments.
It is well recognised that a long and painstaking process is undertaken between the
discovery and the clinical approval of tumour antigen-based therapy or new drugs. An
ideal tumour antigen for molecular therapy or immunotherapy has to conform to several
criteria, briefly: it must not be expressed in normal tissues, it has to be overexpressed in
malignant tissues, it should be involved in tumorigenesis making it essential for tumour
cell survival, it must be immunogenic and be able to induce tumour regression. Impor-
tantly for the use in diagnosis or prognosis, the antigen must be easily detectable in the
patient’s fluids (serum or urine) or biopsy, isolated using minimally invasive procedures
and be highly expressed in metastatic cells.
Prior to this study, novel unpublished breast-associated genes (BUC6, BUC9, BUC10
and BUC11) were identified in our laboratory by UniGene database mining and prelim-
inary mRNA expression analysis in various normal and malignant tissues had been per-
formed. The scope of this research project was to validate these genes as breast cancer-
associated antigens prior to pre-clinical in vivo studies. The first aspect of the study was
to undertake extensive in silico analysis and in vitro expression analysis for all the BUC
genes in order to further select the most promising ones for potential use in the manage-
ment of breast cancer patients. For instance, potential targets for cancer vaccines should
not be expressed in normal tissues in order to avoid the toxicity of auto-immune responses
but overexpressed in malignant tissues and be essential for the survival of the tumour cells.
The research was concerned as to whether any of the BUC genes meet the first re-
quirements for an “ideal tumour antigen”, i.e. no expression in normal tissues and over-
expression in malignant tissues. To address this question, the data collected for each gene
will be summarised individually. The techniques used in this study for the expression
analysis of the BUC genes included sequencing, database mining (gene similarities and
gene function), semi-quantitative RT-PCR and quantitative RT-PCR. Firstly, it was ascer-
tained that the BUC genes were novel genes as they did not correspond or were not highly
similar to already published and well-characterised genes. The BUC genes are located on
chromosome 10p11.21 and they appear to be human-specific genes. The mRNA expres-
sion analysis of BUC6 revealed that it was highly expressed in the melanoma, breast
cancer and mesothelioma samples tested; and expressed to a comparatively lower level in
gastric and colon carcinoma samples. Thus, BUC6 is not tumour-specific to breast cancer
but further studies with larger cohort of cancer patients is justified to reveal its potential as
a diagnostic, prognostic or therapeutic marker for these malignancies. Similarly, BUC9
was not found to be specific to any particular cancer, but interestingly, two splice variants
of its mRNA have been characterised and the semi-quantitative RT-PCR data collected
during this study suggests that the shortest BUC9 variant is solely expressed in the major-
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ity but not all of the normal breast tissues, breast cancer tissues, breast cancer cell lines
and normal testis tissues. Therefore, this particular variant could potentially be a breast
cancer target antigen present in non-vital tissues. The expression pattern of the two splice
variants could also be an indication of the disease state (diagnosis) thus further work on
larger cohorts of patients is required. BUC10 also had a similar mRNA expression pattern
to BUC9 but did not present splice variants. However, its high mRNA expression level in
some normal tissues is a major drawback when considering BUC10 as a target for novel
breast cancer therapies.
Undoubtedly, BUC11 was found to be the most promising gene of the BUC family,
therefore much of the research presented in this thesis focused, at a relatively early stage,
on the characterisation of this gene. BUC11 is not considered to be a tumour-specific
gene either, as its mRNA was found at high levels in prostate cancer tissues (25%), breast
cancer tissues (up to 97%) and testicular cancer tissues (100%) and at lower levels in
melanoma (11.5%). BUC11 mRNA was not detected in any other cancer tissues tested
and is expressed at very low levels in normal tissues except in the non-essential tissues
of the prostate, breast, testis and placenta where it is expressed at a higher level and
therefore not truly cancer-testis specific. However, it has been recently shown that cancer
testis antigens, such as NY-ESO-1, which expression was thought to be restricted to ga-
metogenic tissues (normal and tumour), can actually be expressed at low levels in some
normal tissues, predominantly pancreatic tissues and this does not affect their value in im-
munotherapy as these low levels are unlikely to induce an autoimmune response (Scanlan
et al., 2004). In comparison, the extensively studied breast tissue differentiation antigen
NY-BR-1, which is located next to BUC11 on the chromosome, was found to be ex-
pressed in more than 80% of breast tumours (Wang et al., 2006), in up to 32% of prostate
cancers and sporadically expressed in normal prostate tissues (Jager et al., 2005) which
is similar to BUC11 mRNA expression pattern. However, quantitative RT-PCR analysis
on a small cohort of breast samples suggested that NY-BR-1 gene expression is not re-
lated to BUC11 gene expression (data not shown). The data collected from the analysis
of BUC11 mRNA expression in paired tumours (of various clinical features) and normal
surrounding tissues from 109 breast cancer patients demonstrated that up to 97% of all
tissues expressed BUC11 (3% silencing in tumour tissues only), however only 60.6% of
patients over-expressed BUC11 mRNA in their tumours compared to the normal counter-
part tissues, at widely varying levels, with an overall average of 14 times more BUC11
mRNA molecules in the tumour tissue; whereas the remaining 39.4% had downregulated
BUC11 mRNA expression with an overall average of 3 times less than in the normal tis-
sue. These percentages could represent a drawback when considering BUC11 as a valid
target for breast cancer immunotherapies, however, the importance of this result has to be
moderated because the tissues have not been subjected to laser-capture microdissection
to remove the stromal cell component (Walton et al., 2009). Also, BUC11 mRNA levels
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could not be significantly associated with the progression or aggressiveness of the dis-
ease, and from the overall analysis of the data collected in this study, it may be concluded
that BUC11 may not represent the ideal candidate biomarker for diagnosis, prognosis or
treatment of breast cancer, nevertheless its mRNA expression patterns warrant further val-
idation. Furthermore, most of the therapeutic applicability of the BUC11 gene depends
on the translation of the gene product into protein, its role in the tumour cell behaviour
and the protein expression patterns in normal versus malignant tissues.
Important recent research has shown that short, single-stranded, non-coding RNA
molecules (MicroRNAs or miRNAs) have crucial roles in the post-transcriptional regu-
lation of gene expression through the degradation of target mRNAs or inhibition of the
translation of target proteins. They have been associated with many processes in tumour
development and tumour differentiation in various human cancers, making them very use-
ful to classify tumours for diagnostic and prognostic purposes (Lu et al., 2005). Several
breast cancer-associated miRNAs which expression correlates with ER status, PR status,
HER2 status and stage of the tumour have been identified (Iorio et al., 2005; Mattie et
al., 2006; Lowery et al., 2007; Adams et al., 2007). MiRNAs can deregulate apoptotic
or differentiation pathways in the cell and act as oncogenes by inhibiting the function of
tumour suppressor genes (Lowery et al., 2008). For examples, miR-17-5p is thought to be
a tumour suppressor miRNA which down-regulates the AIB1 protein, previously found
over-expressed in breast cancer (Hossain et al., 2006), whereas miR-21 has been charac-
terised as an oncogenic miRNA whereby its inhibition in vitro in MCF-7 cells caused a
significant decrease in cell proliferation and increase in apoptosis (Si et al., 2007). The
regulatory nature of miRNAs generated great interest in targeting specific pathways of
cancer stem cells such as self-renewal pathways, especially since it has been published
that stem cells differentially expressed particular miRNAs (Suh et al., 2004). Specific
miRNAs have been shown to suppress the activity of multiple inhibitors of the G1/S re-
striction point of the cell cycle in embryonic stem cells, enabling rapid growth of the em-
bryo in normal development (Wang and Blelloch, 2009). Some of these miRNAs, shown
to be overexpressed in cancers, could potentially be targeted to reduce tumour growth
in a therapeutic setting (Shi and Guo, 2009). Even if some of the BUC genes (6, 9 and
10) are not translated into proteins, one can not exclude that they could act in a similar
manner to miRNAs, having an important role in the regulation of crucial pathways for the
cancer cells and this justifies further studies on the BUC family to assess their potential
as markers for diagnosis or prognosis and as targets for treatment of cancer patients. This
forms a potential focus for further research.
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6.2 BUC11 - a novel marker of epithelial luminal-type
breast cancers?
It is widely accepted that mRNA expression levels and protein expression levels do not
necessarily correlate (Greenbaum et al., 2003). Also, as mentioned previously, the most
valuable markers are present in the tumour cell as expressed protein, ideally as cell sur-
face protein antigens that are over-expressed. Consequently, BUC11 protein expression
analysis and protein localisation analysis were carried out during this project using im-
munoassays with the “custom-designed” anti-BUC11 monospecific antibody. Although
the identity of the protein to which the antibody was binding to could not absolutely be
confirmed by mass spectrometry during this study, the immunoassays showed the pres-
ence of BUC11 protein and validated the results of quantitative RT-PCR. In silico analysis
of BUC11 protein sequence (predicted mass of 8.724kDa) revealed that it is dissimilar to
any other deposited protein sequence. Interestingly, the region 49-67 of BUC11 protein
sequence shares similarity to the X-linked XIAP protein, an inhibitor of apoptosis (Lee
and Cho, 2008; Choi et al., 2008; Aird et al., 2008), previously studied as a target for
the treatment of breast cancer using inhibitors of proteins protecting XIAP from degrada-
tion and antisense oligonucleotides (Hong et al., 2009; Tamm, 2008). Moreover, proteins
demonstrating sequence similarities to BUC11 have all been linked to cell growth or sur-
vival, thus providing additional support for the potential function of the BUC11 protein.
Immunohistochemical staining of tissue microarrays composed of archival tumour
samples is a reliable, high-throughput technology commonly used in the expression anal-
ysis of multiple markers of the subgroups of breast cancers in order to determine their
respective relevance in diagnosis and prognosis of the disease. These immunohistochem-
ical techniques applied to TMA preparations are frequently used by Professor Ian Ellis’s
breast cancer research group and proven successful in the expression study of basal and
luminal cell cytokeratins (Abd El-Rehim et al., 2004), in the validation study of markers
identified through cDNA microarrays (Abd El-Rehim et al., 2005), in the evaluation of
the prognostic relevance of mucins (Rakha et al., 2005) and in the characterisation of
breast cancers with myoepithelial and basal phenotypes (Rakha et al., 2006). An exten-
sive immunohistochemical study on tumour tissues from a large cohort of 670 invasive
breast carcinoma patients confirmed the homogenous distribution of BUC11 protein in
different tumour cell compartments, either the nucleus (30.5% tested positive for BUC11
protein presence in at least the nucleus) or the cytoplasm or both but predominantly in
the cytoplasm. The levels varied depending on the tissue type, thus suggesting BUC11
could be involved in different processes depending on the cell requirements, for example,
at particular time points in the cell cycle or in response to external stimuli. Following
post-translational modification processes, proteins synthesised in the cytoplasm which
have a role to fulfill in the nucleus present in their sequence a nuclear localisation sig-
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nal (NLS) which allows their transport to their target compartment through nuclear pore
complexes (Gerace and Burke, 1988; Garcia-Bustos et al., 1991). Thus, BUC11 protein
does not appear to be present on the outer membrane of the tumour cells, making it an
unlikely target for antibody-based therapies in breast cancer patients. Also, its expression
was not significantly associated to the clinical outcome of breast cancer patients (from the
TMA analysis performed) however it was significantly correlated with the expression of
the progesterone receptor and other markers of endocrine hormonally positive epithelial
luminal-type breast cancers, without any distinction between luminal A or non-luminal
A (luminal B and potentially other subtypes associated with poor prognosis) subtypes.
Consequently, BUC11 is a potential marker of the luminal type of breast cancers and a
potential antigen regulated by sex steroid hormones (Theurillat et al., 2008). The basal
and HER2 breast cancer subtypes are already well defined and can be readily identified
through the molecular profiling of their respective validated markers, however clinically
relevant markers defining the luminal subgroups have yet to be ascertained. Luminal-
specific markers are of high interest for the stratification of breast cancer patients likely
to respond to therapies (patients bearing luminal A subtype tumours have good progno-
sis when treated with tamoxifen) as well as targets for novel therapies themselves (Loi,
2008). Also, in the past few years, researchers have provided important information on
the luminal B subtype such as the low expression of the ER and ER-regulated genes, high
expression of proliferation genes and deregulated apoptotic, HER2 and PI3K/ AKT path-
ways; however further pre-clinical studies, using in vitro and in vivo models, are necessary
to refine the knowledge on cellular pathways affected in luminal B as well as luminal A
subtypes of breast cancer and to validate clinically relevant luminal subtype-associated
markers (Loi, 2008).
6.3 BUC11 - a gene involved in cell proliferation path-
ways?
As previously discussed, evasion of apoptosis and unregulated growth are two of the
six hallmarks of cancer (Hanahan and Weinberg, 2000) thus over-expressed genes that
are involved in pathways affecting tumorigenesis, cell growth and proliferation represent
excellent potential molecular targets for new diagnostic, prognostic or therapeutic strate-
gies for the management of breast cancer patients. No conclusions could be drawn on the
potential function of BUC11 in the cells from the in silico analysis, however experiments
based on the transfection and silencing of BUC11 gene were conducted and the results
provided clues on the biological and cellular role of the BUC11 gene product. Using the
incorporation of 3H-thymidine, a significant decrease in cell proliferation was observed in
BUC11-silenced cells whereas the reverse phenomenon was observed in BUC11-induced
cells. This interdependence suggested that BUC11 might have a function in pathways
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controlling the proliferation of cells and a possible anti-apoptotic effect. This hypothesis
was supported by cell cycle analysis performed on BUC11-silenced cells which informed
that BUC11 could be involved in a pathway regulating cell proliferation which allows
damaged or cancer cells to bypass surveillance mechanisms at checkpoints, especially
G1/S, to avoid apoptosis and grow in an unrestrained manner (Nojima, 2004). Further-
more, microarray analysis of the expressed genes of a breast cancer cell line in which
BUC11 mRNA expression has been significantly downregulated correlated with the cell
cycle and proliferation analyses. The interpretation of the microarray data showed that,
under normal circumstances, BUC11 is co-expressed with various genes associated with
cell proliferation (especially metallothioneins), cell survival, cell structure, cell migra-
tion and even angiogenesis. As mentioned before, metallothioneins are associated with
proliferation of breast cancer cells (Bay et al., 2006), making them good targets for an-
tisense therapies (Yang et al., 2002). Although the BUC11 gene could not be assigned
to any specific functional pathways, the genes identified by modulating BUC11 expres-
sion and supposedly co-expressed with BUC11 represent targets for future exploration to
uncover signalling events associated with BUC11, in both normal and malignant breast
cells. Antigens involved in cell proliferation, such as HER2 which is one of the most
studied (Menard et al., 2001; Slamon et al., 1989), are often associated to a poor clinical
outcome. In this study, BUC11 expression could not be linked to an adverse prognosis
for breast cancer patients (quantitative RT-PCR and immunohistochemical experiments)
even though it appears to be critical to the proliferation of the breast cancer cells tested.
6.4 BUC11 - a potential candidate for immunotherapy?
Proteins associated with the malignant process and having an important role in tu-
morigenesis and tumour progression can provide MHC-restricted peptides effective in
promoting immune responses specifically targeted against the tumour cells and promot-
ing tumour regression. Such antigens make desirable targets for novel molecular thera-
pies, based on knowledge of cancer-associated signalling pathways and immunotherapies
(Ostrand-Rosenberg, 2004). The discovery and validation of novel targets for cancer vac-
cine therapy is particularly crucial for the reason that, as previously stated, no therapeutic
vaccine for the treatment of human cancers has been FDA approved to date. Trastuzumab
and lapatinib, both molecular therapies, were the only two targeted breast cancer thera-
peutics approved in 2007 and a novel DNA-based vaccine for immunotherapy of metas-
tasised breast cancer, called polyHER2neu, is currently being tested in phase 1 of a UK
clinical trial (http://www.cancerhelp.org.uk/trials, 2009). The results obtained during the
course of this project provide a rationale to further investigate BUC11 as a target for im-
munotherapy: the protein is expressed; low mRNA expression in normal essential tissues;
high mRNA expression in non-vital normal tissues (placenta, breast, prostate and testis);
high mRNA expression in prostate, testis and breast cancer tissues; appears to have a
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vital role in cell proliferation. Over-expression of the antigen in tumours is an essential
characteristic to be considered as a potential target for therapy. Although BUC11 is only
over-expressed in the tumour of approximately 61% of the breast cancer patients tested
in this study, patients could be pre-screened for BUC11 over-expression following biopsy
and those testing positive for BUC11 over-expression could be referred for BUC11 tar-
geted therapies. Theoretically, more than half of breast cancer patients could benefit from
such treatments.
Due to time restriction, only preliminary immunological experiments to determine the
suitability of BUC11 as a potential target for immunotherapy were performed. Briefly, the
approach was to immunise mice transgenic for HLA molecules with a BUC11 DNA con-
struct encoding for the protein to induce specific immune responses that could be moni-
tored in vitro. The data generated demonstrated no specific killing of target cells by CTL,
no specific production of IFN-gamma and no specific CD4+ T cell proliferation. These
results show that the BUC11 construct might not be suitable or that BUC11 protein might
not be immunogenic, therefore the investigation would have to be repeated, especially
with BUC11-specific peptides.
6.5 Conclusions and future work
The findings from this study suggest that BUC11 is a novel marker of epithelial
luminal-type breast cancers. It was shown to have a role in cell proliferation and meet
the criteria of an antigen that could potentially be used in novel targeted therapies of
breast and possibly other cancers such as testicular or prostate cancers.
It is essential that any novel candidate antigen is rigorously characterised during the
early stages of the research prior to undertaking time consuming and costly work with
pre-clinical animal models followed by clinical trials. Importantly, the candidate anti-
gen has to present additional benefits to already published and validated antigens. Here,
initial studies should focus on further validation of the BUC11 gene. The vital role for
tumour progression, expression patterns as well as the immunogenicity and endogenous
processing of BUC11 protein needs to be unquestionably ascertained in future exper-
iments. However, one should consider also the potential of other BUC genes, which
should be studied in larger cohorts of cancer patients using quantitative RT-PCR, ideally
with RNA isolated from laser micro-dissected tissues to obtain representative expression
patterns in cells from normal and malignant glands as well as the tumour stroma. In
particular, the mRNA expression patterns of BUC9 splice variants should be further in-
vestigated in order to confirm its relevance in patient management. The quantity, quality
and accessibility of materials remain limiting factors in breast cancer research but these
issues need to be addressed so that appropriate clinical samples, collected before and
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during treatments to primary tumours as well as metastatic samples, are used in expres-
sion studies (Thompson et al., 2008). If BUC6, BUC9 or BUC10 do not translate into
proteins, screening of their respective expression at the RNA level could be used in the
context of diagnosis or prognosis if they present valid expression patterns associated with
clinical disease parameters. It would also be essential to assess the species specificity of
the BUC genes using in silico analysis and PCR-based assays with RNA from diverse
species, to validate the full length of mRNA sequences of the BUC genes by sequencing
the 5’ and 3’ ends using a RACE-PCR approach and to confirm the organisation of the
BUC genes on chromosome 10 (one large gene having several splice variants or several
individual genes?). Furthermore, recombinant BUC proteins could be produced through
the cloning of the coding sequences into an expression vector which would give, for ex-
ample, high-level expression of Histidine-tagged proteins. These proteins could be easily
purified using colums containing a resin with immobilised cobalt or nickel ions which
Histidine has an affinity for.
Prior to any further immunoassays, mass spectrometry could be used to validate the
identity of the protein BUC11 antibody is binding to on the Western Blot. Once the tryp-
tic MS fragments are characterised and the key ions identified, the data could be used
in the mass spectrometry analysis to establish the presence of BUC11 in the serum of
cancer patients. It was presumed that the size of proteins detected on the Western Blots
(15kDa/30kDa) could be explained by post-translational formation of dimers or other
modifications. Important denaturation of the protein mixtures to detect post-translational
modifications in BUC11 should be used to further clarify this point. The study of BUC11
mRNA and protein expression patterns should be extended to larger cohorts of melanoma,
breast and prostate cancer patients in order to validate the expression pattern and ob-
tain statistical significance. This would also support the hypothesis that BUC11 is a
novel marker of epithelial luminal-type breast cancers, along with the analysis of the
co-expression of BUC11 with validated epithelial luminal markers by immunohistochem-
istry and quantitative RT-PCR. Also, transcriptional silencing affecting BUC11 gene and
protein expression were observed in up to 10% of the breast tumours tested but not in
the normal counterpart tissues. It would therefore be of interest to identify the processes
underlying this observation as well as identify the BUC11 promoter.
Regarding the biological role of BUC11 in cells, transfection experiments with either
the expression vector or siRNA silencing should be repeated in both malignant and nor-
mal human breast cell lines (BUC11-negative and BUC11-positive cell lines) to confirm
the role of BUC11 in cell proliferation. One could use as a negative control cells that
would have been tranfected with a plasmid encoding a mutated BUC11 protein. Further-
more, the cause of BUC11 protein translocation to the nucleus of the breast cancer cells
should be ascertained with the use of stress-related assays and immunofluorescence. The
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phenomenon should also be studied in normal breast cells using immunohistochemistry to
determine whether expression could be cancer-specific. It has recently been demonstrated
that breast cancer stem cells are more resistant to radiation (Phillips et al., 2006) and to
cytotoxic agents (Dean et al., 2005) than differentiated breast cancer cells, resulting in
failure of current therapies due to the relapse and metastasis of the disease. Therefore,
following conventional therapies that debulk most of the tumour mass, surviving breast
cancer stem cells should be targeted using novel therapies aimed at either inducing differ-
entiation of those cells or elimination through immunotherapy. In the latter case, targets
for immunotherapy must be antigens that are expressed by the breast cancer stem cells,
ideally on their cell surface, but not by the normal stem cells but in association with
MHC class I antigen (Morrison et al., 2008). It would thus be interesting to determine
whether or not BUC11 is expressed in breast cancer stem cells as a novel cancer stem
cell-associated marker that might represent a potential target for novel therapies to treat
and/or prevent recurrence of the disease. Finally, the immunogenicity of BUC11 protein
can be assessed using MHC class I and class II overlapping peptides derived from the
protein using a MHC transgenic mouse model and a tumour cell line expressing MHC
class I and the appropriate class I-restricted epitope(s).
This study has demonstrated for the first time the expression of a novel gene set in
breast/breast cancer cells that potentially have clinical utility and merit further detailed
study. This is considerable scope for research, since the function and biological signifi-
cance of the BUC genes/proteins have not been elucidated and based on the results of the
present study, research to address these issues can be proposed.
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The Ct values of the BUC11 mRNA expression analysis in cell lines and tissues
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